Study ID	Patient ID	Sample ID	Age at Diagnosis	Age At Specimen Acquisition	FLT3-ITD Allelic Ratio	ASXL1	Cancer Type	Cancer Type Detailed	Cause Of Death	CEBPA bi-allelic	Center ID	Cohort	Cumulative Chemo	Unique Regiments	No. Of Cumulative Regiments	Unique Treatment Stages	No. Of Unique Treatment Stages	Unique Treatment Types	No. Of Cumulative Treatments	Current Regimen	Current Stage	Disease Stage At Specimen Collection	Diagnosis At Inclusion	ELN2017	Ethnicity Category	FAB BLAST morphology	FLT3-ITD	De Novo	Relapsed	Transformed	Karyotype	Most Recent Treatment Duration	Most Recent Treatment Type	Mutation Count	Diagnosis non AML, MDS, MPN	NPM1	Oncotree Code	Overall Survival (Months)	Overall Survival Status	Other Cytogenetics	Prior Non-Myeloid	Prior Malignancy Radiation	Type Non-Myeloid	Prior MDS	Prior MDS > Two Months	Prior MDS/MPN	Prior MDS/MPN >Two Months	Prior MPN	Prior MPN > Two Months	Race Category	Response Duration To Induction	Response To Induction	RUNX1	Number of Samples Per Patient	Sex	Somatic Status	Diagnosis MDS, MPN	Specific Diagnosis At Inclusion	Specimen Groups	Specimen Type	Surface Antigens Immunohistochemical Stains	Time Of Sample Collection, Relative To Inclusion	TMB (nonsynonymous)	TP53 Pathway	Treatment Type Induction	Used In Manuscript	Variant Summary
aml_ohsu_2022	aml_ohsu_2022_2000	aml_ohsu_2022_2000_BA2123	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	2	Waves1+2	Yes	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY[20]	214	Standard Chemotherapy	14	FALSE	Positive	AML	8.843835616438355	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199](RUNX1T1, RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33 (bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR (+), GLy-A(-), MPO(partial +), TdT(-).	0	0.9	NA	NA	Yes	DNMT3A (W297*; MAF 44%)|FLT3-D835 (D835Y; MAF 6%)|GATA2 (P161A; MAF 51%)|NPM1 (W288fs*10+; MAF 26%)
aml_ohsu_2022	aml_ohsu_2022_2001	aml_ohsu_2022_2001_BA2702	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	AG-221|Azacitidine|Clofarabine	3	Hypomethylating/Low Dose Cytarabine|Unknown|Experimental	3	Standard Chemotherapy|Targeted Therapy - Other	2	AG-221	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY,r(7)(p1?3q2?2)[12]/46,XY[5]	-1	Targeted Therapy - Other	18	FALSE	Negative	AML	11.013698630136986	1:DECEASED	loss of 7q31 sequences in 85% of assayed cells	No	No	NA	Yes	Yes	No	No	No	No	NA	NA	NA	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	NA	34	1.033333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2003	aml_ohsu_2022_2003_BA2499	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	NA	107	Standard Chemotherapy	19	FALSE	Negative	AML	1.7424657534246575	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	NA	NA	NA	RUNX1 (p.R320*; 46.2%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.966666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2004	aml_ohsu_2022_2004_BA2846	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Hydroxyurea|Decitabine	2	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Decitabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	FALSE	FALSE	FALSE	46,XY[20]	4	Supportive/Palliative Care	11	FALSE	Positive	AML	0.5589041095890411	1:DECEASED	Normal	Yes	No	Rectal Cancer	No	No	No	No	No	No	White	NA	NA	NA	1	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD33, dim CD38, variable CD56, CD58, dim CD64, CD117, CD123, and MPO positive.	0	0.5	NA	NA	Yes	IDH2 (p.R140Q; MAF 47%)|NPM1 (p.W288fs*12 (4 nt insertion with frameshift); MAF 17%)|SRSF2 (p.P95L; MAF 37%)
aml_ohsu_2022	aml_ohsu_2022_2005	aml_ohsu_2022_2005_BA2802	52	53	0	NA	Leukemia	Acute Leukemias of Ambiguous Lineage	Dead-Disease	NA	1	Both	Yes	7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide	6	Salvage|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Decitabine	Salvage	Residual	Acute Leukaemias Of Ambiguous Lineage	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3]	80	Standard Chemotherapy	1	FALSE	Negative	ALAL	13.282191780821917	1:DECEASED	Deleted 5q	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	UNMATCHED	FALSE	Mixed phenotype acute leukaemia, T/myeloid, NOS	Post-Transplant|Post-Chemotherapy|Residual Disease	Peripheral Blood	partial CD7, CD13, CD33, CD34, partial CD56, CD58, HLA-DR, and partial MPO-positive CD117, CD123,	234	0.066666667	TP53 (p.V216M; 66.9%)	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2006	aml_ohsu_2022_2006_BA2665	62	62	NA	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Dead-Unknown	NA	2	Waves1+2	Yes	Fludarabine, Melphalan|Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	NA	Myelodysplastic Syndromes	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	44~45,XX,add(4)(p16),der(5)t(5;12)(q13;q14),-7,-12,del(17)(p11.2p13),+1~3mar[cp14]/45,idem,dup(11)(q23q14)[1]/44,idem,add (1)(p36.3)[cp3]/46,XX[2]	-1	Bone Marrow Transplant	14	FALSE	Negative	MDS	22.652054794520545	1:DECEASED	nuc ish(D5S721x2,D5S23x2,EGR1x1)[149/200],(D7Z1,D7S522)x1[155/200],(D8Z2,D20S108)x2[200], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Yes	No	Breast Cancer	Yes	No	No	No	No	No	NA	61	Refractory	NA	1	Female	MATCHED	TRUE	Myelodysplastic syndrome, unclassifiable	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD2(-), CD4(variably +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+), TdT(-), MPO(-)	0	0.766666667	TP53 (p.E343*; 56.0%)	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2007	aml_ohsu_2022_2007_BA2918	53	53	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	5	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	21	FALSE	Positive	AML	24.328767123287673	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	23	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	partial CD7, CD13, CD33, CD117, CD123, dim HLA-DR, and MPO positive	0	1.2	NA	Standard Chemotherapy	Yes	FLT3 (FLT3 I836 deletion)|NPM1 (An insertion mutation is present in exon 12 (near the C-terminus) of NPM
aml_ohsu_2022	aml_ohsu_2022_2008	aml_ohsu_2022_2008_BA2676	48	48	NA	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Alive	NA	1	Waves1+2	Yes	Decitabine|Busulfan, Cyclophosphamide	2	Induction|Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	NA	Myelodysplastic Syndromes	NonAML	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	47,XY,+8[18]/46,XY[2]	-1	Bone Marrow Transplant	20	FALSE	Negative	MDS	69.50136986301371	0:LIVING	Trisomy 8 (84%)	No	No	NA	Yes	No	No	No	No	No	White	116	Complete Response	NA	1	Male	MATCHED	TRUE	Refractory anaemia with excess blasts	Unknown	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD58, CD117, CD123, MPO+	0	1.133333333	NA	Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 45%)|IDH1 (p.R132C; MAF 44%)|TET2 (p.P455R; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2009	aml_ohsu_2022_2009_BA2451	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine	3	Induction|Re-induction	2	Standard Chemotherapy	1	Azacitidine	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY,t(8;17)(p21;q11.2),del(17)(q2?4)[5]/46,XY[15]	-1	Standard Chemotherapy	18	FALSE	Negative	AML	19.101369863013698	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	7	Refractory	RUNX1 (p.E223*; 41.0%)	2	Male	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim/partial cCD3, variable CD7, CD13, dimCD33, CD34,  CD38, CD117, dim CD123, dim HLA-DR, partial TdT, and partial MPO positive Monoclonal B cell population identified	0	1	NA	Standard Chemotherapy	Yes	BCOR (p.Y1350*; MAF 65%)|FBXW7 (p.T15_G16insP; MAF 50%)|RUNX1 (p.E223*; MAF 25%)|STAG2 (p.G977fs*8; MAF 55%)
aml_ohsu_2022	aml_ohsu_2022_2009	aml_ohsu_2022_2009_BA3322	62	63	0	ASXL1 (p.S1028*; MAF 14%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves3+4	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine	3	Induction|Re-induction	2	Standard Chemotherapy	1	Azacitidine	Re-induction	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Negative	FALSE	FALSE	FALSE	46,XY[20)	-1	Standard Chemotherapy	3	FALSE	Negative	AML	19.101369863013698	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	7	Refractory	RUNX1 (p.E223*; MAF 1%)	2	Male	UNMATCHED	FALSE	AML without maturation	Post-Chemotherapy	Bone Marrow Aspirate	CD5, CD19, CD20 and dim surface kappa light chain +	487	0.133333333	NA	Standard Chemotherapy	No	ASXL1 (p.S1028*; MAF 14%)|BCOR (p.Y1350*; MAF 6%)|FBXW7 (p.T15_G16insP; MAF 49%)|FLT3|RUNX1 (p.E223*; MAF 1%)
aml_ohsu_2022	aml_ohsu_2022_2010	aml_ohsu_2022_2010_BA2304	52	52	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan, ATG, Methotrexate	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M5	Negative	FALSE	FALSE	FALSE	46,XX,t(9;11)(p22;q23)[5]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	26.432876712328763	0:LIVING	11q23 (MLL): rearrangement present (89.5%)	Yes	No	Breast Cancer	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	The monocytic cells (percentages shown) are  atypical in that they express partial CD56 (about 50%  positive), but otherwise demonstrate phenotypically normal  expression of CD13, bright CD33, bright CD64, CD15, HLA-DR,  and partial myeloperoxidase (Flow 	0	0.066666667	NA	Standard Chemotherapy	Yes	KRAS (p.Gly13Asp; MAF 38.9%)
aml_ohsu_2022	aml_ohsu_2022_2012	aml_ohsu_2022_2012_BA2616	48	48	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Lenalidomide|Decitabine	5	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction	3	Standard Chemotherapy	1	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M1	Negative	FALSE	FALSE	FALSE	45,XX,?add(2)(q35~37),inv(3)(q21q26),-7[4]/46,XX[1]	-1	Standard Chemotherapy	15	FALSE	Negative	AML	4.043835616438356	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Female	MATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD38, CD7, CD13, partial CD33, partial CD11c, dim CD5, dim CD19, CD4, HLA-DR, partial CD15, and partial CD117	0	0.833333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2013	aml_ohsu_2022_2013_BA2195	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	42~45,XX,-18[cp14]/43~45,idem,+2~3mar[cp3]/47,XX,+8[cp2]/45,X,-X[1]	-1	Standard Chemotherapy	14	FALSE	Negative	AML	2.3013698630136985	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	NA	-1	Refractory	RUNX1 (p.S322Nfs*277; 9.7%)	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34+ BLAST POPULATION, 33%, EXPRESSING PARTIAL CD38, PARTIAL CD4, PARTIAL CD11C, HLA-DR, CD117, PARTIAL CD13, PARTIAL CD33, PARTIAL CD15, AND MPO	0	0.8	TP53 (p.I195T; 22.2%)|TP53 (p.P151R; 54.8%)	Standard Chemotherapy	Yes	CEBPA (Triple positive)|IDH2
aml_ohsu_2022	aml_ohsu_2022_2014	aml_ohsu_2022_2014_BA2226	53	53	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX[20]	153	Standard Chemotherapy	10	FALSE	Positive	AML	60.26301369863013	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	153	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Blast immunophenotype: partial CD11b, CD13, CD33, CD38, CD58, partial CD64, partial CD117 and a subset with MPO - Blast/promonocyte immunophenotype: CD11b, CD13, partial CD14, CD15, CD33, CD38, CD58 and CD64	0	0.4	NA	Standard Chemotherapy	Yes	FLT3-D835 (p.D835Y; MAF: 40%)|NPM1 (p.W288fs*12; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2015	aml_ohsu_2022_2015_BA2861	22	22	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	mono	1	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XX[24]	-1	Bone Marrow Transplant	9	FALSE	Negative	AML	89.72054794520548	0:LIVING	normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7 ,dim/partial CD10 , CD13 , CD33 , CD34 , CD38 , CD56 , CD64 , dim CD123 , HLA-DR , and MPO positive	0	0.433333333	NA	Standard Chemotherapy	Yes	CEBPA (p.D107fs*; MAF ~50%)|WT1 (p.Y385*; MAF 20%)|WT1 (rs16754; MAF ~50%)
aml_ohsu_2022	aml_ohsu_2022_2016	aml_ohsu_2022_2016_BA2816	21	21	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	SWOG S1203 (7+3 +/- Vorinostat)|Fludarabine, Cyclophosphamide, TBI	2	Allogeneic - Sibling|Induction	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M1	Negative	TRUE	FALSE	FALSE	45,XY,-7[6]/47,XY,+13[cp5]/46,XY[12]	-1	Bone Marrow Transplant	14	FALSE	Negative	AML	19.89041095890411	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	177	Complete Response	RUNX1 (p.R201*; 33.3%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34, CD4, CD13, CD15, partial CD33, CD38, partial CD117, partial CD11c, HLA-DR, MPO and TdT	0	0.733333333	NA	Standard Chemotherapy	Yes	NRAS
aml_ohsu_2022	aml_ohsu_2022_2017	aml_ohsu_2022_2017_BA2156	55	55	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	22	FALSE	Negative	AML	89.85205479452054	0:LIVING	Normal	Yes	No	Other malignant neoplasm without specification of site	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, CD33, CD34, CD38, CD64, CD123, HLA-DR, and MPO	0	1.166666667	NA	Standard Chemotherapy	Yes	CEBPA (c.242?243insCTTGGTT (7bp out-of-frame insertion); MAF 50%)|CEBPA (c.912?913insTTG (3 bp in-frame insertion); MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2018	aml_ohsu_2022_2018_BA2950	44	47	1	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	No	Radiation	1	Unknown	1	Targeted Therapy - Other	1	Radiation	Unknown	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	46,XX[20]	14	Targeted Therapy - Other	6	FALSE	Negative	AML	40.47123287671233	0:LIVING	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small precentage of tumor cells with chromosome abnormalities may not be detected due to the cells e	No	No	NA	No	No	No	No	No	No	Black	NA	NA	RUNX1 (p.L98Pfs*40; 46.8%)	1	Female	UNMATCHED	FALSE	AML with minimal differentiation	Residual Disease|Post-Chemotherapy	Peripheral Blood	The blasts are positive for HLA-DR, CD34, CD117 (PARTIAL), CD13, CD(PARTIAL/DIM), CD33, TDT (DIM, SUBSET) and are negative for CD11b, CD14, CD64, MPO and all B and T cell markers. (Bone Marrow Immunophenotyping)	0	0.2	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2019	aml_ohsu_2022_2019_BA2905	77	77	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	AG-221|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Experimental|Maintenance	3	Standard Chemotherapy|Targeted Therapy - Other	2	AG-221	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	FALSE	FALSE	TRUE	47,XY,+11[8]/46,XY[12]	-1	Targeted Therapy - Other	12	FALSE	Negative	AML	1.2493150684931507	1:DECEASED	35% gain of 11q23	No	No	NA	Yes	Yes	No	No	No	No	NA	NA	NA	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	CD34, CD117, HLA-DR, CD13, and CD33. A subset of the myeloblasts showed aberrant co-expression of CD34 and myeloperoxidase.  A subset of the myeloblasts showed aberrant expression of CD56.	0	0.733333333	NA	NA	Yes	ASXL1 (p.G642fs; MAF 32.1%)|CEBPA (p.K90fs; MAF 39.1%)|EZH2 (p.F246fx; MAF 91.4%)|IDH2 (p.R140Q; MAF 49.2%)|RUNX1 (p.L29S; MAF 52.9%)|STAG2 (p.D884fs; MAF 89.8%)|TET2 (p.P1723S; MAF 48.4%)|TET2 (p.Y867H; MAF 50.3% )
aml_ohsu_2022	aml_ohsu_2022_2020	aml_ohsu_2022_2020_BA2006	78	78	0	ASXL1 (p.G646Wfs*12; 32.6%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	45,XX,+i(5)(p10),psudic(12;5)(p13;q11.2),-16,del(17)(p11.2p13)[5]/44,idem,-i(5)[3]/46,XX[12]	NA	None	4	FALSE	Negative	AML	1.2164383561643834	1:DECEASED	nuc ish(D5S721x2,D5S23x2,EGR1x1)[57/200]/(D5S721x4,D5S23x4,EGR1x1)[29/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[83/200]	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.2	TP53 (p.X307_splice; 76.3%)	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2022	aml_ohsu_2022_2022_BA2032	64	65	15.66666667	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine	5	Salvage|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2]	124	Targeted Therapy - Kinase Inhibitor(s)	4	FALSE	Positive	AML	14.958904109589042	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	NA	21	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +). (80% population of variably-sized cells)	0	0.133333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2023	aml_ohsu_2022_2023_BA2505	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M2	Negative	TRUE	FALSE	FALSE	45,XY,inv(3)(q21q26),-7[20]	4	Standard Chemotherapy	NA	FALSE	Negative	AML	8.613698630136987	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	23	Refractory	NA	2	Male	UNMATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	NA	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2023	aml_ohsu_2022_2023_BA2834	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M2	Negative	TRUE	FALSE	FALSE	45,XY,inv(3)(q21q26),-7[20]	4	Standard Chemotherapy	22	FALSE	Negative	AML	8.613698630136987	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	23	Refractory	NA	2	Male	MATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	1.133333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2024	aml_ohsu_2022_2024_BA2606	60	60	0	ASXL1 (p.S747Pfs*25; 32.6%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	46,XY[20]	8	Standard Chemotherapy	14	FALSE	Negative	AML	2.0383561643835617	1:DECEASED	Normal	No	No	NA	Yes	No	No	No	No	No	White	8	Unknown	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial dim CD7, CD13, dim CD33, CD34, CD38, CD58, CD117,  HLA-Dr and variable MPO	0	0.733333333	NA	Standard Chemotherapy	Yes	ASXL1 (p.S747fs*25; MAF 38%)|IDH1 (p.R132C; MAF 34%)|SRSF2 (p.P95R; MAF 35%)
aml_ohsu_2022	aml_ohsu_2022_2025	aml_ohsu_2022_2025_BA2461	66	66	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	7	FALSE	Negative	AML	7.594520547945205	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy	Bone Marrow Aspirate	The analysis was performed by flow cytometry on the bone marrow aspiratespecimen. The analysis shows CD34+ blasts account for 1% of CD45+ events. Maturing myeloid precursors and monocytic cells demonstrate a normal pattern of myelomonocytic antigen expres	0	0.233333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2026	aml_ohsu_2022_2026_BA2122	75	77	0	ASXL1 (p.Q512*; 56.3%)|ASXL1 (p.G645Vfs*58; 9.1%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M2	Negative	FALSE	FALSE	FALSE	46,XX[8]	1131	Standard Chemotherapy	14	FALSE	Negative	AML	37.28219178082192	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	RUNX1 (p.R162K; 95.1%)	1	Female	MATCHED	FALSE	AML with maturation	Post-Chemotherapy	Bone Marrow Aspirate	NA	716	0.733333333	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2027	aml_ohsu_2022_2027_BA2936	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	2	Induction|Re-induction	2	Standard Chemotherapy	1	5+2 (Cytarabine, Idarubicin)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	50,XY,+8,+9,+13,+22[17]/46,XY[3]	-1	Standard Chemotherapy	13	FALSE	Negative	AML	9.304109589041097	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34, CD38, PARTIAL CD56, CD13, PARTIAL CD64, HLA-DR, CD117, PARTIAL MPO, PARTIAL CD79A, AND DIM PARTIAL TDT	0	0.733333333	NA	Standard Chemotherapy	Yes	IDH1
aml_ohsu_2022	aml_ohsu_2022_2028	aml_ohsu_2022_2028_BA2144	56	56	0	ASXL1 (p.G645Vfs*58; 14.3%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|ME (Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	46,XX[20]	-1	Bone Marrow Transplant	31	FALSE	Negative	AML	56.9095890410959	0:LIVING	Normal	No	No	NA	No	No	Yes	Yes	No	No	White	-1	Refractory	RUNX1 (p.R201*; 45.8%)	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD34, CD38, CD117, and dim HLA-DR +.	0	1.6	NA	Standard Chemotherapy	Yes	ASXL1 (p.T601A; MAF 45%)|BCOR (p.Y1350fs*1; MAF 43%)|DNMT3A (p.R882H; MAF 46%)|FLT3 (p.A680V; MAF 37%)|IDH2 (p.R140Q; MAF 43%)|NRAS (p.Q61K; MAF 9%)|PRDM1 (p.I117M; MAF 49%)|RUNX1 (p.N434fs*166; MAF 37%)|RUNX1 (p.R201*; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2029	aml_ohsu_2022_2029_BA2065	46	47	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	5	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Negative	FALSE	TRUE	FALSE	46,XX[20]	4	Standard Chemotherapy	16	FALSE	Positive	AML	45.13972602739726	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	2	Female	MATCHED	FALSE	AML with mutated NPM1	Relapse	Bone Marrow Aspirate	CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive	424	0.9	NA	Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 39%)|NPM1 (p.W288fs*>9 ; MAF 39%)|PTPN11 (p.E76Q; MAF 41%)
aml_ohsu_2022	aml_ohsu_2022_2029	aml_ohsu_2022_2029_BA2474	46	46	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	5	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XX[20]	4	Standard Chemotherapy	6	FALSE	Positive	AML	45.13972602739726	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	2	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD11b, CD13, CD33, partial CD34, dim CD45, dim CD64, CD117, CD123, and dim HLA-DR+	0	0.266666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882C; MAF 46%)|NPM1 (p.W288fs*12; MAF 43%)|PTPN11 (p.E76Q; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2030	aml_ohsu_2022_2030_BA2336	73	73	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit)	3	Consolidation|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	AC220 (Ambit)	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XY[20]	30	Targeted Therapy - Kinase Inhibitor(s)	4	FALSE	Positive	AML	13.972602739726028	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	5	Complete Response	NA	2	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive, CD34 negative, HLA-DR negative	1	0.1	NA	Standard Chemotherapy	Yes	FLT3-ITD (Low Level)|NPM1
aml_ohsu_2022	aml_ohsu_2022_2030	aml_ohsu_2022_2030_BA2708	73	74	0.923076923	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit)	3	Consolidation|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	AC220 (Ambit)	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	TRUE	FALSE	46,XY[20]	30	Targeted Therapy - Kinase Inhibitor(s)	5	FALSE	Positive	AML	13.972602739726028	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	5	Complete Response	NA	2	Male	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD13, dim CD33, CD56, and CD117 positive	378	0.133333333	NA	Standard Chemotherapy	No	NPM1
aml_ohsu_2022	aml_ohsu_2022_2031	aml_ohsu_2022_2031_BA2501	36	36	0.25	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	Methotrexate, Mercaptopurine, Tretinoin|ATRA, Idarubicin|ATRA, Cytarabine, Idarubicin	3	Consolidation|Induction|Maintenance	3	Standard Chemotherapy	1	Methotrexate, Mercaptopurine, Tretinoin	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M3	Positive	TRUE	FALSE	FALSE	46,XY,t(15;17)(q24;q21)[18]/46,XY[2]	-1	Standard Chemotherapy	1	FALSE	Negative	AML	19.857534246575344	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	weak partial CD2, CD13, CD33, CD64, CD117, and  myeloperoxidase	0	0	NA	Standard Chemotherapy	Yes	CEBPA (c.935A>G; MAF 45%, except VUS)|FLT3-ITD (c.1780_1800dup; MAF 17%)
aml_ohsu_2022	aml_ohsu_2022_2032	aml_ohsu_2022_2032_BA2348	43	44	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,add(3)(q21)[12]/52,sl,+6,+8,+10,+13,+20,+21[8]	-1	Bone Marrow Transplant	4	FALSE	Negative	AML	36.328767123287676	0:LIVING	Positive for an EVI1 rearrangement: < 0.9% |ABNORMAL - Low level gain of chromosome 8 and 20q12 sequences, trisomy:  < 0.3%)	No	No	NA	No	No	No	No	No	No	NA	12	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy	Peripheral Blood	NA	0	0.2	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2033	aml_ohsu_2022_2033_BA2269	34	34	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone	3	Unknown|Induction|Re-induction	3	Standard Chemotherapy|Intrathecal	2	Cytarabine	Unknown	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	6	Intrathecal	5	FALSE	Negative	AML	5.161643835616438	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	35	Refractory	NA	1	Female	UNMATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	NA	0	0.3	TP53 (p.R282Q; 46.6%)	Standard Chemotherapy	Yes	CSF3R (p.A470V, MAF 51%)|DNMT3A (p.R882C, MAF 51%)|NRAS (p.G13R, MAF 48%)|TP53 (p.R282Q, MAF 51%)
aml_ohsu_2022	aml_ohsu_2022_2034	aml_ohsu_2022_2034_BA2712	61	61	0	ASXL1 (p.G646Wfs*12; 28.6%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Both	Yes	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	NA	NA	None	5	FALSE	Negative	AML	0.526027397260274	1:DECEASED	NA	Yes	No	Follicular lymphoma	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	CD2(-), CD4(dim +), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +), CD15(variably and slightly bright +), CD16 (-), CD33(variably bright +), CD34(-), CD36(partial +), CD38(variably +), CD45(variably +), CD56(+), CD64(partial +), CD117(-), HLA-	0	0.266666667	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2035	aml_ohsu_2022_2035_BA2212	75	75	0	ASXL1 (p.G646Wfs*12; 39.3%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	Vidaza|Decitabine|Fludarabine, Cytarabine	3	Salvage|Supportive/Palliative Care	2	Standard Chemotherapy	1	Fludarabine, Cytarabine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY,t(1;12)(p32;p13)[3]/46,XY[17]	-1	Standard Chemotherapy	17	FALSE	Negative	AML	5.227397260273973	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	No	No	NA	Yes	Yes	No	No	No	No	Asian	NA	NA	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD2(-), CD4(-),CD7(-), CD10(partial +), CD11b(-), CD13(dim +), CD14(-), CD38(variably +/small subset -), CD45(dim to moderately +), CD56(-), CD64(-), CD117(variably +), HLA-DR(variably +). | Population #2 (0.48% of total events) comprises small cells with	0	0.8	NA	NA	Yes	ASXL1 (G646fs*12; MAF 37.0%)|BCOR (S1608*; MAF 3.0%)|KRAS (G12R; MAF 5.0%)|STAG2 (Q932fs*6; MAF 91.0%)|SUZ12 (E601fs*10; MAF 38.0%)|TET2 (C127fs*92; MAF 6.0%)|TET2 (S1870*; MAF 45.0%)
aml_ohsu_2022	aml_ohsu_2022_2036	aml_ohsu_2022_2036_BA2731	63	63	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	2	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,del(11)(q14q23)[13]/46,XY[7].ishdel(11)(5'MLL-,3'MLL+)[2].	-1	Bone Marrow Transplant	17	FALSE	Negative	AML	44.25205479452055	0:LIVING	nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(5'MLLx1,3'MLLx2)(5'MLL con 3'MLLx1)[118/200]	No	No	NA	No	No	No	No	No	No	NA	5	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD7(+), CD11b(-), CD13(dim +), CD14(-), CD15(partial +), CD16(-), CD33(variably +/subset bright +), CD34(+), CD36(-), CD38(+), CD45(+), CD56(partial +), CD64(partial +), CD117(+), HLA-DR(+), MPO(+), TdT(-).	0	0.9	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2037	aml_ohsu_2022_2037_BA2300	79	79	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	43-45,X,-Y,del(5)(q22q35),del(7)(q22),+8,-9,add(9)(p13),+11,-13,-14,add(16)(q24),-17,-18,del(20)(q11.2q13.2),+2-3mar[cp21]	NA	None	3	FALSE	Negative	AML	0.03287671232876713	1:DECEASED	5q31 (EGR1): deletion present  8q22 (RUNX1T1): gain present  11q23 (KMT2A; also known as MLL): gain present	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.2	TP53 (p.X225_splice; 93.2%)	NA	Yes	KIT (p.Asp816Val; MAF 44.4%)|TP53 (p.?; MAF 91%)
aml_ohsu_2022	aml_ohsu_2022_2038	aml_ohsu_2022_2038_BA2887	24	24	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Radiation|Busulfan, Cyclophosphamide	8	Consolidation|Salvage|Unknown|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	7	DLI|Standard Chemotherapy|Bone Marrow Transplant|Other	4	Azacitidine	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	47,XY,+10[18]/46,XY[2]	-1	Standard Chemotherapy	NA	FALSE	Negative	AML	83.21095890410959	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, dim CD13, dim CD14, CD33, CD34, dim CD38, partialCD56, CD58, partial CD64, CD117, CD123, dim HLA-DR, and MPO	0	NA	NA	Standard Chemotherapy	Yes	NOTCH1 (p.V1578delV; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2039	aml_ohsu_2022_2039_BA2955	66	66	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin), Bortezomib|MiDAC|Fludarabine, Cytarabine|Ibrutinib	4	Allogeneic - Sibling|Consolidation|Induction|Maintenance	4	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Ibrutinib	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	47,XX,+6[6]/46,XX[19]	382	Targeted Therapy - Kinase Inhibitor(s)	21	FALSE	Negative	AML	71.5068493150685	0:LIVING	IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH re	No	No	NA	No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.P240Qfs*22; 40.0%)	1	Female	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dimCD4, CD11b, CD13, dimCD14, CD33, CD56, CD58, CD64, dimCD123 and HLA-DR positive; Minor subset of blasts with immunophenotype: CD13, CD33, CD34, CD58, CD117, dimCD123, HLA-DR and MPO positive.	0	0.866666667	NA	Standard Chemotherapy	Yes	BCOR (p.G1659E MAF ~10%,)|FLT3-ITD (MAF 38%)|NRAS (p.Q61R MAF ~5%)|RUNX1 (p.P240fs*22; MAF 37%)|RUNX1 (splice site [at invariant AG (G>A) splice acceptor site at end of Intron 6];  MAF 36% ))
aml_ohsu_2022	aml_ohsu_2022_2040	aml_ohsu_2022_2040_BA2295	34	34	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XX,inv(16)(p13,1q22)[17]/46,XX[3]	135	Standard Chemotherapy	NA	FALSE	Negative	AML	62.7945205479452	0:LIVING	Positive for rearrangement of the CBFB gene at 16q22 on chromosome 16. Negative for BCR-ABL1 translocation or other abnormalities in this panel.	No	No	NA	No	No	No	No	No	No	White	6	Complete Response i	NA	1	Female	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, dim CD33, subset CD34, CD38, CD117, 123, MPO(+)	0	0	NA	Standard Chemotherapy	Yes	NRAS (p.G12D; MAF 6%)
aml_ohsu_2022	aml_ohsu_2022_2041	aml_ohsu_2022_2041_BA2724	67	67	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	Decitabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	19	FALSE	Positive	AML	1.1178082191780823	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(partial dim +), CD7(few dim +), CD11b(-), CD13 (variably +), CD14(-), CD15(partial +), CD16(-), CD19(partial dim +), CD33(variably +), CD34(-), CD36(-), CD38(+), CD45 (moderate +), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+), MPO(+). (Po	0	1.066666667	NA	NA	Yes	NPM1 (W288FS*10+; MAF 37.0%)|NRAS (Q61K; MAF 43.0%)
aml_ohsu_2022	aml_ohsu_2022_2042	aml_ohsu_2022_2042_BA2073	72	72	0	ASXL1 (p.E635Rfs*15; 14.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	47,XY,+8[17]/46,XY[3]	-1	Standard Chemotherapy	21	FALSE	Negative	AML	1.2821917808219179	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	NA	-1	Refractory	RUNX1 (p.R201*; 79.4%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD38, CD13, HLA-DR, CD33 (DIM PARTIAL), CD4 (DIM), MPO (DIM PARTIAL), AND TDT	0	1.066666667	NA	Standard Chemotherapy	Yes	IDH1
aml_ohsu_2022	aml_ohsu_2022_2043	aml_ohsu_2022_2043_BA2575	36	36	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XX,inv(16)(p13.1q22)[20]	6	Standard Chemotherapy	6	FALSE	Negative	AML	0.4931506849315068	1:DECEASED	CBFB; 76/100 cells (76%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement.	No	No	NA	No	No	No	No	No	No	White	6	Unknown	NA	1	Female	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Immunophenotyping done on the peripheral blood on 12/1/2014      identified a myeloid blast population with the following immunophenotype:      CD13, partial CD15, CD33, CD34, CD38, CD58, variable CD64, CD117, HLA-DR      and cMPO. And, it identified a pr	0	0.2	NA	Standard Chemotherapy	Yes	KRAS (p.G12D; MAF 9% )|NRAS (p.G12D; MAF 10%)
aml_ohsu_2022	aml_ohsu_2022_2044	aml_ohsu_2022_2044_BA2277	72	72	0.639344262	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	3	Induction|Experimental	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Ponatinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XX[5]	15	Targeted Therapy - Kinase Inhibitor(s)	16	FALSE	Positive	AML	3.8794520547945206	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	10	Refractory	NA	2	Female	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	40	0.833333333	NA	Standard Chemotherapy	No	CEBPA (p.E163*; MAF 40%)|FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 32%)
aml_ohsu_2022	aml_ohsu_2022_2044	aml_ohsu_2022_2044_BA2280	72	72	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	3	Induction|Experimental	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Ponatinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XX[20]	15	Targeted Therapy - Kinase Inhibitor(s)	17	FALSE	Positive	AML	3.8794520547945206	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	10	Refractory	NA	2	Female	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	CD13, CD33, CD38, partial CD56, partialCD64, CD117, dimCD123, and MPO	0	0.866666667	NA	Standard Chemotherapy	Yes	CEBPA (p.E163*; MAF 39%)|FLT3-ITD (MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2045	aml_ohsu_2022_2045_BA2628	51	51	0	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Alive	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|Azacitidine	2	Maintenance|Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	NA	Myelodysplastic Syndromes	NonAML	NON-HISPANIC	M6	Negative	FALSE	FALSE	FALSE	46,XY,del(20)(q12)[14]/46,XY[6]	-1	Bone Marrow Transplant	8	FALSE	Negative	MDS	90.7068493150685	0:LIVING	20q deletion (38%)	No	No	NA	Yes	No	No	No	No	No	White	NA	Complete Response	NA	1	Male	MATCHED	TRUE	Refractory anaemia with excess blasts	NA	Bone Marrow Aspirate	NA	0	0.4	NA	NA	No	U2AF1 (p.S34F, MAF 34)
aml_ohsu_2022	aml_ohsu_2022_2046	aml_ohsu_2022_2046_BA3030	70	70	0.428571429	NA	Myelodysplastic/Myeloproliferative Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	Dead-Disease	NA	1	Waves1+2	No	Hydroxyurea	1	Induction	1	Targeted Therapy - Kinase Inhibitor(s)	1	Hydroxyurea	Induction	NA	Myelodysplastic/Myeloproliferative Neoplasms	NonAML	UNKNOWN	NA	Positive	FALSE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Kinase Inhibitor(s)	10	FALSE	Negative	MDS/MPN	1.084931506849315	1:DECEASED	Normal	No	No	NA	No	No	Yes	No	No	No	Unknown	-1	Unknown	NA	1	Female	MATCHED	TRUE	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	Unknown	Bone Marrow Aspirate	CD13, CD33, CD34, partial CD117, CD123, HLA-DR	0	0.5	NA	Targeted Therapy - Kinase Inhibitor(s)	No	FLT3-ITD (MAF 45%)|IKZF1 (p.N159S ; MAF 45%)|SF3B1 (p.K666N ; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2047	aml_ohsu_2022_2047_BA2634	74	75	1.941176471	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Etoposide, Mitoxantrone	3	Hypomethylating/Low Dose Cytarabine|Salvage|Induction	3	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M2	Positive	FALSE	FALSE	FALSE	46,XY,add(1)(p34),del(7)(q22),del(20)(q11.2)[20]	-1	Standard Chemotherapy	24	FALSE	Negative	AML	13.643835616438357	1:DECEASED	normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with maturation	Residual Disease	Peripheral Blood	Increased CD34 positive myeloblasts, representing approximately 55% of the leukocytes	0	1.433333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2048	aml_ohsu_2022_2048_BA2112	29	29	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	5	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Negative	TRUE	FALSE	FALSE	46,XY,t(6;11)(q27;q23),del(12)(p11.2p13)[13]/46,XY[7]	4	Standard Chemotherapy	19	FALSE	Negative	AML	36.0	1:DECEASED	MLL Rearrangement (53%), 6;11 translocations, ETV6 (44%), deleted chomosome 12 short arm	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	2	Male	MATCHED	FALSE	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	15	1.1	NA	Standard Chemotherapy	Yes	KDM6A (p.R1363* MAF:32%)|NRAS (p.G12D; MAF 15%)
aml_ohsu_2022	aml_ohsu_2022_2048	aml_ohsu_2022_2048_BA3080	29	32	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	5	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M0	Negative	FALSE	TRUE	FALSE	47,XY,t(3;4)(p21;q35),+4,t(6;11)(q27;q23),del(12)(p11.2p13)[16]/46,XY[4]	4	Standard Chemotherapy	6	FALSE	Negative	AML	36.0	1:DECEASED	MLL:  87% of cells had a 1r1g1f split signal pattern consistent with MLL rearrangement.	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	2	Male	UNMATCHED	FALSE	AML with minimal differentiation	Relapse|Post-Transplant|Post-Chemotherapy	Peripheral Blood	NA	1079	0.266666667	NA	Standard Chemotherapy	No	CBL (p.P494A; VAF 16%)|CREBBP (p.E1561fs*72; VAF 30%)|EP300 (p.V1926G; VAF 19%)|PTPN11 (p.G503A; VAF 33%)|TCF3 (p.K522Q; VAF 31%)
aml_ohsu_2022	aml_ohsu_2022_2049	aml_ohsu_2022_2049_BA2623	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	Azacitidine|Momelotinib	2	Hypomethylating/Low Dose Cytarabine|Experimental	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY,inv(16)(p13.1q22)[20]	-1	Standard Chemotherapy	3	FALSE	Negative	AML	6.180821917808219	1:DECEASED	NA	No	No	NA	No	No	No	No	Yes	Yes	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.2	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2050	aml_ohsu_2022_2050_BA2354	37	37	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide	4	Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	45,X,-Y,t(8;21)(q22;q22)[20]	0	Bone Marrow Transplant	10	FALSE	Negative	AML	44.31780821917808	0:LIVING	RUNX1T1/RUNX1:  94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.	No	No	NA	No	No	No	No	No	No	Asian	6	Refractory	NA	1	Male	MATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive	0	0.5	NA	Standard Chemotherapy	Yes	EZH2 (p.F445fs*3; MAF 30% )|KIT (p.N822K (exon 17); MAF 5% )|KIT (p.Y418_D419insFL (exon 8); MAF 29%)|TET2 (p.G1160E; MAF 49% )
aml_ohsu_2022	aml_ohsu_2022_2051	aml_ohsu_2022_2051_BA2380	40	40	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Negative	FALSE	FALSE	FALSE	47,XX,+8[11]/46,XX[10]	-1	Bone Marrow Transplant	2	FALSE	Negative	AML	82.32328767123288	0:LIVING	RUNX1T1 (8q21.3): 55% of cells had three signals for RUNX1T1 (8q21.3) consistent with trisomy 8, as seen on metaphase analysis	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	NA	0	0.1	NA	Standard Chemotherapy	No	ASXL1 (p.E1416G; MAF 52% )
aml_ohsu_2022	aml_ohsu_2022_2052	aml_ohsu_2022_2052_BA2272	12	12	0.538461538	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Cytarabine|Sorafenib|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide	4	Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	HISPANIC	M4	Positive	TRUE	FALSE	FALSE	47,XY,+8[19]/46,XY[1]	-1	Bone Marrow Transplant	2	FALSE	Negative	AML	62.630136986301366	0:LIVING	RUNX1T1 signal consistent with the trisomy 8 clone	No	No	NA	No	No	No	No	No	No	White	0	Refractory	NA	1	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	dimCD11b, dimCD13, CD14, dimCD33, CD64, variable CD123, HLA-DR CD13,dimCD33, dim variable CD34, CD117, CD123, HLA-DR	0	0.066666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (~16 amino acid insertion; MAF 11%)|FLT3-ITD (~8 amino acid insertion; MAF 20%)
aml_ohsu_2022	aml_ohsu_2022_2053	aml_ohsu_2022_2053_BA2673	70	70	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Cytarabine, Methotrexate	4	Consolidation|Induction|Supportive/Palliative Care	3	Standard Chemotherapy|Intrathecal|Targeted Therapy - Other	3	Quizartinib	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	164	Targeted Therapy - Other	5	FALSE	Positive	AML	16.799999999999997	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	CD13, CD33, dimCD45, CD56, partial CD117, MPO/positive	0	0.233333333	NA	Standard Chemotherapy	Yes	FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2053	aml_ohsu_2022_2053_BA2803	70	71	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Cytarabine, Methotrexate	4	Consolidation|Induction|Supportive/Palliative Care	3	Standard Chemotherapy|Intrathecal|Targeted Therapy - Other	3	Quizartinib	Supportive/Palliative Care	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	TRUE	FALSE	46,XX[20]	164	Targeted Therapy - Other	5	FALSE	Positive	AML	16.799999999999997	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, CD38, CD56, CD117, and MPO positive	337	0.2	NA	Standard Chemotherapy	No	FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2054	aml_ohsu_2022_2054_BA2095	69	69	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Negative	TRUE	FALSE	FALSE	45,XX,dic(12;18)(p11.2;p11.2),t(15;17)(q22;q21)[19]/46,XX[1]	-1	Standard Chemotherapy	NA	FALSE	Negative	AML	1.084931506849315	0:LIVING	PML/RARA fusion (91%)	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD2, CD13, CD33, CD34 (variable), CD56, CD58, CD64, CD117, CD123 and cytoplasmic MPO positive; HLA-DR negative	0	NA	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2055	aml_ohsu_2022_2055_BA2106	35	37	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M5	Negative	FALSE	TRUE	FALSE	46,XX[5]	53	Standard Chemotherapy	11	FALSE	Positive	AML	25.01917808219178	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	6	Complete Response	NA	2	Female	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR	1	0.666666667	NA	Standard Chemotherapy	Yes	FLT3-D835|IDH1|NPM1
aml_ohsu_2022	aml_ohsu_2022_2055	aml_ohsu_2022_2055_BA2939	35	37	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M5	Negative	FALSE	FALSE	FALSE	46,XX[5]	53	Standard Chemotherapy	NA	FALSE	Positive	AML	25.01917808219178	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	6	Complete Response	NA	2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy|Post-Transplant	Peripheral Blood	NA	160	NA	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2056	aml_ohsu_2022_2056_BA2292	69	70	1.222222222	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Rituximab	3	Induction|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other	2	Rituximab	Experimental	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M6a	Positive	FALSE	FALSE	TRUE	46,XY[18]	-1	Targeted Therapy - Other	12	FALSE	Negative	AML	14.926027397260274	0:LIVING	Normal	Yes	Yes	Squamous cell carcinoma	Yes	Yes	No	No	No	No	NA	-1	Unknown	NA	1	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy	Bone Marrow Aspirate	NA	55	0.633333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2057	aml_ohsu_2022_2057_BA2659	86	86	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	mono	1	Waves1+2	Yes	AG-221|Azacitidine|Hydroxyurea	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Experimental	3	Standard Chemotherapy|Targeted Therapy - Other	2	Hydroxyurea	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	47,XY,+8[20]	55	Standard Chemotherapy	10	FALSE	Negative	AML	19.594520547945205	1:DECEASED	(FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype.	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease	Bone Marrow Aspirate	dimCD7, CD13, dimCD14, dimCD20, CD33, CD34, CD117, CD123, dim HLA-DR and MPO positive	0	0.4	NA	NA	Yes	BCOR (p.S1139*; MAF 80%)|CEBPA (p.R343fs*79; MAF 40%)|DNMT3A (p.E285*; MAF 45%)|DNMT3A (p.G707fs*72; MAF 45%)|IDH2 (p.R140Q; MAF 40%)|SRSF2 (p.P95H; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2058	aml_ohsu_2022_2058_BA2054	49	49	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M5	Negative	TRUE	FALSE	FALSE	46,XX,del(17)(p11.2)[15]/46,XX[5]	-1	Bone Marrow Transplant	14	FALSE	Positive	AML	38.400000000000006	0:LIVING	consistent with karyotype (68% del 17p13)	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Most of the atypical cells (data not shown) are myeloid blasts that express CD117, partial CD7 (about 30% positive), CD13, CD33, HLA-DR, weak CD4, and partial CD15 (about 50% positive), but do not express CD34, CD14(MO2), or CD64. (The monocytic cells (pe	0	0.733333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2059	aml_ohsu_2022_2059_BA2045	71	72	0.923076923	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XY[20]	9	Supportive/Palliative Care	5	FALSE	Negative	AML	10.158904109589042	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	Unknown	6	Refractory	RUNX1 (p.Q283*; 51.5%)	3	Male	UNMATCHED	FALSE	AML without maturation	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	dim/partial CD7, CD13, CD33, CD34, variable CD38, CD58,variable CD117, CD123, and HLA-DR positive	297	0.266666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2059	aml_ohsu_2022_2059_BA2831	71	71	0.587301587	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XY[20]	9	Supportive/Palliative Care	6	FALSE	Negative	AML	10.158904109589042	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	Unknown	6	Refractory	RUNX1 (p.Q283*; 37.0%)|RUNX1 (p.M236Nfs*25; 20.0%)	3	Male	UNMATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD34, CD38, CD117, CD123, HLA-DR	0	0.3	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2059	aml_ohsu_2022_2059_BA2847	71	71	0.886792453	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XY[20]	9	Supportive/Palliative Care	6	FALSE	Negative	AML	10.158904109589042	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	Unknown	6	Refractory	RUNX1 (p.Q283*; 40.7%)	3	Male	UNMATCHED	FALSE	AML without maturation	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	dim/partial CD7, CD13, CD34, CD38, CD58, CD117, CD123,and HLA-DR positive	262	0.3	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2060	aml_ohsu_2022_2060_BA2322	35	35	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XX,inv(16)(p13.3q22)[21]	112	Standard Chemotherapy	8	FALSE	Negative	AML	63.68219178082191	0:LIVING	CBFB: 83/100 cells (83%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and consistent with the inverted  chromosome 16 in the metaphase karyotype.	No	No	NA	No	No	No	No	No	No	White	10	Complete Response	NA	1	Female	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Partial CD2, CD33, CD34, CD38, CD117, CD123, partial HLA-DR, dim MPO and partial TdT positive.	0	0.4	NA	Standard Chemotherapy	Yes	NRAS (p.Q61P; MAF 15% )
aml_ohsu_2022	aml_ohsu_2022_2061	aml_ohsu_2022_2061_BA2762	22	22	0.666666667	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib	3	Allogeneic - Sibling|Induction|Experimental	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Fludarabine, Melphalan	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	9	FALSE	Positive	AML	19.824657534246576	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	White	39	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(partial dim +), CD7(variably +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +).	0	0.3	NA	Standard Chemotherapy	Yes	FLT3-ITD (K602_W603INSCEYDLK; MAF 33.0%)|NPM1 (K292FS*6+; MFA 35.0%)|TCL1A (E54FS*28; MAF 44.0%)|WT1 (A382FS*4; MAF 40.0%)
aml_ohsu_2022	aml_ohsu_2022_2062	aml_ohsu_2022_2062_BA2078	64	65	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	FLX925|7+3 (Cytarabine, Idarubicin)	2	Induction|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other	2	FLX925	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,t(11;19)(q23;p13.1)[16]/46,sl,add(1)(p34)[2]/46,XX[2]	-1	Targeted Therapy - Other	17	FALSE	Negative	AML	12.657534246575342	1:DECEASED	MLL Rearrangment	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	Negative (CD10, CD20, CD22, Cyt CD79a, Cyt CD3, CD7, CD16, CD56, CD14, CD15, CD64, CD117, HLA-DR, TdT) | Positive (CD38, CD11b, CD13, CD33, CD34, Dim CD45, MPO,)	0	0.866666667	NA	Standard Chemotherapy	Yes	GATA2 (c.1145G>A; p.R382Q)|TET2 (c.5162T>G; p.L1721W (SNP))
aml_ohsu_2022	aml_ohsu_2022_2064	aml_ohsu_2022_2064_BA2589	42	42	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|AG-221|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	3	Salvage|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Other	2	AG-221	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Other	13	FALSE	Negative	AML	14.728767123287671	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Female	MATCHED	FALSE	Acute myelomonocytic leukaemia	Post-Chemotherapy|Residual Disease	Peripheral Blood	positive for CD13, CD34, CD38, dim CD45, CD117, HLA-DR, and MPO	0	0.666666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.G652S; MAF 41.3%)|ASXL1 (p.S1231F; MAF 50.4%)|DNMT3A (p.S307fs; MAF 45.6%)|IDH1 (c.C315T; p.G105G; MAF 46.6%)|IDH2 (p.R140Q; MAF 43.8%)|SRSF2 (p.P95H; MAF 42.2%)
aml_ohsu_2022	aml_ohsu_2022_2065	aml_ohsu_2022_2065_BA2020	51	51	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NA	M4	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	12	FALSE	Positive	AML	25.05205479452055	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, partial CD15, CD33, CD117,  myeloperoxidase, and partial HLA-DR (atypical cells with dim CD45 - 45% of leukocytes) | CD13,  bright CD33, and bright CD64 (Monocytic (19% of leukocytes)) | CD13, CD33, and CD64, with  a left shift (increased percentage	0	0.533333333	NA	Standard Chemotherapy	Yes	FLT3-ITD (c.1775_1816dup; MAF 3%)|IDH2 (R140Q; MAF 42.3%)|NPM1 (c.860_863dup; MAF 14.5%)|PTPN11 (c.1507G>A; MAF 4%)|PTPN11 (c.1508G>A; MAF 15.4%)
aml_ohsu_2022	aml_ohsu_2022_2066	aml_ohsu_2022_2066_BA2066	62	62	0	ASXL1 (p.R693*; 19.8%)	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Child	4	Standard Chemotherapy|Bone Marrow Transplant|Other	3	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]	-1	Bone Marrow Transplant	4	FALSE	Negative	AML	10.421917808219177	1:DECEASED	MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR	0	0.233333333	NA	Standard Chemotherapy	Yes	ASXL1 (p.R693*; MAF 19%)|BCOR (p.S209L (possibly a benign germline polymorphism); MAF 48%)|FLT3 (p.A680V; MAF 17%)|FLT3 (p.I836delI (in-frame deletion of one amino acid in TK domain); MAF 11%)|NRAS (p.G12S; MAF 19%)
aml_ohsu_2022	aml_ohsu_2022_2067	aml_ohsu_2022_2067_BA2482	10	10	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Both	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	1	Induction|Intensification|Re-induction	3	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Intensification	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XX,inv(16)(p13q22)[17]/46,XX[3]	29	Standard Chemotherapy	2	FALSE	Negative	AML	80.64657534246575	0:LIVING	CBFB rearrangement and inverted 16 (85%)	No	No	NA	No	No	No	No	No	No	White	10	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, dim/partial HLA-DR, and MPO positive	0	0.1	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2068	aml_ohsu_2022_2068_BA2692	58	58	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide|Fludarabine, Cytarabine	7	Consolidation|Salvage|Unknown|Induction|Maintenance|Re-induction|Allogeneic - Matched Unrelated Donor	7	DLI|Standard Chemotherapy|Bone Marrow Transplant	3	Azacitidine	Unknown	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	46,XX,inv(16)(p13.1q22)[16]/46,XX[4]	-1	Standard Chemotherapy	8	FALSE	Negative	AML	67.16712328767125	0:LIVING	CBFB: 69/100 cells (69%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement and consistent with the inverted chromosome 16 in the metaphase karyotype.	Yes	Yes	Breast Cancer	Yes	No	No	No	No	No	White	7	Complete Response	NA	1	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, variable CD15, CD33, CD34, variable CD64, CD117, dim CD123, dim HLA-DR, MPO and subset TdT-positive	0	0.466666667	NA	Standard Chemotherapy	Yes	KDM6A (p.I598V; MAF 50%)|KRAS (p.G12D; MAF 4%)|NRAS (p.G12S; MAF 6%)
aml_ohsu_2022	aml_ohsu_2022_2069	aml_ohsu_2022_2069_BA2932	29	29	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy	1	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	IntermediateOrAdverse	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	12	FALSE	Negative	AML	78.34520547945205	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	24	Complete Response	NA	1	Female	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD2, dim CD7, CD13, dim CD19, dim CD20,      CD33, partial CD34, variable CD38, dim CD64, CD117, CD123, and HLA-DR      positive.	0	0.4	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 50%)|MLL (PTD)
aml_ohsu_2022	aml_ohsu_2022_2070	aml_ohsu_2022_2070_BA2258	31	36	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide	9	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction	7	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	TRUE	TRUE	46,XX[20]	24	Targeted Therapy - Kinase Inhibitor(s)	2	FALSE	Negative	AML	87.4849315068493	1:DECEASED	nuc ish(DXZ1x2)[200]	No	No	NA	Yes	Yes	No	No	No	No	NA	-1	Complete Response	NA	2	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Post-Transplant|Relapse	Bone Marrow Aspirate	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(partial +), CD34(+), CD36 (-), CD38(variably +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(-) MPO(-), and TdT(-)	1020	0.133333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2070	aml_ohsu_2022_2070_BA2592	31	38	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide	9	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction	7	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XX[20]	24	Targeted Therapy - Kinase Inhibitor(s)	5	FALSE	Negative	AML	87.4849315068493	1:DECEASED	nuc ish(DXZ1x2)[200]	No	No	NA	Yes	Yes	No	No	No	No	NA	-1	Complete Response	NA	2	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Post-Transplant|Residual Disease	Bone Marrow Aspirate	NA	1496	0.3	NA	Standard Chemotherapy	No	BCOR (S259fs*10; MAF 15%)|CCND2 (P281R; MAF 19%)|FLT3-D835 (D835E; MAF 13%)|GATA2 (N297S; MAF 18%)|IKZF1 (Q44*; MAF 14%)|MLL2 (Y2907*; MAF 7%)|PTPN11 (E76V; MAF 17%)|PTPN11 (V45L; MAF 13%)|SETBP1 (H1100R; MAF 51%)|SF3B1 (K700E; MAF 18%)
aml_ohsu_2022	aml_ohsu_2022_2071	aml_ohsu_2022_2071_BA2007	71	71	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Decitabine, Midostaurin	1	Induction	1	Standard Chemotherapy	1	Decitabine, Midostaurin	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NA	NA	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	8	FALSE	Positive	AML	4.175342465753425	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34+, EXPRESSING CD13, CD33,MPO, AND HLA-DR, WITH ABERRANT COEXPRESSION OF CD15 AND CD117, AND PARTIAL LOSS OF CD38	0	0.4	NA	Standard Chemotherapy	Yes	FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2072	aml_ohsu_2022_2072_BA2355	83	83	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	No	AG-221	1	Experimental	1	Targeted Therapy - Other	1	AG-221	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20]	-1	Targeted Therapy - Other	NA	FALSE	Negative	AML	3.682191780821918	0:LIVING	FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells.	Yes	No	Squamous cell carcinoma|Lung Cancer	No	No	No	No	No	No	NA	NA	NA	NA	2	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for CD34, CD117, HLA-DR, and CD13, with aberrant loss of CD33, and with a subset of the blasts showing aberrant co-expression of CD34 and myeloperoxidase	0	NA	NA	NA	Yes	IDH1 (p.G105G; MAF 50%)|IDH2 (p.R140Q; MAF 37.8%)
aml_ohsu_2022	aml_ohsu_2022_2072	aml_ohsu_2022_2072_BA2642	83	83	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	No	AG-221	1	Experimental	1	Targeted Therapy - Other	1	AG-221	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20]	-1	Targeted Therapy - Other	13	FALSE	Negative	AML	3.682191780821918	0:LIVING	FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells.	Yes	No	Squamous cell carcinoma|Lung Cancer	No	No	No	No	No	No	NA	NA	NA	NA	2	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	positive for CD34, CD117, HLA-DR, and CD13, with aberrant loss of CD33, and with a subset of the blasts showing aberrant co-expression of CD34 and myeloperoxidase	0	0.566666667	NA	NA	Yes	IDH1 (p.G105G; MAF 50%)|IDH2 (p.R140Q; MAF 37.8%)
aml_ohsu_2022	aml_ohsu_2022_2073	aml_ohsu_2022_2073_BA2510	65	65	0	ASXL1 (p.W960*; 48.8%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Venetoclax (ABT-199), Azacitidine|Fludarabine, Cyclophosphamide, TBI	3	Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	48,XY,+8,der(11)t(11;?)(q23;?),+21[19]/46,XY[1]	-1	Bone Marrow Transplant	3	FALSE	Negative	AML	6.904109589041095	1:DECEASED	Gain of 8q22 and 21q22 (88%)	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	positive for CD11b, CD13, CD33, CD38, dim CD45, dim CD56, CD64, and HLA-DR	0	0.1	NA	NA	Yes	ASXL1 (p.W960X; MAF 29.4%)|PTPN11 (p.E76V; MAF 29.5%)
aml_ohsu_2022	aml_ohsu_2022_2074	aml_ohsu_2022_2074_BA2256	25	26	1	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Cladribine, Cytarabine, Idarubicin	4	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	Azacitidine, Sorafenib	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	46,XX,t(7;12)(q22;p13)[12]/46,XX,t(7;17)(p10;q10),-9,+mar[7]/46,XX[1]	67	Standard Chemotherapy	4	FALSE	Negative	AML	10.652054794520549	1:DECEASED	This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells.	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	These are positive for CD34, CD117, HLADR, CD33 but negative for CD13 and CD11b. TdT and CD79a are partially expressed. (Bone Marrow Immunophenotyping)	49	0.1	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2075	aml_ohsu_2022_2075_BA2023	55	55	0	ASXL1 (p.G646Wfs*12; 27.3%)	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	47,XY,+8[16]/46,XY[4]	-1	Bone Marrow Transplant	9	FALSE	Negative	AML	12.69041095890411	1:DECEASED	Trisomy 8 (82%)	No	No	NA	No	No	No	No	No	No	White	5	Refractory	NA	1	Male	MATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD13, CD15,  CD33, CD56, CD38, CD58, CD64, dimCD123, HLA-DR and MPO positive	0	0.466666667	NA	Standard Chemotherapy	Yes	NRAS (p.G12R, MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2076	aml_ohsu_2022_2076_BA2886	66	66	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	Azacitidine	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	1013	Standard Chemotherapy	12	FALSE	Negative	AML	48.85479452054794	0:LIVING	Normal	Yes	No	Uterine Cancer	No	No	No	No	No	No	White	20	Refractory	NA	1	Female	MATCHED	FALSE	Myeloid sarcoma	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD58, CD117 and  HLA-DR	0	0.433333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2077	aml_ohsu_2022_2077_BA2344	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone	5	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,del(7)(q22q36)[20]	-1	Supportive/Palliative Care	23	FALSE	Negative	AML	9.205479452054794	1:DECEASED	ABNORMAL FISH RESULT 7cen (D7Z1), 7q31 (D7S486): deletion present	Yes	No	Follicular lymphoma	No	No	No	No	No	No	NA	-1	Refractory	NA	2	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	CD7, CD13, weak CD33, CD34, CD117, and HLA-DR	0	1.366666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 4%)|WT1 (c.1138delinsAA; MAF 31.2%)
aml_ohsu_2022	aml_ohsu_2022_2077	aml_ohsu_2022_2077_BA2534	71	72	0.315789474	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone	5	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	46,XX,del(7)(q22q36)[18]/46,sl,t(1;10)(p13;q24)[2]	-1	Supportive/Palliative Care	25	FALSE	Negative	AML	9.205479452054794	1:DECEASED	- 3 copies of the MECOM locus at 3q26.2, suggestive of a  rearrangement or gain of this locus, in 156/200 (78.0  percent) cells scored.  - deletion 7q31 involving the D7S486 locus in 162/200 (81.0  percent) cells scored.	Yes	No	Follicular lymphoma	No	No	No	No	No	No	NA	-1	Refractory	NA	2	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	NA	249	1.366666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2078	aml_ohsu_2022_2078_BA2319	66	67	NA	NA	Myeloproliferative Neoplasms	Myeloproliferative Neoplasms	Alive	NA	6	Waves1+2	Yes	Hydroxyurea	1	Unknown	1	Standard Chemotherapy	1	Hydroxyurea	Unknown	NA	Myeloproliferative Neoplasms	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[17]	263	Standard Chemotherapy	11	FALSE	Negative	MPN	6.213698630136986	0:LIVING	This test has not detected clonal abnormalities in the cells analyzed.	No	No	NA	No	No	No	No	Yes	No	White	NA	NA	NA	2	Male	MATCHED	TRUE	Primary myelofibrosis	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	These are positive for CD34, CD117, HLADR, CD33 and CD13. (Bone Marrow Immunophenotyping)	119	0.466666667	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2078	aml_ohsu_2022_2078_BA2838	66	67	NA	NA	Myeloproliferative Neoplasms	Myeloproliferative Neoplasms	Alive	NA	6	Waves1+2	Yes	Hydroxyurea	1	Unknown	1	Standard Chemotherapy	1	Hydroxyurea	Unknown	NA	Myeloproliferative Neoplasms	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[17]	263	Standard Chemotherapy	9	FALSE	Negative	MPN	6.213698630136986	0:LIVING	Normal	No	No	NA	No	No	No	No	Yes	No	White	NA	NA	NA	2	Male	MATCHED	TRUE	Primary myelofibrosis	Residual Disease	Bone Marrow Aspirate	Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. No BCR-ABL1 transcripts are detected. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alterations are detected in the ASXL1, BRAF, EZ	0	0.3	NA	NA	No	ASXL1 (p.A640Dfs*20, MAF 40%)|BRAF (p.G469A, MAF 7%)|EZH2 (MAF 43%)|JAK2 (p.V617F, MAF 46%)|NRAS (p.G12S, MAF 18%)|SETBP1 (p.D868N, MAF 15%)|SETBP1 (p.G870S, MAF 11%)
aml_ohsu_2022	aml_ohsu_2022_2079	aml_ohsu_2022_2079_BA2735	62	64	5.666666667	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	45,XY,der(12;16)(q10;p10)[2]/46,XY[18]	141	Targeted Therapy - Kinase Inhibitor(s)	43	FALSE	Positive	AML	18.673972602739727	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200]	No	No	NA	No	No	No	No	No	No	NA	24	Complete Response	NA	2	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Post-Transplant|Residual Disease	Peripheral Blood	NA	254	2.133333333	NA	Standard Chemotherapy	No	CCND3 (P203S; MAF unlisted)|CHEK2 (T367fs*15; MAF unlisted)|DNMT3A (R882H; MAF unlisted)|FLT3-ITD|NPM1 (W288fs*10+; MAF unlisted)
aml_ohsu_2022	aml_ohsu_2022_2079	aml_ohsu_2022_2079_BA3029	62	63	10.11111111	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	46,XY	141	Targeted Therapy - Kinase Inhibitor(s)	18	FALSE	Positive	AML	18.673972602739727	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	24	Complete Response	NA	2	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD2(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(variably +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD45(moderately +), CD56(-), CD64 (partial +), CD117(variably +), HLA-DR(-), MPO(+), TdT(-).	0	0.966666667	NA	Standard Chemotherapy	Yes	CCND3 (Foundation, P203S; MAF 8%)|CHEK2 (Foundation; T367fs*15; MAF 9%)|DNMT3A (Foundation, R882H; MAF 9%)|FLT3 (Foundation, Y591_V592INSVDFREYEYDLKWEFPRENLEFD; MAF 13%)|NPM1 (Foundation; W288fs*10+;MAF 8%)
aml_ohsu_2022	aml_ohsu_2022_2080	aml_ohsu_2022_2080_BA2034	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)|Azacitidine	2	Induction|Maintenance	2	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Negative	FALSE	FALSE	TRUE	46,XY[19]	7	Standard Chemotherapy	5	FALSE	Negative	AML	4.010958904109589	1:DECEASED	normal	No	No	NA	Yes	Yes	No	No	No	No	White	7	Refractory	NA	2	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	72	0.233333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2080	aml_ohsu_2022_2080_BA2089	68	68	0	ASXL1 (p.G645Wfs*12; 60.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)|Azacitidine	2	Induction|Maintenance	2	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	FALSE	FALSE	TRUE	46,XY[20]	7	Standard Chemotherapy	5	FALSE	Negative	AML	4.010958904109589	1:DECEASED	normal	No	No	NA	Yes	Yes	No	No	No	No	White	7	Refractory	NA	2	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Leukapheresis	NA	0	0.266666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.G645fs*12; MAF 52%)|IDH1 (p.R132L; MAF 47%)|KRAS (p.G12A; MAF 36%)|MLL (Partial tandem duplication )|SRSF2 (p.P95H; MAF 49%)
aml_ohsu_2022	aml_ohsu_2022_2081	aml_ohsu_2022_2081_BA2449	7	7	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves1+2	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	1	Induction|Re-induction	2	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XX,t(8;21)(q22;q22)[19]/46,XX[1]	-1	Standard Chemotherapy	NA	FALSE	Negative	AML	5.1945205479452055	1:DECEASED	91.5% AML/ETO fusion, t(8;21)	No	No	NA	No	No	No	No	No	No	White	9	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD56, CD71, CD117, HLA-DR, MPO-positive	0	NA	NA	Standard Chemotherapy	Yes	KIT (D816V; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2082	aml_ohsu_2022_2082_BA2161	54	54	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)|Azacitidine	2	Salvage|Induction	2	Standard Chemotherapy|Supportive/Palliative Care	2	Azacitidine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	FALSE	FALSE	FALSE	46,XY,add(5)(q23),der(11)t(11;20)(p11.2;p11.2),der(17)t(5;17)(q31;p12),-20,del(21)(q21)+mar[cp21]	196	Supportive/Palliative Care	10	FALSE	Negative	AML	10.421917808219177	1:DECEASED	21q deletion (35.5%) | Three MLL signals (32%)	Yes	No	Other malignant neoplasm without specification of site	No	No	No	No	No	No	White	5	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD117, MPO and HLA-DR	0	0.566666667	TP53 (p.T312Nfs*25; 28.0%)	Standard Chemotherapy	Yes	TP53 (p.T312fs*25 (one nucleotide insertion); MAF 30%)
aml_ohsu_2022	aml_ohsu_2022_2083	aml_ohsu_2022_2083_BA2778	60	60	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|Ruxolitinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea	6	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Ruxolitinib	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX[20]	496	Targeted Therapy - Kinase Inhibitor(s)	5	FALSE	Positive	AML	59.21095890410959	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	18	Refractory	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (CD11b, variable CD13, CD14, CD33, dim CD56, bright CD64, and HLA-DR+)	0	0.166666667	NA	Standard Chemotherapy	Yes	FBXW7 (p.T15_G16insP; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G12S; MAF 40%)|TET2 (p.H437fs*7; MAF 42%)
aml_ohsu_2022	aml_ohsu_2022_2085	aml_ohsu_2022_2085_BA2040	50	51	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Both	Yes	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	182	Standard Chemotherapy	15	FALSE	Negative	AML	13.93972602739726	0:LIVING	RUNX1/RUNX1T1 fusion negative (Cytogenetics)	No	No	NA	No	No	No	No	No	No	Black	20	Refractory	NA	4	Male	MATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Post-Chemotherapy	Bone Marrow Aspirate	Positive for CD34, CD117, HLADR, CD13 AND CD33.  (Bone Marrow Immunphenotyping)	249	0.666666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2085	aml_ohsu_2022_2085_BA2306	50	50	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,t(8;21)(q22;q22)[20]	182	Standard Chemotherapy	NA	FALSE	Negative	AML	13.93972602739726	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	Black	20	Refractory	NA	4	Male	UNMATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	NA	NA	Standard Chemotherapy	Yes	ASXL1 (p.P581R, MAF 46%)|PDGFRB (p.D111N, MAF 52%)|SMC1A (p.R586Q, MAF 96%)
aml_ohsu_2022	aml_ohsu_2022_2085	aml_ohsu_2022_2085_BA2842	50	50	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY,t(8;21)(q22;q22)[20]	182	Standard Chemotherapy	2	FALSE	Negative	AML	13.93972602739726	0:LIVING	RUNX1/RUNX1T1 fusion positive in 6.5% of cells	No	No	NA	No	No	No	No	No	No	Black	20	Refractory	NA	4	Male	MATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Residual Disease	Peripheral Blood	NA	21	0.066666667	NA	Standard Chemotherapy	No	ASXL1 (p.P581R, MAF 46%)|PDGFRB (p.D111N, MAF 52%)|SMC1A (p.R586Q, MAF 96%)
aml_ohsu_2022	aml_ohsu_2022_2085	aml_ohsu_2022_2085_BA2855	50	50	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	182	Standard Chemotherapy	10	FALSE	Negative	AML	13.93972602739726	0:LIVING	RUNX1/RUNX1T1 fusion negative	No	No	NA	No	No	No	No	No	No	Black	20	Refractory	NA	4	Male	MATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Post-Chemotherapy	Bone Marrow Aspirate	No morphological evidence of acute leukemia (Bone Marrow Immunophenotyping)	73	0.466666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2086	aml_ohsu_2022_2086_BA2971	57	57	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Both	Yes	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	13	Bone Marrow Transplant	6	FALSE	Negative	AML	10.093150684931507	0:LIVING	NA	No	No	NA	No	No	No	No	Yes	Yes	White	7	Complete Response	RUNX1 (p.D198N; 47.6%)|RUNX1 (p.P113L; 42.7%)	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	THESE ARE POSITIVE FOR CD34, CD117, HLADR, CD13, AND CD33. (Bone Marrow Immunophenotyping)	0	0.333333333	NA	Standard Chemotherapy	No	DNMT3A (c.2644C>T; p.R882C MAF 47%)|JAK2 (c.1849G>T; p.V617F MAF 91%)|RUNX1 (c.338C>T; p.P113L  MAF 42% c.592G>A; p.D198N MAF 46%)|SETBP1 (c.883G>A; p.V1295M MAF 47%)|SRSF2 (c.284C>A; p.P95H MAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2087	aml_ohsu_2022_2087_BA2858	70	73	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Maintenance	2	Standard Chemotherapy	1	Azacitidine	Maintenance	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY[19]	-1	Standard Chemotherapy	3	FALSE	Negative	AML	38.3013698630137	1:DECEASED	Normal	No	No	NA	Yes	Yes	No	No	No	No	White	6	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy	Bone Marrow Aspirate	NA	93	0.166666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2088	aml_ohsu_2022_2088_BA2113	63	63	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2]	9	Standard Chemotherapy	11	FALSE	Negative	AML	0.821917808219178	1:DECEASED	EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUN	No	No	NA	No	No	No	No	No	No	White	9	Unknown	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, dimCD33, CD34, CD38, CD58, partial CD64, CD117, CD123, and HLA-DR positive.	0	0.6	TP53 (p.R248Q; 53.3%)	Standard Chemotherapy	Yes	TP53 (p.R248Q; MAF 56%)|U2AF1 (p.Q157P; MAF 41%)
aml_ohsu_2022	aml_ohsu_2022_2089	aml_ohsu_2022_2089_BA2330	69	70	0	ASXL1 (p.G645Vfs*58; 15.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Lenalidomide|Azacitidine	3	Unknown|Induction	2	Standard Chemotherapy|Unknown	2	7+3 (Cytarabine, Idarubicin)	Induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	47,XX,del(5)(q22q35),+8[20]	8	Standard Chemotherapy	16	FALSE	Negative	AML	11.30958904109589	1:DECEASED	5q deletion (78%) | Trisomy 8 (80%)	Yes	No	Breast Cancer	No	No	No	No	No	No	White	75	Unknown	NA	1	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD13, partial CD33, CD34, CD38, dimCD45, CD58, partial CD64, CD117, HLA-DR, and MPO positive.	0	0.9	TP53 (p.I251M; 29.0%)|TP53 (p.R249M; 18.6%)	Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 37%)|EZH2 (p.K400del; MAF 48%)|IDH1 (p.R132C; MAF 37%)|TP53 (p.I251M; MAF 34%)|TP53 (p.R249M; MAF 37%)
aml_ohsu_2022	aml_ohsu_2022_2090	aml_ohsu_2022_2090_BA2911	24	24	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	AG-120|ATRA (Tretinoin)|HiDAC|3+7 (Cytarabine, Daunorubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|5+2 (Ara-C, Daunorubicin)	6	Consolidation|Salvage|Induction|Experimental|Re-induction	5	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	3	AG-120	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	NA	Positive	FALSE	FALSE	FALSE	NA	77	Targeted Therapy - Kinase Inhibitor(s)	3	FALSE	Positive	AML	28.306849315068497	1:DECEASED	normal	Yes	No	Hodgkin Lymphoma	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Leukapheresis	CD13, CD33, CD38, CD58, CD117 and CD123 positive.	0	0.1	NA	Standard Chemotherapy	Yes	FLT3 (p.V592G; MAF 6%)|FLT3-ITD ((57 bp in-frame insertion); MAF 3% )|IDH1 (p.W288fs*12; MAF 50%)|NPM1 (p.W288fs*12; MAF 50% )
aml_ohsu_2022	aml_ohsu_2022_2091	aml_ohsu_2022_2091_BA2684	2	5	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Cyclophosphamide, Fludarabine, TBI|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|COG-AAML07P1 	5	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	UNKNOWN	M5	Negative	FALSE	FALSE	FALSE	46,X,del(X)(q24),del(3)(q23q27),t(4;7)(q12;p15),add(5)(p13),+6,del(6)(q13q23),+8,del(8)(q22),-9,add(9)(q34.1),t(10;11)(p12;q23)inv(11)(q13q23),-20[cp12]/46,XX[8]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	127.1013698630137	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	153	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Transplant|Post-Chemotherapy	Peripheral Blood	NA	0	0.033333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2094	aml_ohsu_2022_2094_BA2728	58	58	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Azacitidine|SWOG S0919 (Ida/Ara+Pravastatin) |Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Maintenance	3	Standard Chemotherapy|Bone Marrow Transplant	2	Azacitidine	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	46,XX,t(3;3)(q21;q26)[20]	102	Standard Chemotherapy	12	FALSE	Negative	AML	62.82739726027397	0:LIVING	98/100 (98%) interphase cells scored had a 1 red/ 1 green/ 2 yellow signal pattern, interphase cells scored had a 1 red/ 1 green/ 2 yellow signal pattern, consistent with RPN1/MECOM fusion. Two metaphases showed a fusion signal on one derivative 3 and red	Yes	No	Basal Cell Carcinoma|Squamous cell carcinoma	Yes	No	No	No	No	No	White	70	Complete Response	NA	1	Female	MATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	variable CD11b, CD13, dim CD33, CD34, CD58, CD117, CD123	0	0.7	NA	Standard Chemotherapy	Yes	NRAS (p.G12D; MAF 47%)|SF3B1 (p.K666N; MAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2095	aml_ohsu_2022_2095_BA2614	55	55	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	17	FALSE	Positive	AML	12.591780821917808	0:LIVING	Normal	Yes	No	Multiple Sclerosis	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Increased atypical CD117pos, partial CD34+, partial HLA-DR pos myeloblasts (CD7+), representing about 55% of leukocytes, consistent with AML.	0	0.8	NA	Standard Chemotherapy	Yes	CEBPA (p.Ala40fs; MAF 20.3%)|CEBPA (p.Lys304Thr; MAF 26.5%)|DNMT3A (p.Arg882His; MAF 39.1%)|NPM1 (p.Trp288fs; MAF 9.6%)|TET2 (p.Gln1501*; MAF 39%)
aml_ohsu_2022	aml_ohsu_2022_2097	aml_ohsu_2022_2097_BA2649	65	65	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves1+2	Yes	ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin)	2	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3] (unusual PML-RARA translocation)	3	Standard Chemotherapy	16	FALSE	Negative	AML	0.23013698630136986	1:DECEASED	76% Unusual t(15;17), with the fusion signal on the derivative chromosome 15	No	No	NA	No	No	No	No	No	No	White	5	Unknown	NA	1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive	0	0.866666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 40%)|SF3B1 (p.K66N; MAF 40%)|WT1 (rs16754; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2098	aml_ohsu_2022_2098_BA2164	1	3	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide, Thymoglobulin|Etoposide|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Doxorubicin	5	Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance	4	Standard Chemotherapy|Bone Marrow Transplant	2	Etoposide	Maintenance	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	M7	Negative	FALSE	TRUE	FALSE	48,XX,+14,der(14)t(14;17)(q32;q21),+21[10]/46,XY[10]	-1	Standard Chemotherapy	2	FALSE	Negative	AML	25.676712328767124	1:DECEASED	37% trisomy 21, 38.5% XX, 61.5% XY (donor)	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	Acute megakaryoblastic leukaemia	Relapse|Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	partial CD7, dim/partial CD33, CD34, CD38, CD56, CD58,  and CD117 positive	0	0.1	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2099	aml_ohsu_2022_2099_BA2496	70	70	0.111111111	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Dasatinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	4	Salvage|Experimental|Maintenance|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	Initial Diagnosis	Myelodysplastic/Myeloproliferative Neoplasms	MissingMutations	NON-HISPANIC	M4	Positive	FALSE	FALSE	TRUE	46,XY[20]	4	Standard Chemotherapy	NA	FALSE	Negative	AML	10.224657534246576	1:DECEASED	Normal	No	No	NA	No	No	Yes	Yes	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	Chronic myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive	34	NA	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2100	aml_ohsu_2022_2100_BA2705	39	40	0.923076923	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	Unknown|GCLAC (GCSF, Clofarabine & Cytarabine)	2	Induction|Re-induction	2	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	46,XY[15]	-1	Standard Chemotherapy	6	FALSE	Positive	AML	2.695890410958904	0:LIVING	Negative	No	No	NA	No	No	No	No	No	No	White	-1	UNKNOWN	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	Positive (CD7, CD11b, CD13, CD33, dim CD34, CD38, dim CD45, CD117, HLA-DR)	0	0.133333333	NA	Standard Chemotherapy	Yes	FLT3-ITD (ITD (39bp ins); VAF 39%)|NPM1 (c.859_860insTCTG; p.W288fs)
aml_ohsu_2022	aml_ohsu_2022_2101	aml_ohsu_2022_2101_BA2804	87	87	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	mono	5	Waves1+2	Yes	AG-120|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other	2	AG-120	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M5	Negative	FALSE	FALSE	TRUE	47,XY,+21[3]/46,XY[9]	-1	Targeted Therapy - Other	6	FALSE	Negative	AML	8.186301369863013	1:DECEASED	9.5% gain 21q22	No	No	NA	No	No	No	No	Yes	Yes	NA	NA	NA	NA	1	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	A distinct blastic population, expressing CD7, CD13, CD15, CD33, CD34, CD38, dim CD45, CD64, MPO, and HLA-DR | A large monocytic population, positive for CD11b, CD13, CD14, CD15, CD33, CD38, CD45, CD64, HLA-DR and MPO	0	0.233333333	NA	NA	Yes	ASXL1 (p.G642fs; MAF 31.6%)|CEBPA (p.A66fs; MAF 37.3%)|CEBPA (p.Q162fs; MAF 50.3%)|IDH1 (p.R132C; MAF 48.7%)|TP53 (p.N107D; MAF 97.6%)
aml_ohsu_2022	aml_ohsu_2022_2102	aml_ohsu_2022_2102_BA2498	78	79	0	ASXL1 (p.L823*; 38.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	AG-221|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other	2	AG-221	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XX[20]	-1	Targeted Therapy - Other	17	FALSE	Negative	AML	31.89041095890411	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	Yes	Yes	No	No	No	No	NA	NA	NA	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD2 (-), CD4(partial dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD33(variable to bright +), CD34(+), CD36(-), CD38(bright +), CD45(moderately +), CD56(-), CD64(-), CD117(bright +), HLA-DR(variable +), MPO(partial+) and TdT(-).	0	0.966666667	NA	NA	Yes	ASXL1 (L823fs*1; MAF 47%)|DNMT3A (F609fs*3; MAF 42%)|DNMT3A (F909V; MAF 46%)|IDH2 (R172K; MAF 45%)|ROS1 (R560C; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2103	aml_ohsu_2022_2103_BA2682	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	4	Waves1+2	Yes	Decitabine, Midostaurin	1	Induction	1	Standard Chemotherapy	1	Decitabine, Midostaurin	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M4	Negative	TRUE	FALSE	FALSE	46,XX,t(5;16)(q31;p13)[3]/46,XX[14]	206	Standard Chemotherapy	28	FALSE	Negative	AML	10.520547945205479	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	206	Refractory	NA	1	Female	MATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	Partial CD34, cd38, cd117, cd15, cd33, partial cd13, partial cd64, cd11c, dim partial cd4, hla-dr and mpo	0	1.566666667	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2104	aml_ohsu_2022_2104_BA2313	45	45	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance	4	Standard Chemotherapy|Supportive/Palliative Care	2	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	HISPANIC	M2	Negative	FALSE	FALSE	TRUE	47,XY,der(7)t(1;7)(q10;p10),+8[20]	4	Standard Chemotherapy	17	FALSE	Negative	AML	8.515068493150684	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	White	6	Refractory	RUNX1 (p.S308Qfs*292; 40.7%)	3	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, variable CD33, CD34, CD38, CD117, CD123, HLA-DR positive	0	0.933333333	NA	Standard Chemotherapy	Yes	CBL (Intron 8, 3' splice site mutation (at invariant AG splice acceptor site); MAF 86%)|EZH2 (p.S538L; MAF 85% )|GATA2 (p.K389delinTFFM; MAF 46% )|RUNX1 (p.S308fs*174; MAF 46% )
aml_ohsu_2022	aml_ohsu_2022_2104	aml_ohsu_2022_2104_BA2517	45	46	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance	4	Standard Chemotherapy|Supportive/Palliative Care	2	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	M2	Negative	FALSE	FALSE	TRUE	47,XY,der(7)t(1;7)(q10;p10)+8[20]	4	Standard Chemotherapy	19	FALSE	Negative	AML	8.515068493150684	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	White	6	Refractory	RUNX1 (p.S308Qfs*292; 52.1%)	3	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Peripheral Blood	CD34, CD13, HLA-DR, CD123, and CD58.  In addition there is a predominant (about      60%) and atypical monocytic population expressing: CD11b, CD13, CD14,      patial CD16, CD33dim, partial CD56, CD64bright, HLA-DR.	112	1	NA	Standard Chemotherapy	No	CBL (Intron 8, 3' splice site mutation (at invariant AG splice acceptor site); MAF 94%)|EZH2 (p.S538L; MAF 89%)|GATA2 (p.K389delins; MAF 47%)|RUNX1 (p.S308fs*174; MAF 46%)
aml_ohsu_2022	aml_ohsu_2022_2104	aml_ohsu_2022_2104_BA2657	45	46	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance	4	Standard Chemotherapy|Supportive/Palliative Care	2	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	M2	Negative	FALSE	FALSE	TRUE	47,XY,der(7)t(1;7)(q10;p10)+8[20]	4	Standard Chemotherapy	21	FALSE	Negative	AML	8.515068493150684	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	White	6	Refractory	RUNX1 (p.S308Qfs*292; 42.4%)	3	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	196	1.066666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2105	aml_ohsu_2022_2105_BA2248	21	22	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	HiDAC|Crenolanib|Etoposide|Topotecan|Decitabine|Clofarabine|Thioguanine|7+3 (Cytarabine, Idarubicin)|Cyclophosphamide|Thiotepa|Sorafenib|Mitoxantrone|Vinorelbine	13	Induction|Experimental|Re-induction|Supportive/Palliative Care	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	NA	15	Targeted Therapy - Kinase Inhibitor(s)	12	FALSE	Negative	AML	18.115068493150684	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	5	Refractory	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.6	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2106	aml_ohsu_2022_2106_BA2420	69	69	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Negative	TRUE	FALSE	FALSE	47,XY,+8[2]/46,XY[18]	63	Standard Chemotherapy	6	FALSE	Negative	AML	15.45205479452055	1:DECEASED	Consistent with karyotype	No	No	NA	No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.H242Afs*14; 24.5%)	1	Male	UNMATCHED	FALSE	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD13, dimCD33, CD34, dim CD38, CD58, dimCD64, CD117, CD123, dim HLA-DR, TdT positive	0	0.233333333	NA	Standard Chemotherapy	Yes	MLL (PTD)|RUNX1 (p.H242fs*14; MAF 42% )|RUNX1 (p.N136K; MAF 30%)|U2AF1 (p.S34F; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2107	aml_ohsu_2022_2107_BA2839	44	44	0.960784314	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	FALSE	FALSE	TRUE	47,XY,+21[19]/46,XY[1]	NA	None	9	FALSE	Negative	AML	0.1972602739726027	1:DECEASED	nuc ish(RUNX1T1x2,RUNX1x3)[140/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	Yes	Yes	No	No	No	No	White	NA	NA	RUNX1 (p.E223*; 64.8%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD7(dim + to -), CD11b(-), CD13(+), CD14(-), CD15 (partial +), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(variably +)	0	0.433333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2108	aml_ohsu_2022_2108_BA2832	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	NA	5	Standard Chemotherapy	NA	FALSE	Negative	AML	0.9534246575342467	1:DECEASED	NA	No	No	NA	No	No	No	No	Yes	Yes	NA	5	Refractory	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	NA	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2109	aml_ohsu_2022_2109_BA2894	51	51	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX[20]	2197	Standard Chemotherapy	11	FALSE	Positive	AML	8.515068493150684	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	NA	5	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(partial dim +), CD5(-),CD7(-), CD11b(-), CD15(partial +/subset bright +), CD16(-), CD22(partial +), CD33(bright +), CD34(partial +), CD36(partial +), CD38(variably +), CD41(partial +), CD45(moderately +), CD56(-), CD61(partial +), CD64(-), CD7	0	0.6	NA	Standard Chemotherapy	Yes	FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2110	aml_ohsu_2022_2110_BA2986	48	56	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Mitoxantrone|Busulfan, Cyclophosphamide	7	Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction	5	DLI|Standard Chemotherapy|Bone Marrow Transplant	3	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX,t(1;11)(q44;q13),del(6)(p23)[9]/46,idem,t(17;20)(q25;q11.2)[11]	5	Standard Chemotherapy	34	FALSE	Negative	AML	100.8986301369863	1:DECEASED	All probe results were within normal laboratory limits.      *Note: while it was not disrupted, MLL (11q23) was observed on the end of      the derivative chromosome 1 on available metaphase cells, reflecting the      t(1;11).	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant	Bone Marrow Aspirate	dim CD2, CD13, CD33, CD34, CD38, CD117, dim CD123, dim      HLA-DR, and TdT positive	0	1.833333333	NA	Standard Chemotherapy	Yes	BCOR (p.A1262S; MAF 45% )|DNMT3A (p.R882H; MAF 15% )|GATA1 (c.-12C>T; MAF 35%)
aml_ohsu_2022	aml_ohsu_2022_2111	aml_ohsu_2022_2111_BA2972	40	40	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	1	Waves1+2	Yes	HiDAC|3+7 (Cytarabine, Daunorubicin)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	8	FALSE	Negative	AML	71.11232876712329	0:LIVING	normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD7, CD13, CD33, CD34, CD38, partial CD56 (25%), CD58, dim CD64, CD117, dim CD123, HLA-DR, and MPO+.	0	0.366666667	NA	Standard Chemotherapy	Yes	CEBPA (p.K313_V314insK; MAF 39%)|CEBPA (p.S28fs*81; MAF 28%)|ZRSR2 (p.R378W; VAF 100%)
aml_ohsu_2022	aml_ohsu_2022_2112	aml_ohsu_2022_2112_BA2350	17	17	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	Bu/Cy/ATG|ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC + Midostaurin|Etoposide, Cytarabine	4	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,t(11;19)(q23;p13.1)[19]/46,XY[1]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	2.432876712328767	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Unknown	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.066666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2113	aml_ohsu_2022_2113_BA2699	NA	NA	0	ASXL1 (p.R693*; 64.3%)	Leukemia	Acute Myeloid Leukemia	NA	NA	7	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	NA	NA	None	6	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	Blastic plasmacytoid dendritic cell neoplasm	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.3	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2114	aml_ohsu_2022_2114_BA2952	16	16	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine, Mitoxantrone|Etoposide, Cytarabine	3	Induction|Intensification	2	Standard Chemotherapy	1	Cytarabine, Mitoxantrone	Intensification	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX,t(9;11)(p22;q23)[3]/50,sl,+6,+8,+der(9)t(9;11),+19[14]/51,sdl1,+5[3]	-1	Standard Chemotherapy	1	FALSE	Negative	AML	74.69589041095891	0:LIVING	MLL:  14% of cells had a pattern consistent with the t(9;11) seen on metaphase analysis. An addition 65% of cells had a signal pattern, consistent with the clone with the +der(9). | BCR/ABL+ASS:  62% of cells had three signals for both ABL and ASS (9q3	No	No	NA	No	No	No	No	No	No	White	10	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, dim CD13, dim CD15, CD33, CD38, dim CD45, CD56,      CD58, bright CD64, dim CD117, CD123, HLA-DR, and variable MPO positive	0	0.066666667	NA	Standard Chemotherapy	Yes	KRAS (p.G13D; MAF 6%)|NRAS (p.Q61H; MAF 19%)
aml_ohsu_2022	aml_ohsu_2022_2115	aml_ohsu_2022_2115_BA2072	35	35	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XX,t(16;16)(p13.1;q22)[16]/47,idem,+22[4]	94	Standard Chemotherapy	1	FALSE	Negative	AML	60.75616438356164	0:LIVING	Trisomy 22 (16%) | t(16;16) (90%)	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Myeloid blasts (21%): CD13, CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive. Promonocytic/monocytic cells (55%): CD11b, CD13, CD14, CD33, dim/partial CD34, CD38, CD58, CD64, variable CD123, HLA-DR, and MPO-positive. (Included both populatio	0	0.033333333	NA	Standard Chemotherapy	Yes	CREBBP (P552S; MAF 50%)|KDM6A (K395N; MAF 50%)|KIT (D816V; MAF 1%)|NRAS (G13D; MAF 6%)
aml_ohsu_2022	aml_ohsu_2022_2116	aml_ohsu_2022_2116_BA2867	78	78	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	mono	2	Waves1+2	Yes	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	-1	Standard Chemotherapy	34	FALSE	Negative	AML	11.408219178082192	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	Yes	Yes	No	No	NA	NA	NA	RUNX1 (p.P383Afs*217; 46.0%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD7 (-), CD10(-), CD11b(-), CD13(dim +), CD14(-), CD15(+), CD16(-), CD19(-), CD22(partial +), CD33(-), CD34(bright +), CD36 (-), CD38(variably +), CD45(partial dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(partial +), MPO(-) and TdT(+) (Popul	0	1.7	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2117	aml_ohsu_2022_2117_BA2999	53	54	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	7	Salvage|Induction|Experimental|Re-induction|Maintenance	5	Standard Chemotherapy|Targeted Therapy - Other	2	Incyte trial (azacitidine and JAK 1 inhibitor)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY,t(4;12)(q12;p13)[10]/46,XY[10]	-1	Standard Chemotherapy	6	FALSE	Negative	AML	17.852054794520548	1:DECEASED	42/100 (42%) interphase cells scored were positive for  ETV6 rearrangement. Metaphase FISH showed part of the ETV6 signal (red) on  the long arm of chromosome 4. Based on the breakpoint, ETV6/CHIC2 fusion  is predicted, consistent with AML	No	No	NA	No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.R166*; 41.5%)	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	partial CD7, CD13, CD33, CD38, CD34, CD58, CD117, CD123,  HLA-DR positive	0	0.333333333	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 49%)|IDH1 (p.R132S; MAF 48%)|RUNX1 (p.R166*; MAF 50%)|SRSF2 (p.P95H; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2118	aml_ohsu_2022_2118_BA2059	60	60	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M1	Negative	TRUE	FALSE	FALSE	46,XX[21]	7	Standard Chemotherapy	1	FALSE	Negative	AML	1.1506849315068493	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	7	Complete Response	NA	1	Female	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34+ BLAST POPULATION, 51%, EXPRESSING HLA-DR, CD38, CD7, DIM PARTIAL CD13, PARTIAL CD33, CD117, PARTIAL MPO, AND PARTIAL TDT	0	0.033333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2119	aml_ohsu_2022_2119_BA2718	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	9	FALSE	Negative	AML	79.66027397260274	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, CD33, CD34, CD117, HLA-DR, cMPO (+)	0	0.4	NA	Standard Chemotherapy	Yes	CEBPA (p.A30fs*130; MAF 40%)|CEBPA (p.N307_V308ins; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2120	aml_ohsu_2022_2120_BA2500	59	59	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	ATRA, Arsenic Trioxide, Idarubicin	1	Induction	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide, Idarubicin	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Negative	TRUE	FALSE	FALSE	46,XX,t(15;17)(q22;q21)[20]	-1	Standard Chemotherapy	8	FALSE	Negative	AML	0.9205479452054794	0:LIVING	86/100 cells (86%) had the 1r/1g/2f dual fusion signal pattern consistent  with PML/RARA fusion and with t(15;17) as seen on metaphase analysis.	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD58, CD64, CD117, CD123, MPO	0	0.5	NA	Standard Chemotherapy	Yes	ASXL1 (p.M1050V; MAF 51%)|FLT3-ITD (MAF 46%)
aml_ohsu_2022	aml_ohsu_2022_2121	aml_ohsu_2022_2121_BA2041	32	32	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	47,XX,+8[13]/46,XX[7]	-1	Bone Marrow Transplant	9	FALSE	Negative	AML	36.1972602739726	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[197],(D8Z2x3,D20S108x2)[101/200], (RUNX1T1x3,RUNX1x2)[91/200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[188], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	2	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(dim +), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD41(-), CD45(+), CD56(-), CD64(-), CD71(+), CD117(+), CD123(+), GLy-A(-), HLA-DR(partial + and vari	0	0.433333333	NA	Standard Chemotherapy	Yes	PTPN11 (G60A; MAF 18%)
aml_ohsu_2022	aml_ohsu_2022_2121	aml_ohsu_2022_2121_BA2096	32	32	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	47,XX,+8[3]/46,XX[17]	-1	Bone Marrow Transplant	NA	FALSE	Negative	AML	36.1972602739726	0:LIVING	nuc ish(D8Z2x3,D20S108x2)[27/200]	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	2	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(+ to bright +), CD34(-), CD38(+), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(dim +).	46	NA	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2122	aml_ohsu_2022_2122_BA2024	48	48	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	ADE (Cytarabine, Daunorubicin & Etoposide)	1	Induction	1	Standard Chemotherapy	1	ADE (Cytarabine, Daunorubicin & Etoposide)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	NA	Positive	TRUE	FALSE	FALSE	46,XY[20]	7	Standard Chemotherapy	8	FALSE	Positive	AML	1.084931506849315	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	7	Unknown	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD33, CD117 positive, negative for CD34 and HLA-DR	0	0.266666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 33%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2123	aml_ohsu_2022_2123_BA2956	56	57	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,del(5)(q15q35),inv(16)(p13.1q22)[20]	3	Standard Chemotherapy	3	FALSE	Negative	AML	13.841095890410958	1:DECEASED	nuc ish(D5S721x2,D5S23x2,EGR1x1)[182/200],(D7Z1,D7S522)x2[199], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[192],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB sep 3'CBFBx1)[176/200]	No	No	NA	No	No	No	No	No	No	NA	3	Unknown	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(partial dim +), CD7(partial dim +), CD11b(-), CD13(+), CD14(-), CD15(+), CD16(-), CD19(-), CD20(-), CD22(few dim +), CD25(-), CD33(+), CD34(+), CD36 (-), CD38(variably +), CD45(moderately +), CD56(-), CD64(few dim +), CD79a(-), CD117(+), CD123	0	0.166666667	NA	Standard Chemotherapy	Yes	NRAS (G12D; MAF 16%)|NRAS (G13D; MAF 13%)|NRAS (Q61H; MAF 5%)
aml_ohsu_2022	aml_ohsu_2022_2124	aml_ohsu_2022_2124_BA2491	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	45,XY,del(5)(q13q33),del(7)(q11.2),dic(8;9)(q24.3;p22),-18,+r[cp8]/45,XY,del(5)(q13q33),-7,der(18)t(7;18)(p11.2;p11.1)[cp6]/45,sdl1,del(4)(q21q31.1),del(12)(p11.2p13)[cp5]/46,XY[1]	9	Standard Chemotherapy	17	FALSE	Negative	AML	2.202739726027397	1:DECEASED	NA	No	No	NA	No	No	No	No	Yes	Yes	White	9	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD7, CD13, dim CD33, CD34, CD38, CD58, partial      CD56, CD117, CD123 and HLA-DR positive	0	1	TP53 (p.V272M; 91.9%)	Standard Chemotherapy	Yes	JAK2 (p.V617F; MAF 53% )|TP53 (p.V272M; MAF 88% )
aml_ohsu_2022	aml_ohsu_2022_2125	aml_ohsu_2022_2125_BA2117	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Negative	FALSE	FALSE	FALSE	46,XY,add(2)(p23),t(3;22)(p21;q13),add(3)(q26),del(6)(q13q27),add(9)(q22),add(9)(q13),add(10)(p11.2),del(14)	5	Standard Chemotherapy	2	FALSE	Negative	AML	8.35068493150685	1:DECEASED	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[198],(5'MLL,3'MLL)x2(5'MLLcon3'MLLx2)[199]	No	No	NA	No	No	No	No	No	No	Black	7	Complete Response i	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy	Peripheral Blood	CD2(-), CD7(partial and variably +), CD13(+), CD14(-), CD15(-), CD33(bright +), CD34(+), CD36(variably +), CD38(bright +), CD45(+), CD64(-), CD117(variably +), HLA-DR(partial +).	15	0.066666667	NA	Standard Chemotherapy	No	TP53
aml_ohsu_2022	aml_ohsu_2022_2126	aml_ohsu_2022_2126_BA2082	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	2	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	47,XY,t(8;19)(q24.1;q13.1),+10[17]/46,XY[3]	NA	None	18	FALSE	Negative	AML	0.0	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.833333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2127	aml_ohsu_2022_2127_BA2143	51	51	NA	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Alive	NA	2	Waves1+2	Yes	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	NA	Myelodysplastic Syndromes	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	44,XX,der(5)t(5;9)(p15;q22)del(5)(q11.2q15),-7,-9,-18,del(20)(q11.2q13.1),+mar[cp8]/43~44,XX,-der(5),del(7)(q11.2q32),add(11)(p15),del(12)(p11.2p13),der(15)t(15;17)(p12;q11.2),-16,-18,+mar[cp9]/43,XX,del(5)(q13q33),del(7),add(11),del(12),der(15),-16,-18,+	4	Standard Chemotherapy	7	FALSE	Negative	MDS	16.66849315068493	0:LIVING	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[108/200]	Yes	No	Breast Cancer	Yes	No	No	No	No	No	NA	NA	NA	NA	1	Female	MATCHED	TRUE	Myelodysplastic syndrome, unclassifiable	Unknown	Bone Marrow Aspirate	CD2 (-), CD4(- to dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD25(dim +), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), CD123(dim +), HLA-DR(variably+), MPO(-), TdT(-)	0	0.3	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2128	aml_ohsu_2022_2128_BA2148	31	31	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,inv(16)(p13.1q22)[11]/47,idem,+22[4]/46,XX[5]	95	Standard Chemotherapy	1	FALSE	Negative	AML	4.701369863013698	0:LIVING	nuc ish(D4Z1,D10Z1)x2[199],(SCFD2,LNX,PDGFRA/KIT)x2[200],(5'PDGFRB,3'PDGFRB)x2(5'PDGFRB con 3'PDGFRBx2)[200],(5'FGFR1,3'FGFR1)x2([200],(RUNX1T1,RUNX1)x2[200](ABL1x2,BCRx3)[63/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(ETV6,RUNX1)x2[198],(PML,RARA)x2[20	No	No	NA	No	No	No	No	No	No	NA	5	Complete Response i	NA	1	Female	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial+), CD16(-), CD22(few +), CD33(dim + to -), CD34(+), CD36(-), CD38(variably +), CD41(-), CD45(variably +), CD56(-), CD61(-), CD64(-), CD117(variably +), HLA-DR(partial +), Gly-A(-), 	0	0.066666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2129	aml_ohsu_2022_2129_BA2163	67	67	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|Azacitidine|Hydroxyurea|Idarubicin and Cytarabine	4	Allogeneic - Sibling|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	45,XY,+5,dic(5;8)(q11.2;p12)x2,del(7)(q22q32),-18,del(20)(p11.2)[cp20]	-1	Bone Marrow Transplant	16	FALSE	Negative	AML	14.86027397260274	1:DECEASED	5p/5q: 88/100 (88%) cells had one signal for EGR1 (5q31) and three signals for 5p, consistent with the metaphase karyotype; 5 cells (5%) had one EGR1 signal and four 5p signals, consistent with a previous sideline with three copies of the dicentric 5;8 ch	No	No	NA	No	No	No	No	Yes	Yes	White	1932	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease	Bone Marrow Aspirate	Positive (CD7, CD13, dimCD33, CD34, variable CD38, CD56, dim CD58, variable CD117, dimCD123 and dim HLA-DR positive)	0	0.966666667	TP53 (p.K132R; 39.4%)|TP53 (p.X126_splice; 51.3%)	Standard Chemotherapy	Yes	DNMT3A (p.G570E; MAF 44%)|JAK2 (p.V617F; MAF 3%)|TP53 (Intron 4 3' splice site mutation; MAF 42%)|TP53 (p.K132R; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2130	aml_ohsu_2022_2130_BA2935	78	78	0.886792453	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Azacitidine|Sorafenib|Decitabine, Midostaurin	3	Induction|Experimental|Re-induction	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M5	Positive	TRUE	FALSE	FALSE	46,XY[25]	8	Targeted Therapy - Kinase Inhibitor(s)	3	FALSE	Negative	AML	23.17808219178082	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	317	Refractory	NA	1	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.133333333	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2131	aml_ohsu_2022_2131_BA2590	55	55	1	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Both	Yes	Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Enasidenib	3	Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Maintenance	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Midostaurin	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	TRUE	FALSE	FALSE	46,XY[19]	44	Targeted Therapy - Kinase Inhibitor(s)	6	FALSE	Positive	AML	9.271232876712329	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Negative (CD19, CD22, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD34, CD64, CD117, TdT) | Positive (CD38, Cyt CD79a, CD15, CD33, MPO) | Dim (CD45, HLA-DR)	0	0.233333333	NA	Standard Chemotherapy	No	FLT3 (c.1811_1812insl8; p.E604_P605insYDLKWE; MAF 32%)|IDH1 (c.395G>A; p.R132H; 44%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 42%)|SRSF2 (c.284_307del; p.P95_R102del; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2133	aml_ohsu_2022_2133_BA2675	10	10	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	mono	1	Waves1+2	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|Unknown|MiDAC	4	Unknown|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Other	4	Unknown	Unknown	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	IntermediateOrAdverse	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	2	FALSE	Negative	AML	68.87671232876713	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	10	Refractory	NA	1	Male	UNMATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	variable CD7, dim CD11b, CD13, CD33, partial CD34, dim CD64, CD117, CD123, HLA-DR, and dim MPO positive	0	0.066666667	NA	Standard Chemotherapy	Yes	CEBPA (p.R142fs*19; MAF 52%)|FLT3-ITD (MAF 48%)
aml_ohsu_2022	aml_ohsu_2022_2134	aml_ohsu_2022_2134_BA2524	51	51	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Stanford Protocol 9022 (BU/CY)	4	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Stanford Protocol 9022 (BU/CY)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M4eo	Negative	TRUE	FALSE	FALSE	46,XX,inv(16)(p13q22)[20]	-1	Bone Marrow Transplant	13	FALSE	Negative	AML	27.58356164383562	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	7	Complete Response	NA	1	Female	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34+ EXPRESSING CD38, CD13, CD33, PARTIAL DIM CD2, PARTIAL CD64; DIM PARTIAL CD11C, PARTIAL DIM CD4, COEXPRESSION OF CD117 AND CD15, HLA-DR, MPO, AND PARTIAL DIM TDT	0	0.7	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2135	aml_ohsu_2022_2135_BA2080	77	78	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	mono	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Cytarabine|Bortezomib|Decitabine|Fludarabine, Cytarabine	5	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental	5	Standard Chemotherapy|Targeted Therapy - Other	2	Decitabine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	5	FALSE	Negative	AML	11.30958904109589	0:LIVING	NA	Yes	No	Lung Cancer	No	No	No	No	No	No	NA	6	Refractory	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD2(-), CD4(- to partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(few +), CD16(-), CD19(few +), CD33(variably +), CD34(variably +), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR (+), MPO(partial +), TdT(partial +)	0	0.233333333	NA	Standard Chemotherapy	Yes	ATM (S1993fs*23; MAF 44%)|CEBPA (L81fs*72; MAF 92%)|MUTYH (G382D; MAF 49%)|STAG2 (R1205*; MAF 92%)|TET2 (C1273S; MAF 46%)|TET2 (M823fs*1; MAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2136	aml_ohsu_2022_2136_BA2004	77	77	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M2	Negative	FALSE	FALSE	FALSE	NA	253	Standard Chemotherapy	1	FALSE	Negative	AML	11.210958904109589	1:DECEASED	EGR-1/ D5S23, D5S721: 58/200 cells (29%) had a 1 red/ 2 green signal pattern, consistent with a deleted 5q. D7S522/CEP 7: 38/200 cells (19%) had a 1 red/ 2 green signal pattern, consistent with a deleted 7q. CBFB: 40/200 cells (20%) had a single signal in	Yes	Yes	Breast Cancer	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	0	0.033333333	TP53 (p.V272_R273insL; MAF 75%)	NA	Yes	DNMT3A (p.E285D; MAF 40% )|KDM6A (p.Y215fs*2; MAF 40%)|TP53 (p.V272_R273insL; MAF 75%)
aml_ohsu_2022	aml_ohsu_2022_2137	aml_ohsu_2022_2137_BA2230	54	54	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves1+2	Yes	HiDAC|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	47,XY,+8[3]/46,XY[17]	-1	Bone Marrow Transplant	4	FALSE	Positive	AML	14.893150684931506	1:DECEASED	1% RUNX1T1	No	No	NA	No	No	No	No	No	No	White	5	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.1	NA	Standard Chemotherapy	Yes	FLT3 (p.N841I; MAF 40%)|NPM1 (p.W288fs*12; MAF 20%)|U2AF1 (p.R156H; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2138	aml_ohsu_2022_2138_BA2775	26	27	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY[15]	-1	Standard Chemotherapy	8	FALSE	Positive	AML	21.27123287671233	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	16	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	weak  CD13, CD33, partial CD117, and myeloperoxidase	0	0.433333333	NA	Standard Chemotherapy	Yes	IDH2 (p.Arg140Gln; MAF 45.9%)|NPM1 (p.Trp288fs; MAF 19.5%)
aml_ohsu_2022	aml_ohsu_2022_2139	aml_ohsu_2022_2139_BA2885	81	81	0	ASXL1 (p.G645Vfs*58; 16.7%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	46,XX[20]	6	Standard Chemotherapy	6	FALSE	Positive	AML	0.4602739726027397	1:DECEASED	Normal	Yes	No	Skin cancer	No	No	No	No	No	No	White	6	Unknown	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, variable CD13, variable CD14, CD33, CD56, CD64, dim CD123 and dim HLA-DR positive	0	0.166666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.W796fs*22; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.S825fs*1; MAF 49%)
aml_ohsu_2022	aml_ohsu_2022_2140	aml_ohsu_2022_2140_BA2132	70	70	0.333333333	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	TRUE	FALSE	FALSE	46,XX,del(5)(q22q35)[20]	37	Standard Chemotherapy	4	FALSE	Negative	AML	1.2164383561643834	0:LIVING	Positive for 5q deletion in 91% of cells.	No	No	NA	No	No	No	No	No	No	NA	37	Unknown	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	POSITIVE FOR CD34, HLA-DR, CD117 AND CD33, AND NEGATIVE FOR MPO, TdT, CD13, CD19, CD20 AND CD10. (Bone Marrow Immunophenotyping)	0	0.133333333	NA	Standard Chemotherapy	Yes	FLT3-ITD|MLL |U2AF1 (p.S34F; MAF 35%)
aml_ohsu_2022	aml_ohsu_2022_2141	aml_ohsu_2022_2141_BA2789	66	66	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	4	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	FALSE	FALSE	FALSE	NA	2	Bone Marrow Transplant	9	FALSE	Positive	AML	56.38356164383561	1:DECEASED	Normal	Yes	Yes	Breast Cancer	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, dim CD71, CD117, CD123, and MPO	0	0.333333333	NA	Standard Chemotherapy	Yes	IDH2 (p.R140Q; MAF 46%)|NPM1 (p.W288fs*9; MAF 42%)
aml_ohsu_2022	aml_ohsu_2022_2142	aml_ohsu_2022_2142_BA2991	56	56	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Negative	FALSE	FALSE	TRUE	NA	6	Standard Chemotherapy	3	FALSE	Negative	AML	3.715068493150685	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	Multiracial	6	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.166666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2143	aml_ohsu_2022_2143_BA2406	64	64	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	42,XY,-3,-7,der(12)t(12;?)(q24.3;?)-17,der(17)t(17;?)(p13;?),-21,der(22)t(22;?)(p11.2:?)[10]/46,XY[10]	6	Standard Chemotherapy	3	FALSE	Negative	AML	2.6301369863013697	1:DECEASED	NA	Yes	No	Hodgkin Lymphoma	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	NOT DETECTED for the MLL partial tandem duplication (PTD). NOT DETECTED for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR). NOT DETECTED for the FLT3 TKD Mutation. Pathogenic alterations are DETECTED in the DNMT3A, NF1 and TP53 genes.  (Bone	0	0.133333333	TP53 (p.E204*; 52.3%)	Standard Chemotherapy	Yes	DNMT3A (c.2635_2651delAACATGAGCCGCTTGGC; p.N879Efs*36c.2656C>T; pQ886*MAF 43%, 36% )|NF1 (c.2192_2199delTCTTGCCC; p.L731Qfs*3  MAF 38%)|TP53 (c.610G>T;p.E204*MAF 51%)
aml_ohsu_2022	aml_ohsu_2022_2144	aml_ohsu_2022_2144_BA2902	83	83	1.083333333	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Azacitidine|Decitabine, Midostaurin	2	Hypomethylating/Low Dose Cytarabine|Induction	2	Standard Chemotherapy	1	Decitabine, Midostaurin	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	FALSE	FALSE	TRUE	46,XY[13]	-1	Standard Chemotherapy	16	FALSE	Positive	AML	1.5452054794520547	1:DECEASED	NA	No	No	NA	No	No	Yes	Yes	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	ABNORMAL CD34-NEGATIVE BLAST POPULATION, 65%, EXPRESSING MYELOPEROXIDASE, CD117, CD13, CD33, AND CD56, AND SHOWING PARTIAL EXPRESSION OF CD38, CD64(DIM), CD11c(DIM), CD4(DIM) AND HLA-DR	1	0.8	NA	Standard Chemotherapy	Yes	FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2145	aml_ohsu_2022_2145_BA2821	37	37	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Hydroxyurea	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction	4	Standard Chemotherapy	1	Azacitidine	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M0/M1	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	5	FALSE	Negative	AML	17.81917808219178	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	8	Refractory	NA	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	variable CD11b, CD13, dim CD19, dim CD33, CD34, variable CD64, CD117, CD123, and HLA-DR	0	0.3	NA	Standard Chemotherapy	Yes	ASXL1 (p.A1312V; MAF 50%)|KRAS (p.K117N; MAF 48%)|WT1 (p.L378P; MAF 48%)|WT1 (p.R380fs*69 (1 bp deletion with frameshift); MAF 48%)
aml_ohsu_2022	aml_ohsu_2022_2146	aml_ohsu_2022_2146_BA2801	72	73	NA	ASXL1 (p.R693*; 38.7%)	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Dead-Unknown	NA	6	Waves1+2	Yes	Vidaza	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Vidaza	Supportive/Palliative Care	NA	Myelodysplastic Syndromes	NonAML	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	NA	268	Standard Chemotherapy	8	FALSE	Negative	MDS	9.600000000000001	1:DECEASED	NA	Yes	No	Lung Cancer	Yes	No	No	No	No	No	NA	NA	NA	RUNX1 (p.S322Nfs*277; 44.4%)	1	Male	UNMATCHED	TRUE	Myelodysplastic syndrome, unclassifiable	Residual Disease	Peripheral Blood	NA	0	0.466666667	NA	NA	No	ASXL1 (p.R693* MAF 48%)|EZH2 (p.1131T, MAF 71%)|EZH2 (p.C565R MAF 27%)|JAK2 (p.V617F, MAF 26%)|KRAS (p.Q61P, MAF 13%)|RUNX1 (p.S322Nfs*277, MAF 42%)|TET2 (p.Q1813*, MAF 51%)|TET2 (p.Q866Rfs*14, MAF 39%)|ZRSR2 (p.R295*, MAF 97%)
aml_ohsu_2022	aml_ohsu_2022_2147	aml_ohsu_2022_2147_BA2181	70	70	1.222222222	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	TRUE	FALSE	FALSE	46,XX,del(7)(q22q36)[11]/46,XX[2]	-1	Bone Marrow Transplant	16	FALSE	Negative	AML	26.202739726027396	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	RUNX1 (p.R162S; 96.2%)	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD34, dim CD45, partial CD117, HLA-DR, and minimal (3%) myeloperoxidase	0	0.766666667	NA	Standard Chemotherapy	Yes	DNMT3A (c.2645G>A; MAF 41.8%)|FLT3-ITD (c.1797delins22; MAF 19%)|IDH1 (c.394C>T; MAF 46.7%)|RUNX1 (c.486G>C; MAF 89.5%)
aml_ohsu_2022	aml_ohsu_2022_2148	aml_ohsu_2022_2148_BA2595	65	66	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	HiDAC|AG-221|Gilteritinib (ASP2215)|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|MEC, Lenalidomide|Clofarabine, Cytarabine	8	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction	5	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	3	AG-221	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY,t(4;15)(q31;q22),add(12)(p11~12)[cp7]/46~51,XY,del(7)(q11.2q36),add(12)(p11~12),add(20)(q11.2)[cp5]/46,XY,?inv(8)(p21q22)[cp7]/46,XY[cp2]	-1	Targeted Therapy - Other	13	FALSE	Negative	AML	12.986301369863014	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD38, CD33; WITH PARTIAL CD34, CD56, CD13, CD11C, CD2 AND CD15/CD117	0	0.733333333	NA	Standard Chemotherapy	Yes	IDH2
aml_ohsu_2022	aml_ohsu_2022_2149	aml_ohsu_2022_2149_BA2074	27	27	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M2	Negative	TRUE	FALSE	FALSE	48,XX,+3,+10[2]/46,XX[18]	137	Standard Chemotherapy	36	FALSE	Positive	AML	26.005479452054793	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	8	Complete Response	NA	2	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7	0	1.7	NA	Standard Chemotherapy	No	NPM1
aml_ohsu_2022	aml_ohsu_2022_2149	aml_ohsu_2022_2149_BA3023	27	27	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M2	Negative	TRUE	FALSE	FALSE	48,XX,+3,+10[2]/46,XX[18]	137	Standard Chemotherapy	29	FALSE	Positive	AML	26.005479452054793	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	8	Complete Response	NA	2	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7	0	1.433333333	NA	Standard Chemotherapy	Yes	NPM1
aml_ohsu_2022	aml_ohsu_2022_2150	aml_ohsu_2022_2150_BA2620	65	65	NA	ASXL1 (p.R549Pfs*2; 42.0%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Positive	TRUE	FALSE	FALSE	NA	0	Bone Marrow Transplant	15	FALSE	Negative	AML	79.75890410958904	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive	0	0.766666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2151	aml_ohsu_2022_2151_BA2423	57	58	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Binimetinib (MEK162)	3	Consolidation|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Other	2	Binimetinib (MEK162)	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[14]	-1	Targeted Therapy - Other	9	FALSE	Negative	AML	3.6493150684931512	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.366666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2153	aml_ohsu_2022_2153_BA2088	45	46	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|3+7 (Cytarabine, Daunorubicin)|Cyclophosphamide, Etoposide, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	4	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Salvage	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	45,XX,-7[4]/46,sl,+mar[2]/46,XX[14]	23	Standard Chemotherapy	6	FALSE	Negative	AML	15.287671232876711	0:LIVING	NA	No	No	NA	No	No	Yes	Yes	No	No	Black	25	Refractory	NA	2	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy	Bone Marrow Aspirate	MLL-PTD is not detected. FLT3-ITD not detected. FLT3-TKD mutation not detected. Pathogenic alterations are detected in the DNMT3A and IDH1 genes. Genomic alteration of uncertain significance is detected in the DNMT3A gene. (Bone Marrow Immunophenotyping)	0	0.3	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2153	aml_ohsu_2022_2153_BA3202	45	47	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves3+4	Yes	HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|3+7 (Cytarabine, Daunorubicin)|Cyclophosphamide, Etoposide, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	4	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Salvage	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	45,XX,-7[4]/46,sl,+mar[2]/46,XX[14]	23	Standard Chemotherapy	NA	FALSE	Negative	AML	15.287671232876711	0:LIVING	NA	No	No	NA	No	No	Yes	Yes	No	No	Black	25	Refractory	NA	2	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy	Bone Marrow Aspirate	POSITIVE FOR CD34, CD117, HLADR, CD33 AND CD13. (Bone Marrow Immunophenotype)	148	NA	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2155	aml_ohsu_2022_2155_BA2669	24	24	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Hydroxyurea|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Induction	1	Standard Chemotherapy	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Negative	TRUE	FALSE	FALSE	46,XY,t(15;17)(q22;q21)[20]	24	Standard Chemotherapy	7	FALSE	Negative	AML	12.756164383561645	0:LIVING	Cytogenetic testing (FISH) for the t(15;17) - PML-RARA translocation is positive in about 98% of the cells (GLC-16-338);	No	No	NA	No	No	No	No	No	No	White	24	Complete Response	NA	1	Male	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD64, dim CD71, dim CD117 and MPO (+).	0	0.333333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2156	aml_ohsu_2022_2156_BA2981	76	77	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	Azacitidine	1	Unknown	1	Unknown	1	Azacitidine	Unknown	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	48-51,XX,del(4)(q25),del(5)(q11.2),-17,-18,+22,+3-5mar[20]	424	Unknown	1	FALSE	Negative	AML	4.964383561643836	1:DECEASED	NA	Yes	Yes	Breast Cancer	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	POSITIVE FOR DIM CD45, HLADR, CD34, CD117, CD13, CD33, CD43, CD81, CD58. (Bone Marrow Immunophenotyping)	0	0.033333333	TP53 (p.R175H; 91.7%)	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2157	aml_ohsu_2022_2157_BA2452	34	36	0.960784314	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Both	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Salvage|Induction|Re-induction	4	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	46,XY,add(17)(p13)[19]/46,XY[1]	43	Standard Chemotherapy	6	FALSE	Positive	AML	19.56164383561644	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	partial CD7, CD13, CD33, CD38, dim CD45, dimCD58, CD117, CD123, and HLA-DR	574	0.233333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2158	aml_ohsu_2022_2158_BA2083	52	52	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	39,X,-X,-4,-5,-7,-16,-17,-18[2]/39,idem,add(9)(q22)[3]/38,idem,-12[3]/46,XX[12]	-1	Standard Chemotherapy	23	FALSE	Negative	AML	0.3287671232876712	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PMLx2,RARAx1)[147/200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[125/200]	No	No	NA	No	No	No	No	No	No	Black	-1	Unknown	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4(+), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(bright +), CD34(+), CD36(-/small subset +), CD38(partial +), CD45(+),CD56(-), CD64(partial dim +), CD117(+), HLA-DR(partial +), MPO(-), and TdT(-)	0	1.133333333	TP53 (p.D281G; 43.9%)	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2159	aml_ohsu_2022_2159_BA2481	NA	NA	NA	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Dead-Unknown	NA	2	Waves1+2	Yes	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	NA	Myelodysplastic Syndromes	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	60	Standard Chemotherapy	16	FALSE	Negative	MDS	3.8136986301369866	1:DECEASED	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	Yes	No	No	No	No	No	NA	60	Unknown	NA	1	Male	MATCHED	TRUE	Refractory anaemia with excess blasts	Unknown	Bone Marrow Aspirate	The findings reveal a slightly expanded population of myeloblasts with an essentially unremarkable immunophenotype. There is no definitive immunophenotypic evidence of a hematolymphoid malignancy.	4	0.966666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2160	aml_ohsu_2022_2160_BA2651	22	22	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	ATRA (Tretinoin)|Cyclophosphamide, TBI|3+7 (Cytarabine, Daunorubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)	4	Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Cyclophosphamide, TBI	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M1	Negative	TRUE	FALSE	FALSE	46,XX,t(9;11)(p22;q23)[22]	-1	Bone Marrow Transplant	3	FALSE	Negative	AML	27.15616438356164	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	7	Refractory	NA	1	Female	MATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34, CD38 (dim partial), CD13, CD33 (dim partial), CD11c, CD4 (dim partial), HLA-DR, CD117 and MPO	0	0.133333333	NA	Standard Chemotherapy	Yes	FLT3-D835
aml_ohsu_2022	aml_ohsu_2022_2161	aml_ohsu_2022_2161_BA2903	59	59	0	ASXL1 (p.G646Wfs*12; 50.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	HiDAC|Lenalidomide|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Etoposide, Mitoxantrone|Cytarabine, OXi4503	6	Salvage|Induction|Experimental|Frontline|Re-induction	5	Standard Chemotherapy|Targeted Therapy - Other	2	Cytarabine, OXi4503	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	FALSE	TRUE	NA	4	Targeted Therapy - Other	2	FALSE	Negative	AML	6.8054794520547945	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	NA	8	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.1	NA	Standard Chemotherapy	Yes	NRAS (p.Q61H, MAF 21%)|RAD21 (p.G273V ,MAF 64%)
aml_ohsu_2022	aml_ohsu_2022_2162	aml_ohsu_2022_2162_BA2567	46	46	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Clofarabine|ODSH (2 O, 3-O Desulfated Heparin)	8	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Post-Transplant Relapse	6	DLI|Standard Chemotherapy|Bone Marrow Transplant	3	Donor Lymphocyte Infusion	Post-Transplant Relapse	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	MissingKaryo	NA	M5	Negative	TRUE	FALSE	FALSE	NA	-1	DLI	1	FALSE	Negative	AML	33.04109589041096	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	Increased atypical CD56 positive, weak CD117 positive myelomonocytic cells representing approximately 23% of the leukocytes	0	0.033333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2163	aml_ohsu_2022_2163_BA2647	44	45	0.515151515	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Clofarabine, Cytarabine	5	Consolidation|Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant	2	Azacitidine	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	TRUE	FALSE	NA	4	Standard Chemotherapy	4	FALSE	Negative	AML	25.249315068493146	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	7	Refractory	RUNX1 (p.R107C; 43.8%)|RUNX1 (p.W106*; 36.8%)	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Relapse|Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	POSITIVE for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR) with a signal ratio of 0.045. NOT DETECTED for the FLT3 TKD Mutation.  (Bone Marrow Immunophenotyping) | POSITIVE FOR DIM CD45, CD34, HLADR, CD117, CD13, CD38, NEGATIVE FOR CD33. (B	0	0.2	NA	Standard Chemotherapy	Yes	FLT3-ITD|IDH2 (c.419G>A; p.R140Q   MAF 39%)|NF1 (c.5225A>G; p.N17425 MAF 10%)|PHF6 (c.901T>G; p.Y301D MAF 29%)|RAD21 (c.482-3T>C; MAF 8%)|RUNX1 (c.318G>A; p.W106* MAF 37%, c.319C>T; p.R107C  MAF 37%)|SMC1A (c.3391G>A; p.G1131R  MAF 29%)
aml_ohsu_2022	aml_ohsu_2022_2164	aml_ohsu_2022_2164_BA2916	65	65	1.272727273	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Methotrexate	5	Consolidation|Induction|Experimental|CNS|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Positive	FALSE	FALSE	TRUE	46,XX[20]	-1	Bone Marrow Transplant	5	FALSE	Positive	AML	12.723287671232876	1:DECEASED	normal	No	No	NA	Yes	Yes	No	No	No	No	White	5	Complete Response	NA	2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD7, CD11b, CD13, CD33, variable CD34, dim CD64, CD117, CD123, HLA-DR and MPO positive	0	0.2	NA	Standard Chemotherapy	Yes	FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2164	aml_ohsu_2022_2164_BA3035	65	66	0.785714286	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Methotrexate	5	Consolidation|Induction|Experimental|CNS|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	FALSE	TRUE	46,XX,t(1;15)(p32;q15)[19]/46,XX[1]	-1	Bone Marrow Transplant	6	FALSE	Positive	AML	12.723287671232876	1:DECEASED	normal	No	No	NA	Yes	Yes	No	No	No	No	White	5	Complete Response	NA	2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD7, CD13, CD33, partial CD34, CD38, dim CD45, CD58, CD71, CD117, CD123, and HLA-DR-positive	151	0.3	NA	Standard Chemotherapy	No	FLT3-ITD|NPM1 (Insertion mutation detected in a minority of cells )
aml_ohsu_2022	aml_ohsu_2022_2165	aml_ohsu_2022_2165_BA2063	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|BL-8040	4	Consolidation|Salvage|Induction|Experimental	4	Standard Chemotherapy|Targeted Therapy - Other	2	Cytarabine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	MissingKaryo	NA	NA	Negative	TRUE	FALSE	FALSE	NA	-1	Standard Chemotherapy	3	FALSE	Negative	AML	31.989041095890407	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	2	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.1	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2165	aml_ohsu_2022_2165_BA3330	71	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|BL-8040	4	Consolidation|Salvage|Induction|Experimental	4	Standard Chemotherapy|Targeted Therapy - Other	2	Cytarabine	Salvage	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	45,X,-Y[3]/46,XY[17]	-1	Standard Chemotherapy	3	FALSE	Negative	AML	31.989041095890407	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[197], (RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2 (5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	2	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	NA	201	0.1	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2166	aml_ohsu_2022_2166_BA2792	51	51	NA	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Dead-Treatment	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|Azacitidine, Lenalidomide	2	Induction|Allogeneic - Mismatched Unrelated Donor	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	NA	Myelodysplastic Syndromes	NonAML	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	47,XY,+8[2]/46,XY[18]	-1	Bone Marrow Transplant	18	FALSE	Negative	MDS	9.402739726027397	1:DECEASED	Trisomy 8	No	No	NA	Yes	No	No	No	No	No	White	117	Complete Response	NA	1	Male	MATCHED	TRUE	Refractory anaemia with excess blasts	Unknown	Bone Marrow Aspirate	CD34/CD117 positive myeloid blasts comprise about 4% of total CD45+ cells with possible partial TdT expression	0	0.966666667	NA	Standard Chemotherapy	No	WT1 (p.A382fs*4; MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2167	aml_ohsu_2022_2167_BA2016	62	63	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance	4	Standard Chemotherapy	1	HiDAC	Maintenance	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	TRUE	FALSE	46,XY[20]	5	Standard Chemotherapy	46	FALSE	Negative	AML	17.884931506849316	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	NA	6	Refractory	RUNX1 (p.S331Afs*263; 65.2%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Relapse	Peripheral Blood	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD33(partial +), CD34 (variably +), CD36(-), CD38(variably +), CD45(moderate to dim+), CD56(-), CD64(partial +), CD117(+), and HLA-DR(partial +).	0	2.766666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2168	aml_ohsu_2022_2168_BA2697	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	Vidaza|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)	3	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	45,XX,-7[20]	-1	Bone Marrow Transplant	4	FALSE	Negative	AML	11.112328767123287	0:LIVING	7cen (D7Z1), 7q31 (D7S486): monosomy present	No	No	NA	Yes	Yes	No	No	No	No	NA	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	NA	0	0.233333333	NA	Standard Chemotherapy	Yes	DNMT3A (p.Gln231fs; MAF 33.2%)|IDH2 (p.Arg140Gln; MAF 44.2%)|NRAS (p.Gln61Glu; MAF 47.8%)
aml_ohsu_2022	aml_ohsu_2022_2169	aml_ohsu_2022_2169_BA2086	69	69	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	MEC, Lenalidomide	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[22]	5	Standard Chemotherapy	17	FALSE	Positive	AML	9.994520547945205	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	79	Refractory	NA	2	Male	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	0	0.833333333	NA	Standard Chemotherapy	No	FLT3-ITD|IDH1
aml_ohsu_2022	aml_ohsu_2022_2169	aml_ohsu_2022_2169_BA2756	69	69	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	MEC, Lenalidomide	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	46,XY[22]	5	Standard Chemotherapy	11	FALSE	Negative	AML	9.994520547945205	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	79	Refractory	NA	2	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	NA	0	0.6	NA	Standard Chemotherapy	Yes	FLT3-ITD|IDH1
aml_ohsu_2022	aml_ohsu_2022_2170	aml_ohsu_2022_2170_BA2660	43	43	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction|Supportive/Palliative Care	3	Standard Chemotherapy|Supportive/Palliative Care	2	Cytarabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	46,XX[20]	125	Supportive/Palliative Care	11	FALSE	Negative	AML	8.054794520547945	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.R250Lfs*13; 46.7%)	1	Female	MATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Myeloid blast (52%) immunophenotype: CD13, variable CD33, CD34, variable CD38, variable CD117, HLA-DR, and TdT positive | Monocytic blast/promonocyte (28%) immunophenotype: dim CD2, CD11b,CD13, variable CD14, bright CD33, dim CD34, CD38, CD58, CD64, and	0	0.466666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 47%)|RUNX1 (p.K110Q; MAF 38%)|SUZ12 (p.E261fs*2; MAF 52%)
aml_ohsu_2022	aml_ohsu_2022_2171	aml_ohsu_2022_2171_BA2790	65	66	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Negative	TRUE	FALSE	FALSE	41~47,XY,+1,del(1)(q42),add(2)(q33),del(5)(q13q33),der(7)add(7)(p22)add(7)(q11.2),-9,-10,der(12)add(12)(p13)ins(?;12)(?q13),13,add(13)(q34),-16,17,add(19)(q13.3),21,+r,+1~4mar[cp13]/41~47,idem,-der(7)[cp7]	66	Standard Chemotherapy	11	FALSE	Negative	AML	9.764383561643836	1:DECEASED	deleted 5q, deleted 7q, and monosomy 17 in the majority of cells scored. 52% of cells also had three RUNX1 (21q22) signals consistent with chromosome 21 material being present in marker and/or additional material of uncertain origin | Interestingly, metap	No	No	NA	No	No	No	No	No	No	White	66	UNKNOWN	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dimCD7, CD13, CD33, CD34, partial CD56, CD117, dimCD123	0	0.6	TP53 (p.R248W; 57.8%)	Standard Chemotherapy	Yes	MLL2 (p.P2557L; MAF 51%)|TP53 (p.R248W; MAF 57%)
aml_ohsu_2022	aml_ohsu_2022_2172	aml_ohsu_2022_2172_BA2483	63	64	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	3	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	48,XX,+8,+21[16]/46,XX[4]	29	Supportive/Palliative Care	22	FALSE	Negative	AML	11.441095890410958	1:DECEASED	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on ba	Yes	No	Cervical Cancer	No	No	No	No	No	No	White	-1	Complete Response	NA	2	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease	Peripheral Blood	CD4, partial CD11b, partial CD13, CD33, CD34, CD38,  partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive | CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive	44	1.233333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2172	aml_ohsu_2022_2172_BA3002	63	64	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	3	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	48,XX,+8,+21[16]/46,XX[4]	29	Supportive/Palliative Care	31	FALSE	Negative	AML	11.441095890410958	1:DECEASED	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21 MLL: 68% of cells had a split signal pattern consistent with MLL (11q23)	Yes	No	Cervical Cancer	No	No	No	No	No	No	White	-1	Complete Response	NA	2	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease	Peripheral Blood	CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive	58	1.866666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2173	aml_ohsu_2022_2173_BA2245	65	67	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cladribine	8	Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Unknown|Induction|Re-induction	6	Standard Chemotherapy	1	Cladribine	Unknown	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M2	Negative	FALSE	FALSE	FALSE	NA	5	Standard Chemotherapy	4	FALSE	Negative	AML	33.534246575342465	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with maturation	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.233333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2174	aml_ohsu_2022_2174_BA2805	83	83	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	No	AG-221	1	Experimental	1	Targeted Therapy - Other	1	AG-221	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	45,XX,-7[20]	-1	Targeted Therapy - Other	14	FALSE	Negative	AML	0.7890410958904108	1:DECEASED	Monosomy 7 (94%)	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for CD13, HLA-DR, CD34, and CD117, with aberrant loss of CD33, and with aberrant expression of CD7	0	0.7	NA	NA	Yes	IDH2 (p.R140Q; MAF 46.4%)|KIT (p.M541L; MAF 48.7%)
aml_ohsu_2022	aml_ohsu_2022_2175	aml_ohsu_2022_2175_BA2583	80	80	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	No	AG-221	1	Experimental	1	Targeted Therapy - Other	1	AG-221	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY,del(20)(q11.2q13.1)[12]/45,sl,-7[3]/45,XY,-7[5]/46,XY[2]	-1	Targeted Therapy - Other	12	FALSE	Negative	AML	1.1178082191780823	1:DECEASED	Tetrasomy 5p/q; Monosomy 7; Loss 20q12 (15.5%); Tetrasomy 8cen and 20q12 (7	No	No	NA	No	No	No	No	Yes	Yes	NA	NA	NA	RUNX1 (p.R162G; 80.6%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for CD13, dim CD33, CD34, CD38, dim CD45, CD117, HLA-DR and TdT	0	0.466666667	NA	NA	Yes	IDH1 (C.G395A; p.R132H; MAF unknown)
aml_ohsu_2022	aml_ohsu_2022_2176	aml_ohsu_2022_2176_BA2540	69	69	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	4	Waves1+2	Yes	Hydroxyurea	1	Induction	1	Standard Chemotherapy	1	Hydroxyurea	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M5a	Negative	TRUE	FALSE	FALSE	46,XX[1]	NA	Standard Chemotherapy	12	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	365	Unknown	NA	1	Female	MATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD38, CD56, slightly dim CD4, CD33, dim CD13, CD64, CD11c, CD15 and partial CD117	0	0.566666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2177	aml_ohsu_2022_2177_BA2339	30	31	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[19]/46,XX[1]	93	Standard Chemotherapy	3	FALSE	Negative	AML	15.978082191780823	0:LIVING	This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on prev	No	No	NA	No	No	No	No	No	No	NA	27	Complete Response i	NA	2	Female	UNMATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Post-Chemotherapy|Residual Disease	Peripheral Blood	There are increased abnormal cells in the monocyte gate that stain positive for CD38, CD11b, CD14, CD64, CD33, with partial MPO, HLADR, CD13 expression. (Bone Marrow Immunophenotyping)	0	0.133333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2177	aml_ohsu_2022_2177_BA2786	30	31	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Both	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[20]	93	Standard Chemotherapy	2	FALSE	Negative	AML	15.978082191780823	0:LIVING	This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on prev	No	No	NA	No	No	No	No	No	No	NA	27	Complete Response i	NA	2	Female	UNMATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Residual Disease|Post-Chemotherapy	Peripheral Blood	POSITIVE FOR CD33, CD11B, CD64, CD4 AND MPO (SUBSET/DIM) AND ARE NEGATIVE FOR CD117, CD13, CD34, HLA-DR AND TDT (Bone Marrow Immunophenotyping)	25	0.1	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2178	aml_ohsu_2022_2178_BA2843	84	84	0.851851852	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Decitabine, Midostaurin	1	Induction	1	Standard Chemotherapy	1	Decitabine, Midostaurin	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M0	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	15	FALSE	Negative	AML	2.202739726027397	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34, CD38, CD117, CD13, CD4, HLA-DR, AND TDT	0	0.633333333	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2179	aml_ohsu_2022_2179_BA2069	55	55	1.083333333	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XY,t(9;11)(p22;q23)[20]	4	Standard Chemotherapy	5	FALSE	Positive	AML	8.087671232876712	1:DECEASED	MLL rearrangement and t(9;11) (86%)	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, partial CD13, CD33, CD38, CD56, CD58, CD64, partial CD117, CD123, and HLA-DR+	0	0.1	NA	Standard Chemotherapy	Yes	No gene mutations found in the 43 genes tested
aml_ohsu_2022	aml_ohsu_2022_2180	aml_ohsu_2022_2180_BA2965	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	Cyclophosphamide, Fludarabine, TBI|Venetoclax (ABT-199), Azacitidine	2	Experimental|Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M0	Negative	FALSE	FALSE	FALSE	46,XY[12]	-1	Bone Marrow Transplant	NA	FALSE	Negative	AML	35.73698630136987	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	2	Male	UNMATCHED	FALSE	AML with minimal differentiation	Post-Chemotherapy	Peripheral Blood	NA	30	0	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2180	aml_ohsu_2022_2180_BA3020	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	Cyclophosphamide, Fludarabine, TBI|Venetoclax (ABT-199), Azacitidine	2	Experimental|Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M0	Negative	TRUE	FALSE	FALSE	46,XY[12]	-1	Bone Marrow Transplant	NA	FALSE	Negative	AML	35.73698630136987	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	2	Male	UNMATCHED	FALSE	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34, dim CD45, CD117	0	0	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2181	aml_ohsu_2022_2181_BA2240	61	61	9	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Positive	FALSE	FALSE	FALSE	NA	61	Targeted Therapy - Kinase Inhibitor(s)	3	FALSE	Positive	AML	8.646575342465754	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.1	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2181	aml_ohsu_2022_2181_BA2613	61	61	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Positive	FALSE	FALSE	FALSE	46,XX[19]	61	Targeted Therapy - Kinase Inhibitor(s)	3	FALSE	Positive	AML	8.646575342465754	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD7, CD13, CD33, partial CD34, partial CD64, CD117, CD123, HLA-DR and partial MPO+	9	0.1	NA	Standard Chemotherapy	No	DNMT3A (p.P777S; MAF 90%)|FLT3-ITD (MAF 75%)|IDH1 (p.R132H; MAF 45%)|NPM1 (p.W288fs*12; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2182	aml_ohsu_2022_2182_BA2037	34	34	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|anti-CD33|Azacitidine	5	Induction|Experimental|Re-induction	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	anti-CD33	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY,t(3;3)(q21;q26),der(7)del(7)(p11.1)del(7)(q11.1)[13]/45,idem,-der(7)[6]/46,XY[1]	-1	Targeted Therapy - Kinase Inhibitor(s)	12	FALSE	Negative	AML	9.567123287671233	1:DECEASED	D7S522/CEP 7: 65/100 cells (65%) had a signal pattern consistent with the deleted chromosome 7 long arm from the small marker observed in the metaphase karyotype; 9 cells (9%) had a signal pattern consistent with the monosomy 7 sideline observed in the me	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	MATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2, CD11b, CD13, CD33, CD34, CD38, CD56, CD58, CD117,  CD123, and HLA-DR positive	0	0.566666667	NA	Standard Chemotherapy	Yes	NRAS (p.Q61H; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2183	aml_ohsu_2022_2183_BA3040	69	69	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	45,XY,add(1)(p13),del(5)(q13q33),add(6)(q13),-7,del(7)(q11.2),der(9)t(1;9)(p13;q22),add(12)(p13),-15,-16,-17,+3mar[19]/43~45,idem,der(3)t(3;17)(p21;q11.2),-17[cp3]	7	Standard Chemotherapy	13	FALSE	Negative	AML	7.824657534246575	1:DECEASED	COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML	No	No	NA	No	No	No	No	No	No	White	7	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (ABNORMAL CD34+ BLAST POPULATION, 29%, EXPRESSINGMYELOPEROXIDASE (VARIABLE), CD34, CD38, CD117, CD33, CD4, HLA-DR,CD13 (PARTIAL), CD56 (dim minor subset), AND CD61 (dim subset))	0	0.666666667	TP53 (p.Y220C; 48.0%)|TP53 (p.F113V; 39.4%)	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2184	aml_ohsu_2022_2184_BA2619	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Salvage|Induction	2	Standard Chemotherapy	1	HAM (Cytarabine, Mitoxantrone)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	59~62,XX,+X,+1,+2,del(5)(q13q34),+6,+8,+8,+9,+11,+11,i(11)(q10),+12,+14,+16,+19,+22,+mar[cp19]/46,XX[1]	7	Standard Chemotherapy	17	FALSE	Negative	AML	5.49041095890411	1:DECEASED	Trisomy 9 (88%) | Missing ERG1 signal (75%) | 2 small red/2 normal red pattern with the PML probe (79%) | Trisomy 11 and i(11q) (92%) | Tetrasomy 8 (87%) | Trisomy 16 (81%)	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD34, CD58 and CD117	0	1.033333333	TP53 (p.R280T; 41.1%)|TP53 (p.X33_splice; 37.9%)	Standard Chemotherapy	Yes	GATA1 (p.N160S; MAF:40%)|NRAS (p.G12D; MAF 11%)|TP53 (Intron 4, 3' Splice site (C.97-1G>A); MAF 26%)|TP53 (p.R280T;  MAF 36%
aml_ohsu_2022	aml_ohsu_2022_2185	aml_ohsu_2022_2185_BA2926	58	58	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine	3	Salvage|Induction|Symptom Control	3	Standard Chemotherapy|Supportive/Palliative Care	2	Azacitidine	Symptom Control	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	[46,XY]	-1	Supportive/Palliative Care	11	FALSE	Negative	AML	9.13972602739726	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	10	Refractory	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Increased CD117 positive, partial CD34 positive myeloblasts representing approximately 61% of the leukocytes most consistent with acute myeloid leukemia	0	0.766666667	NA	Standard Chemotherapy	Yes	ASXL2 (p.Val1277Ala; MAF 89.5%)|DNMT3A (p.Trp297* (NM_175629.2); MAF 82.1%)|IDH1 (p.Arg132Cys (NM_005896.3); MAF 39.1%)
aml_ohsu_2022	aml_ohsu_2022_2186	aml_ohsu_2022_2186_BA2329	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	Decitabine	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	47~49,XY,-21,+1~4mar[cp21]/46,XY[2]	126	Standard Chemotherapy	14	FALSE	Negative	AML	12.164383561643836	1:DECEASED	Monosomy 21 (30%)	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	Blasts (15-20%): CD11b, CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, and HLA-DR, and partial TdT positive - Aberrant monocytic population (20%): CD11b, CD13, CD14, bright CD33, dim CD56, CD64, and HLA-DR positive	0	0.8	NA	Standard Chemotherapy	Yes	CSF3R (p. T618I; MAF: 50%)|WT1 (benign SNP rs16754 (R369R: no amino acid change); MAF: 50%)
aml_ohsu_2022	aml_ohsu_2022_2186	aml_ohsu_2022_2186_BA2677	61	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	Decitabine	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	46~49,XY,-21,+1~4mar[cp20]	126	Standard Chemotherapy	18	FALSE	Negative	AML	12.164383561643836	1:DECEASED	Monosomy 21 (45%)	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease	Bone Marrow Aspirate	Myeloid blasts:CD13, CD33, CD34, CD38, CD58, dimCD64, CD117, and HLA-DR+  Promonocytes/immature monocytes:CD11b, CD13, CD14, CD33, CD64, and HLA-DR+	43	0.966666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2187	aml_ohsu_2022_2187_BA2443	50	54	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,X,t(X;2)(q22;p13)[20]	58	Standard Chemotherapy	20	FALSE	Negative	AML	66.87123287671233	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	Black	5	Complete Response	NA	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	The findings reveal a small population of CD34(+) myeloblasts demonstrating immunophenotypic variation of unclear significance	0	1	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2188	aml_ohsu_2022_2188_BA2225	77	77	0	ASXL1 (p.V751Gfs*22; 17.4%)	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	4	Waves1+2	Yes	Azacitidine, Lenalidomide	1	Induction	1	Standard Chemotherapy	1	Azacitidine, Lenalidomide	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M5	Negative	TRUE	FALSE	FALSE	46,XY,del(9)(q13q34)[3]/46,XY[14]	-1	Standard Chemotherapy	20	FALSE	Negative	AML	0.7561643835616438	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD64, DIM CD14, BRIGHT CD56, CD13, AND CD33,SUBSET EXPRESSING CD34	0	1.066666667	TP53 (p.R273C; 15.4%)	Standard Chemotherapy	Yes	TP53
aml_ohsu_2022	aml_ohsu_2022_2189	aml_ohsu_2022_2189_BA2049	42	42	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves1+2	Yes	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[20]	3	Standard Chemotherapy	2	FALSE	Positive	AML	1.1506849315068493	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	3	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, dim HLA-DR and partial MPO+	0	0.066666667	NA	Standard Chemotherapy	Yes	IDH2 (p.R140Q; MAF 46% )|NOTCH1 (p.H2488R; MAF 47%)|NPM1 (p.W288fs*12; MAF 45%)|PTPN11 (p.D61A; MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2190	aml_ohsu_2022_2190_BA2734	77	79	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	No	Lenalidomide|Azacitidine	2	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Lenalidomide	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	45	Supportive/Palliative Care	2	FALSE	Negative	AML	30.608219178082194	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	NA	NA	RUNX1 (p.R204*; 77.3%)	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.133333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2191	aml_ohsu_2022_2191_BA2653	42	42	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	mono	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M7	Negative	TRUE	FALSE	FALSE	NA	4	Standard Chemotherapy	11	FALSE	Negative	AML	8.975342465753425	1:DECEASED	Extra signals were observed for BCR (22q11.2), PML (15q22), MLL (11q23),     RUNX1T1 (8q21.3) and RUNX1 (21q22) in roughly 45-60% of interphase cells.     These results suggest the presence of a hyperdiploid clone.	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Female	MATCHED	FALSE	Acute megakaryoblastic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD7, CD13, CD33, CD58, partial CD61, CD71, and Factor 8 positive	0	0.666666667	NA	Standard Chemotherapy	Yes	CEBPA (p.V119?M120insV; MAF 30% )
aml_ohsu_2022	aml_ohsu_2022_2192	aml_ohsu_2022_2192_BA2116	81	81	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	No	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	2	Supportive/Palliative Care	1	Decitabine	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]	3	Supportive/Palliative Care	20	FALSE	Negative	AML	3.189041095890411	1:DECEASED	nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5CBFB con 3CBFB dimx1,5CBFB con 3CBFBx1)[200]	No	No	NA	Yes	Yes	No	No	No	No	White	NA	NA	NA	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	41	1.1	TP53 (p.R273H; 56.3%)|TP53 (p.L206Wfs*41; 40.7%)	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2192	aml_ohsu_2022_2192_BA2715	81	81	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	No	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	2	Supportive/Palliative Care	1	Decitabine	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]	3	Supportive/Palliative Care	19	FALSE	Negative	AML	3.189041095890411	1:DECEASED	nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5CBFB con 3CBFB dimx1,5CBFB con 3CBFBx1)[200]	No	No	NA	Yes	Yes	No	No	No	No	White	NA	NA	NA	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD4(+), CD5(partial +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(predominantly -), CD16(-), CD33(+), CD34(+), CD36(-),CD38(variably +), CD45(variably +), CD56(predominantly -), CD64(partial +), CD117(+), HLA-DR(predominantly + and variable),MPO(-)	0	1.066666667	TP53 (p.R273H; 39.7%)|TP53 (p.L206Wfs*41; 32.4%)	NA	Yes	EP300 (Foundation; EP300-ZNF205 fusion)|TP53 (Foundation; L206fs*41; MAFs: 31%)|TP53 (Foundation; R273H; MAFs: 38%)
aml_ohsu_2022	aml_ohsu_2022_2193	aml_ohsu_2022_2193_BA2055	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY,inv(16)(p13q22)[20]	108	Standard Chemotherapy	NA	FALSE	Negative	AML	42.31232876712329	1:DECEASED	71% CBFB rearrangement	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	NA	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2194	aml_ohsu_2022_2194_BA2092	46	46	NA	ASXL1 (p.G645Vfs*58; 12.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	7	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	6	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Positive	FALSE	TRUE	FALSE	46,XX[20]	-1	Targeted Therapy - Kinase Inhibitor(s)	17	FALSE	Positive	AML	11.835616438356164	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	Multiracial	-1	Complete Response i	NA	3	Female	MATCHED	FALSE	AML with mutated NPM1	Relapse	Bone Marrow Aspirate	dim CD7, CD13, CD33, CD71, CD117, CD123,  HLA-DR and MPO	0	0.866666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 35% )|FLT3-ITD (MAF 20%)|JAK3 (p.H529R; MAF 49% )|NPM1 (p.W288fs*12; MAF 20%)
aml_ohsu_2022	aml_ohsu_2022_2194	aml_ohsu_2022_2194_BA3164	46	47	11.5	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	7	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	6	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Positive	FALSE	TRUE	FALSE	46,XX,t(10;16)(q22;q24)[10]/46,X,t(X;1)(q23;q44),t(10;16)(q22;q24)[3]/46,X,t(X;13)(p21;q14),t(3;22)(q13.2;p11.1),t(5;6)(q31;q24),add(9)(q13),t(10;16)(q22;q24)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[2]/	-1	Targeted Therapy - Kinase Inhibitor(s)	7	FALSE	Positive	AML	11.835616438356164	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	Multiracial	-1	Complete Response i	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy|Post-Transplant	Peripheral Blood	partial CD7, CD13, CD33, partial CD34, CD38,  CD58, CD71, partial CD117, CD123, and HLA-DR +	124	0.3	NA	Standard Chemotherapy	No	DNMT3A (p.R882H; MAF 43%)|FLT3-ITD (Internal tandem duplication (~75 bp; in-frame); MAF 79%)|JAK3 (p.H529R; MAF 50%)|NPM1 (p.W288fs*12; MAF 36%)
aml_ohsu_2022	aml_ohsu_2022_2194	aml_ohsu_2022_2194_BA3235	46	47	15.66666667	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	7	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	6	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Positive	FALSE	FALSE	FALSE	46,XX,t(10;16)(q22;q24)[cp12]/46,sl,t(1;4)(q41;q33),t(7;9)(p15;q32)[5]/46,sl,t(X;1)(q23;q44)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[1]	-1	Targeted Therapy - Kinase Inhibitor(s)	8	FALSE	Positive	AML	11.835616438356164	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	Multiracial	-1	Complete Response i	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy|Post-Transplant	Peripheral Blood	NA	168	0.333333333	NA	Standard Chemotherapy	No	FLT3-ITD (ITD; MAF 60%)
aml_ohsu_2022	aml_ohsu_2022_2195	aml_ohsu_2022_2195_BA2421	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Consolidation|Induction|Re-induction|Maintenance	4	Standard Chemotherapy	1	Azacitidine	Maintenance	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	47,XY,+8,inv(9)(p11q12)c[1]/48,idem,+3[5]/49,idem,+3,+15[1]/50,idem,+3,+8,+mar(8]/46,XY,inv(9}(p11q12)c[5]	34	Standard Chemotherapy	37	FALSE	Negative	AML	12.591780821917808	1:DECEASED	nuc ish (D8Z2x3~4)[134/200],(D15Z4x3)[114/200]	No	No	NA	No	No	No	No	No	No	Unknown	56	Refractory	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	0	2.233333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2196	aml_ohsu_2022_2196_BA2399	55	55	1	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Idarubicin) plus Crenolanib	4	Consolidation|Induction|Allogeneic - Child|Maintenance	4	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophosphamide	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	TRUE	FALSE	FALSE	46,XY[29]	1	Standard Chemotherapy	15	FALSE	Negative	AML	21.96164383561644	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	Asian	7	Complete Response	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(dim +), CD14(-), CD15(-/few dim +), CD16(-), CD33(+), CD34 (partial +), CD36(equivocal/small subset appears +), CD38(partial +), CD45(+), CD56(-), CD64(-/few dim +), CD117(+), HLA-DR(+ and variable), TDT(	0	0.766666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (S584_S585INSSDNEYFYVDFRE; MAF 29.0%)|IDH1 (R132H; MAF 47.0%)|MLL (Foundation; MLL-PTD Exons 2-8; not GeneTrails)|TET2 (SPLICE SITE 3500+1G>A; MAF 48.0%)
aml_ohsu_2022	aml_ohsu_2022_2197	aml_ohsu_2022_2197_BA2301	42	42	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX[19]	-1	Standard Chemotherapy	10	FALSE	Positive	AML	22.126027397260273	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (A large blastic population is noted, positive for CD45 and CD64. A small subset of blasts also express CD13 and CD14. The blasts are negative for CD10, CD16, CD19, CD34 and CD117.)	0	0.466666667	NA	Standard Chemotherapy	Yes	NPM1 (c.859_860insTCTG; p.W288fs)|WT1 (c.933_934ins10; p.R312fs; c.938_939insCGGTC; p.A314fs)
aml_ohsu_2022	aml_ohsu_2022_2198	aml_ohsu_2022_2198_BA2542	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG)	3	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Cytarabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1]	9	Standard Chemotherapy	1	FALSE	Negative	AML	23.638356164383563	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	2	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7	0	0.033333333	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2198	aml_ohsu_2022_2198_BA2876	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG)	3	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Cytarabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1]	9	Standard Chemotherapy	1	FALSE	Negative	AML	23.638356164383563	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	2	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7	0	0.033333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2199	aml_ohsu_2022_2199_BA2275	57	57	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	FALSE	44~48,XY,-5,del(7)(q22),+11,idic(11)(p11.2)x2,-12,der(13)t(1;13)(p13;p12),add(17)(q25),der(18)t(12;18)(q13;q11.2),-22,+2mar[cp14]/44~47,sl,-9,+16[cp3]/46~47,sl,der(1)t(1;3)(q21;q21),der(3)t(1;3)(q21;q21)ins(3)(3;?)(p21;?),-idic(11)(p11.2)[cp4]/46,XY[1]	10	Standard Chemotherapy	18	FALSE	Negative	AML	1.1506849315068493	1:DECEASED	EGR1/5p; 88% , consistent with monosomy 5  | D7S486; 96% , consistent with deletion 7q  | BCR; 84% of cells had three signals for BCR (22q11.2)| MLL; 28% of cells had three intact signals for MLL, while another 76% of cells had four intact signals.	Yes	Yes	Brain Cancer	No	No	No	No	No	No	White	10	Unknown	NA	1	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD71, CD117, dim CD123 and HLA-DR+	0	1	TP53 (p.R248Q; 95.8%)	Standard Chemotherapy	Yes	TP53 (p.R248Q; MAF 80%)
aml_ohsu_2022	aml_ohsu_2022_2200	aml_ohsu_2022_2200_BA2415	48	49	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|FLAG-IDA, Gemtuzumab|Cytarabine, Methotrexate	6	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|CNS|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Mismatched Unrelated Donor	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M4	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	14.564383561643837	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Post-Chemotherapy	Bone Marrow Aspirate	Relative increase of phenotypically normal, slightly left shifted myeloid cells without flow cytometric evidence of monoclonality, acute leukemia, plasma cell dyscrasia, or   lymphoproliferative disorder.	152	0.066666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2201	aml_ohsu_2022_2201_BA2097	77	77	0.612903226	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	Azacitidine, Sorafenib|Decitabine, Midostaurin	2	Induction|Re-induction	2	Standard Chemotherapy	1	Azacitidine, Sorafenib	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	FALSE	FALSE	TRUE	46,XY[20]	-1	Standard Chemotherapy	18	FALSE	Negative	AML	9.468493150684932	0:LIVING	CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)	No	No	NA	No	No	Yes	Yes	No	No	White	165	Refractory	NA	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56	0	0.866666667	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2201	aml_ohsu_2022_2201_BA2925	77	77	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	Azacitidine, Sorafenib|Decitabine, Midostaurin	2	Induction|Re-induction	2	Standard Chemotherapy	1	Azacitidine, Sorafenib	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	IntermediateOrAdverse	NA	NA	Positive	FALSE	FALSE	TRUE	46,XY[20]	-1	Standard Chemotherapy	12	FALSE	Negative	AML	9.468493150684932	0:LIVING	CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)	No	No	NA	No	No	Yes	Yes	No	No	White	165	Refractory	NA	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56	0	0.633333333	NA	Standard Chemotherapy	No	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2202	aml_ohsu_2022_2202_BA2224	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Decitabine|Hydroxyurea	2	Induction|Re-induction	2	Standard Chemotherapy	1	Hydroxyurea	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]	263	Standard Chemotherapy	11	FALSE	Negative	AML	13.93972602739726	1:DECEASED	EGR1 (73.5%) ;  TP53: (85.5%)	No	No	NA	Yes	No	No	No	Yes	Yes	White	-1	Complete Response i	NA	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD34, CD117, HLA-DR, CD13, CD33, dim CD123, variable CD15 and subset MPO	0	0.5	TP53 (p.G266V; 65.7%)	Standard Chemotherapy	Yes	JAK2 (p.V617F; MAF 1.5%)|SF3B1 (p.G742D; MAF 35%)|TP53 (p.G266V; MAF 55%)
aml_ohsu_2022	aml_ohsu_2022_2202	aml_ohsu_2022_2202_BA2470	62	63	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Decitabine|Hydroxyurea	2	Induction|Re-induction	2	Standard Chemotherapy	1	Hydroxyurea	Re-induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M2	Negative	FALSE	TRUE	TRUE	46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]	263	Standard Chemotherapy	9	FALSE	Negative	AML	13.93972602739726	1:DECEASED	EGR1 (73.5%) ;  TP53: (85.5%)	No	No	NA	Yes	No	No	No	Yes	Yes	White	-1	Complete Response i	NA	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Relapse	Peripheral Blood	NA	412	0.5	TP53 (p.G266V; 91.4%)	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2203	aml_ohsu_2022_2203_BA2552	67	69	0.666666667	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	AG-120|7+3 (Cytarabine, Idarubicin)|Cytarabine|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	6	Consolidation|Salvage|Induction|Experimental|Post-Transplant Relapse|Allogeneic - Matched Unrelated Donor	6	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Cytarabine	Post-Transplant Relapse	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	TRUE	FALSE	NA	3	Standard Chemotherapy	4	FALSE	Positive	AML	31.035616438356165	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy|Post-Transplant	Peripheral Blood	NA	0	0.133333333	NA	Standard Chemotherapy	Yes	IDH1 (p.R132S, MAF 46%)|NPM1 (p.W288Cfs*12, MAF 57%)
aml_ohsu_2022	aml_ohsu_2022_2204	aml_ohsu_2022_2204_BA2963	47	47	NA	NA	Myelodysplastic/Myeloproliferative Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	Alive	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|Fludarabine, Cytarabine	2	Allogeneic - Sibling|Induction	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	NA	Myelodysplastic/Myeloproliferative Neoplasms	NonAML	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	47,XX,+8,del(11)(q23)[18]	-1	Bone Marrow Transplant	12	FALSE	Negative	MDS/MPN	128.28493150684932	0:LIVING	Missing MLL signal (79.5%) | Trisomy 8 (70.5%)	No	No	NA	No	No	Yes	Yes	No	No	Asian	-1	UNKNOWN	NA	1	Female	MATCHED	TRUE	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	Residual Disease	Peripheral Blood	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR	0	0.766666667	NA	Standard Chemotherapy	No	ETV6 (p.V66I; MAF 50%)|TET2 (p.Q491fs*8 (4 bp insertion with frame-shift); MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2205	aml_ohsu_2022_2205_BA2747	85	85	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Decitabine, Midostaurin	1	Induction	1	Standard Chemotherapy	1	Decitabine, Midostaurin	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M4	Negative	TRUE	FALSE	FALSE	46,XY[14]	-1	Standard Chemotherapy	9	FALSE	Negative	AML	11.736986301369862	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	MATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.533333333	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2206	aml_ohsu_2022_2206_BA2813	64	64	0.428571429	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Positive	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	16	FALSE	Positive	AML	20.90958904109589	0:LIVING	Normal	Yes	No	Prostate Cancer	No	No	No	No	No	No	White	41	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (The large majority of cells (around 90%) are an abnormal population of myeloblasts. The myeloblasts are positive for CD33, CD13, HLA-DR, and CD117, and show uniform aberrant expression of CD7. A subset of the blasts are positive for myeloperoxid	0	0.866666667	NA	Standard Chemotherapy	Yes	DNMT3A (c.2645G>A; p.R882H)|FLT3-ITD (FLT3-ITD 63bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)
aml_ohsu_2022	aml_ohsu_2022_2207	aml_ohsu_2022_2207_BA3039	31	33	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Et	9	Consolidation|Salvage|Unknown|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	7	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	4	Donor Lymphocyte Infusion	Unknown	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NOS	Negative	FALSE	FALSE	FALSE	46,XX,t(1;19)(p32;q13.3),t(6;9)(p22;q34),t(12;16)(p12;q21)[cp20]	-1	DLI	3	FALSE	Negative	AML	27.55068493150685	1:DECEASED	80% t(6;9)(p22;q34)	No	No	NA	No	No	No	No	No	No	Multiracial	7	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with t(6;9)(p23;q34); DEK-NUP214	Post-DLI|Residual Disease|Post-Transplant	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD58, dim CD64, dim CD117, TdT and partial MPO	687	0.133333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2208	aml_ohsu_2022_2208_BA2752	68	68	0.162790698	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Vidaza|Fludarabine, Melphalan|HiDAC|3+7 (Cytarabine, Daunorubicin)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	FALSE	FALSE	46,XY[20]	0	Bone Marrow Transplant	18	FALSE	Negative	AML	9.830136986301369	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	34	Refractory	RUNX1 (p.G170Efs*7; 32.5%)|RUNX1 (p.R162W; 36.4%)	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	These are positive for CD34, CD117, HLADR, CD33, and CD13. (Bone Marrow Immunophenotyping)	0	0.8	NA	Standard Chemotherapy	Yes	FLT3-ITD|MLL
aml_ohsu_2022	aml_ohsu_2022_2209	aml_ohsu_2022_2209_BA2764	77	79	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	7	Waves1+2	Yes	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	NA	-1	Standard Chemotherapy	3	FALSE	Positive	AML	16.43835616438356	0:LIVING	Translocation between the long arm of chromosome 3 and short arm of chromosome 12.	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy	Bone Marrow Aspirate	NA	0	0.066666667	NA	Standard Chemotherapy	No	FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2210	aml_ohsu_2022_2210_BA2566	50	50	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	13	FALSE	Negative	AML	18.936986301369863	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	Multiracial	-1	Refractory	NA	4	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD117 stains clusters and scattered immature mononuclear cells with atypia, 20%. CD34 is negative. (Bone Marrow Immunophenotyping)	63	0.6	NA	Standard Chemotherapy	No	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2210	aml_ohsu_2022_2210_BA2850	50	50	1.5	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	15	FALSE	Negative	AML	18.936986301369863	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	Multiracial	-1	Refractory	RUNX1 (p.E454Gfs*149; 21.4%)	4	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Peripheral Blood	These are postive for CD34, CD117, HLADR, CD13 and CD33. These are negative for CD3, CD20, CD4, CD11b. (Bone Marrow Immunophenotyping)	0	0.7	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2210	aml_ohsu_2022_2210_BA2993	50	50	1.5	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	14	FALSE	Negative	AML	18.936986301369863	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	Multiracial	-1	Refractory	RUNX1 (p.E454Gfs*149; MAF 51%)	4	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	30	0.633333333	NA	Standard Chemotherapy	No	DNMT3A (p.r882H; MAF 45%)|FLT3-ITD|MLL |RUNX1 (p.E454Gfs*149; MAF 51%)
aml_ohsu_2022	aml_ohsu_2022_2210	aml_ohsu_2022_2210_BA3389	50	51	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves3+4	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	4	FALSE	Negative	AML	18.936986301369863	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	Multiracial	-1	Refractory	NA	4	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	No increased or immunophenotypically abnormal blast cell populations identified. (Bone Marrow Immunophenotyping)	225	0.133333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2212	aml_ohsu_2022_2212_BA2937	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide	5	Allogeneic - Sibling|Salvage|Induction|Re-induction|Symptom Control	5	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	42~44,XY,t(1;10)(q12;q21),-5,-7,-11,add(13)(p11.1),der(18)t(11;18)(q14;q21.1),add(20)(q12),+1~3mar[cp4]/41~44,sl,add(4)(q23)[cp9]/41~44,sl,del(4)(q21q?27)[cp5]/41~42,	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	7.002739726027398	1:DECEASED	Monosomy 5 (52%) | 5p deletion (39%) | Monosomy 7 (48%) | Abnormal 7q arm (48%)	No	No	NA	No	No	No	No	Yes	Yes	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33,CD34, CD38, dimCD56, CD58, CD117, and HLA-DR+	0	0.166666667	TP53 (p.R248Q; 96.4%)	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2213	aml_ohsu_2022_2213_BA3009	26	26	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Negative	TRUE	FALSE	FALSE	46,XX,r(2)(p23q31),der(4)t(4;16)(q21;q12-13)del(16)(q22q22),der(16)t(4;16)(q21;q12-13),add(18)(p11.2),del(20)(q13.2)[16]/46,XX[4]	-1	Bone Marrow Transplant	15	FALSE	Negative	AML	52.93150684931507	0:LIVING	CBFB: 88% of cells were missing a signal for CBFB, consistent withdeletion associated with the unbalanced t(4;16) seen on chromosome analysis. No evidence for disruption. This probe will be useful in following this abnormal clone.	No	No	NA	No	No	No	No	No	No	Asian	6	Refractory	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, partial CD15, CD34, CD38, partial CD56, CD58, partial CD117 and CD123+	0	0.8	NA	Standard Chemotherapy	Yes	PTPN11 (p.D61G; MAF 15%)|TET2 (p.S1039L; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2214	aml_ohsu_2022_2214_BA2835	75	75	0	ASXL1 (p.E635Rfs*15; 18.8%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	NA	None	3	FALSE	Negative	AML	0.1643835616438356	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Yes	No	Prostate Cancer|Renal cell carcinoma	No	No	No	No	No	No	Unknown	NA	NA	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4(partial +), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD33(partial +), CD34(+), CD36(subset +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(variably +), MPO(partial +), TdT(sma	0	0.133333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2215	aml_ohsu_2022_2215_BA2587	64	64	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea|Cytarabine, Methotrexate	6	Consolidation|Induction|Allogeneic - Child|CNS|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Child	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	46,XY,inv(16)(p13q22)[20]	-1	Bone Marrow Transplant	10	FALSE	Negative	AML	20.67945205479452	1:DECEASED	CBFB (77%)	Yes	No	Esophageal Cancer	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD2, variable CD5, CD13, CD33, CD34, CD38, variable CD64, CD117, dim CD123, HLA-DR, and MPO (Blast immunophenotype) | dim CD4, CD11b, CD14, dim CD15, CD33, dim CD34, CD38, CD64, dim HLA-DR, and bright MPO (Monocytic/blast equivalent immunophenotype)	0	0.5	NA	Standard Chemotherapy	Yes	KIT (p.D816V; MAF 45% )
aml_ohsu_2022	aml_ohsu_2022_2216	aml_ohsu_2022_2216_BA2160	74	74	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Both	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Supportive/Palliative Care	2	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	5	FALSE	Positive	AML	1.9068493150684933	1:DECEASED	Normal	Yes	No	Bladder Cancer	No	No	No	No	No	No	NA	-1	UNKNOWN	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large population of CD117pos, CD34 neg, HLA-DR neg myeloblasts, representing approx 68% of leukocytes, consistent w/ residual/recurrent AML.	0	0.166666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2217	aml_ohsu_2022_2217_BA2157	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine|Clofarabine, Cytarabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction	3	Standard Chemotherapy	1	Clofarabine, Cytarabine	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,add(2)(q13),-3,-5,add(6)(q21),del(7)(q22),+11,dic(11;17)(p11.2;p11.2),inv(11)(q13q23),add(12)(p12),add(14)(q22),-17,add(19)(p12),-22,+3mar[1]/45-48,sl,+add(1)(q12),del(7)(q22),+3-5mar[cp8]/47-48,sdl1,+8[cp4]/46,XX[3]	-1	Standard Chemotherapy	9	FALSE	Negative	AML	7.824657534246575	1:DECEASED	FISH assays were positive for loss of 5q31 sequences in 91.5% of cells, and positive for trisomy for 7 centromere with disomy for 7q31 in 54.2% of cells.	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	The myeloblasts were positive for CD34, CD117, CD13, CD33, and HLA-DR. A subset of the myeloblasts showed aberrant expression of CD56.	0	0.533333333	TP53 (loss exons 10-11)	Standard Chemotherapy	Yes	ETV6 (IL34-ETV6 rearrangement)|IDH1 (p.G105G; MAF 52.8%)|MEN1 (rearrangement intron 3)|NF1 ((From Foundation Medicine) R192*, R1968* - subclonal, R765fs*26 - subclonal, FCHSD2-NF1 fusion)|TP53 (loss exons 10-11)
aml_ohsu_2022	aml_ohsu_2022_2218	aml_ohsu_2022_2218_BA2484	24	24	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cyclophosphamide, TBI |Busulfan, Cyclophosphamide	7	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance|Double Umbilical Cord Blood Transplant (DUCBT)	7	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Negative	FALSE	FALSE	FALSE	46,XY[21]	-1	Bone Marrow Transplant	10	FALSE	Negative	AML	70.12602739726027	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	7	Refractory	NA	2	Male	MATCHED	FALSE	Acute myelomonocytic leukaemia	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	immunophenotype (10% by flow): dim CD13, CD33, CD34, variable  CD56, variable CD117, and dim CD123-positive  - Promonocyte immunophenotype (70% by flow): CD11b, CD13, CD14, variable  CD16, CD33, variable CD56, CD64, and HLA-DR- positive	42	0.566666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2218	aml_ohsu_2022_2218_BA2658	24	24	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cyclophosphamide, TBI |Busulfan, Cyclophosphamide	7	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance|Double Umbilical Cord Blood Transplant (DUCBT)	7	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	13	FALSE	Negative	AML	70.12602739726027	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	7	Refractory	NA	2	Male	MATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	dimCD13, CD33, CD34, CD56, CD117, and  CD123	0	0.7	NA	Standard Chemotherapy	Yes	NRAS (p.G12C; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2219	aml_ohsu_2022_2219_BA2244	67	68	0	ASXL1 (p.G645Vfs*58; 10.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves1+2	Yes	AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Negative	FALSE	FALSE	FALSE	46,XY,t(4;8)(q21;p23)[2]/46,XY[18]	-1	Bone Marrow Transplant	8	FALSE	Positive	AML	28.405479452054795	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	3	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy	Leukapheresis	NA	261	0.333333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2219	aml_ohsu_2022_2219_BA2477	67	67	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves1+2	Yes	AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	4	FALSE	Positive	AML	28.405479452054795	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	3	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7, CD13, dim CD15, CD33, CD38, CD58, CD117, dim CD123, HLA-DR and partial MPO+. (BM) | dim CD4, CD11b, variable CD13, partial CD14, dim CD15, variable CD16, CD33, CD38, CD58, CD64, CD123 and HLA-DR. (Promonocyte/blast equivalents)	0	0.166666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 46% )|FLT3 (p.V592D; MAF 43% )|IDH1 (p.R132H; MAF 46%  )|NPM1 (p.W288fs*12 MAF 47% )|SETBP1 (p.K459E; MAF 50% )
aml_ohsu_2022	aml_ohsu_2022_2219	aml_ohsu_2022_2219_BA3089	67	68	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves3+4	Yes	AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	6	FALSE	Positive	AML	28.405479452054795	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	3	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD7, CD13, CD33, CD38, CD58, CD117, CD123, partial MPO+	429	0.366666667	NA	Standard Chemotherapy	No	DNMT3A (p.R882H; MAF 46%)|FLT3 (p.V592D; MAF 39%)|IDH1 (p.R132H, MAF 39%)|IDH2 (p.R140Q; MAF 39%)|NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.Q61P; MAF 40%)|SETBP1 (p.K459E; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2220	aml_ohsu_2022_2220_BA2162	77	77	0	ASXL1 (p.W583*; 47.9%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Both	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	46,XY,-7,+13,i(17)(q10)[20]	7	Standard Chemotherapy	8	FALSE	Negative	AML	4.241095890410959	1:DECEASED	D7S486/ CEP 7: 92/100 cells (92%) had a 1 red/ 1 green signal pattern, indicating monosomy 7, consistent with the metaphase karyotype. | RARA: 79/100 cells (79%) had three signals, consistent with the isochromosome 17q observed in the metaphase karyotyp	No	No	NA	No	No	No	No	No	No	White	7	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD34, CD117, dim CD123, and HLA-DR-positive	0	0.366666667	NA	Standard Chemotherapy	No	ASXL1 (p.W583*; MAF 50%)|ETV6 (p.N384*; MAF 40%)|FBXW7 (p.T196A; MAF 50%)|SRSF2 (p.P95H; MAF 70%)
aml_ohsu_2022	aml_ohsu_2022_2221	aml_ohsu_2022_2221_BA2087	40	40	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,t(9;11)(p22;q23)[20]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	47.178082191780824	0:LIVING	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	Unknown	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Peripheral Blood	brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR (86% population of cells)	0	0.066666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2222	aml_ohsu_2022_2222_BA2311	53	53	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI	4	Consolidation|Induction|Allogeneic - Child|Maintenance	4	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Cyclophosphamide	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XX[20]	1	Supportive/Palliative Care	10	FALSE	Negative	AML	21.46849315068493	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	MATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34(+), CD13(dim +), CD15(partial +), CD33(dim to partial +), CD34(+), CD38(variably +), CD45(dim +), CD56(-), CD64 (small subset +), CD117(+), HLA-DR(partial +), other myeloid and lymphoid antigens(-).	0	0.6	NA	Standard Chemotherapy	Yes	IDH2 (R140Q; MAF 51.0%)|KMT2A (Foundation; MLL-PTD exons 2-10)|PAX5 (V26G; MAF 1.0%)|SRSF2 (R94_S101DEL; MAF 40.0%)
aml_ohsu_2022	aml_ohsu_2022_2224	aml_ohsu_2022_2224_BA2079	52	52	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib	5	Consolidation|Salvage|Induction|Maintenance	4	Standard Chemotherapy	1	Idarubicin and Cytarabine	Salvage	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	46,XX[20]	3	Standard Chemotherapy	3	FALSE	Negative	AML	18.378082191780823	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	3	Female	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy	Peripheral Blood	NA	34	0.1	NA	Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 14%)
aml_ohsu_2022	aml_ohsu_2022_2224	aml_ohsu_2022_2224_BA2987	52	52	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib	5	Consolidation|Salvage|Induction|Maintenance	4	Standard Chemotherapy	1	Idarubicin and Cytarabine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX[20]	3	Standard Chemotherapy	9	FALSE	Positive	AML	18.378082191780823	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	3	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, CD13, CD14, CD15, CD33, CD56, bright CD64 and dim HLA-DR-positive	0	0.4	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882C; MAF 45%)|FLT3 (p.D835A; MAF 4%)|FLT3 (p.N841K; MAF; 7%)|NPM1 (p.W288fs*12; MAF 46%)|NRAS (p.G12D; 17%)|TET2 (p.G1137D; MAF 31%)
aml_ohsu_2022	aml_ohsu_2022_2224	aml_ohsu_2022_2224_BA3099	52	53	13.28571429	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib	5	Consolidation|Salvage|Induction|Maintenance	4	Standard Chemotherapy	1	Idarubicin and Cytarabine	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Positive	FALSE	TRUE	FALSE	46,X,t(X;7)(q21;q32)[20]	3	Standard Chemotherapy	3	FALSE	Positive	AML	18.378082191780823	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Relapse	Peripheral Blood	variable CD7, CD13, CD33, partial CD34, CD38, CD58,  CD117, CD123 and HLA-DR  (Immunophenotypic shift is noted from the prior leukemic blast  population.)	383	0.1	NA	Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 46%)|FLT3-ITD (MAF ~90%)|NPM1 (p.W288fs*12; MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2225	aml_ohsu_2022_2225_BA2206	46	47	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine	5	Consolidation|Salvage|Induction|Re-induction	4	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	26	FALSE	Positive	AML	28.734246575342468	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	2	Male	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD7, CD13, CD33, partial CD34, CD117 and dim CD123+	375	1.3	NA	Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 47%)|DNMT3A (p.V778M; MAF 48% )|FLT3-ITD (MAF ~3-4%)|IDH1 (p.R132C; MAF 47%)|NPM1 (p.W288fs*9; MAF 50%)|NRAS (p.G13D; MAF 17%)
aml_ohsu_2022	aml_ohsu_2022_2225	aml_ohsu_2022_2225_BA2523	46	46	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine	5	Consolidation|Salvage|Induction|Re-induction	4	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	16	FALSE	Positive	AML	28.734246575342468	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	2	Male	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	MPO, HLA-DR, CD11c,CD13, CD33, DIM CD7, PARTIAL CD64, PARTIAL CD4, AND LACKING CD34	0	0.933333333	NA	Standard Chemotherapy	Yes	DNMT3A|IDH1|NPM1|NRAS
aml_ohsu_2022	aml_ohsu_2022_2226	aml_ohsu_2022_2226_BA2668	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	46,XX,t(9;11)(p22;q23)[20]	752	Standard Chemotherapy	2	FALSE	Negative	AML	77.12876712328767	0:LIVING	85% MLL rearrangement (c/w karyotype)	Yes	No	Acute Myeloid Leukemia	No	No	No	No	No	No	White	8	Complete Response	NA	2	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS, Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	dim CD13, CD33, CD56, bright CD64, CD117, CD123 and HLA-DR-positive; MPO and CD34-negative (Discrete population compared to diagnosis)	0	0.066666667	NA	Standard Chemotherapy	No	No gene mutations found in the 76 genes tested
aml_ohsu_2022	aml_ohsu_2022_2226	aml_ohsu_2022_2226_BA2934	74	74	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|MiDAC	4	Consolidation|Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	NA	FALSE	FALSE	FALSE	46,XX[20]	3	Standard Chemotherapy	NA	FALSE	NA	AML	77.12876712328767	0:LIVING	normal	Yes	No	Acute Myeloid Leukemia	No	No	No	No	No	No	White	8	Refractory	NA	2	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS, Therapy-related myeloid neoplasms	Post-Chemotherapy	Peripheral Blood	NA	0	NA	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2227	aml_ohsu_2022_2227_BA2822	37	38	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Maintenance	2	Standard Chemotherapy|Supportive/Palliative Care	2	Azacitidine	Maintenance	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	48~54,XY,add(2)(p13),+5,add(5)(q13),del(5)(q13),+10,+11,+13,+13,del(13)(q32),+14,-15,-16,del(17)(p12),-20,+21,+21,+22,+mar[cp9]/49~52,sl,-del(17)(p12)[cp8]/51~54,sl	-1	Supportive/Palliative Care	4	FALSE	Negative	AML	6.8054794520547945	1:DECEASED	Extra chromosome 5 (98%) | 5q deletion (98%) | Monosomy 16 (93%) | Extra copies of chromosome 21 (63%) | Monosomy 17 (99%) | Extra chromosome 11 (99%)	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Peripheral Blood	CD10, CD13, CD33, CD34, CD56 and HLA-DR positive	0	0.2	TP53 (p.R273H; 90.9%)	Standard Chemotherapy	Yes	NRAS (p.G13D, MAF 46%)|TP53 (p.R273H, MAF 96%)
aml_ohsu_2022	aml_ohsu_2022_2228	aml_ohsu_2022_2228_BA2951	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	47,XX,+X,inv(3)(q21q26.2),-7,+22[2]/48,sl,+21[18]	NA	None	2	FALSE	Negative	AML	0.8876712328767123	0:LIVING	evidence of monosomy 7 in 191/200 (95.5 percent) cells scored	No	No	NA	No	No	No	No	Yes	Yes	NA	NA	NA	RUNX1 (p.D198G; 66.7%)	1	Female	UNMATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	3	0.1	NA	NA	Yes	CALR (p.Leu367fs; MAF 24%)|CBL (p.? ; MAF 16.5%)|DNMT3A (p.Ala571Pro; MAF 51.5%)|EZH2 (p.Pro636Ala; MAF 94.7%)|FLT3 (p.Val579Ala; MAF 2.3 %)|PTPN11 (p.Gly60Ser; MAF 49.1%)|RUNX1 (p.Asp198Gly; MAF 63.7%)
aml_ohsu_2022	aml_ohsu_2022_2229	aml_ohsu_2022_2229_BA2779	53	53	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction	3	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	NA	45	Standard Chemotherapy	15	FALSE	Negative	AML	7.9890410958904114	0:LIVING	Monosomy 7 (74%) | Extra copy of RUNX1 (39%)	No	No	NA	Yes	No	No	No	No	No	White	7	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, partial CD33, CD34, partial CD56, partial CD64, CD117, partial CD123, HLA-DR and MPO-positive	0	0.833333333	NA	Standard Chemotherapy	Yes	No gene mutations found in the 43 genes tested
aml_ohsu_2022	aml_ohsu_2022_2230	aml_ohsu_2022_2230_BA2645	73	73	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Decitabine|Stanford Protocol 9153 (TLI, ATG)	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Stanford Protocol 9153 (TLI, ATG)	Allogeneic - Mismatched Unrelated Donor	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M5	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	15	FALSE	Negative	AML	10.84931506849315	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD4(subset), CD11c(partial), CD13(partial), CD14(partial), CD15(partial), CD33(subset), CD34(subset), CD38, CD64(subset), CD117(subset), HLA-DR and MPO	0	0.866666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2231	aml_ohsu_2022_2231_BA2094	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	5	Consolidation|Induction	2	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M4	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	NA	FALSE	Negative	AML	11.013698630136986	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	21	Complete Response	NA	3	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	265	NA	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2231	aml_ohsu_2022_2231_BA2561	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	5	Consolidation|Induction	2	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M4	Negative	TRUE	FALSE	FALSE	46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]	-1	Standard Chemotherapy	2	FALSE	Negative	AML	11.013698630136986	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	21	Complete Response	NA	3	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Large population of atypical myelomonocytic cells (CD4+, bright CD64+, MPO positive, partial CD14), representing 85% of the total leukocytes	0	0.066666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2231	aml_ohsu_2022_2231_BA2977	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	5	Consolidation|Induction	2	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M4	Negative	TRUE	FALSE	FALSE	46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]	-1	Standard Chemotherapy	NA	FALSE	Negative	AML	11.013698630136986	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	21	Complete Response	NA	3	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large population of atypical myelomonocytic cells (CD4+, bright CD64+, MPO positive, partial CD14), representing 85% of the total leukocytes	5	0	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2232	aml_ohsu_2022_2232_BA2744	76	76	0.176470588	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	No	Hydroxyurea	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Positive	FALSE	FALSE	TRUE	46,XY[20]	7	Supportive/Palliative Care	5	FALSE	Positive	AML	0.263013698630137	1:DECEASED	Normal	No	No	NA	No	No	Yes	Yes	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	CD13, CD33, CD38, variable CD56, CD58, CD117 and MPO positive	0	0.166666667	NA	NA	Yes	FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 50%)|TET2 (p.W564*; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2233	aml_ohsu_2022_2233_BA2781	68	68	0	NA	Leukemia	Acute Leukemias of Ambiguous Lineage	Dead-Other	NA	1	Waves1+2	Yes	HyperCVAD Course B (Cytarabine, Methotrexate)|EWALL Protocol|Bu/Cy/TBI|HyperCVAD Course A (Cyclophosphamide, Dexamethasone, Doxorubicin, Vincristine)	4	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Bu/Cy/TBI	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Leukaemias Of Ambiguous Lineage	Adverse	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	20	FALSE	Negative	ALAL	12.657534246575342	1:DECEASED	c/w karyotype	Yes	No	Skin cancer	No	No	No	No	No	No	White	3	Refractory	RUNX1 (p.R107H; 21.1%)	1	Male	MATCHED	FALSE	Acute undifferentiated leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7, partial CD10, dimCD13, CD34, partial CD117, dim TdT positive	0	1.233333333	NA	Standard Chemotherapy	Yes	GATA2 (p.L359V; MAF: 40%)|NRAS (p.A59D; MAF: 10%)|NRAS (p.G12S; MAF: 15%)|RUNX1 (p.R107H; MAF: 19%)
aml_ohsu_2022	aml_ohsu_2022_2234	aml_ohsu_2022_2234_BA2454	73	73	0	ASXL1 (p.R693*; 50.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	Decitabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	20	FALSE	Negative	AML	1.0191780821917809	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[195],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	White	NA	NA	RUNX1 (p.S322*; 51.4%)	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	1.1	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2235	aml_ohsu_2022_2235_BA2782	53	53	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	3	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY[20]	NA	None	5	FALSE	Positive	AML	24.723287671232875	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	atypical monocytic cells expressing weaker than   normal CD13 and CD33, with increased promonocytes/monoblasts representing approximately 44% of the leukocytes, (and increased atypical CD117 positive, CD34 negative myeloblasts showing weak expression   of	0	0.266666667	NA	NA	Yes	NPM1
aml_ohsu_2022	aml_ohsu_2022_2236	aml_ohsu_2022_2236_BA3011	32	32	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	ATRA, Arsenic Trioxide	1	Consolidation|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other	2	ATRA, Arsenic Trioxide	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,XY,t(15;17)(q22;q21)[20]	232	Standard Chemotherapy	1	FALSE	Negative	AML	69.17260273972603	0:LIVING	70% PML/RARA	No	No	NA	No	No	No	No	No	No	Multiracial	NA	NA	NA	1	Male	UNMATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD64, CD117, CD123 and  MPO-positive	0	0	NA	NA	Yes	FLT3-ITD (MAF 7%)|MPL (p.E484G, MAF 3%)|WT1 (p.F451C; MAF 51% )
aml_ohsu_2022	aml_ohsu_2022_2237	aml_ohsu_2022_2237_BA2671	73	73	0	ASXL1 (p.G646Wfs*12; 47.4%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	FLX925|Azacitidine, Lenalidomide|Venetoclax (ABT-199)	3	Salvage|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	3	Azacitidine, Lenalidomide	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M5	Negative	FALSE	FALSE	TRUE	46,XY[20]	76	Standard Chemotherapy	10	FALSE	Negative	AML	14.498630136986302	1:DECEASED	Normal	No	No	NA	Yes	Yes	No	No	No	No	NA	NA	NA	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for CD34, CD117, CD13, CD33, and HLA-DR	1	0.333333333	NA	NA	Yes	ASXL1 (p.G643fs; MAF 32.9%)|GATA2 (p.A318T; MAF 48.8%)|IDH1 (p.G105G; MAF 50%)|SRSF2 (p.P95H; MAF 46.9%)|TET2 (p.E798X; 49.6%)|TET2 (p.Q414X; MAF 49.6%)
aml_ohsu_2022	aml_ohsu_2022_2238	aml_ohsu_2022_2238_BA2249	53	54	9	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	FALSE	FALSE	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	49	Targeted Therapy - Kinase Inhibitor(s)	20	FALSE	Positive	AML	5.523287671232877	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	4	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	dimCD7, CD13, dimCD11b, CD33, variable CD34, CD58,  CD117, CD123, and HLA-DR positive	63	1.1	NA	Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 45%)|FLT3-D835 (p.D835H; MAF 15%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2238	aml_ohsu_2022_2238_BA2579	53	54	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	FALSE	FALSE	46,XY[12]	49	Targeted Therapy - Kinase Inhibitor(s)	2	FALSE	Positive	AML	5.523287671232877	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	4	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	dim variable CD7, dim CD11b, CD13, CD33, CD34, CD58, CD117, and CD123	30	0	NA	Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 6%)|FLT3-ITD (MAF 15-20%)|NPM1 (p.W288fs*12; MAF 6%)|TET2 (p.Q548*, MAF 6%)
aml_ohsu_2022	aml_ohsu_2022_2238	aml_ohsu_2022_2238_BA2829	53	54	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	FALSE	FALSE	46,XY,add(3)(p24)[cp4]/46,XY[14]	49	Targeted Therapy - Kinase Inhibitor(s)	20	FALSE	Positive	AML	5.523287671232877	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	4	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD117 (Initial diagnosis on 7/27/2015 BMBX: CD7, dim CD11b, CD13, CD33, partial CD34, CD58, CD117, CD123, dim MPO, and HLA-DR positive)	7	1	NA	Standard Chemotherapy	Yes	CBL (p.I423N; MAF <0.5%)|DNMT3A (p.R882C; MAF 0.9%)|FLT3-ITD (MAF 2.9)|NPM1 (p.W288fs*12; MAF 0.7%)|TET2 (p.Q548*; MAF 0.7%)
aml_ohsu_2022	aml_ohsu_2022_2238	aml_ohsu_2022_2238_BA2979	53	54	19	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	FALSE	FALSE	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	49	Targeted Therapy - Kinase Inhibitor(s)	17	FALSE	Positive	AML	5.523287671232877	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	4	Male	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	75	0.9	NA	Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 45%)|FLT3-D835 (p.D835H; MAF 15%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2239	aml_ohsu_2022_2239_BA3006	33	33	4	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M2	Positive	TRUE	FALSE	FALSE	46,XX[7]	-1	Bone Marrow Transplant	11	FALSE	Positive	AML	14.432876712328767	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	increased CD117 positive, partial CD34 positive myeloblasts,   representing approximately 91% of the leukocytes, consistent with acute myeloid leukemia	0	0.533333333	NA	Standard Chemotherapy	Yes	FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2240	aml_ohsu_2022_2240_BA2229	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	Cyclophosphamide, Fludarabine, TBI|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	46,XX,del(5)(q31q33),der(21)(qter->q22::p11.2->qter),del(21)(q22)[19]	-1	Bone Marrow Transplant	21	FALSE	Negative	AML	29.063013698630137	0:LIVING	65% Loss 5q31; 14.5% Gain of 8 centromere, trisomy; Trisomy for 21q22  (40.5%), and trisomy for 8q22 and 21q22 (7.0%)	No	No	NA	Yes	Yes	No	No	No	No	NA	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	positive CD13, CD34, dim CD45, CD117 and HLA-DR	0	1.2	NA	Standard Chemotherapy	Yes	BCOR (p.1189_1192del; MAF 33.1%)|NRAS (p.G12D; MAF 10%)|SRSF2 (p.P95H; MAF 34.4%)
aml_ohsu_2022	aml_ohsu_2022_2241	aml_ohsu_2022_2241_BA2463	57	58	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea	4	Consolidation|Induction|Re-induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Decitabine, Hydroxyurea	Supportive/Palliative Care	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	TRUE	FALSE	46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]	-1	Supportive/Palliative Care	NA	FALSE	Negative	AML	4.536986301369863	1:DECEASED	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Yes	No	Ovarian cancer	No	No	No	No	No	No	NA	5	Refractory	NA	2	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Relapse|Post-Chemotherapy	Peripheral Blood	CD2(-), CD4(+), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +),CD15(variably +), CD16(-), CD33(variably +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56 (variable +), CD64(partial +), CD117(-), HLA-DR(+).	111	NA	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2241	aml_ohsu_2022_2241_BA2737	57	57	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea	4	Consolidation|Induction|Re-induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Decitabine, Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]	-1	Supportive/Palliative Care	NA	FALSE	Negative	AML	4.536986301369863	1:DECEASED	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Yes	No	Ovarian cancer	No	No	No	No	No	No	NA	5	Refractory	RUNX1 (Y414*; MAF 16%)	2	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	CD2(-), CD4(+), CD5(equivocal), CD7(-), CD11b(+), CD13(-), CD14(partial +), CD15(+), CD16(-), CD33 (bright +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56(+), CD64(+), CD117(partial +), HLA-DR(+)	0	NA	NA	Standard Chemotherapy	Yes	CREBBP (MYST3-CREBBP fusion; MAF unlisted)|RUNX1 (Y414*; MAF 16%)
aml_ohsu_2022	aml_ohsu_2022_2242	aml_ohsu_2022_2242_BA2836	59	59	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY[20]	107	Standard Chemotherapy	15	FALSE	Positive	AML	14.136986301369863	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	NA	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(- to partial dim +), CD16(-), CD25(-), CD33(+ to slightly bright +), CD34(partial +), CD36(equivocal), CD38(slightly dim and variable), CD45(dim +), CD56(-), CD64(-), CD117(+), CD123(+), HLA-DR(+), MPO(+), 	0	0.733333333	NA	Standard Chemotherapy	Yes	CEBPA (H224fs*97; MAF 7%)|CEBPA (Y181*; MAF 15%)|IDH2 (R140Q; MAF 35%)|NPM1 (W288fs*10+; MAF 26%)|POT1 (splice site 1164-1G>A; MAF 48%)|SRSF2 (P95R; MAF 37%)
aml_ohsu_2022	aml_ohsu_2022_2243	aml_ohsu_2022_2243_BA2759	73	73	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	43,XX,-5,add(7)(q22),t(10;13)(p13;q22),-12,-17[12]/46,XX[8]	-1	Standard Chemotherapy	8	FALSE	Negative	AML	0.5589041095890411	1:DECEASED	deletion 5q31 involving the EGR1 locus in 96/200 (48.0  percent) cells scored,  deletion 7q31 involving the D7S486 locus in 85/200 (42.5  percent) cells scored.	Yes	No	Breast Cancer	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	Large population of CD34 positive myeloblasts, representing approximately 50% of the leukocytes, consistent with acute myeloid leukemia	1	0.4	TP53 (p.R273H; 46.8%)	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2244	aml_ohsu_2022_2244_BA2722	82	82	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	43~46,XX,add(2)(q11.2),-4,del(5)(q23),add(7)(q32),+8,add(11)(q23),-16,del(17)(p12),-18,+22[cp19]/46,XX[1]	122	Standard Chemotherapy	2	FALSE	Negative	AML	1.1506849315068493	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease	Peripheral Blood	NA	0	0.133333333	TP53 (p.P151S; 96.9%)	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2245	aml_ohsu_2022_2245_BA2357	52	52	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]	-1	Bone Marrow Transplant	17	FALSE	Negative	AML	40.66849315068493	1:DECEASED	nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]	No	No	NA	No	No	No	No	No	No	Unknown	15	Refractory	RUNX1 (p.R201Q; 33.9%)	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partialCD4, partialCD15, dimCD33, CD34, CD38, dimCD45, CD117, HLA-DR, TdT, MPO	0	0.9	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2245	aml_ohsu_2022_2245_BA2640	52	54	1	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	TRUE	FALSE	89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]	-1	Bone Marrow Transplant	15	FALSE	Negative	AML	40.66849315068493	1:DECEASED	nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]	No	No	NA	No	No	No	No	No	No	Unknown	15	Refractory	NA	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Relapse	Bone Marrow Aspirate	NA	506	0.733333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2246	aml_ohsu_2022_2246_BA2494	60	60	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M7	Negative	FALSE	FALSE	TRUE	46,XY,del(13)(q12q14)[3]/46,XY[17]	-1	Standard Chemotherapy	15	FALSE	Negative	AML	6.706849315068494	1:DECEASED	Normal	No	No	NA	No	No	No	No	Yes	No	NA	-1	Complete Response	RUNX1 (p.A338Rfs*262; 22.2%)	1	Male	MATCHED	FALSE	Acute megakaryoblastic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD3  - Scattered cells positive, 5-10% of marrow cells CD20  - Scattered cells positive, 5-10% of marrow cells CD34  - Rare cells positive, <1% of marrow cells CD30  - Negative CD43  - Positive in >60% of marrow cells, including the clusters of immature c	0	0.8	NA	Standard Chemotherapy	Yes	JAK2 (p.V617F; MAF 3.8%)|TET2 (p.R1261L; MAF 27.7%)
aml_ohsu_2022	aml_ohsu_2022_2247	aml_ohsu_2022_2247_BA2234	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	46,XX,t(1;11)(p32;q23)[20]	5	Standard Chemotherapy	4	FALSE	Negative	AML	4.865753424657534	1:DECEASED	MLL: 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal	Yes	No	Non-Hodgkins Lymphoma	No	No	No	No	No	No	White	6	Refractory	NA	1	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	dim CD4, CD11b, partial CD13, partial CD14, CD15, CD33, partial CD56, CD58, bright CD64, partial CD123 and HLA-DR-positive	1	0.133333333	NA	Standard Chemotherapy	Yes	DNMT3A (p.E283*; MAF 30%)
aml_ohsu_2022	aml_ohsu_2022_2248	aml_ohsu_2022_2248_BA2308	71	72	5.25	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	45,XY,-7,t(3;3)[20]	-1	Standard Chemotherapy	16	FALSE	Negative	AML	18.246575342465754	1:DECEASED	NA	Yes	No	Prostate Cancer	No	No	No	No	No	No	NA	-1	Refractory	NA	2	Male	MATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Residual Disease|Post-Chemotherapy	Peripheral Blood	CD34+ CD38, CD13,CD33, CD117, HLA-DR, DIM CD7, PARTIAL CD11C, CD2(SUBSET), CD15(MINOR SUBSET), DIM cCD79a(MINOR SUBSET), AND PARTIAL CD4	0	0.833333333	NA	Standard Chemotherapy	Yes	FLT3-D835
aml_ohsu_2022	aml_ohsu_2022_2248	aml_ohsu_2022_2248_BA2413	71	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	45,XY,-7,t(3;3)[20]	-1	Standard Chemotherapy	NA	FALSE	Negative	AML	18.246575342465754	1:DECEASED	NA	Yes	No	Prostate Cancer	No	No	No	No	No	No	NA	-1	Refractory	NA	2	Male	UNMATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD34+ CD38, CD13,CD33, CD117, HLA-DR, DIM CD7, PARTIAL CD11C, CD2(SUBSET), CD15(MINOR SUBSET), DIM cCD79a(MINOR SUBSET), AND PARTIAL CD4	0	NA	NA	Standard Chemotherapy	No	FLT3-D835
aml_ohsu_2022	aml_ohsu_2022_2249	aml_ohsu_2022_2249_BA2257	41	41	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	5	Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XX,t(8;21)(q22;q22)[12]/45,idem,-X[6]/46,XX[2]	4	Standard Chemotherapy	16	FALSE	Negative	AML	49.21643835616439	1:DECEASED	RUNX1T1 / RUNX1 t(8;21): 87% of cells had a dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, dim CD33, CD34, CD38, CD58, dim/partial CD64, CD117, dim CD123, HLA-DR, and MPO	0	0.966666667	NA	Standard Chemotherapy	Yes	TET2 (p.N752fs*60; MAF 40% )
aml_ohsu_2022	aml_ohsu_2022_2250	aml_ohsu_2022_2250_BA2441	50	50	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage|Induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	HISPANIC	M0	Negative	FALSE	FALSE	TRUE	43~47,XY,del(1)(q42),r(2)(p2?3q37),t(3;5)(q27;q31),del(4)(q31),+del(5)(q31),add(5)(q11.2),-7,del(11)(q23),add(12)(p13),-22,+mar[cp11]/43~46,idem,add(14)(q24)[cp8]	4	Standard Chemotherapy	12	FALSE	Negative	AML	3.254794520547945	1:DECEASED	deleted 5q and three short arm signals; monosomy 7 and the metaphase karyotype; no evidence for MLL deletion or rearrangement	No	No	NA	Yes	Yes	No	No	No	No	White	6	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD7, CD11b, CD13, dim CD33, CD34, CD38, CD58, CD117 and HLA-DR+	0	0.5	TP53 (p.R273H; 53.6%)|TP53 (p.G105D; 52.9%)	Standard Chemotherapy	Yes	NRAS ( p.Q61K; MAF 37%)|TP53 (p.G105D, MAF 60%)|TP53 (p.R273H; MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2251	aml_ohsu_2022_2251_BA2109	52	52	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	MissingKaryo	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	NA	81	Standard Chemotherapy	1	FALSE	Negative	AML	19.232876712328768	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	8	Complete Response	NA	1	Female	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.066666667	NA	Standard Chemotherapy	Yes	NOTCH1 (p.K2181R ; MAF 50%)|SRSF2 (p.P95H ; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2252	aml_ohsu_2022_2252_BA2960	79	79	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	4	Waves1+2	Yes	Hydroxyurea|Azacitidine, MLN4924	2	Induction|Supportive/Palliative Care	2	Standard Chemotherapy|Supportive/Palliative Care	2	Azacitidine, MLN4924	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M2	Negative	FALSE	FALSE	TRUE	46,XX,add(5)(q31),del(17)(p11.2)[12]/46,XX[3]	63	Standard Chemotherapy	22	FALSE	Negative	AML	8.646575342465754	1:DECEASED	NA	No	No	NA	No	No	No	No	Yes	Yes	NA	63	Refractory	NA	1	Female	MATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	1.066666667	TP53 (p.R337C; 58.9%)|TP53 (p.R175H; 47.3%)	Standard Chemotherapy	Yes	TP53
aml_ohsu_2022	aml_ohsu_2022_2254	aml_ohsu_2022_2254_BA2600	64	64	1	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	Fludarabine, BCNU, Melphalan|Decitabine, Midostaurin	2	Allogeneic - Sibling|Induction	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, BCNU, Melphalan	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M4	Positive	TRUE	FALSE	FALSE	46,XX,t(2;3)(p13;q25~26)[2]/46,idem,i(14)(q10)[18]	-1	Bone Marrow Transplant	26	FALSE	Negative	AML	33.56712328767124	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	249	Complete Response	RUNX1 (p.P430S; 60.0%)|RUNX1 (p.R166*; 41.2%)	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34, partial CD117, CD38, CD33, partial CD13,partial CD11C, CD4, partial CD14, partial CD64, partial CD2, and HLA-DR	0	1.433333333	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2255	aml_ohsu_2022_2255_BA2704	61	61	0.851851852	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Hydroxyurea	1	Induction	1	Standard Chemotherapy	1	Hydroxyurea	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	8	Standard Chemotherapy	4	FALSE	Positive	AML	0.263013698630137	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	8	Unknown	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO	3	0.133333333	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF ~50%)|IDH2 (p.R140Q; MAF ~50%)|NPM1 (p.W288fs*12; MAF ~50%)
aml_ohsu_2022	aml_ohsu_2022_2256	aml_ohsu_2022_2256_BA2060	57	60	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	4	Consolidation|Induction|Re-induction|Maintenance	4	Standard Chemotherapy	1	Azacitidine	Maintenance	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	7	FALSE	Negative	AML	88.83287671232875	0:LIVING	NA	Yes	No	Basal Cell Carcinoma	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	Acute myelomonocytic leukaemia	Post-Chemotherapy	Bone Marrow Aspirate	The atypical, previously identified myeloid blast population (CD117+/CD34-) is not seen. Lymphocytes are about 5%, and mostly T cells which have a reversed CD4:CD8 ratio and no antigen aberrancy. B cells are essentially absent, and NK cells are not increa	883	0.3	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2257	aml_ohsu_2022_2257_BA2512	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	No	SGN-CD33A	1	Experimental	1	Targeted Therapy - Other	1	SGN-CD33A	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M5	Negative	TRUE	FALSE	FALSE	NA	-1	Targeted Therapy - Other	5	FALSE	Positive	AML	5.884931506849314	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	partial CD56, bright CD33, CD13, bright CD64, HLA-DR (Monocytic cells)	0	0.266666667	NA	NA	Yes	DNMT3A (c.2645G>A; MAF 45.4%)|FLT3-D835 (c.2503G>T (D835Y); MAF 15.5%)|NPM1 (c.860_863dup; MAF 11%)|PTPN11 (c.178G>C; MAF 8.4%)|PTPN11 (c.211T>C; MAF 10%)|TET2 (c.3955-2A>G; MAF 45.4%)
aml_ohsu_2022	aml_ohsu_2022_2258	aml_ohsu_2022_2258_BA2777	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[20]	113	Standard Chemotherapy	25	FALSE	Positive	AML	58.61917808219178	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD38, CD58, CD117, CD123, MPO      positive | CD5+ B cell lymphoproliferative disorder (approximately 5% of total      marrow cellularity)                - Immunophenotype: CD5, CD19, dim CD20, CD23, dim kappa positive	0	1.3	NA	Standard Chemotherapy	Yes	NPM1 (p.W288fs*12; MAF 45%)|NRAS (p.G12D; MAF 4%)|NRAS (p.G13D; MAF 17%)|PTPN11 (p.T73I; MAF4% )
aml_ohsu_2022	aml_ohsu_2022_2259	aml_ohsu_2022_2259_BA2546	63	63	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Decitabine	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	42~45,XY,del(4)(q31q35),del(5)(q13q35),add(9)(q21),add(13)(p11.2),-16,-21[cp15]/40~46,sl,+9,-add(9)(q21),-15,+der(16)t(15;16)(q11.1;p13.3),-18,+mar[cp5]	-1	Standard Chemotherapy	9	FALSE	Negative	AML	7.4958904109589035	1:DECEASED	Extra MLL signal (5%) | 5q deletion (95%) | Abnormal 9q (33%) | Partial deletion of RUNX1 (34%)	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD56, CD58, dim CD64, CD117 and partial HLA-DR.	0	0.433333333	TP53 (p.X307_splice; 46.6%)|TP53 (p.R273S; 40.4%)	Standard Chemotherapy	Yes	TP53 (Intron 7, 5' splice site mutation; MAF 40%)|TP53 (p.R273S; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2260	aml_ohsu_2022_2260_BA2412	85	86	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Decitabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	NA	169	Standard Chemotherapy	4	FALSE	Negative	AML	10.947945205479453	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	0	0.266666667	TP53 (p.R248W; 72.2%)	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2261	aml_ohsu_2022_2261_BA2910	79	79	0.470588235	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Crenolanib	2	Induction|Experimental	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	TRUE	FALSE	NA	14	Targeted Therapy - Kinase Inhibitor(s)	17	FALSE	Positive	AML	4.076712328767123	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	4	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Relapse	Peripheral Blood	NA	0	0.966666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (High level (>50%))|NPM1 (Positive for insertion mutation in exon 12)
aml_ohsu_2022	aml_ohsu_2022_2262	aml_ohsu_2022_2262_BA3025	28	30	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	bi	1	Waves1+2	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	6	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NOS	Negative	FALSE	FALSE	FALSE	46,XX,t(2;9)(q31;p21)[17]/46,X,t(X;9)(q22;p21)[3]	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	27.71506849315069	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated CEBPA	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD7, CD13, CD33, CD34, CD38, CD58, dim CD71, CD117, HLA-DR, MPO and partial TDT positive.	2	0.2	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2263	aml_ohsu_2022_2263_BA2440	76	76	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	41~42,XY,del(3)(p13p21),add(4)(q21),add(5)(q11.2),-7,-10,add(12)(p11.2),-15,add(15)(q21),add(17)(p11.2),-19,-20,-22,+2mar[cp6]/42~43,sl,+21[cp5]/42,sl,i(21)(q10)[cp2]/43~44,sl,+add(7)(p11)[cp2]/43~46,sl,+add(7)(p11),+21[cp4]/81~87<4n>,slx2[cp2]	NA	None	36	FALSE	Negative	AML	1.0191780821917809	0:LIVING	Loss of chromosome 5q31 sequences (73.5%)|Loss of chromosome 7 sequences (monosomy 7) (61.5%)|Gain of 21q22 (AML1) sequences (11.5%)|Polysomy for 8, 20q (7.5%), 11q, 15q, 16q and 17q sequences	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	1	1.7	NA	NA	Yes	ASXL1 (p.E1102D; MAF 31.1%)|DNMT3A (p.F543C; MAF 35.7%)
aml_ohsu_2022	aml_ohsu_2022_2264	aml_ohsu_2022_2264_BA2397	59	59	NA	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	7	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	MissingKaryo	NA	NA	Positive	TRUE	FALSE	FALSE	NA	NA	None	5	FALSE	Positive	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Atypical monocytes (are about 91.5%). They are CD45+, CD33+, HLADR++.CD13+, CD14+. CD15++, CD64++, CD116++, CD11b+++,CD11c++,CD38+ and CD34(-),CD117(-). A small population of monoclonal B-cells, CD19+, CD5+(<1%)	0	0.233333333	NA	NA	Yes	DNMT3A (p.Arg882His)|FLT3-ITD (p.Val579_Leu601dup)|NPM1 (p.Trp288Cysfs*12)
aml_ohsu_2022	aml_ohsu_2022_2265	aml_ohsu_2022_2265_BA2046	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY[19]	-1	Standard Chemotherapy	25	FALSE	Negative	AML	16.306849315068494	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	RUNX1 (N260fs*223+; MAF 26%)	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(subset +), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).	0	1.2	NA	Standard Chemotherapy	Yes	IDH1 (R132C; MAF 42%)|NF1 (N935H; MAF 49%)|RUNX1 (N260fs*223+; MAF 26%)|SRSF2 (P95L; MAF 38%)
aml_ohsu_2022	aml_ohsu_2022_2266	aml_ohsu_2022_2266_BA2685	67	67	0	ASXL1 (p.G646Wfs*12; 28.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy	1	Decitabine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]	83	Standard Chemotherapy	25	FALSE	Negative	AML	7.561643835616438	1:DECEASED	Trisomy 8 is detected in 28% of cells.	Yes	No	Not specified	Yes	Yes	No	No	No	No	NA	8	Complete Response	NA	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	Positive for CD34, CD117, HLADR, CD33, CD13 and Negative for CD11b and CD64 (Bone Marrow Immunophenotyping)	0	1.366666667	NA	Standard Chemotherapy	Yes	BCOR (p.KB39Qfs*5; MAF 45%)|KIT (p.T916A; MAF 50%)|NRAS (p.G12A; MAF 24%)|SRSF2 (p.P95R; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2266	aml_ohsu_2022_2266_BA2875	67	67	0	ASXL1 (p.G646Wfs*12; 40.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy	1	Decitabine	Salvage	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]	83	Standard Chemotherapy	9	FALSE	Negative	AML	7.561643835616438	1:DECEASED	Trisomy 8 is detected in 28% of cells.	Yes	No	Not specified	Yes	Yes	No	No	No	No	NA	8	Complete Response	NA	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy	Bone Marrow Aspirate	Positive for CD34, CD117, CD13, HLA-DR, CD33 and CD38 (Bone Marrow Immunophenotyping)	55	0.4	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2267	aml_ohsu_2022_2267_BA2044	57	57	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, TBI	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan, TBI	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY,hsr(6)(p21p23)[17]/46,XY[5]	-1	Bone Marrow Transplant	23	FALSE	Negative	AML	8.054794520547945	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	371	Complete Response	RUNX1 (p.Y377*; 11.5%)|RUNX1 (p.I114Afs*25; 33.0%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+	0	1.266666667	NA	Standard Chemotherapy	Yes	RUNX1 (p.I114fs*25; MAF ~50% )|U2AF1 (p.S34F; MAF 43%)
aml_ohsu_2022	aml_ohsu_2022_2268	aml_ohsu_2022_2268_BA2353	72	74	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Both	No	Dasatinib	1	Experimental	1	Targeted Therapy - Kinase Inhibitor(s)	1	Dasatinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX,inv(16)(p13q22)[18]/46,XX[2]	16	Targeted Therapy - Kinase Inhibitor(s)	2	FALSE	Negative	AML	26.564383561643833	0:LIVING	CBFB: 79/100 cells (79%) reflecting CBFB rearrangement and the inverted chromosome 16 observed in the metaphase karyotype.	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	2	Female	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD13, CD33, CD34, variable CD38, CD117,  CD123, and HLA-DR +.	33	0.066666667	NA	NA	No	KIT (p.D816H; MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2268	aml_ohsu_2022_2268_BA2830	72	74	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	No	Dasatinib	1	Experimental	1	Targeted Therapy - Kinase Inhibitor(s)	1	Dasatinib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	TRUE	FALSE	NA	16	Targeted Therapy - Kinase Inhibitor(s)	2	FALSE	Negative	AML	26.564383561643833	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	2	Female	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Relapse	Peripheral Blood	NA	0	0.066666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2269	aml_ohsu_2022_2269_BA2922	11	14	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Cyclophosphamide, TBI|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Cytarabine, Mitoxantrone, Sorafenib|ADE (Cytarabine, Daunorubicin & Etoposide)|Donor Lymphocyte Infusion|Cytarabine|Sorafenib|FLAG (Fludarabine, High	13	Allogeneic - Sibling|Consolidation|Unknown|Induction|Experimental|Intensification|Re-induction|Allogeneic - Matched Unrelated Donor	8	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)|Intrathecal|Targeted Therapy - Other	6	Sorafenib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M2	Positive	FALSE	TRUE	FALSE	48,X,-Y,+4,t(6;9)(p22;q34),+8,+10,del(15)(q11.2q15)[20]	187	Targeted Therapy - Kinase Inhibitor(s)	NA	FALSE	NA	AML	54.41095890410959	1:DECEASED	DEK/NUP probe set; 70/100 (70%) interphasecells scored had a 1 red/ 1 green/ 2 yellow fusion signal pattern,consistent with DEK/NUP fusion and the 6;9 translocation observed in themetaphase karyotype.	No	No	NA	No	No	No	No	No	No	White	9	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with t(6;9)(p23;q34); DEK-NUP214	Relapse|Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD117,CD123, dim HLA-DR, partial MPO	950	NA	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2270	aml_ohsu_2022_2270_BA2050	30	31	3.761904762	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	6	Salvage|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]	52	Targeted Therapy - Kinase Inhibitor(s)	NA	FALSE	NA	AML	18.673972602739727	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	2	Female	UNMATCHED	FALSE	AML with t(6;9)(p23;q34); DEK-NUP214	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myelo	3	NA	NA	Standard Chemotherapy	No	FLT3-D835|FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2270	aml_ohsu_2022_2270_BA2334	30	31	2.125	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	6	Salvage|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]	52	Targeted Therapy - Kinase Inhibitor(s)	14	FALSE	Negative	AML	18.673972602739727	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	2	Female	MATCHED	FALSE	AML with t(6;9)(p23;q34); DEK-NUP214	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myelo	0	0.666666667	NA	Standard Chemotherapy	Yes	FLT3-D835|FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2271	aml_ohsu_2022_2271_BA2865	50	50	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|HiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	4	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M0	Negative	TRUE	FALSE	FALSE	46,XX,t(11;17)(q13;q21)[20]	-1	Bone Marrow Transplant	NA	FALSE	Positive	AML	102.87123287671233	0:LIVING	While the chromosome 17 breakpoint is clearly within band 17q21 by metaphase chromosome analysis, these results suggest that it is not within the RARA gene	No	No	NA	No	No	No	No	No	No	White	27	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD4, CD13, dim CD15, dim CD33, CD38, CD58,CD64, CD117, CD123, dim HLA-DR, and cMPO	0	NA	NA	Standard Chemotherapy	Yes	FLT3 (A680V)|NPM1 (W288fs*12 )|WT1 (5000/10,000 copies)
aml_ohsu_2022	aml_ohsu_2022_2272	aml_ohsu_2022_2272_BA2996	64	64	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[21]	NA	None	4	FALSE	Negative	AML	19.200000000000003	1:DECEASED	Loss of ERG1 signal (2%)	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, partial CD56, CD58, CD117, partial CD123, and HLA-DR positive	0	0.2	TP53 (C238R; MAF 5% (not confirmed by Sanger seq))	NA	Yes	CSF3R (p. H599N; MAF 50%)|TP53 (C238R; MAF 5% (not confirmed by Sanger seq))
aml_ohsu_2022	aml_ohsu_2022_2273	aml_ohsu_2022_2273_BA2871	80	80	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	No	Bevacizumab	1	Unknown	1	Unknown	1	Bevacizumab	Unknown	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	44-47,XX,del(5)(q13q33),der(14;18)(q10;q10),-20,-21,+1-4mar[cp15]	-1	Unknown	2	FALSE	Negative	AML	0.3287671232876712	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.133333333	TP53 (p.R306*; 28.8%)|TP53 (p.X187_splice; 21.9%)	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2274	aml_ohsu_2022_2274_BA2841	31	32	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI	7	Allogeneic - Sibling|Consolidation|Salvage|Unknown|Induction|Re-induction	6	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	4	Decitabine	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	TRUE	FALSE	46,XY[20]	-1	Supportive/Palliative Care	16	FALSE	Negative	AML	45.27123287671233	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	Asian	8	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated CEBPA	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD34, CD117, CD38, MPO, CD11c (dim),CD13, CD33, CD15, and HLA-DR,CD7 and CD56 (partial)	0	0.766666667	NA	Standard Chemotherapy	Yes	CEBPA (Double mutation)
aml_ohsu_2022	aml_ohsu_2022_2275	aml_ohsu_2022_2275_BA2844	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	3	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	60	FALSE	Negative	AML	6.41095890410959	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	Unknown	-1	Complete Response	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD19(few appear very dim +), CD25(-), CD33(variably +), CD34(variably +), CD36(subset +), CD38(+), CD45 (variably +), CD56(+), CD64(partial +), CD117(+), CD123(-), HLA-D	0	2.066666667	NA	Standard Chemotherapy	Yes	ASXL1 (G967DEL; MAF 45%)|CEBPA (A111FS*56; MAF 48%)|GATA2 (A318V; MAf 37%)|GATA2 (L321F; MAF 7%)|NRAS (G13V; MAF 37%)
aml_ohsu_2022	aml_ohsu_2022_2276	aml_ohsu_2022_2276_BA2369	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Vidaza	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Vidaza	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	-1	Standard Chemotherapy	8	FALSE	Negative	AML	9.928767123287672	0:LIVING	NA	No	No	NA	Yes	Yes	No	No	No	No	NA	NA	NA	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	These are positive for HLA-DR, CD34,CD117, CD33, CD11B, CD64 but Negative for CD13, CD14, CD16, MPO, TDT and all B and T cell markers (Bone Marrow Immunophenotyping)	0	0.366666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2277	aml_ohsu_2022_2277_BA2385	81	81	NA	NA	Myelodysplastic/Myeloproliferative Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	NA	NA	6	Waves1+2	Yes	NA	NA	NA	NA	NA	NA	NA	NA	NA	Myelodysplastic/Myeloproliferative Neoplasms	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	45,X,-X,del(9)(q13)[12]/46,sl,i(X)(q10)[8]	NA	NA	11	FALSE	Negative	MDS/MPN	0.0	NA	NA	Yes	Yes	Rectal Cancer	No	No	Yes	No	No	No	White	NA	NA	NA	1	Female	MATCHED	TRUE	Chronic myelomonocytic leukaemia	Unknown	Bone Marrow Aspirate	Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alteration is detected in the TET2 gene. Genomic alterations of uncertain significanc	0	0.566666667	NA	NA	No	EZH2 (p.L128S ,MAF 49%)|NF1 (p.F2388I, MAF 45%)|TET2 (p.R1452*, MAF 98%)
aml_ohsu_2022	aml_ohsu_2022_2278	aml_ohsu_2022_2278_BA3038	24	24	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine, Methotrexate|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	HISPANIC	M4	Negative	TRUE	FALSE	FALSE	47,XY,inv(16)(p13q22),+22[20]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	99.97808219178083	0:LIVING	62.5% CBFB rearrangement|74% BCR/ABL/ASS	No	No	NA	No	No	No	No	No	No	Multiracial	6	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	- 14% Myeloid blasts: CD13, CD34, CD38, CD58, partial CD64,     CD117, CD123,          HLA-DR, and MPO positive     - 30% Monoblasts/promonocytes: CD11b, CD13, CD14, CD38, CD58, bright CD64,     HLA-DR, and MPO	0	0.066666667	NA	Standard Chemotherapy	Yes	KIT (p.D816H; MAF ~50%)|WT1 (rs16754; MAF ~50%)
aml_ohsu_2022	aml_ohsu_2022_2279	aml_ohsu_2022_2279_BA2948	67	67	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	Azacitidine|Decitabine|Clofarabine	3	Hypomethylating/Low Dose Cytarabine|Induction	2	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	42,X,add(Y)(p11.1),add(3)(q12),add(4)(q25),del(5)(q12q33),-7,add(8)(p11.2),-11,add(13)(p11.2),del(16)(q22),-17,add(19)(q12.3),-20,add(21)(p11.2),-22,+mar[20]	-1	Standard Chemotherapy	NA	FALSE	Negative	AML	0.9863013698630136	1:DECEASED	43% del 5q31, 56% del 7q31, 58% del20q	No	No	NA	Yes	Yes	No	No	No	No	NA	-1	UNKNOWN	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2280	aml_ohsu_2022_2280_BA2011	63	63	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC	3	Consolidation|Induction|Allogeneic - Child	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Child	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY[11]	-1	Bone Marrow Transplant	3	FALSE	Negative	AML	10.06027397260274	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	2	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	1	0.166666667	NA	Standard Chemotherapy	Yes	BCOR (p.Tyr354*; MAF 72.2%)|DNMT3A (p.Phe755Ser; MAF 38.6%)|DNMT3A (p.Thr835Met; MAF 47%)|IDH1 (p.Arg132Cys; MAF 2.9%)
aml_ohsu_2022	aml_ohsu_2022_2280	aml_ohsu_2022_2280_BA2644	63	63	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC	3	Consolidation|Induction|Allogeneic - Child	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Child	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY[11]	-1	Bone Marrow Transplant	2	FALSE	Negative	AML	10.06027397260274	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	2	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.133333333	NA	Standard Chemotherapy	No	BCOR (p.Tyr354*; MAF 72.2%)|DNMT3A (p.Phe755Ser; MAF 38.6%)|DNMT3A (p.Thr835Met; MAF 47%)|IDH1 (p.Arg132Cys; MAF 2.9%)
aml_ohsu_2022	aml_ohsu_2022_2281	aml_ohsu_2022_2281_BA2995	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY	55	Standard Chemotherapy	22	FALSE	Negative	AML	5.1287671232876715	1:DECEASED	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Yes	No	Prostate Cancer	No	No	No	No	No	No	White	NA	NA	RUNX1 (p.P333Rfs*261; 48.9%)|RUNX1 (p.D332G; 51.1%)|RUNX1 (p.R162G; 47.3%)	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial 	0	1.1	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2282	aml_ohsu_2022_2282_BA2218	39	40	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|ME (Etoposide, Mitoxantrone)|Decitabine	4	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	Decitabine	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	TRUE	FALSE	NA	69	Standard Chemotherapy	4	FALSE	Positive	AML	14.235616438356164	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	39	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Peripheral Blood	NA	0	0.166666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2283	aml_ohsu_2022_2283_BA2538	81	81	0	ASXL1 (p.G646Wfs*12; 25.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	No	AG-221|Hydroxyurea	2	Experimental|Supportive/Palliative Care	2	Supportive/Palliative Care|Targeted Therapy - Other	2	AG-221	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	14	Targeted Therapy - Other	22	FALSE	Negative	AML	2.367123287671233	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(CCND1,IGH)x2[199]	Yes	No	Colon Cancer	No	No	No	No	No	No	NA	NA	NA	RUNX1 (p.Q213Rfs*24; 85.5%)	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	1.266666667	NA	NA	Yes	ASXL1 (Foundation, G646fs*12; MAF 33%)|FLT3 (Foundation, E596_Y597INSYEYDLPYDPRS; MAF 27%)|IDH2 (Foundation, R140Q; MAF 45%)|RUNX1 (Foundation, Q213fs24; MAF 82%)|SRSF2 (FOUNDATION, P95R; MAF 48%)
aml_ohsu_2022	aml_ohsu_2022_2284	aml_ohsu_2022_2284_BA2450	46	46	0.25	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	5	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Sunitinib	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	FALSE	FALSE	NA	2	Standard Chemotherapy	13	FALSE	Positive	AML	8.843835616438355	1:DECEASED	metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid	No	No	NA	No	No	No	No	No	No	White	32	Complete Response	NA	3	Female	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.533333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2284	aml_ohsu_2022_2284_BA2824	46	47	0.515151515	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	5	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Sunitinib	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	FALSE	FALSE	NA	2	Standard Chemotherapy	14	FALSE	Positive	AML	8.843835616438355	1:DECEASED	Positive	No	No	NA	No	No	No	No	No	No	White	32	Complete Response	NA	3	Female	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	variable CD7, CD13, dim CD33, partial CD34, CD38,dim CD58, partial and variable CD117 and CD123 positive	23	0.633333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2284	aml_ohsu_2022_2284_BA2994	46	47	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	5	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Sunitinib	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	NA	2	Standard Chemotherapy	13	FALSE	Positive	AML	8.843835616438355	1:DECEASED	metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid	No	No	NA	No	No	No	No	No	No	White	32	Complete Response	NA	3	Female	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	14	0.6	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2285	aml_ohsu_2022_2285_BA2806	42	42	0.960784314	ASXL1 (p.G645Vfs*58; 8.0%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	TRUE	FALSE	FALSE	NA	-1	Bone Marrow Transplant	6	FALSE	Positive	AML	33.4027397260274	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	Unknown	5	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT	0	0.166666667	NA	Standard Chemotherapy	Yes	FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2286	aml_ohsu_2022_2286_BA2667	74	74	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	UNKNOWN	M2	Negative	FALSE	FALSE	TRUE	46,XY[20]	NA	None	3	FALSE	Negative	AML	4.142465753424657	1:DECEASED	NA	No	No	NA	No	No	Yes	Yes	No	No	Unknown	NA	NA	RUNX1 (p.A142Gfs*4; 32.2%)	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7, CD13, CD33, CD34, CD38, CD58, CD117, CD123, TdT, and HLA-DR positive	0	0.166666667	NA	NA	Yes	RUNX1 (p.A142Gfs*4; MAF 30% )|SRSF2 (p.P95L; MAF 48%)
aml_ohsu_2022	aml_ohsu_2022_2287	aml_ohsu_2022_2287_BA2661	56	56	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	20	FALSE	Positive	AML	20.843835616438355	0:LIVING	Normal	Yes	No	Prostate Cancer	No	No	No	No	No	No	White	12	Complete Response i	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	84% are monocytes, and 9% are myeloid  cells. The monocytic cells (percentages shown) appear  atypical with expression of CD13, bright CD33, and bright  CD64, but weaker than normal HLA-DR and include 48% that  are phenotypically consistent with promonocy	0	1.266666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.Val716Asp; MAF 45%)|FLT3-D835 (p.Asp835Val; MAF 30.5%)|NPM1 (p.Trp288fs; MAF 16.1%)|RAD21 (p.Glu178*; MAF 12%)
aml_ohsu_2022	aml_ohsu_2022_2288	aml_ohsu_2022_2288_BA2681	68	68	0	ASXL1 (p.G645Vfs*58; 8.3%)|ASXL1 (p.C789Wfs*2; 30.5%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	Cyclophosphamide, Fludarabine, TBI|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	3	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Myeloproliferative Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	46,XX,der(9)t(9;12)(p13;q13),del(11)(q21q25),der(12)add(12)(p11.2)add(12)(q13),del(13)(q14q22)[9]/46,idem,add(12)(q24.3),+13,-del(13)[9]/46,idem,add(17)(p13)[2]	-1	Standard Chemotherapy	18	FALSE	Negative	AML	11.145205479452054	1:DECEASED	NA	Yes	No	Not specified	No	No	No	No	Yes	Yes	NA	-1	Complete Response	NA	1	Female	MATCHED	FALSE	Secondary myelofibrosis	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	NA	49	0.9	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2289	aml_ohsu_2022_2289_BA2688	53	53	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin|Fludarabine, Cyclophosphamide, TBI	4	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M6	Negative	TRUE	FALSE	FALSE	46,XX,del(9)(q22q34)[20].	-1	Bone Marrow Transplant	8	FALSE	Negative	AML	4.5041095890410965	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	NA	6	Complete Response	NA	1	Female	MATCHED	FALSE	Acute erythroid leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34 (partial +), CD2(partial dim +), CD13(dim +), CD33(variably to bright +), CD25(-), CD38(+), CD45(moderately +), CD15 (partial +), CD117(+), CD123(dim +), HLA-DR(partial +), MPO(+), TdT(-), other myeloid and lymphoid antigens (-)	0	0.366666667	NA	Standard Chemotherapy	Yes	DNMT3A (R882C; MAF 43%)|IDH2 (R140Q; MAF 3%)|WT1 (splice site 1099-6_1104delCTGCAGGATGTG; MAF 28%)
aml_ohsu_2022	aml_ohsu_2022_2290	aml_ohsu_2022_2290_BA2597	79	79	0	ASXL1 (p.G645Vfs*58; 12.5%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Azacitidine, Lenalidomide	1	Induction	1	Standard Chemotherapy	1	Azacitidine, Lenalidomide	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	46,XX,del(16)(p11.2)[3]/46,XX[2]	137	Standard Chemotherapy	10	FALSE	Negative	AML	6.213698630136986	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	NA	137	Refractory	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34, CD4(dim), CD7, CD11c(dim), CD13, CD33(dim),CD38, CD117, and HLA-DR	0	0.466666667	NA	Standard Chemotherapy	Yes	IDH2 (R140Q)
aml_ohsu_2022	aml_ohsu_2022_2291	aml_ohsu_2022_2291_BA2201	68	68	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves1+2	Yes	HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	10	FALSE	Positive	AML	28.306849315068497	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	23	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive	0	0.4	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 91%)|IKZF1 (p.Q156H; MAF 45%)|NPM1 (p.W288fs*; MAF 49%)|SF3B1 (p.K666Q; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2292	aml_ohsu_2022_2292_BA2386	52	52	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M1	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	5	FALSE	Positive	AML	20.81095890410959	1:DECEASED	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	Unknown	7	Complete Response	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+ and dim +), CD14(-), CD15(+), CD16(-), CD25(-), CD33(slightly bright +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(small subset +), CD64(-), CD117(dim and variably +), CD123(variably +), HLA-DR(+), TdT(	0	0.233333333	NA	Standard Chemotherapy	Yes	FLT3 (Foundation; A680V; MAF 6%)|FLT3 (Foundation; Y842C; MAF 2%)|KDM6A (Foundation; P738fs*2;MAF 31%)|NPM1 (Foundation; W288fs*10+; MAF 25%)|TET2 (Foundation; Q742*; MAF 45%)|TET2 (Foundation; R1712fs*6;MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2292	aml_ohsu_2022_2292_BA2879	52	53	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M1	Negative	FALSE	TRUE	FALSE	46,XX[20]	-1	Standard Chemotherapy	3	FALSE	Negative	AML	20.81095890410959	1:DECEASED	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	Unknown	7	Complete Response	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse	Bone Marrow Aspirate	NA	462	0.166666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2292	aml_ohsu_2022_2292_BA3400	52	54	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M1	Negative	FALSE	TRUE	FALSE	46,XX[20]	-1	Standard Chemotherapy	5	FALSE	Positive	AML	20.81095890410959	1:DECEASED	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	Unknown	7	Complete Response	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse	Peripheral Blood	NA	616	0.233333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2293	aml_ohsu_2022_2293_BA2268	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	No	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Unknown	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[19]	-1	Unknown	NA	FALSE	Negative	AML	2.663013698630137	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Peripheral Blood	positive for CD34, CD117,  CD13, CD33 and HLA-DR	0	0	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2294	aml_ohsu_2022_2294_BA2276	80	80	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	Decitabine, ABT-199|Hydroxyurea	2	Unknown|Supportive/Palliative Care	2	Standard Chemotherapy	1	Decitabine, ABT-199	Unknown	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	21	FALSE	Negative	AML	11.967123287671233	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	Unknown	NA	NA	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(few +), CD16 (-), CD33(variably +), CD34(+), CD36(-), CD38(partial + with an unusual pattern of expression vs. CD34), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), HLA-DR(dim 	0	1.1	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2295	aml_ohsu_2022_2295_BA2216	74	77	0.923076923	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	Decitabine|Quizartinib|Mitoxantrone	3	Induction|Experimental|Supportive/Palliative Care	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Mitoxantrone	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	46,XY[17]	18	Supportive/Palliative Care	3	FALSE	Negative	AML	41.556164383561644	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	1025	Refractory	RUNX1 (p.R166*; 40.0%)	2	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive	0	0.133333333	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2295	aml_ohsu_2022_2295_BA2859	74	77	0.01010101	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	Decitabine|Quizartinib|Mitoxantrone	3	Induction|Experimental|Supportive/Palliative Care	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Mitoxantrone	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	46,XY[20]	18	Supportive/Palliative Care	3	FALSE	Negative	AML	41.556164383561644	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	1025	Refractory	RUNX1 (p.R166*; 47.6%)	2	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive	166	0.133333333	NA	Standard Chemotherapy	No	FLT3-D835|FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2296	aml_ohsu_2022_2296_BA2605	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	NA	None	2	FALSE	Positive	AML	0.0	NA	NA	Yes	No	Pyoderma Gangrenosum	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Relative increase in CD117pos,CD34neg myeloid blasts, representing 16% of total leukocytes, most consistent with myeloid neoplasm such as advanced MDS or AML.	0	0.1	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2297	aml_ohsu_2022_2297_BA2168	47	48	3.166666667	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	TRUE	FALSE	46,XX	-1	Standard Chemotherapy	1	FALSE	Negative	AML	19.134246575342466	1:DECEASED	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	Unknown	-1	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Post-Transplant|Relapse	Peripheral Blood	CD2(-), CD4(partial +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(variably +), CD56(partial +), CD64(-), CD117(partial +), HLA-DR(partial dim +)	0	0	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2298	aml_ohsu_2022_2298_BA2360	78	79	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	bi	1	Waves1+2	Yes	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	45,X,-Y[19]/46,XY[1]	-1	Standard Chemotherapy	3	FALSE	Negative	AML	8.778082191780822	1:DECEASED	Normal	Yes	No	Bladder Cancer	No	No	No	No	No	No	White	-1	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with mutated CEBPA	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +	0	0.133333333	NA	Standard Chemotherapy	Yes	CEBPA (1031?1032 ins AAC; MAF 50%)|CEBPA (347?348 del GACCTGT; MAF 50%)|WT1 (p.R369R; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2300	aml_ohsu_2022_2300_BA2808	56	56	0.388888889	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	TRUE	FALSE	FALSE	40~43,XY,add(1)(p36),-2,-4,-5,-8,-12,-14,-15,-16,-17,?add(17)(p13),der(19)?t(8;19)(q11.2;p13),-20,-22,+7mar[cp18]	-1	Bone Marrow Transplant	12	FALSE	Negative	AML	6.50958904109589	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	27	Complete Response	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34, CD38 (dim), CD13, CD33 (dim),CD64 (partial), CD11c, CD4 (partial), CD15, CD117, HLA-DR, and MPO(partial).	0	0.633333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2301	aml_ohsu_2022_2301_BA2153	70	70	0	ASXL1 (p.Q588*; MAF 43% )	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine	4	Salvage|Induction	2	Standard Chemotherapy|Supportive/Palliative Care	2	Azacitidine, Itacitinib	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M0	Negative	FALSE	FALSE	FALSE	47,XY,+4[9]/46,XY[11]	449	Standard Chemotherapy	6	FALSE	Negative	AML	45.66575342465754	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	3	Male	MATCHED	FALSE	AML with minimal differentiation	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD7, CD13, CD33, CD34, CD38, CD56, CD117, CD123, HLA-DR and MPO+ (see Note) (Expression of the following antigens is dim and/or partial: CD7, CD33, CD34, CD38, CD56, CD123, HLA-DR and MPO.) | Small clonal B cell population (<1% of total cells); CD19, CD2	15	0.233333333	NA	Standard Chemotherapy	Yes	ASXL1 (p.Q588*; MAF 43% )
aml_ohsu_2022	aml_ohsu_2022_2301	aml_ohsu_2022_2301_BA2674	70	71	0	ASXL1 (p.Q588*; MAF 49%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine	4	Salvage|Induction	2	Standard Chemotherapy|Supportive/Palliative Care	2	Azacitidine, Itacitinib	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M0	Negative	FALSE	TRUE	FALSE	47,XY,+4[2]/46,XY[18]	449	Standard Chemotherapy	6	FALSE	Negative	AML	45.66575342465754	1:DECEASED	Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	3	Male	MATCHED	FALSE	AML with minimal differentiation	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	partial CD7 (~35%), CD13, partial dim CD33, CD34, CD38, variable CD56, and CD117	281	0.266666667	NA	Standard Chemotherapy	No	ASXL1 (p.Q588*; MAF 49%)
aml_ohsu_2022	aml_ohsu_2022_2301	aml_ohsu_2022_2301_BA2809	70	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine	4	Salvage|Induction	2	Standard Chemotherapy|Supportive/Palliative Care	2	Azacitidine, Itacitinib	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M0	Negative	FALSE	FALSE	FALSE	47,XY,+4[2]/46,XY[18]	449	Standard Chemotherapy	4	FALSE	Negative	AML	45.66575342465754	1:DECEASED	Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	3	Male	MATCHED	FALSE	AML with minimal differentiation	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	423	0.2	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2302	aml_ohsu_2022_2302_BA2881	66	67	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Quizartinib	4	Consolidation|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Quizartinib	Experimental	Residual	Myeloproliferative Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	57	Targeted Therapy - Kinase Inhibitor(s)	4	FALSE	Positive	AML	12.0	1:DECEASED	normal	No	No	NA	No	No	No	No	Yes	Yes	White	7	Complete Response	NA	1	Male	UNMATCHED	FALSE	Mastocytosis	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, partial CD34, CD38, CD117 and CD123	386	0.2	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2303	aml_ohsu_2022_2303_BA2281	25	25	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,XY,t(4;15;17)(q21;q22;q21),add(12)(p12)[1]/46,idem,t(5;22)(q11.2;q11.2)[18]/46,XY[1]	28	Standard Chemotherapy	NA	FALSE	Negative	AML	1.1506849315068493	0:LIVING	FISH c/w PML/RARA fusion	No	No	NA	No	No	No	No	No	No	White	28	Complete Response	NA	1	Male	UNMATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, dim CD15, CD34, bright CD33, variable CD56, CD64, CD117, CD123, variable HLA-DR, and bright MPO	0	NA	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2304	aml_ohsu_2022_2304_BA2000	24	24	0.666666667	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	mono	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	6	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	14	FALSE	Negative	AML	20.81095890410959	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Leukapheresis	weak CD4, partial  CD7, partial CD11b, CD13, CD33, partial CD34, weak CD64,  CD117, MPO, and HLA-DR	0	0.7	NA	Standard Chemotherapy	Yes	CEBPA (p.Gln41fs; MAF 4%)|FLT3-ITD (p.Glu611_Phe612ins27; MAF 8%)|JAK3 (p.Gln865Glu; MAF 48.9%)
aml_ohsu_2022	aml_ohsu_2022_2305	aml_ohsu_2022_2305_BA2110	65	65	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Fludarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC	5	Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	46,XX[20]	4	Standard Chemotherapy	7	FALSE	Positive	AML	14.432876712328767	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive	0	0.266666667	NA	Standard Chemotherapy	Yes	DNMT3A ( p.R882H; MAF 50%)|FLT3-ITD (MAF 10%)|FLT3-N676K (MAF 12%)|NPM1 (p.W288fs*12; MAF 50%)|PTPN11 (p.F71L; MAF 14%)
aml_ohsu_2022	aml_ohsu_2022_2306	aml_ohsu_2022_2306_BA2828	64	64	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Induction|Re-induction	2	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	FALSE	FALSE	FALSE	46,XY,inv(16)(p13q22)[17]/46,XY[3]	5	Standard Chemotherapy	2	FALSE	Negative	AML	71.5068493150685	0:LIVING	c/w karyotype	Yes	No	Mature B-Cell Neoplasm	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.1	NA	Standard Chemotherapy	Yes	KRAS (p.G12D; MAF 27%)|NOTCH1 (p.G2299S; MAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2307	aml_ohsu_2022_2307_BA2414	50	50	0.818181818	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	5	Waves1+2	Yes	GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	FALSE	FALSE	FALSE	46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20]	-1	Bone Marrow Transplant	10	FALSE	Negative	AML	6.608219178082191	1:DECEASED	Loss of 5q31 sequences for 99% of total cells | Loss of 7q31 sequences for 96% of total cells	Yes	No	Hodgkin Lymphoma	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	Positive: CD38, CD56, CD13, CD34, CD45, CD117, HLA-DR | Partially positive: CD7, CD11b, CD33, CD64 | Negative: CD19, CD22, Cyt CD79a, Cyt CD3, CD14, CD15, MPO, TdT	0	0.366666667	NA	Standard Chemotherapy	Yes	BCOR (C.3067T>C; p.F1023L)|FLT3-ITD|NOTCH1 (c.7625G>A; p.S2542N)
aml_ohsu_2022	aml_ohsu_2022_2308	aml_ohsu_2022_2308_BA2197	50	55	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Supportive/Palliative Care	2	Decitabine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20]	-1	Supportive/Palliative Care	30	FALSE	Negative	AML	63.71506849315068	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	6	Complete Response	NA	2	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT	0	1.8	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2308	aml_ohsu_2022_2308_BA2526	50	55	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Supportive/Palliative Care	2	Decitabine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20]	-1	Supportive/Palliative Care	NA	FALSE	Negative	AML	63.71506849315068	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	6	Complete Response	NA	2	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Peripheral Blood	ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT	0	NA	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2309	aml_ohsu_2022_2309_BA2726	29	29	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	5	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	2	Supportive/Palliative Care	2	FALSE	Positive	AML	4.241095890410959	1:DECEASED	Normal	Yes	No	Basal Cell Carcinoma	No	No	No	No	No	No	White	5	Refractory	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD11b, CD13, CD14, CD33, CD56 and bright CD64+	0	0.1	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2309	aml_ohsu_2022_2309_BA3076	29	29	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	5	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Hydroxyurea	Supportive/Palliative Care	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Negative	FALSE	TRUE	FALSE	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	2	Supportive/Palliative Care	2	FALSE	Positive	AML	4.241095890410959	1:DECEASED	Normal	Yes	No	Basal Cell Carcinoma	No	No	No	No	No	No	White	5	Refractory	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Relapse|Post-Transplant	Peripheral Blood	NA	82	0.066666667	NA	Standard Chemotherapy	No	KRAS (p.G12V; MAF 76%)
aml_ohsu_2022	aml_ohsu_2022_2309	aml_ohsu_2022_2309_BA3077	29	29	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	5	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	2	Supportive/Palliative Care	4	FALSE	Positive	AML	4.241095890410959	1:DECEASED	Normal	Yes	No	Basal Cell Carcinoma	No	No	No	No	No	No	White	5	Refractory	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease|Post-Transplant	Peripheral Blood	NA	126	0.166666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2310	aml_ohsu_2022_2310_BA2124	67	67	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|IDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	IDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	25	FALSE	Positive	AML	19.035616438356165	0:LIVING	Normal	Yes	No	Skin cancer	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD33, CD38, CD56, CD117, and myeloperoxidase	0	1.433333333	NA	Standard Chemotherapy	Yes	NPM1 (p.Trp288fs; MAF 16.4%)|TET2 (p.Leu1081fs; MAF 42.3%)|TET2 (p.Leu1780fs; MAF 46.3%)|ZRSR2 (p.Arg126*; MAF 97.7%)
aml_ohsu_2022	aml_ohsu_2022_2311	aml_ohsu_2022_2311_BA2529	64	64	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Radiation|Paclitaxel|Doxorubicin|Cisplatin|5-FU	5	Symptom Control|Supportive/Palliative Care	2	Supportive/Palliative Care|Other	2	Paclitaxel	Supportive/Palliative Care	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	274	Supportive/Palliative Care	4	FALSE	Negative	AML	14.728767123287671	0:LIVING	NA	Yes	No	Endometrial cancer	No	No	No	No	No	No	NA	NA	NA	NA	2	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy	Bone Marrow Aspirate	No increased or immunophenotypically abnormal nlast cell populations identified. (Bone Marrow Immunophenotyping)	126	0.166666667	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2311	aml_ohsu_2022_2311_BA2945	64	64	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Radiation|Paclitaxel|Doxorubicin|Cisplatin|5-FU	5	Symptom Control|Supportive/Palliative Care	2	Supportive/Palliative Care|Other	2	Paclitaxel	Supportive/Palliative Care	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	274	Supportive/Palliative Care	8	FALSE	Negative	AML	14.728767123287671	0:LIVING	NA	Yes	No	Endometrial cancer	No	No	No	No	No	No	NA	NA	NA	NA	2	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy	Bone Marrow Aspirate	Granulocytes are significantly decreased (Bone marrow Immunophenotyping)	0	0.333333333	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2312	aml_ohsu_2022_2312_BA2337	53	53	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	FALSE	FALSE	FALSE	46,XX,t(8;21)(q21.3;q22)[18]/46,XX[2]	109	Standard Chemotherapy	14	FALSE	Negative	AML	92.18630136986302	0:LIVING	RUNX1T1/RUNX1 fusion	Yes	No	Other malignant neoplasm without specification of site	No	No	No	No	No	No	Multiracial	6	Complete Response	NA	1	Female	MATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, dim CD33, CD34, partal CD117, dim CD123, HLA-DR, MPO, and partial dim TdT	4	0.633333333	NA	Standard Chemotherapy	Yes	KDM6A (p.Q154fs*7; MAF 8%)|KDM6A (p.V1113fs*; MAF 30%)|KIT (p.D820G; MAF 4%)
aml_ohsu_2022	aml_ohsu_2022_2313	aml_ohsu_2022_2313_BA2707	68	72	0	ASXL1 (p.G646Wfs*12; 27.9%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Both	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|Decitabine	3	Consolidation|Induction|Supportive/Palliative Care	3	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Negative	FALSE	TRUE	FALSE	47,XY,del(9)(q22),+13[18]/48,idem,+mar[2]	9	Standard Chemotherapy	5	FALSE	Negative	AML	40.701369863013696	1:DECEASED	Missing ABL and ASS signal (84%)	Yes	Yes	Lung Cancer	No	No	No	No	No	No	White	7	Complete Response	RUNX1 (p.A147Gfs*13; 42.3%)|RUNX1 (p.R162S; 46.5%)	1	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Relapse|Post-Chemotherapy	Peripheral Blood	partial CD7, CD11b, CD13, CD33, CD34, partial CD64, partial CD117, CD123, HLA-DR, and TdT-positive.	1207	0.233333333	NA	Standard Chemotherapy	No	RUNX1 (p.A147fs*13 (1 bp insertion frameshift); MAF 35%)|RUNX1 (p.R162S; MAF 50%)|SRSF2 (p.P95R; MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2314	aml_ohsu_2022_2314_BA2603	63	63	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	10	FALSE	Positive	AML	80.15342465753425	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive (Myeloid blast phenotype) | CD11b, variable CD13, CD14, CD33, dimCD56, CD64, HLA-DR-positive (Monocytic phenotype)	0	0.533333333	NA	Standard Chemotherapy	Yes	CREBBP (p.V319I; MAF 50%)|DNMT3A (p.R882H; MAF 50%)|DNMT3A (p.T138I; MAF 50%)|NPM1 (p.W288fs*12; MAF 50%)|NRAS (p.Q61H; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2315	aml_ohsu_2022_2315_BA2519	61	62	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	7	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	TRUE	FALSE	46,XX[20]	NA	None	7	FALSE	Positive	AML	11.868493150684932	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	Black	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Peripheral Blood	NA	0	0.333333333	NA	NA	Yes	CUX1 (VAF: 43.9%)|DNMT3A (VAF: 42.8%)|NPM1 (VAF: 44.9%)|WT1 (VAF: 23.2%)
aml_ohsu_2022	aml_ohsu_2022_2316	aml_ohsu_2022_2316_BA2233	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea	2	Induction	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M1	Negative	TRUE	FALSE	FALSE	46,XY[5]	-1	Standard Chemotherapy	11	FALSE	Positive	AML	3.1232876712328768	0:LIVING	D5S721, EGR1 del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR	0	0.5	NA	Standard Chemotherapy	Yes	FLT3 (p.D839G; MAF~45%)|IDH2 (p.R140L; MAF ~50%)|MLL2 (p.V2338I; MAF ~50%)|NPM1 (p.W288fs*12;MAF ~35%)|SRSF2 (p.P95H, MAF~55%)
aml_ohsu_2022	aml_ohsu_2022_2317	aml_ohsu_2022_2317_BA2199	34	34	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX[20]	105	Standard Chemotherapy	11	FALSE	Negative	AML	29.391780821917806	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	24	Complete Response	NA	2	Female	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34, CD117,partial CD13, CD33, CD38, partial CD64, dim CD7, variable CD15, HLA-DR and bright MPO	0	0.6	NA	Standard Chemotherapy	Yes	CEBPA (Double positive: p.Ser17Profs*99 and p.Lys313dup)|KRAS
aml_ohsu_2022	aml_ohsu_2022_2317	aml_ohsu_2022_2317_BA2915	34	34	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX[20]	105	Standard Chemotherapy	11	FALSE	Negative	AML	29.391780821917806	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	24	Complete Response	NA	2	Female	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34, CD117,partial CD13, CD33, CD38, partial CD64, dim CD7, variable CD15, HLA-DR and bright MPO	0	0.566666667	NA	Standard Chemotherapy	No	CEBPA (Double positive: p.Ser17Profs*99 and p.Lys313dup)|KRAS
aml_ohsu_2022	aml_ohsu_2022_2318	aml_ohsu_2022_2318_BA2022	33	33	0.923076923	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	ATRA, Arsenic Trioxide	1	Consolidation|Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M3	Positive	TRUE	FALSE	FALSE	NA	-1	Standard Chemotherapy	1	FALSE	Negative	AML	18.378082191780823	0:LIVING	This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored.	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large population of CD117pos, CD34neg, HLA-DR neg myeloblasts, representing 78% of leukocytes consistent w/AML.	0	0	NA	Standard Chemotherapy	Yes	FLT3-ITD (p.Leu601_Lys602ins9; MAF 15%)
aml_ohsu_2022	aml_ohsu_2022_2319	aml_ohsu_2022_2319_BA2027	70	70	4	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Hydroxyurea	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Hydroxyurea	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	FALSE	FALSE	FALSE	NA	1	Standard Chemotherapy	12	FALSE	Positive	AML	0.1315068493150685	1:DECEASED	Negative	Yes	No	Prostate Cancer	No	No	No	No	No	No	White	1	NA	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Positive (increased CD34 positive blasts (50-60%), CD71 Decreased erythroid cells (less than 5%), CD61 Few scattered megakaryocytes, E-cadherin; Scattered immature erythroid precursors, CD117: Increased immature myeloid cells and blasts (70-80%), CD3: Sca	0	0.466666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 50%)|NPM1 (p.W288fs*12;MAF 40%)|SOCS1 (p.Q210H; MAF 50%)|TET2 (p.S460F; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2320	aml_ohsu_2022_2320_BA2184	47	47	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	bi	1	Waves1+2	Yes	HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	7	FALSE	Negative	AML	19.134246575342466	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	5	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, CD33, CD34, CD38, CD58, CD117, dim CD123 HLA-DR and MPO+ ,	0	0.3	NA	Standard Chemotherapy	Yes	CEBPA (p.D320_N321ins22; MAF 50%)|CEBPA (p.R35fs*125; MAF 50%)|CREBBP (p.P505L; VAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2321	aml_ohsu_2022_2321_BA2171	73	73	0.428571429	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	UNKNOWN	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	3	Standard Chemotherapy	8	FALSE	Positive	AML	0.1315068493150685	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	Unknown	3	Unknown	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, and MPO	0	0.266666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.R326P; MAF 50%)|FLT3-ITD (MAF 46%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2322	aml_ohsu_2022_2322_BA2837	78	80	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	AG-120|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	5	Consolidation|Induction|Experimental|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Other	2	AG-120	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	45,XY,-7[2]/45,XY,t(6;8)(q21;q21.2),-7,del(10)(q24q26),t(12;15)(p13;q15)[19]	-1	Targeted Therapy - Other	2	FALSE	Negative	AML	19.89041095890411	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Yes	No	Esophageal Cancer	No	No	No	No	No	No	White	7	Complete Response	NA	1	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy	Peripheral Blood	CD2(subset +), CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial +), CD38(variably +), CD45(+), CD56(partial +), CD64(-), CD117(+), HLA-DR(partial +). (63% population)	0	0.1	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2323	aml_ohsu_2022_2323_BA2532	42	42	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate|Methotrexate	3	Induction|Experimental|Maintenance	3	Standard Chemotherapy|Targeted Therapy - Other|Intrathecal	3	ATRA, 6-MP, Methotrexate	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M3	Negative	FALSE	FALSE	FALSE	46,XX,t(15;17)(q24;q21.1)[1]	-1	Standard Chemotherapy	7	FALSE	Negative	AML	31.2986301369863	0:LIVING	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x3(PML con RARAx2)[154/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Yes	No	Cervical Cancer|Pituitary Tumor	No	No	No	No	No	No	Unknown	22	Complete Response	NA	1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(partial +), CD11b(few dim +), CD13(+), CD14(-), CD15(-), CD16 (-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(+), CD117(variably +), CD123(+), HLA-DR(-), myeloperoxidase(+), and TdT(-).	0	0.366666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2324	aml_ohsu_2022_2324_BA3027	53	53	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)	2	Induction|Re-induction	2	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	53~55,XX,+1,+2,der(5)t(5;13)(q13;q12),+6,add(7)(q32),+8,+11,-13,+14,i(17)(q10),+19,+19,+21,+mar[cp7]/46,XX[7]	17	Standard Chemotherapy	7	FALSE	Negative	AML	2.367123287671233	1:DECEASED	Gain of 8 (4/301 cells); Gain of 8q22/21q22 (7.7/301 cells); Gain 11q23 (5/200 cells)	Yes	No	Ovarian cancer	No	No	No	No	No	No	NA	29	Complete Response	NA	1	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	33	0.266666667	TP53 (p.S215R; 15.2%)	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2325	aml_ohsu_2022_2325_BA2864	77	78	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	mono	4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M4	Negative	FALSE	FALSE	TRUE	45,X,-Y,del(7)(p15)[4]/46,XY[16]	-1	Standard Chemotherapy	5	FALSE	Negative	AML	2.334246575342466	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	NA	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	CD34, CD117, CD2,PARTIAL CD4, CD13, CD33, CD38, PARTIAL CD64, PARTIAL CD11c, HLA-DR AND DIM MPO	0	0.233333333	NA	Standard Chemotherapy	Yes	CEBPA (Double positive)
aml_ohsu_2022	aml_ohsu_2022_2326	aml_ohsu_2022_2326_BA2239	66	66	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XY[20]	74	Standard Chemotherapy	9	FALSE	Positive	AML	90.60821917808218	0:LIVING	normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, dim/partial CD13, CD14, CD33, CD38, CD58, CD64,     partial CD117, dim/partial CD123, and HLA-DR positive	0	0.566666667	NA	Standard Chemotherapy	Yes	CREBBP (p.Q2208H; MAF 50%)|DNMT3A (p.R882H; MAF 50%)|NPM1 (W288fs*>9; MAF 50%)|WT1 (rs16754; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2327	aml_ohsu_2022_2327_BA2970	63	63	9	ASXL1 (p.W898*; 42.1%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	No	Ruxolitinib|Hydroxyurea	2	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Positive	FALSE	FALSE	TRUE	46,XY[20]	103	Supportive/Palliative Care	11	FALSE	Positive	AML	0.263013698630137	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	Yes	Yes	Black	NA	NA	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-).	0	0.4	NA	NA	Yes	ASXL1 (Foundation; W898*; MAF 47%)|KRAS (Foundation; A59T mutation; MAF 47%)|KRAS (Foundation; G13C; MAF 3%)|SUZ12 (Foundation; W617*; MAF 49%)
aml_ohsu_2022	aml_ohsu_2022_2328	aml_ohsu_2022_2328_BA2502	50	50	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction	5	Standard Chemotherapy|Other	2	Hydroxyurea	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M0	Negative	FALSE	FALSE	FALSE	48,XX,+11,+13[19]	365	Other	5	FALSE	Negative	AML	9.928767123287672	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with minimal differentiation	Residual Disease	Peripheral Blood	NA	0	0.266666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2329	aml_ohsu_2022_2329_BA2559	42	42	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, TBI	4	Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M5	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	28.865753424657534	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Female	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	The immature cells were positive for CD13, CD33, and many showed aberrant expression of CD7. The myeloblast portion was positive for CD34, CD117, and HLA-DR.  The immature monocyte portion was negative for CD34 and CD117, and expressed variable CD64 (incl	0	0.133333333	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 34.8%)|RUNX1 (p.L29S; MAF 52.7%)
aml_ohsu_2022	aml_ohsu_2022_2330	aml_ohsu_2022_2330_BA2375	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Negative	FALSE	FALSE	TRUE	46,XY,-7,+mar.ishder(7)del(7)(p11.2)del(7)(q11.2)(D7Z1+)[20]/45,XY,-7[2]/46,XY[3]	-1	Standard Chemotherapy	11	FALSE	Negative	AML	3.5178082191780824	1:DECEASED	Two of twenty-five metaphase cells examined were monosomy 7, shown by  fluorescent in situ hybridization (FISH) in  a companion study  (GLC-13-06587) to be a true clone.  Twenty cells appeared to be missing a  chromosome 7 with an additional small marker.	No	No	NA	No	No	No	No	Yes	Yes	Black	NA	NA	RUNX1 (p.R166G; MAF 22%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	CD13, dimCD19, partial CD33, partial CD34, CD38, CD58, dim cCD79a, CD117, and TdT positive.	0	0.466666667	NA	NA	Yes	CBL (p.L370del; MAF 63%)|JAK2 (p.V617F; MAF 43%)|RUNX1 (p.R166G; MAF 22%)|U2AF1 (p.Q157R; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2331	aml_ohsu_2022_2331_BA2332	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Azacitidine|Methotrexate|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Unknown|Induction	4	Standard Chemotherapy|Unknown|Bone Marrow Transplant	3	Azacitidine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Negative	FALSE	FALSE	TRUE	46,XY[20]	182	Standard Chemotherapy	15	FALSE	Negative	AML	90.34520547945205	0:LIVING	Normal	Yes	No	Squamous cell carcinoma	Yes	Yes	No	No	No	No	White	4	Refractory	RUNX1 (p.S100F; 12.8%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and TdT-positive	0	0.833333333	NA	Standard Chemotherapy	Yes	RUNX1 (p.A142?E143insGA; MAF 14%)|RUNX1 (p.S100F; MAF 17%)
aml_ohsu_2022	aml_ohsu_2022_2332	aml_ohsu_2022_2332_BA2989	70	71	0.086956522	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	47,XY,+21[19]/46,XY[1]	98	Standard Chemotherapy	8	FALSE	Negative	AML	10.027397260273972	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],	No	No	NA	No	No	No	No	No	No	White	NA	NA	RUNX1 (p.I366Vfs*231; 65.5%)	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD2(-), CD4(dim +), CD7(-), CD10(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD22(-), CD19(partial +), CD33(partial +), CD34(+), CD36(-), CD38(bright and variably +), CD45(+), CD56(-), CD64(-), CD79a(-), CD117(+), HLA-DR(predominantly	0	0.4	NA	NA	Yes	BCOR (Foundation; R1480*; MAFs: 88%)|BCORL1 (Foundation; P304fs*117; MAFs: 72%)|FLT3-ITD|NF1 (Foundation; I679fs*21; MAFs: 5%)|NF1 (Foundation; V2649fs*31 (subclonal); MAFs: 12%)|PHF6 (Foundation; R225*; MAFs: 87%)|PTPN11 (Foundation; A72T; MAFs: 8%)|RUNX
aml_ohsu_2022	aml_ohsu_2022_2333	aml_ohsu_2022_2333_BA2417	70	70	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	3	Standard Chemotherapy	1	Vidaza	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	NA	4	Standard Chemotherapy	NA	FALSE	Negative	AML	15.978082191780823	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD11b(partial +), CD13(equivocal), CD15(bright +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(bright +), CD45(bright +), CD56(+),CD64(bright+), CD117(-), and HLA-DR(+).	0	0	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2334	aml_ohsu_2022_2334_BA2251	85	85	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	bi	1	Waves1+2	Yes	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	105	Standard Chemotherapy	1	FALSE	Negative	AML	5.49041095890411	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with mutated CEBPA	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	0	0.033333333	NA	NA	Yes	CEBPA (p.F77*83; MAF 50%)|CEBPA (p.K313_V314insK; MAF 50%)|TET2 (p.I1025L; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2335	aml_ohsu_2022_2335_BA2309	64	77	NA	NA	Myeloproliferative Neoplasms	Myeloproliferative Neoplasms	Alive	NA	7	Waves1+2	Yes	Ruxolitinib|Imatinib|Hydroxyurea	3	Induction|Re-induction	2	Standard Chemotherapy	1	Ruxolitinib	Re-induction	NA	Myeloproliferative Neoplasms	NonAML	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	47,XY,+der(1;9)(q10;p10)[17]/94,idemx2[2]/46,XY[1]	-1	Standard Chemotherapy	3	FALSE	Negative	MPN	177.43561643835616	0:LIVING	Fluorescent in situ hybridization (FISH) was performed with a 9p/CEP 9 probe set. Both probes hybridized to the derivative chromosome. 90/100 (90%) interphase cells scored had a 3 red/ 3 green signal pattern, reflecting the extra derivative.	No	No	NA	No	No	No	No	Yes	No	White	4626	NA	NA	1	Male	UNMATCHED	TRUE	Essential thrombocythaemia	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive	0	0.166666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2336	aml_ohsu_2022_2336_BA2302	78	78	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Azacitidine, MLN4924	1	Induction	1	Standard Chemotherapy	1	Azacitidine, MLN4924	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	111	Standard Chemotherapy	24	FALSE	Negative	AML	5.293150684931507	1:DECEASED	NA	Yes	No	Uterine Sarcoma	No	No	No	No	No	No	NA	111	Refractory	NA	2	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR	0	1.133333333	NA	Standard Chemotherapy	Yes	IDH1
aml_ohsu_2022	aml_ohsu_2022_2336	aml_ohsu_2022_2336_BA2343	78	78	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Azacitidine, MLN4924	1	Induction	1	Standard Chemotherapy	1	Azacitidine, MLN4924	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	111	Standard Chemotherapy	16	FALSE	Negative	AML	5.293150684931507	1:DECEASED	NA	Yes	No	Uterine Sarcoma	No	No	No	No	No	No	NA	111	Refractory	NA	2	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR	0	0.9	NA	Standard Chemotherapy	No	IDH1
aml_ohsu_2022	aml_ohsu_2022_2337	aml_ohsu_2022_2337_BA2363	79	79	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Azacitidine|Decitabine|Hydroxyurea|V212	4	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	2	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	3	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY[22]	-1	Supportive/Palliative Care	2	FALSE	Negative	AML	4.997260273972603	1:DECEASED	Normal	No	No	NA	No	No	Yes	Yes	No	No	White	NA	NA	RUNX1 (p.R320*; 44.9%)	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD13, dim CD33, bright CD34, CD38, CD117, dim HLA-DR positive	35	0.133333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2338	aml_ohsu_2022_2338_BA2198	61	61	0	ASXL1 (p.E635Rfs*15; 10.5%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M2	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	26	FALSE	Negative	AML	1.3808219178082193	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	RUNX1 (p.R166Q; 46.0%)|RUNX1 (p.R162K; 44.5%)	2	Male	MATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)	0	1.5	NA	Standard Chemotherapy	Yes	ASXL1 (p.Glu635Argfs*15; MAF 9%)|CSF3R (p.Tyr779*; MAF 5.4%)|IDH2 (p.Arg140Gln; 37.7%)|PHF6 (p.Arg319*; MAF 88.6%)|RUNX1 (p.Arg162Lys; MAF 43%)|RUNX1 (p.Arg166Gln; MAF 35.3%)|SMC1A (p.Arg790Gln; 9.2%)|U2AF1 (p.Gln157Pro; MAF 51.3%)
aml_ohsu_2022	aml_ohsu_2022_2338	aml_ohsu_2022_2338_BA2933	61	61	NA	ASXL1 (p.E635Rfs*15; 20.2%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M2	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	28	FALSE	Negative	AML	1.3808219178082193	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	RUNX1 (p.R166Q; 41.5%)|RUNX1 (p.R162K; 47.6%)	2	Male	MATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)	0	1.566666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.Glu635Argfs*15; MAF 9%)|CSF3R (p.Tyr779*; MAF 5.4%)|IDH2 (p.Arg140Gln; 37.7%)|PHF6 (p.Arg319*; MAF 88.6%)|RUNX1 (p.Arg162Lys; MAF 43%)|RUNX1 (p.Arg166Gln; MAF 35.3%)|SMC1A (p.Arg790Gln; 9.2%)|U2AF1 (p.Gln157Pro; MAF 51.3%)
aml_ohsu_2022	aml_ohsu_2022_2339	aml_ohsu_2022_2339_BA2564	18	18	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	1	Induction|Re-induction	2	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XX,inv(16)p13.1q22)[4]/47,idem,+22[15]/46,XX[1]	-1	Standard Chemotherapy	1	FALSE	Negative	AML	17.753424657534246	0:LIVING	CBFB rearrangement and inv(16) (64%) | +22 (71%)	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	Blast phenotype:  CD13, CD33, CD34, CD38, CD58, dim CD123,     HLA-DR-positive               - Monocytic phenotype:  CD11b, CD13, CD14, CD33, CD58, CD64, HLA-DR-positive	0	0.066666667	NA	Standard Chemotherapy	Yes	KRAS (p.G13D; MAF 10%)|NRAS (p.G13D; MAF 30%)
aml_ohsu_2022	aml_ohsu_2022_2340	aml_ohsu_2022_2340_BA2286	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[20]	7	Standard Chemotherapy	NA	FALSE	Negative	AML	1.084931506849315	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	7	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD117, dim CD123, HLA-DR,partial MPO (+)	0	NA	NA	Standard Chemotherapy	Yes	FLT3-D835
aml_ohsu_2022	aml_ohsu_2022_2341	aml_ohsu_2022_2341_BA2174	46	46	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	7	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan, ATG	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18]	-1	Bone Marrow Transplant	24	FALSE	Negative	AML	20.942465753424656	1:DECEASED	Normal	Yes	No	Anaplastic Astrocytoma	No	No	No	No	No	No	White	1	Refractory	NA	2	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	Immunophenotype: CD13, CD34, CD38, CD58, CD117, CD123, HLA-DR and TdT-positive; small subset of blasts also express CD19, CD22, and CD79a	0	1.266666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.I824V; VAF 50%)|GATA1 (p.S412R; MAF 60%)|NRAS (p.G13R; MAF 50%)|RUNX1 (p.T196I ; MAF 50%)|U2AF1 (p.I24T; MAF 5%)
aml_ohsu_2022	aml_ohsu_2022_2341	aml_ohsu_2022_2341_BA2314	46	46	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	7	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan, ATG	Double Umbilical Cord Blood Transplant (DUCBT)	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX[19]	-1	Bone Marrow Transplant	30	FALSE	Negative	AML	20.942465753424656	1:DECEASED	Normal	Yes	No	Anaplastic Astrocytoma	No	No	No	No	No	No	White	1	Refractory	NA	2	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	163	1.733333333	NA	Standard Chemotherapy	No	NRAS (p.G13R;MAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2342	aml_ohsu_2022_2342_BA2139	48	48	0.785714286	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16	4	Consolidation|Induction|CNS|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	TBI, VP-16	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M5b	Positive	TRUE	FALSE	FALSE	46,XX	-1	Bone Marrow Transplant	3	FALSE	Positive	AML	30.871232876712327	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia. | Large population o	0	0.1	NA	Standard Chemotherapy	Yes	DNMT3A (p.Arg882Cys; MAF 47.1%)|FLT3-ITD|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.9%)
aml_ohsu_2022	aml_ohsu_2022_2343	aml_ohsu_2022_2343_BA2093	51	51	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|Bu/Cy/TBI	5	Consolidation|Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant	2	Azacitidine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Negative	TRUE	FALSE	FALSE	60~61<3n>,XYY,-1,-2,-3,-4,-5,del(5)(q13q33),-6,-7,+8,-9,+11,-12,+13,-15,-16,-17,-18,+21,+22[cp15]/70~73,idem,+Y,+1,+2,+5,+del(5)(q13q33),+6,+9,+11,+12,+20,+20[cp4]/46,XY[1]	62	Standard Chemotherapy	17	FALSE	Negative	AML	20.646575342465752	1:DECEASED	EGR-1/ D5S23, D5S721: 60/100 cells (60%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the first clone, above; 38 cells (38%) had a 2 red/ 4 green signal pattern, consistent with two copies of the deleted 5q in the second c	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7, CD13, dim partial CD22, CD33, CD3,  partial CD56, dim CD71, CD117, dim CD123, and dim HLA-DR	0	1.033333333	TP53 (p.X187_splice; 40.1%)|TP53 (p.X125_splice; 28.4%)	Standard Chemotherapy	Yes	NRAS (p.G13D; MAF ~40%)|TP53 (Splice site (3' splice site mutation, intron 5); MAF 42%)|TP53 (Splice site (5' splice site mutation in intron 4); MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2344	aml_ohsu_2022_2344_BA3001	51	51	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	22	FALSE	Positive	AML	62.7945205479452	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	2	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Immunophenotype: CD7, CD13, CD33, CD38, CD117, CD123 and MPO positive	0	1.166666667	NA	Standard Chemotherapy	Yes	CBL (p.R420Q; MAF ~20%)|FLT3 (p.N841K; MAF ~30%)|IDH2 (p.R140Q; MAF ~30%)|NPM1 (p.W288fs*12; MAF ~25%)
aml_ohsu_2022	aml_ohsu_2022_2345	aml_ohsu_2022_2345_BA2227	17	17	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Clofarabine, Cyclophosphamide, Etoposide|HAM (Cytarabine, Mitoxantrone)	3	Induction|Re-induction	2	Standard Chemotherapy	1	Clofarabine, Cyclophosphamide, Etoposide	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY[20]	5	Standard Chemotherapy	5	FALSE	Negative	AML	23.44109589041096	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	74	Refractory	NA	1	Male	UNMATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, partial CD33, CD34, CD38, moderate CD45, CD58, CD117, CD123, TdT, and partial MPO positive.	0	0.233333333	NA	Standard Chemotherapy	Yes	MLL (PTD)|WT1 (MAF A382fs*6; 40%)|WT1 (MAF p.R462G; 40%)|WT1 (p.R462G ; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2346	aml_ohsu_2022_2346_BA2709	30	30	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,inv(16)(p13q22)[20]	-1	Standard Chemotherapy	9	FALSE	Negative	AML	33.66575342465754	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(RUNX1T1,RUNX1)x2[200],(PML,RARA)x2[200], (5'CBFBx2,3'CBFBx1)(5CBFB sep 3'CBFBx1)[195/200],(ABL1,BCR)x2[200]	No	No	NA	No	No	No	No	No	No	Unknown	40	Complete Response	NA	1	Female	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34, CD13, partialCD15, CD38, CD45, CD117, CD123, HLA-DR, dimMPO (15% population of variably-sized blasts)	0	0.4	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2347	aml_ohsu_2022_2347_BA2621	74	74	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	6	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	45,XY,-7,del(12)(p11.2p13)[20]	NA	None	5	FALSE	Negative	AML	0.4602739726027397	1:DECEASED	Monosomy 7 is detected in 87% of cells.	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.233333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2348	aml_ohsu_2022_2348_BA2992	52	52	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,inv(16)(p13.1q22)[cp20]	8	Standard Chemotherapy	5	FALSE	Negative	AML	1.1835616438356165	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	8	Complete Response	NA	1	Female	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34, PARTIAL CD117, CD15, CD38, PARTIAL CD13, CD33, CD64, PARTIAL CD14(SUBSET), PARTIAL CD11c, DIM CD4, HLA-DR AND BRIGHT MPO	0	0.333333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2350	aml_ohsu_2022_2350_BA2459	55	55	0.234567901	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M1	Positive	TRUE	FALSE	FALSE	92<4n>,XXYY[13]/46,XY[7]	8	Standard Chemotherapy	18	FALSE	Negative	AML	1.4794520547945205	0:LIVING	The AML FISH panel analysis showed evidence of extra copies of the RUNX1T1 (8q24) and RUNX1 (21q22) genes in 95.5%, extra copies of the PML (15q24) and RARA (17q21.1) genes in 95.5%, and extra copies of the CBFB (16q22) gene in 96% of the cells examined.)	No	No	NA	No	No	No	No	No	No	NA	8	Unknown	NA	1	Male	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(partial dim +), CD7(-), CD11b (variably +), CD13(variably +), CD14(predominantly -), CD15(predominantly -/few scattered +), CD16(-), CD20(small subset +), CD33(partial +), CD34(variably +), CD36(small subset +), CD38(variably +), CD45(variably	0	0.966666667	NA	Standard Chemotherapy	Yes	IDH1 (p.R132C; MAF unlisted)
aml_ohsu_2022	aml_ohsu_2022_2351	aml_ohsu_2022_2351_BA2539	50	50	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|MiDAC	4	Consolidation|Induction|Re-induction|Maintenance	4	Standard Chemotherapy	1	Azacitidine	Maintenance	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	8	Standard Chemotherapy	1	FALSE	Negative	AML	13.972602739726028	1:DECEASED	showed multiple RUNX1 signals as well as a 3rd RUNX1 signal at 7p consistent with t(7;21)(p22;q22).	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy	Bone Marrow Aspirate	NA	0	0.033333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2352	aml_ohsu_2022_2352_BA2557	62	62	0.923076923	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	3	Induction|Re-induction	2	Standard Chemotherapy	1	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0/M1	Positive	FALSE	FALSE	TRUE	NA	4	Standard Chemotherapy	20	FALSE	Negative	AML	2.663013698630137	1:DECEASED	Tetrasomy 8 (67%)	No	No	NA	No	No	No	No	Yes	Yes	White	7	Refractory	NA	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	partial CD7, CD13, CD33 (variable), CD34, CD38 (variable), CD117(variable)	0	1.033333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2354	aml_ohsu_2022_2354_BA2018	44	44	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction	5	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Ponatinib	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	IntermediateOrAdverse	NA	NA	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Kinase Inhibitor(s)	12	FALSE	Negative	AML	11.243835616438357	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Unknown	NA	2	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia	0	0.766666667	NA	Standard Chemotherapy	No	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2354	aml_ohsu_2022_2354_BA2405	44	44	0.449275362	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction	5	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Ponatinib	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Kinase Inhibitor(s)	18	FALSE	Negative	AML	11.243835616438357	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Unknown	RUNX1 (p.Q262*; 72.4%)	2	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia	0	0.933333333	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2355	aml_ohsu_2022_2355_BA2891	63	63	NA	NA	Mature B-Cell Neoplasms	Mature B-Cell Neoplasms	Dead-Disease	NA	1	Waves1+2	Yes	CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone)|RVD (Bortezomib, Dexamethasone, Lenalidomide)	2	Induction|Re-induction	2	Standard Chemotherapy	1	RVD (Bortezomib, Dexamethasone, Lenalidomide)	Re-induction	NA	Mature B-Cell Neoplasms	NonAML	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	44,XX,+5,add(5)(q11.1),der(8)t(8;13)(p12;q12),-13,-14,t(15;21)(q10;q10),add(20)(p13)[13]/46,XX[7]	-1	Standard Chemotherapy	NA	TRUE	Negative	MBN	11.967123287671233	1:DECEASED	87% IgH/MAF fusion; 62% 5q deletion	No	No	NA	No	No	No	No	No	No	White	16	Unknown	NA	1	Female	UNMATCHED	FALSE	Plasma cell myeloma	NA	Peripheral Blood	bright CD38, moderate CD45, CD138, cytoplasmic kappalight chain+.	0	0	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2356	aml_ohsu_2022_2356_BA2121	36	36	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	HiDAC|3+7 (Cytarabine, Daunorubicin)|Hydroxyurea	3	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	45,X,-Y,t(8;2;21)(q22;p21;q22)[20]	103	Standard Chemotherapy	1	FALSE	Negative	AML	18.147945205479452	0:LIVING	RUNX1T1/RUNX1: (92%)	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, partial CD34, CD64, CD19 dim, CD71, CD117 partial, HLA-DR, dim CD123, CD58 and MPO	0	0.033333333	NA	Standard Chemotherapy	Yes	CBL (p.E369_Y371delinsH; MAF 31%)
aml_ohsu_2022	aml_ohsu_2022_2357	aml_ohsu_2022_2357_BA2166	70	70	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)|MiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XX[19]	78	Standard Chemotherapy	19	FALSE	Positive	AML	24.0	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD38, CD117 and subset MPO positive	0	0.933333333	NA	Standard Chemotherapy	Yes	NPM1 (p.W288fs*12; MAF ~11%)
aml_ohsu_2022	aml_ohsu_2022_2358	aml_ohsu_2022_2358_BA2081	64	64	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |R-CHOP (Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab,	6	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy|Bone Marrow Transplant	2	R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XX,del(17)(q25)[3]/46,sl,del(3)(q12q21)[cp17]	3	Standard Chemotherapy	17	FALSE	Negative	AML	81.69863013698631	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.R162K; 82.0%)	1	Female	MATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD4, partial variable CD7, CD13, CD33, partial CD34, CD38, partial CD58, CD117, CD123, HLA-DR, TDT and partial MPO positive.	0	0.8	NA	Standard Chemotherapy	Yes	KRAS (p.G12V; MAF 30%)|NRAS (p.G12D; MAF 7%)|RUNX1 (p.R162K; MAF 85% )
aml_ohsu_2022	aml_ohsu_2022_2359	aml_ohsu_2022_2359_BA2672	67	67	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine|MiDAC	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	3	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M6	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	3	FALSE	Negative	AML	24.756164383561647	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	MATCHED	FALSE	Acute erythroid leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	Atypical myeloblasts (partial CD7+) representing approximately 35% of the total leukocytes. 31% of the leukocytes are lymphocytes, 1% are monocytes, 33% are myeloid cells, and 35% are atypical cells with dim CD45. (Most of the atypical cells are CD34 posi	0	0.1	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2360	aml_ohsu_2022_2360_BA2889	34	34	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	ATRA, Arsenic Trioxide	1	Induction	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Negative	FALSE	FALSE	FALSE	46,XX,t(15;17)(q22;q21)[8]/46,idem,add(6)(p23),der(6)add(6)(p21)add(6)(q13),add(9)(p22),add(11)(q21),add(14)(q24)[12]	-1	Standard Chemotherapy	1	FALSE	Negative	AML	61.84109589041096	0:LIVING	21/200 (10.5%) interphase cells  scored had the 1 red/ 1 green/ 2 yellow fusion signal pattern consistent  with PML/RARA fusion.	Yes	No	Pituitary macroadenoma	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD38, CD58, CD64, CD117, CD123, and  MPO-positive	0	0.033333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2362	aml_ohsu_2022_2362_BA2479	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	Venetoclax (ABT-199), Azacitidine	1	Induction	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX[20]	115	Standard Chemotherapy	NA	FALSE	Positive	AML	34.323287671232876	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	115	Complete Response	NA	2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR	0	NA	NA	Standard Chemotherapy	Yes	ASXL1 (p.A1312V; MAF 33.6%)|IDH1 (p.A1312V; MAF 32.1%)|NPM1 (p.L258fs; MAF 31.1%)
aml_ohsu_2022	aml_ohsu_2022_2362	aml_ohsu_2022_2362_BA3028	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	Venetoclax (ABT-199), Azacitidine	1	Induction	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX[20]	115	Standard Chemotherapy	16	FALSE	Positive	AML	34.323287671232876	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	115	Complete Response	NA	2	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR	0	0.766666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.A1312V; MAF 33.6%)|IDH1 (p.A1312V; MAF 32.1%)|NPM1 (p.L258fs; MAF 31.1%)
aml_ohsu_2022	aml_ohsu_2022_2363	aml_ohsu_2022_2363_BA2209	59	64	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	TRUE	FALSE	47,XY,+13[2]/94,slx2[2]/46,XY[19]	-1	Bone Marrow Transplant	12	FALSE	Negative	AML	59.96712328767123	1:DECEASED	5p15.2/5q31(EGR1), 7 centromere/7q31, 8 centromere/20q12, 12 centromere/13q14 D13S319/13q34 (13qter)	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Relapse	Peripheral Blood	Negative (CD10, CD19, CD20, CD22, Cyt CD79a, Cyt CD3, CD7, CD16, CD56, CD11b, CD14, CD15, CD33, CD64, MPO) | Positive (CD38, CD13, CD34, Dim CD45, Dim CD117, HLA-DR, TdT)	0	0.6	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2364	aml_ohsu_2022_2364_BA2870	77	77	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	FALSE	FALSE	TRUE	47,XX,+1,add(1)(p22)[15]/47,XX,+1,i(1)(q10)[5]	6	Standard Chemotherapy	25	FALSE	Positive	AML	0.526027397260274	1:DECEASED	1p36/1q25: 81% of cells had three signals for 1q25 and two for 1p36, consistent with the larger clone above (ie. the clone with add(1)(p22). Another 13% of cells had four signals for 1q25 and two signals for 1p36, consistent with the smaller clone above (	No	No	NA	Yes	Yes	No	No	No	No	White	NA	NA	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD4, CD11b, CD15, CD33, CD38, CD58, CD64, CD123 and partial HLA-DR positive	0	1.333333333	NA	NA	Yes	FLT3-V491L (p.V491L; MAF 9%)|NPM1 (p.W288fs*12; MAF ~50% )|PTPN11 (p.S502L; MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2365	aml_ohsu_2022_2365_BA2019	39	39	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	Nelarabine|POMP (Prednisone, Methotrexate, 6-MP, Vincristine)|3+7 (Cytarabine, Daunorubicin)|HyperCVAD|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	7	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance|Re-induction	5	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY,t(10;11)(p13;q14)[11]/45,sl,-Y[7]/46,sdl1,t(1;8)(q12;p21)[2]	-1	Standard Chemotherapy	8	FALSE	Negative	AML	5.556164383561644	1:DECEASED	Normal	Yes	No	T lymphoblastic leukaemia/lymphoma	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Residual Disease	Peripheral Blood	Increased atypical myeloblasts (partial CD34+, weak CD7+, partial CD61+), representing approximately 91% of the leukocytes, consistent with persistent acute myeloid leukemia.	0	0.366666667	TP53 (p.R282W; 72.5%)	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2366	aml_ohsu_2022_2366_BA2714	60	60	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)	3	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	Azacitidine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY[20]	6	Standard Chemotherapy	16	FALSE	Positive	AML	28.6027397260274	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	167	Complete Response	NA	2	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD4, dim CD7, dim CD11b, CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT	0	0.766666667	NA	Standard Chemotherapy	Yes	FLT3-V491L (p.V491L; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)|SF3B1 (p.K666Q; MAF 47%)|WT1 (p.Y395fs*51; MAF 49%)
aml_ohsu_2022	aml_ohsu_2022_2366	aml_ohsu_2022_2366_BA3317	60	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)	3	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	Azacitidine	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Negative	FALSE	TRUE	FALSE	46,XY,t(3;4)(p21;q21)[20]	6	Standard Chemotherapy	13	FALSE	Positive	AML	28.6027397260274	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	167	Complete Response	NA	2	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	CD13, CD34, dim CD33, CD38, CD58, CD71, CD117, CD123, partial TdT, and partial MPO+	769	0.733333333	NA	Standard Chemotherapy	No	FLT3 (p.N841T; MAF 43%)|NPM1 (p.W288fs*12; MAF 41%)|SF3B1 (p.K666Q; MAF 48%)|WT1 (p.Y395fs*51; MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2367	aml_ohsu_2022_2367_BA2570	46	46	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	HISPANIC	NA	Negative	TRUE	FALSE	FALSE	46,XY[20]	6	Standard Chemotherapy	8	FALSE	Negative	AML	0.2958904109589041	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	NA	6	Unknown	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(+), surface CD3(-),  cytoplasmic CD3(dim +), CD4(-), CD7(partial +), CD11b(partial +),  CD13(variably +), CD14(few +), CD15(-), CD16(-),  CD33(-), CD34(partial +), CD36(-), CD38(bright +), CD45(dim  +), CD56(small subset +), CD64(-), CD117(+), HLA-DR(	0	0.266666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2368	aml_ohsu_2022_2368_BA2639	36	36	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XX,t(16;16)(p13.2;q22)[20]	-1	Bone Marrow Transplant	12	FALSE	Negative	AML	68.21917808219177	0:LIVING	CBFB: 191/200 cells (95.5%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement, consistent with the 16;16 translocation observed in the metaphase karyotype.	No	No	NA	No	No	No	No	No	No	White	1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	Immunophenotype: CD13, partial CD15, dim CD33, CD34, CD38, dim CD45, CD58, variable CD64, variable CD117, CD123, and dim HLA-DR positive.	0	0.433333333	NA	Standard Chemotherapy	Yes	KIT (p.T417_D419delinsY; MAF 33%)
aml_ohsu_2022	aml_ohsu_2022_2369	aml_ohsu_2022_2369_BA2631	60	60	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[21]	114	Standard Chemotherapy	5	FALSE	Positive	AML	91.03561643835616	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive	0	0.166666667	NA	Standard Chemotherapy	Yes	CEBPA (p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50%)|FLT3 ( p.N841I; MAF 12%)|FLT3 (p.I836delI; MAF 25%)|NPM1 (p.W288fs*>9; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2370	aml_ohsu_2022_2370_BA2053	31	31	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,inv(16)(p13.1q22)[7]/46,idem,add(17)(p11.2)[13]	5	Standard Chemotherapy	2	FALSE	Negative	AML	19.56164383561644	0:LIVING	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[198],(CBFBx2)(5CBFB sep 3CBFBx1)[164/200]	No	No	NA	No	No	No	No	No	No	NA	5	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(partial +), CD4(partial +), CD5(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CDCD33(variably +), CD34(variably +), CD36(few +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(partial +),CD117(+), CD123(variab	0	0.1	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2371	aml_ohsu_2022_2371_BA2200	59	59	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	Azacitidine, Sorafenib	Re-induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	TRUE	FALSE	46,XY,t(3;4)(p21;q25)[3]/46,XY[17]	-1	Standard Chemotherapy	3	FALSE	Positive	AML	8.416438356164385	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD4, CD7, CD11b, CD13,  CD33, partial CD34, CD117, HLA-DR, partial weak TdT and  partial CD64	0	0.1	NA	Standard Chemotherapy	Yes	DNMT3A (c.2251T>C; MAF 36.9% (33.1% on 3/13/15))|FLT3-ITD (c.1759_1800dup; MAF 24% (39% on 3/13/15))|NPM1 (c.860_863dup; MAF 9.9% (24% on 3/13/15))
aml_ohsu_2022	aml_ohsu_2022_2372	aml_ohsu_2022_2372_BA3036	43	43	0.492537313	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Both	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	FALSE	FALSE	TRUE	46,XX[20]	6	Standard Chemotherapy	2	FALSE	Negative	AML	1.1506849315068493	0:LIVING	nucish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	Yes	Yes	Black	6	Unknown	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.033333333	NA	Standard Chemotherapy	No	FLT3-D835
aml_ohsu_2022	aml_ohsu_2022_2373	aml_ohsu_2022_2373_BA2455	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	No	Hydroxyurea	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M5	Negative	TRUE	FALSE	FALSE	48,XYY,+8[21]	-1	Supportive/Palliative Care	11	FALSE	Positive	AML	1.084931506849315	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD38, CD56, CD13(dim), CD64, CD11c, CD4, CD56, HLA-DR, and CD15	0	0.666666667	NA	NA	Yes	FLT3-D835|NPM1
aml_ohsu_2022	aml_ohsu_2022_2374	aml_ohsu_2022_2374_BA2480	56	60	2.448275862	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|3+3 plus Sorafenib|Clofarabine|Clofarabine, Cytarabine	8	Consolidation|Salvage|Induction|Re-induction	4	Standard Chemotherapy	1	Cytarabine	Consolidation	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	TRUE	FALSE	46,XY[4]	64	Standard Chemotherapy	NA	FALSE	Positive	AML	57.04109589041096	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	Asian	6	Complete Response	NA	2	Male	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Peripheral Blood	CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive	309	NA	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2374	aml_ohsu_2022_2374_BA3021	56	60	4.555555556	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|3+3 plus Sorafenib|Clofarabine|Clofarabine, Cytarabine	8	Consolidation|Salvage|Induction|Re-induction	4	Standard Chemotherapy	1	Cytarabine	Consolidation	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	TRUE	FALSE	46,XY[4]	64	Standard Chemotherapy	6	FALSE	Positive	AML	57.04109589041096	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	Asian	6	Complete Response	NA	2	Male	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive	309	0.233333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2375	aml_ohsu_2022_2375_BA2457	44	44	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	46,XX[20]	4	Standard Chemotherapy	14	FALSE	Positive	AML	23.736986301369864	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2 (-), CD4(partial +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34 (-), CD36(-), CD38(bright +/variable), CD45(+), CD56(-), CD64(-), CD117(+) and HLA-DR(partial +).	0	0.833333333	NA	Standard Chemotherapy	Yes	NPM1 (W288FS*10+; MAF 24.0%)
aml_ohsu_2022	aml_ohsu_2022_2376	aml_ohsu_2022_2376_BA2856	55	55	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	3	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY[20]	129	Standard Chemotherapy	20	FALSE	Positive	AML	33.599999999999994	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Increased atypical CD117 positive myeloid blasts (weak CD7  positive, HLA-DR negative), representing 18% of the total  leukocytes, consistent with a myeloid neoplasm	0	1.066666667	NA	Standard Chemotherapy	Yes	NPM1
aml_ohsu_2022	aml_ohsu_2022_2377	aml_ohsu_2022_2377_BA2507	33	33	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,inv(16)(p13.1q22)[20]	-1	Standard Chemotherapy	8	FALSE	Negative	AML	13.216438356164382	0:LIVING	Positive for CBFB rearrangment for 91% of cells	No	No	NA	No	No	No	No	No	No	Black	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	Positive (CD38, CD13, CD33, CD34, CD45, CD117, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD14, CD15, CD64, TdT)	0	0.333333333	NA	Standard Chemotherapy	Yes	TET2 (c.652G>A; p.V218M; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2378	aml_ohsu_2022_2378_BA2104	83	83	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Both	Yes	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	47,XY,+8[6]/46,XY[13] (Specimen Source: Blood)	NA	None	5	FALSE	Positive	AML	0.2958904109589041	1:DECEASED	trisomy 8 (Specimen Source: Blood)	Yes	No	Colon Cancer	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	CD11b, CD13, dimCD14, CD15, dim CD16, CD33,     CD56,     CD58, CD64, CD123, and HLA-DR positive	0	0.266666667	NA	NA	No	FLT3-D835 (bone marrow)|NPM1 (An insertion mutation is present in exon 12 (near the C-terminus) of NPM.)
aml_ohsu_2022	aml_ohsu_2022_2379	aml_ohsu_2022_2379_BA3024	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Induction	2	Standard Chemotherapy|Supportive/Palliative Care	2	Decitabine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	MissingKaryo	NA	NA	Negative	TRUE	FALSE	FALSE	NA	5	Supportive/Palliative Care	NA	FALSE	Negative	AML	4.898630136986301	1:DECEASED	nuc ish(RUNX1T1x2,RUNX1x1)[34/200],(ABL1x2,BCRx1)[51/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	No	No	NA	No	No	No	No	No	No	White	5	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(-/few dim +), CD16(-),CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(partial +), CD64(-), CD117(variably +), HLA-DR(+and dim/few -), MPO(-), TdT(-).	0	0	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2380	aml_ohsu_2022_2380_BA2435	70	71	1.083333333	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine	4	Consolidation|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Quizartinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M0	Positive	FALSE	FALSE	FALSE	46,XY[20]	155	Targeted Therapy - Kinase Inhibitor(s)	11	FALSE	Positive	AML	13.150684931506849	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	2	Male	UNMATCHED	FALSE	AML with minimal differentiation	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD34, CD38, CD58, CD117, dimCD123,  HLA-DR, TDT	185	0.333333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2380	aml_ohsu_2022_2380_BA2825	70	70	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine	4	Consolidation|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Quizartinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M0	Negative	FALSE	FALSE	FALSE	46,XY[18]	155	Targeted Therapy - Kinase Inhibitor(s)	7	FALSE	Negative	AML	13.150684931506849	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	2	Male	UNMATCHED	FALSE	AML with minimal differentiation	Residual Disease	Bone Marrow Aspirate	partial CD7, dim CD11b, dim CD13, CD22, dim CD33, bright CD34, CD38, dim CD45, partial CD117, CD123, HLA-DR, and TdT positive	0	0.266666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2381	aml_ohsu_2022_2381_BA2394	73	73	0	ASXL1 (c.1940dup; MAF 37.9%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	45,X,-Y[20]	7	Standard Chemotherapy	1	FALSE	Negative	AML	1.1835616438356165	1:DECEASED	Normal	Yes	No	Lung Cancer	No	No	No	No	No	No	NA	NA	NA	RUNX1 (c.319C>G; MAF 73.9%)	1	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	0	0.066666667	NA	NA	Yes	ASXL1 (c.1940dup; MAF 37.9%)|BCORL1 (c.3496dup: MAF 7.5%)|RUNX1 (c.319C>G; MAF 73.9%)|TET2 (c.3803+1G>A; MAF 39.3%)
aml_ohsu_2022	aml_ohsu_2022_2382	aml_ohsu_2022_2382_BA2175	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	Decitabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	45,XX,der(5)inv(5)(p13q15)del(5)(q15q33),-16,-17,der(17)t(17;17)(p13;q11.2),der(18;22)(q10;q10),+22,+r[cp20] .ish r(MLL+)[2]	-1	Standard Chemotherapy	NA	FALSE	Negative	AML	12.263013698630136	0:LIVING	nuc ish(D4Z1,D10Z1)x2[200],(D5S2064x2,D5S630x2,EGR1x1)[196/200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[197],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3) [142/200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBF	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2383	aml_ohsu_2022_2383_BA2133	73	73	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	Ruxolitinib|AG-221|Cytarabine|Azacitidine	4	Induction|Experimental|Maintenance|Supportive/Palliative Care	4	Standard Chemotherapy|Targeted Therapy - Other	2	Cytarabine	Supportive/Palliative Care	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	NA	8	Standard Chemotherapy	6	FALSE	Positive	AML	18.410958904109588	1:DECEASED	NA	Yes	No	Breast Cancer	No	No	No	No	Yes	Yes	White	90	Complete Response	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy	Peripheral Blood	NA	0	0.266666667	NA	Standard Chemotherapy	No	IDH2 (p.R140Q; MAF 32%)|JAK2 (p.V617F; MAF 30%)|NPM1 (p.W288Cfs*12; MAF 35%)|SRSF2 (p.R94dup; MAF 31%)|WT1 (p.R440Tfs*14; MAF 29%)
aml_ohsu_2022	aml_ohsu_2022_2383	aml_ohsu_2022_2383_BA2222	73	74	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	Ruxolitinib|AG-221|Cytarabine|Azacitidine	4	Induction|Experimental|Maintenance|Supportive/Palliative Care	4	Standard Chemotherapy|Targeted Therapy - Other	2	Cytarabine	Supportive/Palliative Care	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XX[20]	8	Standard Chemotherapy	4	FALSE	Negative	AML	18.410958904109588	1:DECEASED	This test has not detected clonal abnormalities in the cells analyzed.	Yes	No	Breast Cancer	No	No	No	No	Yes	Yes	White	90	Complete Response	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy	Bone Marrow Aspirate	NA	252	0.166666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2383	aml_ohsu_2022_2383_BA2473	73	73	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Both	Yes	Ruxolitinib|AG-221|Cytarabine|Azacitidine	4	Induction|Experimental|Maintenance|Supportive/Palliative Care	4	Standard Chemotherapy|Targeted Therapy - Other	2	Cytarabine	Supportive/Palliative Care	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XX[20]	8	Standard Chemotherapy	6	FALSE	Positive	AML	18.410958904109588	1:DECEASED	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited	Yes	No	Breast Cancer	No	No	No	No	Yes	Yes	White	90	Complete Response	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy	Bone Marrow Aspirate	CD34 positive blasts are rare, <1% (Bone Marrow Immunophenotyping)	56	0.3	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2384	aml_ohsu_2022_2384_BA2763	72	73	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)|Azacitidine|Azacitidine, Lenalidomide|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction	3	Standard Chemotherapy	1	Azacitidine, Lenalidomide	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Negative	FALSE	TRUE	FALSE	46,XY[20]	-1	Standard Chemotherapy	21	FALSE	Positive	AML	20.449315068493153	1:DECEASED	NA	Yes	No	Colon Cancer	No	No	No	No	No	No	White	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Relapse	Bone Marrow Aspirate	dim CD33, CD38, CD58, CD117, dim CD123, and MPO positive	0	1.2	NA	Standard Chemotherapy	Yes	IDH1 (p.R132S; MAF 20%)|NPM1 (p.W288fs*12; MAF 36%)|SRSF2 (p.P95L; MAF 35%)|TET2 (p.Q642*, p.C1135Y; MAF 7%,7%  )
aml_ohsu_2022	aml_ohsu_2022_2385	aml_ohsu_2022_2385_BA2377	35	35	2.448275862	ASXL1 (p.D943Qfs*6; 38.5%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide, Thymoglobulin	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	TRUE	FALSE	FALSE	46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1]	-1	Bone Marrow Transplant	23	FALSE	Positive	AML	38.00547945205479	0:LIVING	nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(+), CD7(-), CD11b(+), CD13(partial +), CD14(-), CD15(+), CD16(-), CD33(+), CD34(-), CD36(partial +), CD45(+), CD56(variably +), CD64(+), CD117(partial +), CD79a(-), HLA-DR(+), MPO(-), Tdt(-)	0	1.1	NA	Standard Chemotherapy	Yes	ASXL1 (D943fs*6; MAF 25%)|FLT3-D835 (BMA)|KMT2A (MLL-AF9 fusion)
aml_ohsu_2022	aml_ohsu_2022_2386	aml_ohsu_2022_2386_BA2271	8	8	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine	2	Induction|CNS	2	Standard Chemotherapy|Intrathecal	2	Cytarabine	CNS	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	HISPANIC	M1	Negative	TRUE	FALSE	FALSE	47,XY,+21c[20]	151	Intrathecal	1	FALSE	Positive	AML	64.33972602739726	0:LIVING	RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.	No	No	NA	No	No	No	No	No	No	White	151	Complete Response	NA	1	Male	UNMATCHED	FALSE	Myeloid leukaemia associated with Down syndrome	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD11b, variable CD13, dim variable CD14, CD15, CD38, CD58, dim CD64, and MPO	0	0.033333333	NA	Standard Chemotherapy	Yes	NPM1 (p.W288fs*12; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2387	aml_ohsu_2022_2387_BA2031	2	2	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	4	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX,t(6;11)(q27;q23)[19]/46,XX[1]	-1	Bone Marrow Transplant	2	FALSE	Negative	AML	63.68219178082191	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	136	Complete Response	NA	2	Female	UNMATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4, CD11b, variable CD13, CD15, CD33, variable CD56, CD58, CD64, lysozyme, and dim HLA-DR positive	0	0.133333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2387	aml_ohsu_2022_2387_BA2146	2	3	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	4	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Negative	FALSE	TRUE	FALSE	46,XX,t(6;11)(q27;q23)[12]/46,XX[8]	-1	Bone Marrow Transplant	2	FALSE	Negative	AML	63.68219178082191	0:LIVING	71/100 (71%) interphase cells scored had the 1 red/ 1 green/ 1 yellow signal pattern, consistent with MLL rearrangement and the 6;11 translocation observed in the metaphase karyotype.	No	No	NA	No	No	No	No	No	No	White	136	Complete Response	NA	2	Female	UNMATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	CD4, CD11b, variable CD13, CD15, CD33, CD58, CD64, CD117, and dim HLA-DR positive	397	0.1	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2388	aml_ohsu_2022_2388_BA2147	69	70	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|5+2 (Ara-C, Daunorubicin)	3	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Negative	FALSE	FALSE	TRUE	46,XY,del(5)(q22q33),del(21)(q22q22)[cp20]	4	Standard Chemotherapy	9	FALSE	Negative	AML	5.983561643835617	1:DECEASED	5q deletion (92%) | 21q deletion (91%)	Yes	No	Prostate Cancer	Yes	Yes	No	No	No	No	White	6	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease	Bone Marrow Aspirate	CD13, CD15, CD34 (subset), CD38, CD58, CD64, CD117, CD123 and HLA-DR.	0	0.466666667	NA	Standard Chemotherapy	Yes	BCOR (p.L1483* (premature protein truncation); MAF 90%)|MLL (PTD)|U2AF1 (p.S34F; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2389	aml_ohsu_2022_2389_BA2266	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[20]	6	Standard Chemotherapy	20	FALSE	Negative	AML	0.9205479452054794	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response i	RUNX1 (p.Y349*; 14.6%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+	0	0.766666667	NA	Standard Chemotherapy	Yes	RUNX1 (p.Y349*; MAF 26% )|SRSF2 (p.P95H; MAF 32% )
aml_ohsu_2022	aml_ohsu_2022_2390	aml_ohsu_2022_2390_BA2492	25	26	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	6	Waves1+2	Yes	Bu/Cy/ATG|HiDAC|3+7 (Cytarabine, Daunorubicin)|Decitabine|Clofarabine, Cytarabine	5	Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant	2	Decitabine	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY,-3,del(5)(q31q35),der(7)t(7;?)(p11.2;?),+der(11)(q23),-12,+mar[20]	9	Standard Chemotherapy	1	FALSE	Negative	AML	15.221917808219178	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	7	Refractory	NA	2	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	MONOBLASTS, 61%. These are dim45positive and also express CD13, CD33, CD11b, CD14, CD64  but lack CD16, CD34, CD117, HLADR  (Bone Marrow Immunophenotyping)	28	0.066666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2390	aml_ohsu_2022_2390_BA2723	25	26	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	6	Waves1+2	Yes	Bu/Cy/ATG|HiDAC|3+7 (Cytarabine, Daunorubicin)|Decitabine|Clofarabine, Cytarabine	5	Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant	2	Decitabine	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	TRUE	FALSE	NA	9	Standard Chemotherapy	1	FALSE	Negative	AML	15.221917808219178	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	7	Refractory	NA	2	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Relapse|Post-Chemotherapy|Post-Transplant	Peripheral Blood	NA	0	0.066666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2391	aml_ohsu_2022_2391_BA3037	55	55	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	NA	FALSE	Positive	AML	23.243835616438353	1:DECEASED	Normal	Yes	No	Hodgkin Lymphoma	No	No	No	No	No	No	White	7	Complete Response	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	partial CD7, CD13, CD25, CD33, partial CD34, dim CD45, CD117, CD123, and partial HLA-DR positive	0	NA	NA	Standard Chemotherapy	Yes	FLT3-ITD|NPM1|WT1 (8000/10000 copies (High))
aml_ohsu_2022	aml_ohsu_2022_2393	aml_ohsu_2022_2393_BA2662	65	65	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea	4	Consolidation|Unknown|Induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant|Other	3	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	6	FALSE	Positive	AML	64.5041095890411	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.233333333	NA	Standard Chemotherapy	Yes	CEBPA (p.K298Q; MAF 25%)|DNMT3A (p.R882C; MAF 44%)|FLT3-ITD (MAF 25%)|IDH2 (p.R140Q; MAF 18%)|NPM1 (p.W288fs*12; MAF 46%)
aml_ohsu_2022	aml_ohsu_2022_2394	aml_ohsu_2022_2394_BA2220	23	23	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin)	2	Consolidation|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Trametinib	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M6b	Negative	FALSE	FALSE	FALSE	48,XY,add(6)(p22),der(7)t(7;19)(p11.1;p12),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp20]	197	Targeted Therapy - Kinase Inhibitor(s)	12	FALSE	Negative	AML	10.454794520547946	1:DECEASED	Low-level tetraploidy or near-tetraploidy (5%)	Yes	No	Mediastinum mass	No	No	No	No	No	No	White	8	Complete Response	NA	2	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	NA	0	0.566666667	TP53 (p.G245S; 83.1%)	Standard Chemotherapy	Yes	NRAS (p.G12C; MAF 86%)|TP53 (p.G245S; MAF 87%)
aml_ohsu_2022	aml_ohsu_2022_2394	aml_ohsu_2022_2394_BA2720	23	24	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin)	2	Consolidation|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Trametinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M6b	Negative	FALSE	FALSE	FALSE	48,XY,add(6)(p22),der(7)t(7;19)(p11.2;p12),del(9)(p13p22),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp2]/46~48,sl,add(17)(p1?3),add(22)(q13)[cp9]/46~48,sl,add(21)(p11.2)[cp6]/47~48,sl,add(1)(p36.1)[cp2]/48,sl,t(2;17)(p21;p11.2)[1]	197	Targeted Therapy - Kinase Inhibitor(s)	71	FALSE	Negative	AML	10.454794520547946	1:DECEASED	Low-level tetraploidy or near-tetraploidy	Yes	No	Mediastinum mass	No	No	No	No	No	No	White	8	Complete Response	NA	2	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	A CD34 positive blasts population comprises approximately 4% of cellular gated events. Approximately 3% of cells are lymphocytes composed of 28% B cells, 45% T cells and 27% NK cells. | T cells are present in a CD4:CD8 ratio of about 1.1:1 and do not demo	163	4.233333333	TP53 (p.G245S; 89.1%)	Standard Chemotherapy	No	NRAS (p.G12C; MAF 97%)|TP53 (p.G245S; MAF 96%)
aml_ohsu_2022	aml_ohsu_2022_2395	aml_ohsu_2022_2395_BA2798	71	71	0	ASXL1 (p.Q428*; 43.9%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	AG-120|KB004|Lenalidomide|Venetoclax (ABT-199), Azacitidine|Decitabine	5	Salvage|Induction|Experimental|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Other	2	Venetoclax (ABT-199), Azacitidine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY,del(7)(q32),add(13)(p11.2)[15]	77	Standard Chemotherapy	19	FALSE	Negative	AML	18.016438356164386	1:DECEASED	This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.	No	No	NA	No	No	No	No	Yes	Yes	White	32	Refractory	RUNX1 (p.G408Vfs*193; 34.8%)	3	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	These are positive for CD34, CD117, HLADR, CD33 and CD13 (Bone Mrrow Immunophenotyping)	0	1.066666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.Q428*; MAF 44%)|CEBPA (p.A4S; MAF 47%)|IDH1 (p.R132C; MAF 45%)|JAK2 (p.V617F; MAF 57%)|MLL |RUNX1 (p.G406Vfs*193; MAF 39%)|TET2 (p.R1366S; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2395	aml_ohsu_2022_2395_BA2883	71	71	0	ASXL1 (p.Q428*; 43.4%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	AG-120|KB004|Lenalidomide|Venetoclax (ABT-199), Azacitidine|Decitabine	5	Salvage|Induction|Experimental|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Other	2	Venetoclax (ABT-199), Azacitidine	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY,del(7)(q32),add(13)(p11.2)[20]	77	Standard Chemotherapy	20	FALSE	Negative	AML	18.016438356164386	1:DECEASED	This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.	No	No	NA	No	No	No	No	Yes	Yes	White	32	Refractory	RUNX1 (p.G408Vfs*193; 20.4%)	3	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	They are positive for CD34, HLADR, CD117, CD13 and MPO and negative for TDT. (Bone Marrow Immunophenotyping)	57	1.066666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2395	aml_ohsu_2022_2395_BA3342	71	72	0	ASXL1 (p.Q428*; 44.3%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves3+4	Yes	AG-120|KB004|Lenalidomide|Venetoclax (ABT-199), Azacitidine|Decitabine	5	Salvage|Induction|Experimental|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Other	2	Venetoclax (ABT-199), Azacitidine	Salvage	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY,del(7)(q32),add(13)(p11.2)[20]	77	Standard Chemotherapy	9	FALSE	Negative	AML	18.016438356164386	1:DECEASED	This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.	No	No	NA	No	No	No	No	Yes	Yes	White	32	Refractory	NA	3	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Peripheral Blood	NA	315	0.533333333	TP53 (p.R248W; 8.8%)	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2396	aml_ohsu_2022_2396_BA2315	53	53	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	HiDAC|7+3 (Cytarabine, Idarubicin)|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NA	NA	Positive	TRUE	FALSE	FALSE	46,XY[7]	-1	Bone Marrow Transplant	7	FALSE	Positive	AML	41.16164383561644	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	7	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD117,HLA-DR, CD13 and CD33.  Blasts also show partial expression of CD34, CD7, CD11c, CD38, CD15, dim CD64, and dim CD4	0	0.333333333	NA	Standard Chemotherapy	Yes	FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2397	aml_ohsu_2022_2397_BA2772	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY[20]	5	Standard Chemotherapy	15	FALSE	Positive	AML	2.334246575342466	0:LIVING	nuc ish(D4Z1,D10Z1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200]	No	No	NA	No	No	No	No	No	No	NA	5	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-),CD4(partial dim +), CD7(-), CD11b(few +), CD13(+), CD14(-), CD15(partialCD22(-), CD25(appears partial dim +), CD33(bright +), CD34(few +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(partial +), CD79a(-), CD117(+), CD123(partial +)	0	0.766666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2398	aml_ohsu_2022_2398_BA2172	NA	18	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	7	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	NA	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	unknown	Unknown	Peripheral Blood	NA	0	NA	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2399	aml_ohsu_2022_2399_BA2169	38	39	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Salvage|Unknown|Induction|Maintenance	4	Standard Chemotherapy|Supportive/Palliative Care	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Unknown	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	FALSE	TRUE	NA	6	Standard Chemotherapy	11	FALSE	Negative	AML	13.676712328767124	0:LIVING	NA	No	No	NA	Yes	Yes	No	No	No	No	White	5	NA	NA	2	Male	MATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.566666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2399	aml_ohsu_2022_2399_BA2246	38	39	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Salvage|Unknown|Induction|Maintenance	4	Standard Chemotherapy|Supportive/Palliative Care	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Unknown	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY,t(3;3)(q21;q26.2),del(5)(q13q31)[cp12]/43~45,idem,-7[cp3]/46,XY[6]	6	Standard Chemotherapy	17	FALSE	Negative	AML	13.676712328767124	0:LIVING	nuc ishFGFR3,IGH)x2[200],(D5S721x2,D5S23x2,EGR1x1)[130/200],(D7Z1x1,D7S522x1)[50/200],(D8Z2,D20S108)x2[198],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],IGH,BCL2)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[198]	No	No	NA	Yes	Yes	No	No	No	No	White	5	NA	NA	2	Male	MATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD2(-),CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(slightly bright +),CD34(+), CD36(equivocal), CD38(partial dim +), CD45(+), CD56(variably +), CD64(-), CD117(+), HLA-DR(+/variable).	89	0.8	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2400	aml_ohsu_2022_2400_BA2520	80	80	0	ASXL1 (p.D720Rfs*18; 14.1%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	Cytarabine|Decitabine|PF-04449913 (Hedgehog Inhibitor), LDAC	3	Consolidation|Salvage|Experimental	3	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	3	Decitabine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M0	Negative	FALSE	FALSE	FALSE	46,XY,del(20)(q11.2q13.1)[15]/46,XY[5]	-1	Targeted Therapy - Kinase Inhibitor(s)	20	FALSE	Negative	AML	10.158904109589042	1:DECEASED	Positive for deletion of 20q12 in 11.5% of 200 cells	Yes	No	Mature B-Cell Neoplasm	No	No	No	No	No	No	NA	NA	NA	RUNX1 (p.R204*; 45.5%)|RUNX1 (p.S141*; 45.1%)	1	Male	MATCHED	FALSE	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Peripheral Blood	positive for dim CD7, dim CD10, CD34, CD38, dim CD45, cCD79a, CD99, HLA-DR, TdT, dim PAX5	0	0.966666667	NA	NA	Yes	ASXL1 (p.718_724del; MAF 50.3%)|RUNX1 (p.R177X; MAF 47%)|RUNX1 (p.S114X; MAF 44.8%)|SRSF2 (p.P95H; MAF 45.1%)
aml_ohsu_2022	aml_ohsu_2022_2401	aml_ohsu_2022_2401_BA2067	59	59	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Quizartinib|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	IntermediateOrAdverse	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	47,XX,+13[18]/46,XX[2]	4	Standard Chemotherapy	4	FALSE	Negative	AML	17.786301369863015	1:DECEASED	trisomy 13	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	1	Female	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	Blast immunophenotype: dim CD4, variable CD11b, CD13, CD33, partial CD34, dim CD45, variable CD64, partial CD117, CD123, HLA-DR and MPO positive; Promonocyte immunophenotype: dim CD4, CD11b, CD13, CD33, CD45, bright CD64, CD123, HLA-DR, and dim MPO positi	0	0.166666667	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2402	aml_ohsu_2022_2402_BA2155	72	73	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	bi	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction	4	Standard Chemotherapy|Supportive/Palliative Care	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M0	Negative	FALSE	TRUE	FALSE	46,XX,der(3)t(3;17)(q29;q21)[19]/46,XX,t(3;21)(q26.2;q22)[2]	112	Supportive/Palliative Care	21	FALSE	Negative	AML	18.575342465753423	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	Unknown	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated CEBPA	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD19 (-/few dim +), CD25(-), CD33(partial +), CD34(partial +), CD36(-), CD38(bright and variably +), CD45(+), CD56(variably +), CD64(-), CD117(variably +), CD12	0	1.166666667	TP53 (p.X187_splice; 30.4%)	Standard Chemotherapy	Yes	CEBPA (Foundation; M1fs*60; MAF 34%)|CEBPA (Foundation; N307_V308insVETQQK; MAF 36%)|TP53 (Foundation; splice site 560-2insA; MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2403	aml_ohsu_2022_2403_BA2316	62	62	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XY[20]	NA	None	5	FALSE	Negative	AML	0.06575342465753425	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	NA	NA	RUNX1 (p.X205_splice; 44.3%)	2	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38, partial CD56, CD58, CD64, CD123, and HLA-DR positive	1	0.2	NA	NA	No	DNMT3A (p. R882C; MAF 50%)|DNMT3A (p.R882C; MAF 50%)|FLT3-ITD (MAF 90%)|RUNX1 (Intron 5, 3' splice site mutation; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2403	aml_ohsu_2022_2403_BA2742	62	62	15.66666667	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XY[20]	NA	None	9	FALSE	Negative	AML	0.06575342465753425	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	NA	NA	RUNX1 (p.X205_splice; 56.7%)	2	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38,      partial CD56, CD58, CD64, CD123, and HLA-DR positive	0	0.366666667	NA	NA	Yes	DNMT3A (p. R882C; MAF 50%)|DNMT3A (p.R882C; MAF 50%)|FLT3-ITD (MAF 90%)|RUNX1 (Intron 5, 3' splice site mutation; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2404	aml_ohsu_2022_2404_BA3008	68	69	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	4	Standard Chemotherapy	4	FALSE	Negative	AML	3.7479452054794518	1:DECEASED	NA	No	No	NA	No	No	Yes	Yes	No	No	White	4	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.2	NA	Standard Chemotherapy	Yes	CBL (p.C404Y; MAF 28%)|SF3B1 (p.K666N; MAF 36% )|TET2 (p.L1047fs*11; MAF 34% )
aml_ohsu_2022	aml_ohsu_2022_2405	aml_ohsu_2022_2405_BA2418	47	47	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	Crenolanib|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage|Experimental	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	NA	4	Standard Chemotherapy	14	FALSE	Positive	AML	30.706849315068492	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	2	0.733333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2406	aml_ohsu_2022_2406_BA2753	60	62	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M2	Negative	FALSE	TRUE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	21	FALSE	Positive	AML	84.1972602739726	0:LIVING	normal	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	CD7, CD13, CD33, CD34, CD38, and CD123 positive (Initial 7/8/2014 diagnosis: dim CD7, CD13, CD33, CD34, CD38, CD58, and CD117-positive)	461	1.266666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2407	aml_ohsu_2022_2407_BA2235	60	60	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XX[20]	104	Standard Chemotherapy	4	FALSE	Positive	AML	92.08767123287672	0:LIVING	normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7, partial CD11b, CD13, CD33, dim CD45, CD58,     partial CD64, partial CD117, CD123, dimHLA-DR,  MPO positive	0	0.2	NA	Standard Chemotherapy	Yes	DNMT3A (p.Q696fs*9; MAF 40% )|IDH1 (p.R132H; MAF 40%)|NPM1 (p.W288fs*12; MAF ~40%)|PTPN11 (p.G503A; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2408	aml_ohsu_2022_2408_BA2193	33	33	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	47,XX,inv(16)(p13.1q22),+22	103	Standard Chemotherapy	7	FALSE	Negative	AML	30.246575342465754	0:LIVING	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5CBFB sep 3CBFBx1)[140/200]	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	2	Female	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+)	0	0.233333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2408	aml_ohsu_2022_2408_BA2733	33	33	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	47,XX,inv(16)(p13.1q22),+22	103	Standard Chemotherapy	1	FALSE	Negative	AML	30.246575342465754	0:LIVING	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5CBFB sep 3CBFBx1)[140/200]	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	2	Female	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+)	0	0.033333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2409	aml_ohsu_2022_2409_BA2514	67	67	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea	4	Salvage|Experimental|Supportive/Palliative Care	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other|Bone Marrow Transplant	4	Sorafenib	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Kinase Inhibitor(s)	3	FALSE	Negative	AML	14.761643835616438	1:DECEASED	nuc ish(DXZ1x2)[182]//(DXZ1,DYZ3)x1[18]. nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2) [200]	Yes	No	Acute Myeloid Leukemia	No	No	No	No	No	No	NA	NA	NA	NA	2	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Post-Transplant|Post-DLI|Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD33(variably +), CD34(+), CD36 (-), CD38(+), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+)	0	0.166666667	TP53 (p.R283C; 47.5%)	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2409	aml_ohsu_2022_2409_BA2695	67	68	1.325581395	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea	4	Salvage|Experimental|Supportive/Palliative Care	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other|Bone Marrow Transplant	4	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	47,XX,+11[5]/48,idem,+19[15]	-1	Targeted Therapy - Kinase Inhibitor(s)	3	FALSE	Negative	AML	14.761643835616438	1:DECEASED	nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	Yes	No	Acute Myeloid Leukemia	No	No	No	No	No	No	NA	NA	NA	NA	2	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Post-DLI|Post-Transplant|Residual Disease	Peripheral Blood	NA	254	0.133333333	TP53 (p.R283C; 45.1%)	NA	No	FLT3-ITD|IDH1 (R132G)|IDH1 (p.R132G; MAF 51%)|KMT2A (MLL-PTD (exons 2-10))|TP53 (p.R283C; MAF 49%)
aml_ohsu_2022	aml_ohsu_2022_2410	aml_ohsu_2022_2410_BA2402	82	82	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX	NA	None	3	FALSE	Negative	AML	8.810958904109588	1:DECEASED	trisomy 8 in 5 of 20 metaphase cells	Yes	Yes	Breast Cancer	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.2	NA	NA	Yes	DNMT3A (p.R882H; MAF 39%)|GATA1 (p.R191C; MAF 51%)|IDH2 (p.R172K; MAF 36%)
aml_ohsu_2022	aml_ohsu_2022_2411	aml_ohsu_2022_2411_BA2978	14	14	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Donor Lymphocyte Infusion|HiDAC|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busul	8	Allogeneic - Sibling|Salvage|Induction|Re-induction	4	DLI|Standard Chemotherapy|Bone Marrow Transplant	3	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XX,t(8;21)(q21.3;q22)[17]/49,sl,+4,+15,+der(21)t(8;21)[2]/53,sdl,-4,+13,+18,+19,+20,+21[4]	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	68.48219178082192	0:LIVING	All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21).	No	No	NA	No	No	No	No	No	No	Declined	189	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD34, CD38, CD56, CD58, dim/partial CD64, CD117, CD123, HLA-DR and MPO	0	0.266666667	NA	Standard Chemotherapy	Yes	FBXW7 (p.G79S; MAF 50%)|KIT (p.D816Y; MAF 45%)|NRAS (p.G12D; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2412	aml_ohsu_2022_2412_BA2052	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	No	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Supportive/Palliative Care	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,inv(4)(p14p16.1)[3]/46,XY[16]	-1	Supportive/Palliative Care	33	FALSE	Negative	AML	9.468493150684932	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200]	No	No	NA	No	No	No	No	No	No	Unknown	NA	NA	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2 (-), CD7(few +), CD11b(-), CD13(partial dim +), CD14(-), CD15(partial dim +), CD16(-), CD22(partial dim +), CD33(-), CD34(bright +), CD36(-), CD38(moderately bright +), CD45(partial +), CD56(-), CD64(-), CD117(partial +), HLADR(+) (32% population of m	0	1.833333333	NA	NA	Yes	BCOR (Foundation; Q1337*; MAF 56%)|CTCF (Foundation; R49H; MAF 19%)|RUNX1 (Foundation; loss, splice site 477_508+22>GGG; MAF 50%)|SRSF2 (Foundation; R94_S101del;MAF 39%)|TET2 (Foundation; splice site 3409+2T>G; MAF 51%)
aml_ohsu_2022	aml_ohsu_2022_2413	aml_ohsu_2022_2413_BA2860	68	68	NA	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Dead-Unknown	NA	1	Waves1+2	Yes	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	NA	Myelodysplastic Syndromes	NonAML	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	45~48,XY,del(5)(q22q35),+8,del(13)(q12q14),- 20,der(21)t(20;21)(p11.2;p11.1),+der(22)t(?;22)(?;q11.2)[cp15]/46,XY[4]	6	Standard Chemotherapy	17	FALSE	Negative	MDS	9.830136986301369	1:DECEASED	NA	No	No	NA	Yes	No	No	No	No	No	White	6	Unknown	NA	1	Male	MATCHED	TRUE	Myelodysplastic syndrome, unclassifiable	Unknown	Peripheral Blood	CD13, CD33, CD34, CD38, CD58, CD117, CD123 and HLA-DR positive	0	1	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2414	aml_ohsu_2022_2414_BA2090	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	UNKNOWN	M5	Negative	FALSE	FALSE	FALSE	46,XX[19]	-1	Bone Marrow Transplant	7	FALSE	Negative	AML	60.16438356164383	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	2	Female	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy	Peripheral Blood	NA	34	0.233333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2414	aml_ohsu_2022_2414_BA2098	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	UNKNOWN	M5	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	7	FALSE	Positive	AML	60.16438356164383	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	2	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (dim CD4, CD11b, variable CD13, partial CD14, CD33, variable CD56, bright CD64, dim CD123 and HLA-DR-positive, comprising ~75% of WBCs. There is also about 5% of blasts are positive for CD117, CD13, CD33, HLA-DR, CD123, amd CD11b. Lymphocytes acc	0	0.266666667	NA	Standard Chemotherapy	Yes	IDH1 (p.R132H; MAF 37%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13D; MAF 38%)
aml_ohsu_2022	aml_ohsu_2022_2415	aml_ohsu_2022_2415_BA2872	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin)	3	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	Decitabine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	FALSE	46,XY,i(17)(q10)[20]	9	Standard Chemotherapy	7	FALSE	Negative	AML	5.1945205479452055	1:DECEASED	TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metapha	Yes	No	Pancreatic adenocarcinoma	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, CD34, CD117, and HLA-DR positive	0	0.233333333	NA	Standard Chemotherapy	Yes	ASXL1 (p.R693fs*10; MAF 49% )|CREBBP (p.S893L; MAF 52% )|NRAS (p.G12D; MAF 46% )
aml_ohsu_2022	aml_ohsu_2022_2416	aml_ohsu_2022_2416_BA2356	62	63	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY[19]	4	Standard Chemotherapy	12	FALSE	Negative	AML	5.095890410958904	1:DECEASED	NA	Yes	No	Melanoma	No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.R162K; 35.1%)	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease	Bone Marrow Aspirate	Partial CD7, CD13, CD33, CD34, CD38, partial CD56, CD58, CD117, CD123, HLA-DR, and partial TdT	0	0.566666667	NA	Standard Chemotherapy	Yes	BCOR (p.N119fs*40; MAF 65%)|RUNX1 (p.K117R; MAF 36%)|RUNX1 (p.R162K; MAF 31%)
aml_ohsu_2022	aml_ohsu_2022_2417	aml_ohsu_2022_2417_BA2134	72	72	0	ASXL1 (p.A619fs*14; MAF 50%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	FALSE	FALSE	TRUE	46,XY,del(12)(p11.2p13)[15]/46,XY[5]	6	Standard Chemotherapy	NA	FALSE	Negative	AML	5.786301369863014	1:DECEASED	84% 12p deletion	No	No	NA	No	No	Yes	Yes	No	No	White	6	Complete Response	NA	2	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	8	NA	NA	Standard Chemotherapy	No	ASXL1 (p.A619fs*14; MAF 50%)|EZH2 (p.R583*; MAF 95%)|FLT3-D835|FLT3-D835 (MAF unavailable)|PTPN11 (p.D61H; MAF 15%)|RUNX1 ( p.P345?S356del; MAF 25%)|RUNX1 (p.P345?S356del; MAF 25%)|RUNX1 (p.V51; MAF 50%)|RUNX1 (p.V5I; MAF 50%)|TET2 (p.Y867H; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2417	aml_ohsu_2022_2417_BA2598	72	72	0	ASXL1 (p.A619Pfs*15; 38.1%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	FALSE	FALSE	TRUE	46,XY,del(12)(p11.2p13)[15]/46,XY[5]	6	Standard Chemotherapy	13	FALSE	Negative	AML	5.786301369863014	1:DECEASED	84% 12p deletion	No	No	NA	No	No	Yes	Yes	No	No	White	6	Complete Response	NA	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Myeloid blast immunophenotype: CD13, dim CD33, CD34, CD38, CD58, CD117, HLA-DR and MPO positive | Promonocyte immunophenotype: CD11b, CD13, CD14, CD33, CD38, CD56, CD58, CD64 and HLA-DR positive	0	0.733333333	NA	Standard Chemotherapy	Yes	ASXL1 (p.A619fs*14; MAF 50%)|EZH2 (p.R583*; MAF 95%)|FLT3-D835|FLT3-D835 (MAF unavailable)|PTPN11 (p.D61H; MAF 15%)|RUNX1 ( p.P345?S356del; MAF 25%)|RUNX1 (p.P345?S356del; MAF 25%)|RUNX1 (p.V51; MAF 50%)|RUNX1 (p.V5I; MAF 50%)|TET2 (p.Y867H; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2418	aml_ohsu_2022_2418_BA2409	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	NA	FALSE	Negative	AML	13.052054794520549	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	7	Refractory	NA	1	Female	UNMATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Blast Immunphenotype: CD13, CD33, CD34, CD38, dim CD45, CD117, CD123, and HLA-DR positive; Promonocyte Immunophenotype: CD11b, CD13, CD14, CD33, CD64, and HLA-DR	0	NA	NA	Standard Chemotherapy	Yes	BRAF (G596R)|WT1 (2400/10000 copies)
aml_ohsu_2022	aml_ohsu_2022_2419	aml_ohsu_2022_2419_BA2701	51	51	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	2	FALSE	Negative	AML	48.88767123287671	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD1a(-), CD2(-), surface CD3(-), cytoplasmic CD3(partial dim +), CD4(partial dim +), CD5(dim +), CD7(+), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16 (-), CD22(partial dim +), CD33(variably +), CD34(+), CD36(-), CD38(partial +), CD45	0	0.133333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2420	aml_ohsu_2022_2420_BA3004	76	76	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|Decitabine	2	Induction|Re-induction	2	Standard Chemotherapy	1	5+2 (Cytarabine, Idarubicin)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[22]	4	Standard Chemotherapy	11	FALSE	Positive	AML	0.8547945205479452	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	8	Refractory	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive	0	0.4	NA	Standard Chemotherapy	Yes	ASXL1 (p.G966delG; MAF 50%)|DNMT3A (p.R736H; MAF 45%)|FLT3-ITD (MAF 20%)|NPM1 (p.W288fs*12; MAF 35%)
aml_ohsu_2022	aml_ohsu_2022_2421	aml_ohsu_2022_2421_BA2114	68	68	0	NA	Myelodysplastic/Myeloproliferative Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC|Enasidenib|Hydroxyurea|Enasidenib, Cytarabine	7	Consolidation|Salvage|Induction|Re-induction|Maintenance|Supportive/Palliative Care	6	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	NA	Myelodysplastic/Myeloproliferative Neoplasms	NonAML	NON-HISPANIC	M4	Negative	FALSE	FALSE	FALSE	46,XX[20]	4	Standard Chemotherapy	24	FALSE	Positive	MDS/MPN	64.47123287671234	0:LIVING	Normal	Yes	No	Colon Cancer	No	No	Yes	No	No	No	White	23	Complete Response	NA	1	Female	MATCHED	TRUE	Chronic myelomonocytic leukaemia	Unknown	Bone Marrow Aspirate	CD19, CD20, and surface kappa light chain positive (For B cell population)	0	1.266666667	NA	Standard Chemotherapy	No	DNMT3A (p.R882H; MAF 34%)|FLT3-D835 (p.D835V; MAF 11%)|KRAS (p.G13D; MAF 8%)|MYD88 (p.L265P; MAF 8%)|NPM1 (p.W288fs*12; MAF 25%)
aml_ohsu_2022	aml_ohsu_2022_2422	aml_ohsu_2022_2422_BA2584	42	42	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	45,XY,t(3;17)([21;q11.2),add(4)(q21),add(5)(p15),ins(10;11)(p12;q23q13),der(12;18)(q10;q10)[19]/46,XY[1]	-1	Bone Marrow Transplant	NA	FALSE	Negative	AML	14.038356164383561	0:LIVING	11q23 rearrangement involving the  KMT2A (MLL) locus in 184/200 (92.0 percent) cells scored | One cell line showed the following clonal abnormalities in 19/20 (95%) cells: an apparent insertion of material form the long arm of chromosome 11 into the short	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2423	aml_ohsu_2022_2423_BA2358	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	47,XX,+8[20]	-1	Standard Chemotherapy	27	FALSE	Negative	AML	2.6301369863013697	1:DECEASED	Trisomy 8 (70%)	No	No	NA	No	No	No	No	No	No	White	NA	NA	RUNX1 (p.T437A; 24.0%)	1	Female	MATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, partial dim CD33, CD34, CD38, dim CD58, CD117, CD123, dim HLA-DR, and partial MPO.	0	1.633333333	NA	NA	Yes	ASXL1 (p.A636V; MAF 52%)|IDH2 (p.R140Q; MAF 27%)|MLL (PTD)|RUNX1 (p.T437A; MAF 13%)|SRSF2 (p.P95R; MAF 28%)
aml_ohsu_2022	aml_ohsu_2022_2424	aml_ohsu_2022_2424_BA2035	61	61	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Midostaurin|Hydroxyurea	5	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Maintenance	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Midostaurin	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	NA	284	Targeted Therapy - Kinase Inhibitor(s)	4	FALSE	Negative	AML	71.73698630136987	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD33, CD34, CD38, dim CD45, CD117, and MPO	0	0.166666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF ~50%)|FLT3-ITD (MAF 40%)|IDH1 (p.R132S; MAF ~50%)|SRSF2 (p.P95L; MAF ~40% )
aml_ohsu_2022	aml_ohsu_2022_2425	aml_ohsu_2022_2425_BA2738	66	66	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	46,XY,t(4;9)(q21;p22)[7]/46,sl,add(1)(p13),add(15)(q15)[6]/45,sdl1,-18[4]/49,sdl2,+add(1)(p13),+6,+8,+18[2]/46,XY[1]	-1	Standard Chemotherapy	13	FALSE	Negative	AML	9.961643835616439	1:DECEASED	20% CEP 8, 24% RUNX1T1/RUNX1, 23% PML/RARA	No	No	NA	No	No	No	No	Yes	Yes	White	-1	Unknown	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD58, CD117, and HLA-DR positive	0	0.633333333	NA	Standard Chemotherapy	Yes	JAK2 (p.V16F. MAF 15%)
aml_ohsu_2022	aml_ohsu_2022_2426	aml_ohsu_2022_2426_BA2400	44	44	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	NA	99	Standard Chemotherapy	9	FALSE	Positive	AML	61.019178082191786	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	8	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD117, CD123, dim HLA-DR and MPO | CD11b, CD13, CD33, CD117, CD64, CD123, and dim HLA-DR. (Blasts with monocytic differentiation (about 10% of blasts).)	0	0.5	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 2%)|IDH1 (p.R132H; MAF 44%)|NPM1 (p.W288fs*12; MAF 44%)|PTPN11 (p.R265Q; MAF 3%)
aml_ohsu_2022	aml_ohsu_2022_2429	aml_ohsu_2022_2429_BA2025	30	31	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Decitabine	Supportive/Palliative Care	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Negative	FALSE	TRUE	FALSE	46,XX,t(9;11)(p22;q23)[20]/46,XX[1]	31	Supportive/Palliative Care	16	FALSE	Negative	AML	8.876712328767123	1:DECEASED	MLL disruption and t(9;11) (70%)	Yes	No	Acute Promyelocytic Leukemia	No	No	No	No	No	No	Pacific Islander	6	Complete Response	NA	2	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	dim/partial CD13, CD33, CD38, CD56, CD58, CD64, partialCD117, CD123 and HLA-DR positive	147	0.766666667	NA	Standard Chemotherapy	No	FLT3-D835 (MAF 70%)
aml_ohsu_2022	aml_ohsu_2022_2429	aml_ohsu_2022_2429_BA2446	30	30	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Decitabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Negative	FALSE	FALSE	FALSE	46,XX,t(9;11)(p11;q34)[19]/46,XX[1]	31	Supportive/Palliative Care	14	FALSE	Negative	AML	8.876712328767123	1:DECEASED	Disruption of MLL signal and t(9;11) (65%)	Yes	No	Acute Promyelocytic Leukemia	No	No	No	No	No	No	Pacific Islander	6	Complete Response	NA	2	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD11b, CD13, CD14,  CD33, CD64, CD56, CD123 and HLA-DR positive	0	0.633333333	NA	Standard Chemotherapy	Yes	CREBBP (p.A254T; MAF 50%)|CREBBP (p.T910S; MAF 40%)|FLT3-D835 (p.D835; MAF 35%)
aml_ohsu_2022	aml_ohsu_2022_2430	aml_ohsu_2022_2430_BA2652	50	50	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	mono	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	11	FALSE	Negative	AML	63.51780821917808	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	13	Refractory	NA	1	Female	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, dimCD33, CD34, CD38, CD117, dimCD123, dim HLA-DR, and dim MPO positive.	0	0.566666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.N1036S; MAF 50%)|CEBPA (p.N321D; MAF 20%)|DNMT3A (p.R882C; MAF 20%)|IDH1 (p.R132C; MAF 20%)|MLL (Partial tandem duplication )
aml_ohsu_2022	aml_ohsu_2022_2431	aml_ohsu_2022_2431_BA2776	61	61	9	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	No	Hydroxyurea	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	FALSE	FALSE	TRUE	46,XX[20]	-1	Supportive/Palliative Care	3	FALSE	Positive	AML	10.389041095890411	1:DECEASED	Normal	No	No	NA	No	No	No	No	Yes	Yes	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD38, CD56, CD58, CD117, CD123 and dim MPO positive	0	0.066666667	NA	NA	Yes	FLT3-ITD (30 bp insertion; MAF 70%)|NPM1 (p.W288fs*12; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2432	aml_ohsu_2022_2432_BA2033	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	Lenalidomide|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	2	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q2	-1	Standard Chemotherapy	15	FALSE	Negative	AML	0.36164383561643837	1:DECEASED	FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells.	Yes	No	Non-Hodgkins Lymphoma	Yes	Yes	No	No	No	No	NA	NA	NA	NA	1	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry.	0	0.733333333	TP53 (p.P151H; 97.9%)	NA	Yes	TET2 (p.G355D; MAF 33.8%)|TP53 (p.P19H; MAF 8.9%)
aml_ohsu_2022	aml_ohsu_2022_2433	aml_ohsu_2022_2433_BA2521	44	44	2.333333333	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Both	Yes	Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea|Busulfan, Cyclophosphamide|7+3 (Cytarabine, Idarubicin) plus Dasatinib	6	Allogeneic - Sibling|Induction|Experimental|Re-induction|Post-Transplant Relapse	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Azacitidine	Post-Transplant Relapse	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XX[20]	81	Standard Chemotherapy	5	FALSE	Positive	AML	10.487671232876712	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	28	Complete Response i	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, subset CD34, variable CD117, CD123, HLA-DR, and variable MPO positive - Monocytic/blast equivalent immunophenotype: CD11b, CD13, subset CD14, variable CD16, CD33, CD64, dim CD123, and HLA-DR positive	0	0.166666667	NA	Standard Chemotherapy	No	DNMT3A (p.R882H; MAF 48%)|FLT3-ITD (MAF 70%)|NPM1 (p.W288fs*12; MAF 46%)
aml_ohsu_2022	aml_ohsu_2022_2434	aml_ohsu_2022_2434_BA2576	28	29	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Fludarabine, Cyclophosphamide, TBI, Rituximab	5	Allogeneic - Sibling|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI, Rituximab	Allogeneic - Sibling	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	15	FALSE	Negative	AML	54.50958904109589	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated CEBPA	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD7, CD13, CD33, CD34, partial CD56, CD117,  HLA-DR,      MPO and dim TdT-positive	0	0.733333333	NA	Standard Chemotherapy	Yes	ASXL1 (p.D656N; MAF 46%)|CEBPA (p.Q311*; MAF 15%)|TET2 (p.R544*; MAF 16%)
aml_ohsu_2022	aml_ohsu_2022_2435	aml_ohsu_2022_2435_BA2974	69	69	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY[20]	5	Standard Chemotherapy	13	FALSE	Negative	AML	6.8054794520547945	0:LIVING	FISH normal	No	No	NA	No	No	No	No	No	No	Pacific Islander	5	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, CD33, CD34, CD38,  CD64, CD117, HLA-DR and MPO positive (Myeloid blasts) | CD13, CD14,CD33, CD64, dimCD34, and MPO positive (Monocytes)	0	0.533333333	NA	Standard Chemotherapy	Yes	CEBPA (p.K313del; MAF 34%)|CEBPA (p.P23fs*81; MAF 41%)|TET2 (p.G1160E; MAF 51%)|TET2 (p.S1039L; MAF 48%)|WT1 (p.R380fs*5; MAF 31%)
aml_ohsu_2022	aml_ohsu_2022_2436	aml_ohsu_2022_2436_BA2852	74	75	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Azacitidine, MLN4924	1	Induction	1	Standard Chemotherapy	1	Azacitidine, MLN4924	Induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	48,XY,+8,del(20)(q11.2),+21[14]/46,XY[6]	498	Standard Chemotherapy	2	FALSE	Negative	AML	17.72054794520548	0:LIVING	This test has detected a 20q deletion, trisomy 8, and trisomy 21 in 14 cells. All these abnormalities are commonly seen in AML and MDS.	No	No	NA	Yes	No	No	No	No	No	White	498	Complete Response	RUNX1 (p.G165Dfs*2; 11.1%)	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Relapse	Peripheral Blood	These are positive for CD34, CD117, HLA-DR, and CD33. (Bone Marrow Immunophenotyping)	0	0.066666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2437	aml_ohsu_2022_2437_BA2851	53	53	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XX[20]	7	Standard Chemotherapy	2	FALSE	Negative	AML	4.208219178082192	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	4	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7, CD13, CD33, CD34, variable CD38, CD117, CD123, partial HLA-DR and dim MPO	0	0.133333333	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 45%)|FLT3-D835 (p.D835Y; MAF 3%)|MLL (Partial Tandem Duplication)|NRAS (p.G13D; MAF 35%)|NRAS (p.Q61R; MAF 3%)
aml_ohsu_2022	aml_ohsu_2022_2439	aml_ohsu_2022_2439_BA2547	69	69	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus CX-01|IDAC	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	MissingKaryo	NA	NA	Negative	TRUE	FALSE	FALSE	NA	-1	Bone Marrow Transplant	18	FALSE	Negative	AML	8.383561643835616	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	normocytic, normochromic, mild anisopoikilocytosis, no sig. polychromasia. Leukocyte number-decreased,leukocyte morph-within normal limits.	0	0.933333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2440	aml_ohsu_2022_2440_BA2180	62	63	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown|Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	Residual	Myelodysplastic/Myeloproliferative Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY[12]	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	9.23835616438356	0:LIVING	The abnormalities normally seen in MDS are not detected.	No	No	NA	No	No	Yes	No	No	No	White	NA	NA	NA	3	Male	UNMATCHED	FALSE	Chronic myelomonocytic leukaemia	Residual Disease	Peripheral Blood	NA	232	0.266666667	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2440	aml_ohsu_2022_2440_BA2347	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown|Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Myelodysplastic/Myeloproliferative Neoplasms	Intermediate	NA	M4	Negative	FALSE	FALSE	TRUE	46, XY [20]	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	9.23835616438356	0:LIVING	The abnormalities normally seen in MDS are not detected.	No	No	NA	No	No	Yes	No	No	No	White	NA	NA	NA	3	Male	UNMATCHED	FALSE	Chronic myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	34	0.266666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2440	aml_ohsu_2022_2440_BA2379	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown|Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	Residual	Myelodysplastic/Myeloproliferative Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY[12]	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	9.23835616438356	0:LIVING	The abnormalities normally seen in MDS are not detected.	No	No	NA	No	No	Yes	No	No	No	White	NA	NA	NA	3	Male	UNMATCHED	FALSE	Chronic myelomonocytic leukaemia	Residual Disease	Bone Marrow Aspirate	A very dim/negative CD45 population was also detected by the flow analysis. This population is negative for all the myeloid and lymphoid markers including CD34. This is mentioned here for documentation purposes but we believe that they do not represent bl	81	0.266666667	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2441	aml_ohsu_2022_2441_BA2588	59	59	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	5	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[20]	4	Standard Chemotherapy	17	FALSE	Positive	AML	19.627397260273973	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD117, CD123, and HLA-DR	0	0.9	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882C; MAF 40%)|NPM1 (p.W288fs*12 ; MAF 40%)|PTPN11 (p.K70R; MAF 40%)|SOCS1 (p.Q210H ; MAF 55%)
aml_ohsu_2022	aml_ohsu_2022_2442	aml_ohsu_2022_2442_BA2868	69	69	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	bi	3	Waves1+2	Yes	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	NA	-1	Standard Chemotherapy	19	FALSE	Negative	AML	8.21917808219178	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Peripheral Blood	weak  CD7, CD13, partial CD15, weak CD33, CD34, weak CD64, CD117,  myeloperoxidase, and HLA-DR, but do not express CD14(MO2),  CD42b, or CD61.	0	1.066666667	NA	Standard Chemotherapy	Yes	CEBPA (c.117delC; MAF 27.2%)|CEBPA (c.938_939insATC; MAF 18.1%)|TET2 (c.3454G>T; MAF 40.9%)|WT1 (c.1137_1138insA; MAF 43.7%)|WT1 (c.872+1G>A; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2444	aml_ohsu_2022_2444_BA2361	55	55	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin) plus Enasidenib|Busulfan, Cyclophosphamide	2	Allogeneic - Sibling|Induction	2	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,del(5)(q22q35)[2]/46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.2)[14]/46,XX[3]	-1	Bone Marrow Transplant	12	FALSE	Negative	AML	14.07123287671233	0:LIVING	Probe: 8 centromere/20q12 | Normal (5p15.2/ 5q31 (EGR1); 7 centromere/ 7q31)	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Negative (CD19) | Negative (CD22) | Positive (CD38) | Negative (CD7) | Negative (CD56) | Negative (CD11b) | Positive (CD13) | Negative (CD14) | Negative (CD15) | Negative (CD33) | Positive (CD34) | Negative (CD45) | Negative (CD64) | Negative (CD117) | Ne	0	0.6	NA	Standard Chemotherapy	Yes	ASXL1 (c.190 0_1922 delAGAGAGGCGGCCACCACTGCCAT; p.R634Rfs; MAF 33%)|IDH2 (c.419G>A; P.R140Q; MAF 46%)
aml_ohsu_2022	aml_ohsu_2022_2445	aml_ohsu_2022_2445_BA2036	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	NA	-1	Standard Chemotherapy	3	FALSE	Positive	AML	0.6904109589041096	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	UNKNOWN	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large population of atypical myeloblasts (CD56 positive,  weak CD117 positive, CD34 negative, HLA-DR negative),  representing approximately 87% of the leukocytes,  consistent with acute myeloid leukemia	0	0.133333333	NA	Standard Chemotherapy	Yes	KMT2A (p.Ile3572Ser (NM_001197104.1); MAF 44.1%)|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.4%)|TET2 (p.His724fs; MAF 43.5%)
aml_ohsu_2022	aml_ohsu_2022_2446	aml_ohsu_2022_2446_BA2236	54	57	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	7	Consolidation|Salvage|Induction|Re-induction|Maintenance	5	Standard Chemotherapy	1	Decitabine	Re-induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Negative	FALSE	TRUE	FALSE	47,XY,+21[17]/47,idem,t(10;22)(q22;q13)[cp3]/46,XY[1]	160	Standard Chemotherapy	4	FALSE	Positive	AML	45.30410958904109	1:DECEASED	80% Trisomy 21	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123	349	0.233333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2447	aml_ohsu_2022_2447_BA2260	58	58	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	3	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M4	Negative	TRUE	FALSE	FALSE	48,XY,+8,inv(16)(p13.1q22),+22[18]/49,sl,+21[2]	210	Standard Chemotherapy	19	FALSE	Negative	AML	41.0958904109589	0:LIVING	8q22 (RUNX1T1): gain present  16q22 (CBFB): rearrangement present  21q22 (RUNX1): gain or rearrangement present (96%, 71.5%, 11% respectively)	No	No	NA	No	No	No	No	No	No	NA	5	Complete Response	NA	2	Male	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	Relative increase of CD34 positive myeloblasts representing approximately 20% of the leukocytes and increased promonocytes/monoblasts consistent with acute myeloid leukemia with   myelomonocytic differentiation	0	1.066666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2447	aml_ohsu_2022_2447_BA2787	58	58	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	3	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M4	Negative	FALSE	FALSE	FALSE	46,XY[20]	210	Standard Chemotherapy	5	FALSE	Negative	AML	41.0958904109589	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	NA	5	Complete Response	NA	2	Male	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Post-Chemotherapy	Peripheral Blood	NA	100	0.166666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2448	aml_ohsu_2022_2448_BA2811	47	47	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Consolidation|Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,XX,t(15;17)(q24;q21)[4]/45,idem,-22[15]/46,XX[1]	31	Standard Chemotherapy	5	FALSE	Negative	AML	72.23013698630137	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	26	Complete Response	NA	1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2, CD13, CD33, CD34, CD56, CD58, CD64, CD117, CD123, dim/partial HLA-DR, dim/partial TdT and MPO positive	0	0.166666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2449	aml_ohsu_2022_2449_BA2422	74	74	NA	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Dead-Unknown	NA	2	Waves1+2	Yes	Lenalidomide|Azacitidine	2	Hypomethylating/Low Dose Cytarabine|Maintenance	2	Standard Chemotherapy|Supportive/Palliative Care	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	NA	Myelodysplastic Syndromes	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	42~44,XX,-3,del(4)(q25q33),der(5)t(3;5)(q21;q22),del(7)(p15p22),-9,-9,-13,-16,add(17)(p11.2),add(19)(p13.3), +mar1,+mar2[cp4]/41~43,idem,-del(7),+der(7)t(7;15)(p12;q15)add(7)(q11.2),+der(7;9)(q11.2;q13)del(7)(q11.2q22), -15,-21,+mar3[cp5]/42~44,idem,-del(	6	Supportive/Palliative Care	18	FALSE	Negative	MDS	6.147945205479452	1:DECEASED	nuc ish(D5S2064x2,D5S630x2,EGR1x1) [91/200],(D7Z1x3,D7S522x2)[11/200],(D8Z2,D20S108)x2[196],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[196],(PMLx3,RARAx2)[28/200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[101/200]	Yes	No	Uterine Sarcoma|Breast Cancer	Yes	No	No	No	No	No	NA	NA	NA	NA	1	Female	MATCHED	TRUE	Myelodysplastic syndrome associated with isolated del(5q)	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD2(-), CD7(partial dim +), 11b(-), CD13(+), CD14 (-), CD15(-), CD33(variably +), CD34(bright +), CD36(+), CD38(slightly variably +), CD45(+), CD117(variably +), HLA-DR(-).	0	1	TP53 (p.R337L; 45.2%)	NA	No	TP53 (Foundation; R337L)
aml_ohsu_2022	aml_ohsu_2022_2450	aml_ohsu_2022_2450_BA2904	60	61	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|IDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	IDAC	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,inv(16)(p13q22)[20]	-1	Standard Chemotherapy	2	FALSE	Negative	AML	11.046575342465754	1:DECEASED	NA	Yes	No	Adenocarcinoma	No	No	No	No	No	No	NA	-1	UNKNOWN	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Residual Disease	Peripheral Blood	Increased atypical CD34+myeloblasts representing 80%of leukocytes suggestive of recurrent AML.	0	0.1	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2451	aml_ohsu_2022_2451_BA2335	60	60	0.5625	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Hydroxyurea|Quizartinib|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Induction|Experimental	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	5	FALSE	Positive	AML	3.9123287671232876	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	5	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, CD33, CD34, CD117, CD123, and HLA-DR-positive	0	0.166666667	NA	Standard Chemotherapy	Yes	FLT3-ITD|NPM1 (exon 12 insertion W288fs*1)
aml_ohsu_2022	aml_ohsu_2022_2452	aml_ohsu_2022_2452_BA3026	53	54	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	3	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,del(17)(p11.2p13)[19]/46,XX[1]	-1	Standard Chemotherapy	16	FALSE	Negative	AML	12.82191780821918	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[197]	Yes	No	Breast Cancer	No	No	No	No	No	No	NA	6	Complete Response	NA	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15 (partial +), CD16(-), CD33(variably +), CD34(+), CD36(-), CD38(partial +), CD45(dim to moderately +), CD56(-), CD64(-), CD117(partial +), HLA-DR(-), TdT(predominantly -), MPO(+).	0	0.8	TP53 (p.R248W; 87.0%)	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2453	aml_ohsu_2022_2453_BA2622	76	76	0	ASXL1 (p.G646Wfs*12; 20.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	3	Consolidation|Induction	2	Standard Chemotherapy	1	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Negative	FALSE	FALSE	FALSE	47,XY,+8[3]/46,XY[17]	77	Standard Chemotherapy	11	FALSE	Negative	AML	17.0958904109589	1:DECEASED	5% trisomy 8	Yes	No	Basal Cell Carcinoma	No	No	No	No	No	No	White	35	Complete Response	RUNX1 (p.A338Rfs*256; 73.3%)	3	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	#1 Immunophenotype: CD13, CD34, CD38, dim CD45, CD58, CD117, HLA-DR and TdT positive | #2 Immunophenotype: dim CD4, partial CD13, dim CD34, CD38, CD58, CD123, HLA-DR, and partial TdT positive	0	0.633333333	NA	Standard Chemotherapy	Yes	CBL (p.Y371H; MAF 43%)|EZH2 (p.K30fs*8; MAF 48%)|RUNX1 (p.A338fs*; MAF 41%)|SF3B1 (p.H662Q; MAF 28%)
aml_ohsu_2022	aml_ohsu_2022_2453	aml_ohsu_2022_2453_BA2758	76	77	0	ASXL1 (p.G646Wfs*12; 21.1%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	3	Consolidation|Induction	2	Standard Chemotherapy	1	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M0	Negative	FALSE	TRUE	FALSE	47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1]	77	Standard Chemotherapy	14	FALSE	Negative	AML	17.0958904109589	1:DECEASED	50/100 (50%) interphase cells scored had a signal pattern reflecting trisomy 8.	Yes	No	Basal Cell Carcinoma	No	No	No	No	No	No	White	35	Complete Response	RUNX1 (p.A338Rfs*256; 71.0%)	3	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Relapse	Peripheral Blood	dim CD4, CD13, bright CD34, dim CD45, CD117, HLA-DR, and dim TdT positive	417	0.733333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2453	aml_ohsu_2022_2453_BA2930	76	77	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	3	Consolidation|Induction	2	Standard Chemotherapy	1	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M0	Negative	FALSE	FALSE	FALSE	47,XY,+8[cp15]/47,sl,der(22)t(1;22)(q11;p11.2)[2]/46,XY,dup(1)(q21q42)[cp2]	77	Standard Chemotherapy	18	FALSE	Negative	AML	17.0958904109589	1:DECEASED	60/100 (60%) interphase cells scored had a signal pattern reflecting trisomy 8.	Yes	No	Basal Cell Carcinoma	No	No	No	No	No	No	White	35	Complete Response	RUNX1 (p.A338Rfs*256; 76.9%)	3	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	Positive (The myeloid blasts are CD13, CD34, CD38, CD117, and HLA-DR;Atypical monocytic cells comprise approximately 41% of analyzed events and are CD11b, CD13, CD14, CD64, and dim HLA-DR positive. T cells show a CD4:CD8 ratio of 6.9:1 without aberrant an	472	0.866666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2454	aml_ohsu_2022_2454_BA2387	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Mismatched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	46,XX,idic(7)(q11.2)[20]	-1	Bone Marrow Transplant	10	FALSE	Negative	AML	15.18904109589041	1:DECEASED	NA	Yes	No	Thyroid Cancer	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, CD13, CD33, partial CD34,      CD38, CD58, CD64, CD117, CD123, partial HLA-DR and cMPO positive	0	0.5	NA	Standard Chemotherapy	Yes	BCOR (p.T870fs*46 (2 bp deletion); MAF 50%)|IDH1 (p.R132C; MAF 50%)|MLL (PTD)|PTPN11 (p.S502L; MAF 50% )
aml_ohsu_2022	aml_ohsu_2022_2455	aml_ohsu_2022_2455_BA2893	59	59	1	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Azacitidine, Sorafenib	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	4	FALSE	Positive	AML	8.35068493150685	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia.	0	0.133333333	NA	Standard Chemotherapy	Yes	NPM1
aml_ohsu_2022	aml_ohsu_2022_2456	aml_ohsu_2022_2456_BA2670	72	73	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine|Maintenance	2	Standard Chemotherapy|Other	2	Clofarabine, Cytarabine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14]	-1	Other	7	FALSE	Negative	AML	15.287671232876711	1:DECEASED	nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]	No	No	NA	Yes	Yes	No	No	No	No	White	NA	NA	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	0	0.3	NA	NA	Yes	RUNX1 (PB)|SF3B1 (PB)
aml_ohsu_2022	aml_ohsu_2022_2457	aml_ohsu_2022_2457_BA2278	47	47	4	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide	5	Consolidation|Induction|CNS|Re-induction|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Intrathecal	3	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M5	Positive	TRUE	FALSE	FALSE	46,XY,t(11;19)(q23;p13.1)[20]	9	Supportive/Palliative Care	7	FALSE	Negative	AML	7.4958904109589035	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	7	Complete Response	NA	2	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19	0	0.233333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2457	aml_ohsu_2022_2457_BA3013	47	47	0.075268817	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide	5	Consolidation|Induction|CNS|Re-induction|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Intrathecal	3	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M5	Positive	TRUE	FALSE	FALSE	46,XY,t(11;19)(q23;p13.1)[20]	9	Supportive/Palliative Care	8	FALSE	Negative	AML	7.4958904109589035	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	7	Complete Response	NA	2	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19	0	0.266666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2458	aml_ohsu_2022_2458_BA2655	58	59	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	E7070, Idarubicin, Cytarabine|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|BL-8040|IGN523	8	Salvage|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Other	2	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	7	FALSE	Negative	AML	11.736986301369862	1:DECEASED	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x1[47/200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD2 (-), CD4(+), CD7(+), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(bright +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).	0	0.433333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2459	aml_ohsu_2022_2459_BA2071	40	39	0.333333333	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Induction	4	Standard Chemotherapy	1	HiDAC	Consolidation	NA	Myelodysplastic Syndromes	NonAML	NA	NA	Positive	FALSE	FALSE	FALSE	46,XX[20]	5	Standard Chemotherapy	14	FALSE	Negative	MDS	12.887671232876713	0:LIVING	nuc ish(D4Z1,D10Z1)x2[200],(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[	No	No	NA	Yes	Yes	No	No	No	No	NA	5	NA	NA	1	Female	MATCHED	TRUE	Myelodysplastic syndrome, unclassifiable	NA	Bone Marrow Aspirate	NA	0	0.766666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2461	aml_ohsu_2022_2461_BA2593	53	53	1.083333333	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M4	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	NA	FALSE	Negative	AML	0.6904109589041096	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	large population of atypical CD117 positive myeloblasts (partial CD34+, weak CD4+, weak partial CD7+, partial CD64+), representing approximately 57% of the leukocytes and increased   promonocytes/monoblasts representing approximately 13% of the total leuk	0	NA	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2462	aml_ohsu_2022_2462_BA2967	58	58	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)	2	Induction|Re-induction	2	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	44-45,XY,-4,-5,add(7)(q11.2),  der(16)del(16)(p13.1)del(16)(q22),-17,add(18)(q21),+1-3mar[cp18]  /46,XY[2]	-1	Standard Chemotherapy	2	FALSE	Negative	AML	2.0712328767123287	1:DECEASED	NA	No	No	NA	No	No	No	No	Yes	Yes	NA	-1	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	Increased CD34+ myeloblasts, representing 42% of leukocytes, suspicious for AML	0	0.133333333	TP53 (p.R248Q; 71.7%)	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2463	aml_ohsu_2022_2463_BA2882	29	29	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Induction|Re-induction	2	Standard Chemotherapy	1	HiDAC	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	46,XY,t(9;11)(p22;q23)[20]	4	Standard Chemotherapy	5	FALSE	Negative	AML	2.1369863013698627	1:DECEASED	94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, consistent with MLL rearrangement and the 9;11 translocation observed in the metaphase karyotype.	Yes	No	Non-Hodgkins Lymphoma	No	No	No	No	No	No	White	19	Complete Response	NA	1	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	CD11b, varibleCD13, CD14, brightCD33, CD64, and HLA-DR positive	0	0.233333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2464	aml_ohsu_2022_2464_BA2051	60	60	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	HiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,inv(16)(p13.1q22)[18]/47,sl,+22[2]	-1	Bone Marrow Transplant	23	FALSE	Negative	AML	19.101369863013698	1:DECEASED	FISH positive for CBFB rearrangement in 49% of cells	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Flow cytometry shows the large majority of analyzed cells fall within the monocyte gate, which are predominantly mature as evidenced by coexpression of CD14 and CD64. A smaller subset of cells within the monocyte gate consists of immature monocytes with d	0	0.833333333	NA	Standard Chemotherapy	Yes	NRAS (p.Q61K; MAF 24.1%)
aml_ohsu_2022	aml_ohsu_2022_2465	aml_ohsu_2022_2465_BA2866	58	58	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	Sorafenib|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Induction|Experimental	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M2	Negative	TRUE	FALSE	FALSE	47,XY,t(8;22)(p11.2;q11.2),+19[20]	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	6.312328767123287	0:LIVING	t(8;22) clone observed, consistent with a neoplastic process	No	No	NA	No	No	No	No	No	No	NA	1	Complete Response	RUNX1 (p.S322Ffs*278; 45.9%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (CD34-Dim)	0	0.166666667	NA	Standard Chemotherapy	Yes	ATM (p.P604S; VAF ~50%)|PHF6 (p.G306R; VAF ~75%)|RUNX1 (p.S322fs*278 (Single base pair insertion, frame shift  mutation); MAF ~40%)
aml_ohsu_2022	aml_ohsu_2022_2466	aml_ohsu_2022_2466_BA2921	70	71	0.01010101	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Both	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Hypomethylating/Low Dose Cytarabine|Induction	2	Standard Chemotherapy|Supportive/Palliative Care	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	FALSE	FALSE	46,XY,del(7)(q22q36)[7]/47,idem,+22[cp12]/46,XY[1]	-1	Supportive/Palliative Care	5	FALSE	Negative	AML	6.378082191780822	1:DECEASED	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[187/200], (D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.2	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2467	aml_ohsu_2022_2467_BA2047	69	69	0.851851852	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	ATRA, Idarubicin|ATRA, Arsenic Trioxide	2	Consolidation|Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,XX,t(15;17)(q24;q21)[20]	-1	Standard Chemotherapy	3	FALSE	Negative	AML	50.69589041095891	0:LIVING	PML/RARA fusion	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD2, CD13, dim CD15, CD33, CD38, CD58, CD64, CD117, CD123, variable HLA-DR and bright MPO positive	1	0.066666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 42%)|NOTCH1 (p.P2438L ; MAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2468	aml_ohsu_2022_2468_BA2840	78	78	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	Ruxolitinib|Hydroxyurea|Decitabine, Ruxolitinib	3	Induction|Experimental|Maintenance	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Decitabine, Ruxolitinib	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M7	Negative	FALSE	FALSE	TRUE	46,XX,t(7;13)(q22;q12),del(20)(q11.2)[1]/46,sl,dup(1)(p25),del(2)(q21q23),add(8)(q13q22)[3]/46,sdl,add(5)(p15)[8]/46,sdl,add(12)(p13)[3]/46,sdl,add(12)(p13),add(13)(p12)[4]/46,XX[1]	7	Standard Chemotherapy	10	FALSE	Negative	AML	0.7890410958904108	1:DECEASED	RUNX1T1 (8q21.3): 35% of cells had three signals for RUNX1T1 on 8q. No evidence for t(8;21). | FISH was also performed with a probe for chromosome 20, so that the stemline clone and all subclones could be followed by interphase FISH. 88/100 cells were mis	No	No	NA	No	No	No	No	Yes	Yes	White	7	Refractory	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD33, CD34 (subset), CD41, CD58, CD61 and Factor-8 positive	0	0.566666667	NA	Standard Chemotherapy	Yes	GATA1 (p.M1V; MAF 32%)|MPL (p.S505N; MAF 70%)|TET2 (p.V636fs*3; MAF 46%)
aml_ohsu_2022	aml_ohsu_2022_2469	aml_ohsu_2022_2469_BA2068	64	64	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Induction	2	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	46,XX[14]	5	Standard Chemotherapy	22	FALSE	Positive	AML	36.55890410958904	0:LIVING	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],	No	No	NA	No	No	No	No	No	No	Black	7	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4(few +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(partial +), CD16(-), CD34(-), CD36(-), CD38(+), CD45(+), CD56(few +), CD64(-), CD117(partial +), HLA-DR(-), MPO(+) and TdT (+)	0	1.166666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2470	aml_ohsu_2022_2470_BA2238	33	33	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Clofarabine, Cytarabine	2	Induction|Re-induction	2	Standard Chemotherapy	1	Clofarabine, Cytarabine	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	45,XX,-17[15]/46,XX[2]	-1	Standard Chemotherapy	13	FALSE	Negative	AML	2.334246575342466	0:LIVING	90.5% monosomy 17, 6% trisomy 11q23	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	RUNX1 (p.R201*; 48.0%)	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	positive for CD13, CD33, CD34, CD38, CD45, CD117, HLA-DR and MPO	2	0.733333333	TP53 (p.R175H; 92.9%)	Standard Chemotherapy	Yes	DNMT3A (p.V468M; MAF 51.2%)|IDH2 (p.R172K; MAF 46.1%)|RUNX1 (p.R174X; MAF 48.2%)|TET2 (p.G355D; MAF 50.5%)|TP53 (p.R43H; MAF 76.7%)
aml_ohsu_2022	aml_ohsu_2022_2471	aml_ohsu_2022_2471_BA2211	65	65	1	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Consolidation|Induction	2	Standard Chemotherapy	1	Azacitidine	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	34	Standard Chemotherapy	8	FALSE	Positive	AML	4.668493150684932	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	17	Complete Response i	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD38, CD56, CD58, partial CD64, CD117, CD123, and MPO positive	0	0.3	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 50%)|NPM1 (p.W288fs*12; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2473	aml_ohsu_2022_2473_BA2429	78	78	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Maintenance	2	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Negative	FALSE	FALSE	TRUE	NA	-1	Standard Chemotherapy	4	FALSE	Negative	AML	11.704109589041096	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.233333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2474	aml_ohsu_2022_2474_BA2982	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |7+3 (Cytarabine, Idarubicin) plus Sorafenib|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	5	Consolidation|Induction|Experimental|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	SGN-CD33A	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,inv(3)(q21;q26.2)[20]	-1	Targeted Therapy - Other	25	FALSE	Negative	AML	10.61917808219178	1:DECEASED	3q21.3q26.2 (RPN1/MECOM): rearrangement present (86%)	No	No	NA	No	No	No	No	No	No	NA	24	Complete Response	RUNX1 (p.S100Lfs*39; 35.6%)	1	Female	MATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Most of the atypical cells (percentages shown) are myeloid blasts that express dim CD7, dim CD13, CD33, CD34, CD117, weak myeloperoxidase, and HLA-DR, but do not express cytoplasmic CD3, TDT,   CD14(MO2), CD42b, CD61, or CD64. (Increased atypical CD34 pos	0	1.333333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2475	aml_ohsu_2022_2475_BA2924	66	67	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Both	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	TRUE	FALSE	NA	63	Standard Chemotherapy	6	FALSE	Positive	AML	9.863013698630137	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	23	Complete Response	NA	2	Male	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Peripheral Blood	NA	0	0.266666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2475	aml_ohsu_2022_2475_BA3192	66	67	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	49,XY,+4,+8,+14[9]/49,sl,del(4)(q21q31.1)[11]	63	Standard Chemotherapy	10	FALSE	Positive	AML	9.863013698630137	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	23	Complete Response	NA	2	Male	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	POSITIVE FOR CD117, HLA-DR, CD13, CD33, CD14 AND MPO AND NEGATIVE FOR CD34, CD11B, CD64, CD10 AND TDT. (Bone Marrow Immunophenotype)	80	0.5	NA	Standard Chemotherapy	No	DNMT3A (c.2645G>A; p.R882H MAF 42%)|FLT3-ITD|KIT (c.2447A>T; p.D816V MAF 81%)|NPM1 ((NPM1) c.860_863dupTCTG; p.W288Cfs*12  MAF 51%)|SETBP1 (c.3209C>T; p.P1070L MAF 46%)|TET2 (c.3638T>G; p.V1213G MAF 87%)
aml_ohsu_2022	aml_ohsu_2022_2476	aml_ohsu_2022_2476_BA2005	27	31	1.173913043	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	TRUE	FALSE	46,XX,del(6)(q13q23)[18]/46,XY[2]	99	Targeted Therapy - Kinase Inhibitor(s)	4	FALSE	Positive	AML	48.0986301369863	1:DECEASED	Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal (40%)	Yes	No	Juvenile pilocytic astrocytoma	No	No	No	No	No	No	White	2	Complete Response	NA	5	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	partial CD7, variable CD13, CD33, partial CD34,CD38, CD58, CD117, CD123, and partial HLA-DR positive	1339	0.066666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2476	aml_ohsu_2022_2476_BA2102	27	27	0.960784314	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XX[20]	99	Targeted Therapy - Kinase Inhibitor(s)	3	FALSE	Positive	AML	48.0986301369863	1:DECEASED	Normal	Yes	No	Juvenile pilocytic astrocytoma	No	No	No	No	No	No	White	2	Complete Response	NA	5	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, CD33, partial CD34, dim CD45, CD117, CD123, HLA-DR and MPO positive	0	0.033333333	NA	Standard Chemotherapy	Yes	CEBPA|FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2476	aml_ohsu_2022_2476_BA2555	27	31	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	TRUE	FALSE	46,XX,del(6)(q13q23)[15]/46,XY[5]	99	Targeted Therapy - Kinase Inhibitor(s)	3	FALSE	Positive	AML	48.0986301369863	1:DECEASED	6q deletion (79%)	Yes	No	Juvenile pilocytic astrocytoma	No	No	No	No	No	No	White	2	Complete Response	NA	5	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Transplant|Post-Chemotherapy	Peripheral Blood	NA	1465	0.066666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2476	aml_ohsu_2022_2476_BA3073	27	31	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	NA	FALSE	FALSE	FALSE	46,XX,del(6)(q13q23)[15]/46,XY[5]	99	Targeted Therapy - Kinase Inhibitor(s)	NA	FALSE	Positive	AML	48.0986301369863	1:DECEASED	6q deletion (79%)	Yes	No	Juvenile pilocytic astrocytoma	No	No	No	No	No	No	White	2	Complete Response	NA	5	Female	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Transplant	Peripheral Blood	NA	1465	NA	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2476	aml_ohsu_2022_2476_BA3074	27	31	2.03030303	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XX,del(6)(q13q23)[18]/46,XY[2]	99	Targeted Therapy - Kinase Inhibitor(s)	4	FALSE	Positive	AML	48.0986301369863	1:DECEASED	Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal (40%)	Yes	No	Juvenile pilocytic astrocytoma	No	No	No	No	No	No	White	2	Complete Response	NA	5	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Transplant|Residual Disease	Peripheral Blood	NA	1354	0.1	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2477	aml_ohsu_2022_2477_BA2008	NA	NA	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	4	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	unknown	FALSE	unknown	NA	NA	None	1	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	unknown	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.066666667	TP53 (p.G266E; 82.1%)	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2478	aml_ohsu_2022_2478_BA3010	71	71	0	ASXL1 (p.G646Wfs*12; 39.4%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	6	Waves1+2	Yes	Vidaza|Rituximab|Decitabine	3	Consolidation|Maintenance	2	Standard Chemotherapy	1	Decitabine	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	86	Standard Chemotherapy	6	FALSE	Negative	AML	1.6767123287671235	1:DECEASED	NA	Yes	No	Non-Hodgkins Lymphoma	Yes	Yes	No	No	No	No	White	NA	NA	RUNX1 (p.R320*; 40.9%)	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	Positive for CD34, CD117, HLADR, CD33, CD13 but negative for CD14, CD64, CD11b, CD19, and CD3 (Peripheral Immunophenotyping) | The blasts are positive for CD34 and CD117 (Bone marrow Immunophenotyping)	0	0.333333333	NA	NA	Yes	BCOR (p.A603pfs*66; MAF55%)|KRAS (p.G12V; MAF 49%)|RUNX1 (pR320*; MAF 47%)|SRSF2 (p.P95H; MAF 49%)|STAG2 (p.Y636*; MAF 96%)
aml_ohsu_2022	aml_ohsu_2022_2479	aml_ohsu_2022_2479_BA2012	60	61	2.448275862	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Etoposide, Mitoxantrone	Supportive/Palliative Care	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	TRUE	FALSE	46,XX[20]	0	Supportive/Palliative Care	6	FALSE	Positive	AML	12.953424657534246	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse	Bone Marrow Aspirate	partial CD7, CD13, CD33, partial CD34, partial dim CD64, CD117, and CD123 positive	0	0.233333333	NA	Standard Chemotherapy	Yes	FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2479	aml_ohsu_2022_2479_BA2352	60	61	7.333333333	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Etoposide, Mitoxantrone	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	FALSE	FALSE	46,XX[20]	0	Supportive/Palliative Care	6	FALSE	Positive	AML	12.953424657534246	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	partial CD7, CD13, CD33, partial CD34, CD58, CD64, CD117, and CD123 positive	138	0.266666667	NA	Standard Chemotherapy	No	FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2479	aml_ohsu_2022_2479_BA2630	60	61	19	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Etoposide, Mitoxantrone	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	FALSE	FALSE	46,XX[20]	0	Supportive/Palliative Care	6	FALSE	Positive	AML	12.953424657534246	1:DECEASED	normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	181	0.233333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2480	aml_ohsu_2022_2480_BA2489	63	63	0	ASXL1 (p.G646Wfs*12; 31.2%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	AG-221|Azacitidine|Fludarabine, Melphalan, TBI, ATG	3	Hypomethylating/Low Dose Cytarabine|Experimental|Allogeneic - Child	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	-1	Bone Marrow Transplant	12	FALSE	Negative	AML	38.00547945205479	0:LIVING	NA	No	No	NA	Yes	Yes	No	No	No	No	NA	NA	NA	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	NA	0	0.666666667	NA	NA	Yes	ASXL1 (G646fs*12; MAF 30%)|CIITA (Q320fs*41; MAF 51%)|CUX1 (P442fs*16; MAF 38%)|IDH2 (R140Q; MAF 46%)|SRSF2 (P95H; MAF 40%)|STAG2 (R614*; MAF 90%)
aml_ohsu_2022	aml_ohsu_2022_2481	aml_ohsu_2022_2481_BA2456	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	Cytarabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Cytarabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	FALSE	FALSE	FALSE	NA	-1	Standard Chemotherapy	17	FALSE	Positive	AML	0.06575342465753425	1:DECEASED	nuc ish (PML,RARA)x2[199]	Yes	No	Skin cancer	No	No	No	No	No	No	White	NA	NA	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.833333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2482	aml_ohsu_2022_2482_BA2769	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine, Midostaurin	3	Induction|Maintenance|Re-induction	3	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XX[20]	62	Standard Chemotherapy	15	FALSE	Negative	AML	13.709589041095892	0:LIVING	NA	No	No	NA	Yes	Yes	No	No	No	No	NA	186	Complete Response	RUNX1 (p.R320*; 24.2%)|RUNX1 (p.R207W; 20.0%)	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease	Peripheral Blood	NA	0	0.933333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2483	aml_ohsu_2022_2483_BA2101	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY,del(7)(q22),inv(16)(p13.1q22)[18]/46,XY[2]	-1	Standard Chemotherapy	2	FALSE	Negative	AML	1.1506849315068493	0:LIVING	CBFB, D7S486/ CEP 7	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD5, CD19, dim CD20, dim CD22, CD23 and light chain negative	0	0.066666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 3%)|FLT3(p.D839G; MAF 3%)|DNMT3A(p.R882H; MAF 16%)
aml_ohsu_2022	aml_ohsu_2022_2484	aml_ohsu_2022_2484_BA2541	39	39	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Methotrexate	4	Induction|CNS|Re-induction	3	Standard Chemotherapy|Intrathecal	2	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XY,t(6;11)(q27;q23)[20]	4	Standard Chemotherapy	2	FALSE	Negative	AML	7.101369863013699	1:DECEASED	MLL: 80% of cells had a split signal pattern consistent with the disruption of MLL due to the t(6;11).	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD4, partial CD11b, CD13, CD33, CD34, partial      CD38, partial CD64, CD117, CD123, HLA-DR and dim MPO positive.	0	0.066666667	NA	Standard Chemotherapy	Yes	MLL (PTD)
aml_ohsu_2022	aml_ohsu_2022_2485	aml_ohsu_2022_2485_BA2100	73	74	1.222222222	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	7	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction	6	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	TRUE	46,XY,+1,dic(1;15)(q12;p11.2)[2]/46,XY[18]	33	Targeted Therapy - Kinase Inhibitor(s)	17	FALSE	Negative	AML	21.632876712328766	1:DECEASED	18].nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Yes	No	Prostate Cancer	Yes	Yes	No	No	No	No	Unknown	39	Refractory	RUNX1 (p.R201Q; 47.2%)	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD4(partial dim +), CD7(-), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variably +), CD34(+), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(-), CD79a(-) | CD117(variably +), HLA-DR (variably +), MPO	0	0.766666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (NOT FOUNDATION NO MAF AVAILABLE)
aml_ohsu_2022	aml_ohsu_2022_2485	aml_ohsu_2022_2485_BA2953	73	74	3	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves1+2	Yes	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	7	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction	6	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	TRUE	46,XY	33	Targeted Therapy - Kinase Inhibitor(s)	11	FALSE	Negative	AML	21.632876712328766	1:DECEASED	nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	Yes	No	Prostate Cancer	Yes	Yes	No	No	No	No	Unknown	39	Refractory	RUNX1 (p.R201Q; 51.8%)	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(-), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variable and bright +), CD34(variably +) (Within this population, there is a small subset of cells (1.7% of total events) that i	37	0.5	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2486	aml_ohsu_2022_2486_BA2629	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Negative	TRUE	FALSE	FALSE	46,XY,t(1;4)(q21;p14)[20]	44	Standard Chemotherapy	7	FALSE	Negative	AML	3.419178082191781	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.R250Lfs*13; 50.0%)	1	Male	MATCHED	FALSE	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7, partial CD13, CD34, partial CD38,      partial CD117, dim CD123, HLA-DR and TDT positive	0	0.366666667	NA	Standard Chemotherapy	Yes	BCOR (p.S571*; MAF 90% )|MLL (PTD)|ZRSR2 (p.C181F; MAF 88%)
aml_ohsu_2022	aml_ohsu_2022_2487	aml_ohsu_2022_2487_BA2374	36	36	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Induction|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other	2	ATRA, Arsenic Trioxide	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,XX,der(15)t(15;17)(q22;q21),der(17)t(15;17)del(17)(q21)[15]/46,XX[1]	-1	Targeted Therapy - Other	12	FALSE	Negative	AML	71.67123287671232	0:LIVING	95% of cells had a variant abnormal signal pattern with PML/RARA fusion.  PML (15q22) (SO) / RARA (17q21) (SG) t(15;17)	No	No	NA	No	No	No	No	No	No	Black	27	Complete Response	NA	1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Immunophenotype: CD13, CD33, partial CD34, CD64, CD117, CD123 and MPO positive	0	0.466666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2488	aml_ohsu_2022_2488_BA2545	37	37	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	4	FALSE	Negative	AML	62.26849315068493	0:LIVING	Normal	Yes	No	Not specified	No	No	No	No	No	No	White	24	Unknown	NA	1	Male	MATCHED	FALSE	Myeloid sarcoma	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.133333333	NA	Standard Chemotherapy	Yes	TET2 (p.L307R; MAF 51%)
aml_ohsu_2022	aml_ohsu_2022_2489	aml_ohsu_2022_2489_BA2488	83	83	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Ruxolitinib|ATRA, Arsenic Trioxide|Idarubicin	3	Induction|Maintenance|Symptom Control	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Idarubicin	Symptom Control	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Negative	FALSE	FALSE	TRUE	46,XX,t(15;17)(q24;q21)[12]/46,XX,idem,del(16)(q12.1q24)[3]/46,XX[5]	0	Standard Chemotherapy	15	FALSE	Negative	AML	92.25205479452055	0:LIVING	7% 16q deletion	No	No	NA	No	No	No	No	Yes	Yes	White	253	Complete Response	NA	1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, partial CD34, CD64, CD117, CD123, and MPO-positive	0	0.933333333	NA	Standard Chemotherapy	Yes	FLT3-D835 (D835H; MAF Unlisted)|JAK2 (p.V617F; MAF 90%)
aml_ohsu_2022	aml_ohsu_2022_2490	aml_ohsu_2022_2490_BA2928	48	48	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Both	Yes	Fludarabine, Melphalan|Idarubicin and Cytarabine	2	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	47,XX,+8,t(9;11)(p22;q23)[20]	-1	Bone Marrow Transplant	3	FALSE	Negative	AML	56.054794520547944	1:DECEASED	MLL rearrangement (80%) | Trisomy 8 (78%)	No	No	NA	No	No	No	No	No	No	White	5	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD4, partial CD11b, CD15, CD33, CD56, CD58, CD64, CD117, CD123, HLA-DR, and butyrate esterase positive	0	0.133333333	NA	Standard Chemotherapy	No	FLT3-D835 (MAF 10%)|JAK1 (p.I878V; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2491	aml_ohsu_2022_2491_BA2003	57	58	2.125	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Both	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	4	FALSE	Positive	AML	8.449315068493151	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Unknown	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	215	0.133333333	NA	Standard Chemotherapy	No	FLT3-ITD|NPM1
aml_ohsu_2022	aml_ohsu_2022_2492	aml_ohsu_2022_2492_BA2325	74	74	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Both	Yes	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46, XX,t(2;16)(p23;p13.3)(13)	6	Standard Chemotherapy	3	FALSE	Positive	AML	0.9534246575342467	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD14, CD16, CD33, CD64 and HLA-DR	0	0.1	NA	Standard Chemotherapy	No	NPM1 (p.W288fs*>9 (C-terminal frame-shift); MAF 44%)|PTPN11 (p.E76Q; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2493	aml_ohsu_2022_2493_BA2563	61	61	0.063829787	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	15	FALSE	Positive	AML	13.084931506849315	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.6	NA	Standard Chemotherapy	Yes	DNMT3A (p.Arg326Cys; MAF 44.5%)|FLT3-ITD (p.Phe594_Asp600dup; MAF 45%)|NPM1 (p.Trp288fs; MAF 20.7%)|TET2 (p.Ala911fs; MAF 40.6%)|TET2 (p.His1036fs; MAF 39.4%)
aml_ohsu_2022	aml_ohsu_2022_2494	aml_ohsu_2022_2494_BA2976	85	85	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Azacitidine	1	Maintenance	1	Standard Chemotherapy	1	Azacitidine	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M4	Negative	FALSE	FALSE	TRUE	46,XY,del(12)(p11.2p13)[20]	232	Standard Chemotherapy	2	FALSE	Negative	AML	2.6301369863013697	1:DECEASED	ETV6: 84% of cells were missing a signal for ETV6 (12p13), consistent with the deletion seen on metaphase analysis.	No	No	NA	No	No	Yes	Yes	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD34, CD117, dim CD123, CD33, dim HLA-DR, CD13, and CD58. (Blasts) | CD64, CD11b, CD33, CD15, dim HLA-DR, CD13, dim CD71, and CD58. (Monoblasts/promonocytes.)	0	0.1	NA	NA	Yes	NRAS (p.Q61R; MAF 30%)|U2AF1 (p.S34F ; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2495	aml_ohsu_2022_2495_BA2410	57	57	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin) plus Crenolanib	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Crenolanib	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	13	FALSE	Positive	AML	2.663013698630137	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response i	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	It reveals 0.23% CD34 (+) myeloid blasts with the following immunophenotype: CD2(-), CD7(-), CD13(+), CD15(-/few +), CD33 (bright +), CD36(few +), CD38(partial +), CD45(+), CD64(-), CD117(+), HLA-DR(-), MPO (partial +). (A limited/targeted immunophenotypi	0	0.633333333	NA	Standard Chemotherapy	Yes	ASXL1 (E981G; MAF 49%)|DNMT3A (F290fs*24; MAF 40%)|FLT3-ITD (MAF 18%)|JAK2 (N322I; MAF 51%)|NPM1 (W288fs*10+; MAF 38%)
aml_ohsu_2022	aml_ohsu_2022_2497	aml_ohsu_2022_2497_BA2296	46	46	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XX[19]	120	Standard Chemotherapy	18	FALSE	Negative	AML	64.10958904109589	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	5	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, partial CD64, CD71, CD117, CD123, and HLA-DR	0	1	NA	Standard Chemotherapy	Yes	CEBPA (p.R297P ; MAF 50%)|CEBPA (p.T98fs*10 ; MAF 40%)|TET2 (p.Q758*; MAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2498	aml_ohsu_2022_2498_BA2618	83	83	0	ASXL1 (p.Y425*; 46.8%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	AG-221|Azacitidine, SGN-CD33A	2	Induction|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other	2	AG-221	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	-1	Targeted Therapy - Other	17	FALSE	Negative	AML	14.268493150684932	1:DECEASED	Normal	No	No	NA	Yes	Yes	No	No	No	No	White	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	NA	0	1	NA	Standard Chemotherapy	Yes	CREBBP (p.M2408V; MAF 48%)|IDH2 (p.R140Q; MAF 47%)|NRAS (p.G12D; MAF 49%)
aml_ohsu_2022	aml_ohsu_2022_2499	aml_ohsu_2022_2499_BA2294	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,t(8;21)(q22;q22)[14]	-1	Standard Chemotherapy	19	FALSE	Negative	AML	7.857534246575343	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34, PARTIAL CD38, CD33, CD13, CD64, PARTIAL CD11C, PARTIAL CD19, HLA-DR, PARTIAL CD15, CD117, AND MPO	0	1.066666667	NA	Standard Chemotherapy	Yes	NRAS
aml_ohsu_2022	aml_ohsu_2022_2500	aml_ohsu_2022_2500_BA2516	70	70	0	ASXL1 (p.E635Dfs*22; 42.9%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Both	Yes	Imatinib|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Salvage|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	-1	Standard Chemotherapy	7	FALSE	Negative	AML	11.901369863013699	1:DECEASED	Normal	No	No	NA	No	No	No	No	Yes	Yes	White	61	Refractory	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.266666667	NA	Standard Chemotherapy	No	BCOR (p.S1024; MAF 5%)|NRAS (p.G13D; MAF 34%)|PTPN11 (p.G60V; MAF 3%)|SRSF2 (p.P95H; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2501	aml_ohsu_2022_2501_BA2359	56	56	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	19	FALSE	Positive	AML	8.12054794520548	1:DECEASED	normal	Yes	No	Other malignant neoplasm without specification of site	No	No	No	No	No	No	White	7	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, CD13, CD33, CD38, CD58, CD64, dim CD117, CD123, MPO+	0	1	NA	Standard Chemotherapy	Yes	DNMT3A (p.N879D; MAF 50%)|FLT3-ITD (MAF 50%)|NPM1 (W228fs*12; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2502	aml_ohsu_2022_2502_BA2666	77	77	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	No	Vincristine, Dexamethasone	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Vincristine, Dexamethasone	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	HISPANIC	NA	Negative	TRUE	FALSE	FALSE	45~54,XX,+2,del(5)(q22q35),+6,+6,+8,-11,add(13)(p11.2),+19,+22,+r,1~48dmin[cp19]/69~70,idem,+1,+3,+4,+del(5),+8,+8,+10,+10,+11,+13,+14,+14,+15,+15,+17,+18,+19[cp3]/46,XX[1].ishadd(13)(5'MLLamp,3'MLLamp)[2]	13	Supportive/Palliative Care	14	FALSE	Negative	AML	0.9534246575342467	1:DECEASED	(D5S2064x3~4,D5S630x3~4, EGR1x2)[7/200],(D7Z1,D7S522)x2[200],(D8Z2x3~5,D20S108x2)[115/200],(RUNX1T1x3~5,RUNX1x2)[109/200], (ABL1x2,BCRx3)[110/200],(5'MLL,3'MLL)x1(5'MLL con 3'MLLx1,5'MLL amp,3'MLL amp)[110/200],(ETV6,RUNX1)x2 [199],(PMLx4,RARAx3)[95/200],	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7(-), CD10(-), CD11b(partial dim +), CD13(variably +), CD15(+), CD19(+), CD20(-), CD22(partial +), CD25(few +), CD33(-), CD34(+), CD36 (-), CD38(variably +), CD45(dim+/variably +), CD56(-), CD64(appears partially dim +), CD117(partial +), CD123(dim +), 	0	0.866666667	TP53 (p.R280Efs*65; 35.7%)|TP53 (p.R175H; 27.2%)	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2503	aml_ohsu_2022_2503_BA2136	60	62	0	ASXL1 (p.S846Vfs*21; 33.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide, Fludarabine, TBI	3	Allogeneic - Sibling|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Sibling	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M2	Negative	FALSE	TRUE	FALSE	46,XY,del(20)(q11.2)[2]/46,XY[18]	-1	Bone Marrow Transplant	3	FALSE	Negative	AML	42.016438356164386	1:DECEASED	20/200 cells (10%) were missing a signal for D20S108 (20q12)	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with maturation	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD117, and dim HLA-DR positive	783	0.166666667	NA	Standard Chemotherapy	Yes	JAK2 (V617F; MAF 1.3% (Clinical significance of this very low-level mutation is unknown.) )|SRSF2 (p.P95H ; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2504	aml_ohsu_2022_2504_BA2191	55	55	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	ATRA, Arsenic Trioxide	1	Induction	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M3	Negative	TRUE	FALSE	FALSE	NA	-1	Standard Chemotherapy	19	FALSE	Negative	AML	27.682191780821917	0:LIVING	PML-RARA+ 0.70743	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large population of atypical CD117 positive, bright myeloperoxidase positive, CD34 negative, HLA-DR negative immature myeloid cells, representing approximately 90% of the leukocytes.	0	1.2	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2506	aml_ohsu_2022_2506_BA2947	14	14	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)	1	Induction	1	Standard Chemotherapy	1	COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	45,X,-Y,t(8;21)(q22;q22)[4]/45,idem,del(9)(q12q22)[13]/46,XY[3]	133	Standard Chemotherapy	NA	FALSE	Negative	AML	81.76438356164384	0:LIVING	RUNX1T1/ RUNX1 fusion and t(8;21) (94%)	No	No	NA	No	No	No	No	No	No	White	133	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD34, dim CD45, partial CD56, CD58, dim CD117, HLA-DR, MPO, and partial TdT-positive	0	NA	NA	Standard Chemotherapy	Yes	TP53 (p.S366A; MAF 50% )
aml_ohsu_2022	aml_ohsu_2022_2507	aml_ohsu_2022_2507_BA2242	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|Ruxolitinib|7+3 (Cytarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC|Ibrutinib	6	Consolidation|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Ruxolitinib	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	NA	-1	Targeted Therapy - Kinase Inhibitor(s)	6	FALSE	Positive	AML	66.64109589041095	0:LIVING	normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	partial CD13, CD33, CD38, moderate CD45, CD56, CD58,  CD64, dim CD117, CD123 and MPO+	0	0.2	NA	Standard Chemotherapy	Yes	CREBBP (p.R2353Q; MAF 51%)|NPM1 (p.W288fs*12; MAF 46%)|TET2 (p.Q270*; MAF 90%)
aml_ohsu_2022	aml_ohsu_2022_2508	aml_ohsu_2022_2508_BA2914	38	38	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XX[20]	106	Standard Chemotherapy	14	FALSE	Positive	AML	52.14246575342466	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD117, dimCD4, heterogeneous CD13, CD33, dimCD64 and  MPO positive  (Myeloid Blast Population) | heterogeneous CD13, bright CD33, dimCD4,  dimCD14, bright CD64 positive  (Monocytes/promonocytes Population)	0	0.633333333	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 46%)|IDH1 (p.R132H; MAF 25%)|KRAS (p.Q61L; MAF 10%)|NPM1 (p.W288fs*12; MAF 51%)|NRAS (p.G13D; MAF 24%)
aml_ohsu_2022	aml_ohsu_2022_2509	aml_ohsu_2022_2509_BA2909	8	8	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	1	Induction|Intensification	2	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Intensification	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY,t(8;21)(q22;q22)[5]/46,idem,der(7)t(7;8)(q22;q11.2)[13]/46,XY[2]	62	Standard Chemotherapy	1	FALSE	Negative	AML	87.51780821917808	0:LIVING	t(8;21) (34%) | t(8;21) and der(7)t(7;8) (56%) | Missing D7S486 signal (70%)	No	No	NA	No	No	No	No	No	No	Asian	11	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD7, CD13, CD33, CD34, CD38, partial CD56,CD58, CD117, CD123, dim HLA-DR, and MPO	0	0.066666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2510	aml_ohsu_2022_2510_BA2727	36	38	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide	7	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	6	DLI|Standard Chemotherapy|Bone Marrow Transplant	3	Decitabine	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX,inv(3)(q21q26)[5]	4	Standard Chemotherapy	3	FALSE	Negative	AML	17.52328767123288	1:DECEASED	FISH) was performed with a MECOM/RPN1 probe set. 125/200 (62.5%) interphase cells scored had a 1 red/ 1 green/ 2 yellow double fusion signal pattern reflecting MECOM/RPN1 fusion and the paracentric inversion of the long arm of a chromosome 3 observed in t	No	No	NA	No	No	No	No	No	No	White	4	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant	Peripheral Blood	NA	494	0.2	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2511	aml_ohsu_2022_2511_BA2426	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY,inv(16)(p13.1q22)[20]	-1	Standard Chemotherapy	15	FALSE	Negative	AML	0.8547945205479452	0:LIVING	positive for rearrangement of CBFB in 60.5% of cells.	Yes	No	Non-Hodgkins Lymphoma	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for CD13, CD33, HLA-DR, CD34, and CD117, with partial aberrant expression of CD7. (Peripheral blood) | positive for CD34, CD117, HLA-DR, CD13, and CD33 (Marrow)	0	0.566666667	NA	Standard Chemotherapy	Yes	EZH2 (p.D146H; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2512	aml_ohsu_2022_2512_BA2998	63	63	0	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Dead-Disease	NA	2	Waves1+2	Yes	Azacitidine|Decitabine|Rigosertib|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental	4	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	3	Decitabine	Hypomethylating/Low Dose Cytarabine	NA	Myelodysplastic Syndromes	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Supportive/Palliative Care	2	FALSE	Negative	MDS	69.04109589041096	1:DECEASED	nuc ish(FGFR3,IGH)x2[200],(D5S721,D5S23,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(IGH,BCL2)x2[198],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	No	No	NA	Yes	Yes	No	No	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	TRUE	Refractory anaemia with excess blasts	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(few +), CD16(-), CD33(+), CD34(bright +), CD33(-), CD38(dim and variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+) (6.2% population)	0	0.066666667	NA	Standard Chemotherapy	No	TYK2 (V15A; MAF 49.0%)
aml_ohsu_2022	aml_ohsu_2022_2513	aml_ohsu_2022_2513_BA2376	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XY[20]	6	Standard Chemotherapy	5	FALSE	Positive	AML	62.16986301369863	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD4, CD11b, partial CD14, CD15, dim CD33, CD38, CD56, CD58, CD64 and HLA-DR positive	0	0.2	NA	Standard Chemotherapy	Yes	DNMT3A (p.S714C; MAF 35%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13V; MAF 6%)|PTPN11 (p.A72V; MAF 10%)|TET2 (p.Q876*; MAF 6%)
aml_ohsu_2022	aml_ohsu_2022_2514	aml_ohsu_2022_2514_BA2103	54	54	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	NA	88	Standard Chemotherapy	16	FALSE	Positive	AML	22.06027397260274	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[196],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198] (MDS Fish Panel) | nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(-), CD16(-), CD33(variably +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(partial +), CD64 (partial +), CD117(variably +), HLA-DR(-).	0	0.8	NA	Standard Chemotherapy	Yes	FLT3 (I836DEL; MAF 18.0%)|FLT3 (N841I; MAF 8.0%)|FLT3 (V491L; MAF 3.0%)|FLT3 (V592A; MAF 1.0%)|IDH2 (R140Q; MAF 47.0%)|NPM1 (W288FS*10+; MAF 35.0%)|SRSF2 (P95L; MAF 41.0%)
aml_ohsu_2022	aml_ohsu_2022_2515	aml_ohsu_2022_2515_BA2288	72	73	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	7	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	NA	NA	None	4	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	unknown	Residual Disease	Bone Marrow Aspirate	NA	0	0.233333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2516	aml_ohsu_2022_2516_BA2908	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine	4	Consolidation|Induction|Maintenance|Supportive/Palliative Care	4	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY,del(13)(q12q2?1)[14]	58	Standard Chemotherapy	14	FALSE	Negative	AML	21.895890410958906	0:LIVING	all 100 interphase cells scored (100%) were missing one set of 13S319 and RB1 probe signals, consistent with deleted 13q and the metaphase karyotype	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, partial/dim CD33, CD38, CD58, CD117 and MPO	0	0.766666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 44% )|IDH2 (p.R172K; MAF 43%)
aml_ohsu_2022	aml_ohsu_2022_2517	aml_ohsu_2022_2517_BA2497	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	47,XY,t(1;11)(p32;q23),+8[cp20]	5	Standard Chemotherapy	7	FALSE	Negative	AML	5.326027397260274	1:DECEASED	CEP 8:  56% had three signals, consistent with the trisomy 8 in the metaphase karyotype|RUNX1T1: 70% had three signals, consistent with the trisomy 8 in the metaphase karyotype|MLL: 72% reflected MLL rearrangement and its involvement in the 1;11 transloca	No	No	NA	No	No	No	No	No	No	White	5	Complete Response	NA	1	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, CD13, partial CD14, CD15, CD33,CD38, CD45, CD56, CD58, CD64, HLA-DR and MPO-positive	0	0.333333333	NA	Standard Chemotherapy	Yes	CREBBP (p.Q1765*; MAF 4% )|KRAS (p.G13D; MAF 27%)
aml_ohsu_2022	aml_ohsu_2022_2518	aml_ohsu_2022_2518_BA2751	72	72	1	NA	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	46,XY[20]	NA	None	NA	FALSE	Negative	AML	0.09863013698630135	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Leukapheresis	Blast phenotype: CD13, partial CD33, CD34, CD38, CD58, CD123, HLA-DR and TdT-positive; Monocytic phenotype: CD11b, CD14, CD33, CD38, CD58, CD64 and HLA-DR-positive	0	NA	NA	NA	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2519	aml_ohsu_2022_2519_BA2663	67	66	0	NA	Myelodysplastic/Myeloproliferative Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	Alive	NA	7	Waves1+2	Yes	Cytarabine|Decitabine	2	Induction|Supportive/Palliative Care	2	Standard Chemotherapy	1	Cytarabine	Induction	NA	Myelodysplastic/Myeloproliferative Neoplasms	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	NA	-1	Standard Chemotherapy	26	FALSE	Negative	MDS/MPN	9.994520547945205	0:LIVING	Trisomy 8	No	No	NA	No	No	Yes	Yes	No	No	NA	-1	UNKNOWN	RUNX1 (p.R166*; 44.9%)	1	Male	MATCHED	TRUE	Chronic myelomonocytic leukaemia	Residual Disease	Bone Marrow Aspirate	NA	0	1.133333333	NA	Standard Chemotherapy	No	ASXL1|EZH2|PTPN11|RUNX1|STAG2
aml_ohsu_2022	aml_ohsu_2022_2520	aml_ohsu_2022_2520_BA2984	81	81	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Vidaza, BI836858 (anti-CD33)	1	Induction	1	Standard Chemotherapy	1	Vidaza, BI836858 (anti-CD33)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY[19]	-1	Standard Chemotherapy	15	FALSE	Positive	AML	19.101369863013698	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD13, CD33, CD38, CD58, dim CD64, CD71, dim CD117 and CD123-positive	0	0.7	NA	Standard Chemotherapy	Yes	CSF3R ( p.T640N; MAF: 14%)|EZH2 (p.G709D; MAF: 17%)|EZH2 (p.R684C; MAF: 4%)|IDH2 (p.R140Q; MAF: 46%)|KDM6A (Splice site-Intron 5 3' end mutation; MAF:3%)|NPM1 (p.W288fs*12; MAF: 39%)
aml_ohsu_2022	aml_ohsu_2022_2521	aml_ohsu_2022_2521_BA2691	83	83	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	MissingKaryo	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	NA	NA	None	2	FALSE	Negative	AML	1.643835616438356	1:DECEASED	NA	Yes	Yes	Prostate Cancer	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.133333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2522	aml_ohsu_2022_2522_BA2746	56	56	0.111111111	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy|Bone Marrow Transplant	2	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	HISPANIC	NA	Positive	TRUE	FALSE	FALSE	46,XX[19]	-1	Standard Chemotherapy	6	FALSE	Positive	AML	10.61917808219178	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	27	Complete Response	NA	2	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (Approximately 55% of assayed cells are an abnormal population of immature monocytic cells (consistent with monoblasts and promonocytes). Approximately 30% of assayed cells are mature monocytes. Both the immature and mature monocytic cells show u	0	0.166666667	NA	Standard Chemotherapy	Yes	ASXL1 (c.1954G>A; p.G652S)|DNMT3A (c.2644C>T; p.R882C)|FLT3 (c.2503G>T; p.D835Y)|FLT3-ITD (FLT3-ITD 21 bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)
aml_ohsu_2022	aml_ohsu_2022_2522	aml_ohsu_2022_2522_BA3075	56	56	7.333333333	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy|Bone Marrow Transplant	2	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Positive	FALSE	TRUE	FALSE	46,XX[19]	-1	Standard Chemotherapy	6	FALSE	Positive	AML	10.61917808219178	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	27	Complete Response	NA	2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Transplant|Relapse	Bone Marrow Aspirate	NA	224	0.2	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2523	aml_ohsu_2022_2523_BA2232	74	74	0.111111111	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	Crenolanib|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Azacitidine, Pracinostat	3	Induction|Maintenance	2	Standard Chemotherapy|Targeted Therapy - Other	2	Crenolanib	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Positive	FALSE	FALSE	FALSE	46,XY,t(6;9)(p23;q34)[18]/46,XY[2]	433	Targeted Therapy - Other	15	FALSE	Negative	AML	32.97534246575343	1:DECEASED	DEK-NUP214 fusion; MAF unavailable	Yes	Yes	Prostate Cancer	No	No	No	No	No	No	White	-1	Complete Response	NA	2	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(bright +), CD34 (partial +), CD36(equivocal), CD38(variably +), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(partial +), TdT (-), MPO(-).	0	0.633333333	NA	Standard Chemotherapy	Yes	DNMT3A (F827fs*4; MAF 35%)|FLT3 (S585_D586ins28; MAF 14% )|ZRSR2 (D242fs*13; MAF 25%)
aml_ohsu_2022	aml_ohsu_2022_2523	aml_ohsu_2022_2523_BA3145	74	77	NA	ASXL1 (p.G645Vfs*58; 10.5%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves3+4	Yes	Crenolanib|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Azacitidine, Pracinostat	3	Induction|Maintenance	2	Standard Chemotherapy|Targeted Therapy - Other	2	Crenolanib	Maintenance	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	FALSE	FALSE	47,XY,t(6;9)(p23;q34),+8[13]/48,idem,+13[4]/46,XY[3]	433	Targeted Therapy - Other	5	FALSE	Negative	AML	32.97534246575343	1:DECEASED	DEK-NUP214 fusion; MAF unavailable (DEK-NUP214 fusion; MAF unavailable) | nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[198], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[17/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2	Yes	Yes	Prostate Cancer	No	No	No	No	No	No	White	-1	Complete Response	NA	2	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	979	0.2	NA	Standard Chemotherapy	No	DNMT3A (F827fs*4)|FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2524	aml_ohsu_2022_2524_BA2760	54	54	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin) plus Sorafenib	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Sorafenib	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	50,XX,+8,+10,+12,+21[20]	19	Standard Chemotherapy	6	FALSE	Negative	AML	1.1835616438356165	1:DECEASED	- Gain of chromosome 8 in 55% of cells - Gain of 8q22 (ETO) sequence in 77.8% of cells; 21q22 (AML1) gain in 12% and loss in 77.8% cells	No	No	NA	No	No	No	No	No	No	NA	19	Complete Response	RUNX1 (p.D198N; 35.5%)	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, CD13, CD14 (subset), CD33, CD34 (subset), CD38, CD45, CD64 (subset), HLA-DR and MPO	0	0.3	NA	Standard Chemotherapy	Yes	EZH2 (p.D146H; MAF 51.6%)|RUNX1 (p.D171N; MAF 19.8%)
aml_ohsu_2022	aml_ohsu_2022_2526	aml_ohsu_2022_2526_BA2190	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M0	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	7	FALSE	Negative	AML	6.213698630136986	1:DECEASED	normal	Yes	No	Prostate Cancer	No	No	No	No	No	No	White	12	Refractory	NA	1	Male	MATCHED	FALSE	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, bright CD34, CD38, CD58, CD117, and TdT	0	0.366666667	NA	Standard Chemotherapy	Yes	CREBBP (p.M118I; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2527	aml_ohsu_2022_2527_BA2365	NA	74	NA	NA	Myelodysplastic/Myeloproliferative Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	NA	NA	7	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	NA	Myelodysplastic/Myeloproliferative Neoplasms	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	NA	None	NA	FALSE	Negative	MDS/MPN	0.0	NA	NA	No	No	NA	No	No	Yes	u	No	No	NA	NA	NA	NA	1	Female	UNMATCHED	TRUE	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	Unknown	Bone Marrow Aspirate	NA	0	0	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2528	aml_ohsu_2022_2528_BA2261	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	Vidaza|7+3 (Cytarabine, Idarubicin)|Lenalidomide|Hydroxyurea	4	Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care	3	Standard Chemotherapy|Supportive/Palliative Care	2	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46~47,XX,del(5)(q15q35),i(8)(q10),add(11)(q23),add(17)(p11.2),add(21)(q22),+2~3mar[cp3]/47~49,idem,add(7)(q11.2),-add(11),+11,+14,-20[cp4]/45~49,idem,del(7)(q22q36),-add(11),+11,+14,-20[cp2]/45~48,idem,der(7)del(7)(q22q31)dic(7;20)(q36;q11.2),-add(11),+11	-1	Supportive/Palliative Care	19	FALSE	Negative	AML	6.50958904109589	1:DECEASED	nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20S108x1)[142/200],(RUNX1T1x3,RUNX1x2)[180/200],(5'MLL amp,3'MLL amp)(5'MLL con 3'MLL amp)[66/200],(PML,RARA)x2[197],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	Yes	Yes	No	No	No	No	White	7	Refractory	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+),CD56(+), CD64(-), CD117(partial +), HLA-DR(partial +). | In addition, there is a 0.01% population of small cells with	0	1.066666667	TP53 (p.R213Dfs*34; 85.5%)	Standard Chemotherapy	Yes	TP53 (R213fs; MAF 34%)
aml_ohsu_2022	aml_ohsu_2022_2529	aml_ohsu_2022_2529_BA2221	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Induction|Re-induction|Maintenance	4	Standard Chemotherapy	1	Azacitidine	Maintenance	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY	-1	Standard Chemotherapy	3	FALSE	Negative	AML	39.55068493150685	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Yes	No	Melanoma	No	No	No	No	No	No	NA	-1	Complete Response	NA	2	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy	Bone Marrow Aspirate	CD38(bright +), CD45(-), CD56(+), intracellular kappa(+), intracellular lambda(-)	184	0.133333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2529	aml_ohsu_2022_2529_BA2901	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Induction|Re-induction|Maintenance	4	Standard Chemotherapy	1	Azacitidine	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY	-1	Standard Chemotherapy	12	FALSE	Positive	AML	39.55068493150685	0:LIVING	IGH-MYEOV and IGH-CCND1 rearrangement; MAF unlisted	Yes	No	Melanoma	No	No	No	No	No	No	NA	-1	Complete Response	NA	2	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(equivocal), CD7(partial +), CD11b (equivocal), CD13(+), CD14(-), CD15(-), CD16(equivocal), CD33(-), CD34(bright +), CD36(-), CD38(dim +), CD45(+), CD56(equivocal), CD64(-), CD117(+), CD123(equivocal), HLA-DR(dim +), MPO(partial +), TdT(-) (Pop	0	0.5	NA	Standard Chemotherapy	Yes	DNMT3A (R882C; MAF 50%)|NPM1 (W288fs*10+; MAF 34%)|NRAS (G13D; MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2530	aml_ohsu_2022_2530_BA2469	50	51	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib	4	Unknown|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Unknown	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	4	FALSE	Negative	AML	23.539726027397258	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Unknown	NA	1	Female	UNMATCHED	FALSE	AML without maturation	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	FLT3 (ITD) Not detected. Not detected for the FLT3 TKD Mutation. Pathogenic alterations are detected in the BCOR, IDH2 and WT1 genes. Positive for CD34, HLADR, CD117, CD13, CD33 and CD43 and negative for CD11B, CD14, CD64, TDT and MPO. (Bone Marrow Immuno	0	0.166666667	NA	Standard Chemotherapy	Yes	BCOR (p.E1348Ifs, MAF 32%)|IDH2 (p.R172K, MAF 41%)|WT1 (p.T171Cfs*116, MAF 39%)
aml_ohsu_2022	aml_ohsu_2022_2531	aml_ohsu_2022_2531_BA2528	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Frontline|Maintenance	3	Standard Chemotherapy	1	Azacitidine	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[19]	-1	Standard Chemotherapy	20	FALSE	Negative	AML	63.64931506849315	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	Declined	7	Refractory	NA	1	Male	MATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD117, CD123, dim HLA-DR, TdT, and MPO positive	0	1.166666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 41%)|SF3B1 (p.K700E; MAF 43%)
aml_ohsu_2022	aml_ohsu_2022_2532	aml_ohsu_2022_2532_BA2425	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	43-45,XX,del(5)(q16q33),der(7)t(7;12)(q11.1;q12)ins(7;?)(q11.1;?),-12,der(21;22)(q10;q10),+mar[cp20]/46,XX[1]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	10.323287671232876	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD34, CD71, CD117, dimCD123, HLA-DR, and dim CD 64 positive (Peripheral Blood)	0	0.033333333	TP53 (p.L130Pfs*19; 33.3%)	Standard Chemotherapy	Yes	TP53 (p.I254N; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2533	aml_ohsu_2022_2533_BA2515	74	75	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	mono	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	3	Standard Chemotherapy	1	HiDAC	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[18]	48	Standard Chemotherapy	18	FALSE	Negative	AML	10.652054794520549	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[198],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	Unknown	-1	Refractory	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD22 (-), CD25(-), CD33(variably +), CD34(bright +), CD36(-), CD38(bright +), CD45(moderate/dim +), CD56(-), CD64(-), CD79a (-), CD117(+), CD123	0	1.066666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2534	aml_ohsu_2022_2534_BA2586	58	58	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)	2	Induction|Re-induction	2	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,ins(10;11)(p12;q23q23)[9]/49,sl,+4,+6,+21[4]/46,XY[7]	143	Standard Chemotherapy	8	FALSE	Negative	AML	8.876712328767123	1:DECEASED	- 11q23 rearrangement involving the KMT2A (MLL) locus in  51/200 (25.5 percent) cells scored,  - 3 copies of the RUNX1 locus at 21q22 in 91/200 (45.5  percent) cells scored.	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, partial CD15, CD33, CD34, weak CD64,  very weak partial CD117, and myeloperoxidase	0	0.433333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2535	aml_ohsu_2022_2535_BA2646	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	ATRA, Arsenic Trioxide	1	Induction	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Negative	TRUE	FALSE	FALSE	46,XY,t(3;16)(p13;q22),t(13;14)(q32;q24),t(15;17)(q22;q21)[20]	-1	Standard Chemotherapy	4	FALSE	Negative	AML	56.515068493150686	0:LIVING	PML/RARA: 98/100 cells (98%) had a 1 red/ 1 green/ 2 yellow signal pattern, reflecting PML/RARA fusion and consistent with the 15;17 translocation observed in the metaphase karyotype.	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD38, CD58, CD64, dim CD71, CD123, CD117, MPO positive -FISH for t(15;17)	0	0.2	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2536	aml_ohsu_2022_2536_BA2784	83	85	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	NA	-1	Standard Chemotherapy	4	FALSE	Positive	AML	19.857534246575344	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.233333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2537	aml_ohsu_2022_2537_BA2312	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	mono	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX[20]	7	Standard Chemotherapy	5	FALSE	Negative	AML	5.556164383561644	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	7	Refractory	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	partial weak  CD7, CD13, CD33, CD34, CD117, myeloperoxidase, and partial  HLA-DR	0	0.233333333	NA	Standard Chemotherapy	Yes	CEBPA (c.68dup; MAF 21%)|DNMT3A (c.2645G>A; MAF 43.9%)|NRAS (c.35G>A; MAF 30.2%)|WT1 (c.1140dup; MAF 4%)|WT1 (c.1142C>A; MAF 36.4%)
aml_ohsu_2022	aml_ohsu_2022_2538	aml_ohsu_2022_2538_BA2217	47	47	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY[20]	116	Standard Chemotherapy	14	FALSE	Negative	AML	7.035616438356165	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, CD33, CD34, CD38, partial CD56,  CD58, dim CD64, CD117, CD123, HLA-DR, and cMPO	0	0.7	NA	Standard Chemotherapy	Yes	CEBPA (p.I68fs; MAF 50%)|CEBPA (p.K313_V314insK; MAF 50%)|EZH2 (p.S519P; MAF 51%)|NRAS (p.G13D, MAF 3%)|WT1 (p.M392fs*10; MAF 13%)|WT1 (p.R458*; MAF 23%)
aml_ohsu_2022	aml_ohsu_2022_2539	aml_ohsu_2022_2539_BA2255	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin)	5	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, TBI	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M5a	Negative	FALSE	FALSE	FALSE	47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]	-1	Bone Marrow Transplant	14	FALSE	Negative	AML	32.18630136986302	1:DECEASED	8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present (83.5% 11q23, 84.5% 8q22)	Yes	No	Prostate Cancer	No	No	No	No	No	No	NA	-1	Complete Response	NA	2	Male	MATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.	0	0.833333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2539	aml_ohsu_2022_2539_BA2814	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin)	5	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, TBI	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M5a	Negative	FALSE	FALSE	FALSE	47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]	-1	Bone Marrow Transplant	17	FALSE	Negative	AML	32.18630136986302	1:DECEASED	8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present (83.5% 11q23, 84.5% 8q22)	Yes	No	Prostate Cancer	No	No	No	No	No	No	NA	-1	Complete Response	NA	2	Male	MATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.	0	0.866666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2540	aml_ohsu_2022_2540_BA2254	56	56	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XY[20]	111	Standard Chemotherapy	15	FALSE	Positive	AML	45.66575342465754	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	Multiracial	6	Refractory	NA	2	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive	0	0.733333333	NA	Standard Chemotherapy	Yes	FLT3-ITD (Internal tandem duplication; MAF: 40%)|IDH2 (p.R140Q; MAF: 50%)|NPM1 (p.W288fs*9; MAF: 40%)
aml_ohsu_2022	aml_ohsu_2022_2540	aml_ohsu_2022_2540_BA2485	56	56	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XY[20]	111	Standard Chemotherapy	NA	FALSE	Positive	AML	45.66575342465754	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	Multiracial	6	Refractory	NA	2	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive	0	NA	NA	Standard Chemotherapy	Yes	FLT3-ITD (Internal tandem duplication; MAF: 40%)|IDH2 (p.R140Q; MAF: 50%)|NPM1 (p.W288fs*9; MAF: 40%)
aml_ohsu_2022	aml_ohsu_2022_2542	aml_ohsu_2022_2542_BA2820	73	73	1	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea	2	Induction	1	Standard Chemotherapy	1	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M4	Positive	FALSE	FALSE	TRUE	46,XY[20]	21	Standard Chemotherapy	7	FALSE	Positive	AML	0.9205479452054794	1:DECEASED	normal	Yes	No	Prostate Cancer	No	No	Yes	Yes	No	No	White	167	unknown	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (Myeloid blast immunophenotype: CD13, CD33, dim CD64, CD117, CD123 (+) Monocytic/monoblastic immunophenotype: bright CD11b, CD13, bright CD14, CD33, bright CD64, HLA-DR (+))	0	0.233333333	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 42%)|EP300 (p.N674D; MAF 50%)|EP300 (p.V2140I; MAF 50%)|FLT3-ITD (MAF ~48%)|MLL2 (p.M3398V; MAF 51%)|NPM1 (p.W288fs*12; MAF 43%)
aml_ohsu_2022	aml_ohsu_2022_2543	aml_ohsu_2022_2543_BA2525	72	72	0.538461538	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Azacitidine, Lenalidomide|Temozolomide, Vorinostat	2	Induction|Re-induction	2	Standard Chemotherapy	1	Temozolomide, Vorinostat	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	TRUE	FALSE	FALSE	46,XX,del(5)(q31q35),inv(7)(p15q32),del(12)(q?15)[2]/45~46,idem,add(3)(q27),-9,-del(12)(q?15),+add(12)(q13),-16,-17,+mar1,+mar2x2[cp16]/46,XX[2]	-1	Standard Chemotherapy	6	FALSE	Positive	AML	13.80821917808219	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.133333333	TP53	Standard Chemotherapy	Yes	TP53
aml_ohsu_2022	aml_ohsu_2022_2544	aml_ohsu_2022_2544_BA2273	67	67	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	Cytarabine|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	2	Standard Chemotherapy	1	Cytarabine	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	35	Standard Chemotherapy	20	FALSE	Negative	AML	5.424657534246575	1:DECEASED	The translocations commonly seen in AML are not detected. Loss of RARA and CBFB genes are detected in 14-39% of cells.	No	No	NA	No	No	No	No	Yes	Yes	NA	7	Complete Response	NA	2	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	These are positive for CD34, CD117, HLADR, CD33, CD13, CD14 and CD11b. (Bone Marrow Immunophenotyping)	0	1.066666667	TP53 (p.Y220C; 42.0%)	Standard Chemotherapy	Yes	BCOR (MAF 49%)|IDH1 (p.R132C MAF 12%)|JAK2 (p.V617F; MAF 43%)|MLL |NF1 (MAF 18%)|TP53 (p.Y220C; MAF 35%)
aml_ohsu_2022	aml_ohsu_2022_2544	aml_ohsu_2022_2544_BA2490	67	67	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves1+2	Yes	Cytarabine|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	2	Standard Chemotherapy	1	Cytarabine	Consolidation	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	35	Standard Chemotherapy	6	FALSE	Negative	AML	5.424657534246575	1:DECEASED	The translocations normally seen in AML are not detected.	No	No	NA	No	No	No	No	Yes	Yes	NA	7	Complete Response	NA	2	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	No increased or immunophenotypically abnormal blast cell populations identified. (Bone Marrow Immunophenotyping)	36	0.233333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2545	aml_ohsu_2022_2545_BA2923	81	81	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Azacitidine	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Azacitidine	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Negative	FALSE	FALSE	TRUE	46,XX,t(8;16)(p11.2;p13.3)[8]/46,XX,del(7)(q11.2q22),del(20)(q13.1q13.3)[cp3]/46,XX[12]	42	Supportive/Palliative Care	NA	FALSE	Negative	AML	4.832876712328767	1:DECEASED	NA	Yes	Yes	Anal carcinoma|Breast Cancer	No	No	Yes	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	NA	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2546	aml_ohsu_2022_2546_BA2472	78	78	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Decitabine|7+3 (Cytarabine, Idarubicin) plus Azacitidine|IDAC|Etoposide, Cytarabine	5	Induction|Re-induction|Maintenance|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Etoposide, Cytarabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	3	FALSE	Negative	AML	12.230136986301371	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	Asian	-1	Refractory	RUNX1 (p.L89Pfs*49; 15.8%)	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD3(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(small subset+), CD16(-), CD19(-), CD20(-), CD33(+), CD34(+),CD36(-), CD38(dim+), CD45(dim +), CD56(-), CD64(variably+), CD117(+), HLA-DR(dim +), MPO(partial +), and TdT(-).	0	0.166666667	NA	Supportive/Palliative Care	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2547	aml_ohsu_2022_2547_BA2135	73	73	0	ASXL1 (p.G646Wfs*12; 32.6%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves1+2	Yes	Decitabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1]	-1	Standard Chemotherapy	2	FALSE	Negative	AML	4.010958904109589	0:LIVING	Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	2	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	blasts 55% of all events; they are positive for cd34, hla-dr, cd117, cd13, cd33, and negative for cd11b, cd14, cd64, tdt and mpo	0	0.1	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2547	aml_ohsu_2022_2547_BA3321	73	73	0	ASXL1 (p.G646Wfs*12; 26.9%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves3+4	Yes	Decitabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,del(1)(p22),der(15)t(15;?)(q15:?),-17,+mar[18]/46,XX[2]	-1	Standard Chemotherapy	5	FALSE	Negative	AML	4.010958904109589	0:LIVING	Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	2	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	POSITIVE FOR CD34, CD117, HLA-DR, CD13, CD33, CD38, CYCD3 (DIM) AND NEGATIVE FOR TDT AND MPO	122	0.166666667	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2549	aml_ohsu_2022_2549_BA2442	66	66	0.428571429	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	TRUE	FALSE	FALSE	47,XX,+8[18]	6	Standard Chemotherapy	2	FALSE	Negative	AML	0.4273972602739726	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	6	UNKNOWN	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large population of CD117 pos myeloblasts, representing 80% of leukocytes, consistent w/ AML.	0	0.033333333	NA	Standard Chemotherapy	Yes	FLT3-ITD (p.Tyr591_Val592ins16; MAF 10%)|WT1 (p.Val379fs; MAF 13%)|ZRSR2 (p.Arg415Trp; MAF 48.9%)
aml_ohsu_2022	aml_ohsu_2022_2550	aml_ohsu_2022_2550_BA2765	39	40	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	4	Allogeneic - Sibling|Salvage|Induction|Re-induction|Supportive/Palliative Care	5	Standard Chemotherapy|Bone Marrow Transplant	2	Azacitidine	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XX,der(7)t(3;7)(q26;q21)[9]/46,XX[11]	4	Standard Chemotherapy	2	FALSE	Negative	AML	7.627397260273973	1:DECEASED	NA	Yes	No	Leiomyosarcoma	Yes	Yes	No	No	No	No	NA	30	Refractory	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Post-Transplant|Residual Disease	Peripheral Blood	Increased atypical CD34 positive, CD7 positive myeloblasts	0	0.133333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2551	aml_ohsu_2022_2551_BA2265	69	69	0.851851852	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Hydroxyurea	Re-induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	TRUE	FALSE	47,XY,+8[cp20]	3	Standard Chemotherapy	3	FALSE	Negative	AML	13.775342465753425	1:DECEASED	trisomy 8	No	No	NA	No	No	No	No	No	No	White	4	Complete Response	NA	3	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Relapse|Post-Chemotherapy	Peripheral Blood	CD7, CD13, CD33, CD34, CD117, CD123, HLA-DR, and MPO-positive	163	0.1	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2551	aml_ohsu_2022_2551_BA2460	69	70	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Hydroxyurea	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	47,XY,+8[cp20]	3	Standard Chemotherapy	3	FALSE	Negative	AML	13.775342465753425	1:DECEASED	trisomy 8	No	No	NA	No	No	No	No	No	No	White	4	Complete Response	NA	3	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD7, CD13, CD33, CD34, CD117, CD123 and HLA-DR positive	333	0.066666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2551	aml_ohsu_2022_2551_BA2643	69	69	0.960784314	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Hydroxyurea	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	47,XY,+8[cp9]/46,XY[11]	3	Standard Chemotherapy	3	FALSE	Negative	AML	13.775342465753425	1:DECEASED	Signal copy for CEP 8 and ETO	No	No	NA	No	No	No	No	No	No	White	4	Complete Response	NA	3	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	dim CD4, partial CD7, CD13, CD33, CD34, dim CD45, dim CD56, variable CD64, CD117, CD123, HLA-DR and MPO positive	0	0.1	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2552	aml_ohsu_2022_2552_BA2650	76	76	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	AG-221|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other	2	AG-221	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	-1	Targeted Therapy - Other	70	FALSE	Negative	AML	22.35616438356164	1:DECEASED	Normal	Yes	No	Basal Cell Carcinoma	Yes	Yes	No	No	No	No	NA	NA	NA	RUNX1 (p.E422Afs*173; 53.3%)	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease	Bone Marrow Aspirate	positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers	0	4	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2552	aml_ohsu_2022_2552_BA2694	76	76	0	ASXL1 (p.E657*; 50.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	AG-221|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other	2	AG-221	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	-1	Targeted Therapy - Other	64	FALSE	Negative	AML	22.35616438356164	1:DECEASED	Normal	Yes	No	Basal Cell Carcinoma	Yes	Yes	No	No	No	No	NA	NA	NA	RUNX1 (p.E422Afs*173; 58.1%)	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease	Peripheral Blood	positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers	0	3.833333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2553	aml_ohsu_2022_2553_BA2656	NA	20	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	7	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	4	FALSE	Positive	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Unknown	Peripheral Blood	NA	2	0.166666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2554	aml_ohsu_2022_2554_BA2594	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Azacitidine|Decitabine	2	Consolidation|Induction|Maintenance	3	Standard Chemotherapy	1	Azacitidine	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	FALSE	FALSE	FALSE	43~44,X,-Y,t(3;11)(p21.3;p11.2),del(5)(q11.1;q31.1),add(12)(p11.2),-21[cp17]/44~45,idem,-t(3;11),+9[cp4]	36	Standard Chemotherapy	7	FALSE	Negative	AML	8.284931506849315	1:DECEASED	Previous FISH results were consistent with the deleted 5q and trisomy 9	Yes	No	Other malignant neoplasm without specification of site	No	No	No	No	No	No	White	38	Unknown	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, partial CD56,variable CD117, dim CD123, and dim HLA-DR+	0	0.366666667	TP53 (p.H193R; 90.7%)	Standard Chemotherapy	Yes	TP53 (p.H193R; MAF 92%)
aml_ohsu_2022	aml_ohsu_2022_2555	aml_ohsu_2022_2555_BA2284	44	44	0.851851852	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	TRUE	FALSE	FALSE	45,XX,der(13;14)(q10;q10)?c[20]	-1	Bone Marrow Transplant	15	FALSE	Positive	AML	12.131506849315068	0:LIVING	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.733333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2556	aml_ohsu_2022_2556_BA2401	69	69	0.075268817	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|IMGN779 (Immunogen Trial)|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924|Azacitidine, Midostaurin, Ponatinib	8	Salvage|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	3	IMGN779 (Immunogen Trial)	Salvage	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M2	Positive	FALSE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Other	3	FALSE	Negative	AML	18.575342465753423	1:DECEASED	normal	Yes	No	Breast Cancer	No	No	No	No	No	No	White	6	Refractory	NA	2	Female	UNMATCHED	FALSE	AML with maturation	Post-Chemotherapy	Bone Marrow Aspirate	Positive (CD13, dim CD33, CD34, CD38, CD58 and CD123+)	46	0.1	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2556	aml_ohsu_2022_2556_BA2721	69	69	1	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|IMGN779 (Immunogen Trial)|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924|Azacitidine, Midostaurin, Ponatinib	8	Salvage|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	3	IMGN779 (Immunogen Trial)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Positive	FALSE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Other	5	FALSE	Negative	AML	18.575342465753423	1:DECEASED	normal	Yes	No	Breast Cancer	No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.A187T; MAF 42%)	2	Female	UNMATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD34, CD58, CD117, partial MPO and HLA-DR +	0	0.166666667	NA	Standard Chemotherapy	Yes	CREBBP (p.S893L; MAF 41%)|FLT3-ITD (MAF 47%)|RUNX1 (p.A187T; MAF 42%)|SF3B1 (p.K700E; MAF 51%)|TET2 (p.K751fs*61; MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2557	aml_ohsu_2022_2557_BA2817	73	77	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	No	Vidaza|AG-221|Bortezomib|Cytarabine|Lenalidomide|Decitabine	6	Hypomethylating/Low Dose Cytarabine|Experimental|Supportive/Palliative Care	3	Supportive/Palliative Care|Targeted Therapy - Other	2	AG-221	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	88<4n>,XXYY,+del(1)(p22p36),i(2)(p10),-5,-7,-7,-21,-21[12]	267	Targeted Therapy - Other	9	FALSE	Negative	AML	48.986301369863014	1:DECEASED	nuc ish(RUNX1T1x4,RUNX1x2)[200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[200],(PML,RARA)x4[200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[174/200]	Yes	No	Prostate Cancer	No	No	No	No	No	No	Black	NA	NA	RUNX1 (loss)	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	92% population of variably-sized cells with the following immunophenotype: CD2(-), CD4(-), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(+), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(variably +), HLA-DR(par	0	0.5	NA	NA	Yes	IDH2 (R140Q)|PTPN11 (E76Q)|RUNX1 (loss)
aml_ohsu_2022	aml_ohsu_2022_2558	aml_ohsu_2022_2558_BA2962	75	75	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Cytarabine|Fludarabine, TBI|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, TBI	Allogeneic - Mismatched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	IntermediateOrAdverse	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	10.75068493150685	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim partial CD11b, dim variable CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, CD123, HLA-DR, partial TdT, dim MPO positive	0	0.133333333	NA	Standard Chemotherapy	Yes	DNMT3A (intron 7 splice site (at invariant AG splice donor); MAF 50% )|DNMT3A (p.P777L; MAF 50%)|FLT3-ITD (MAF 40%)|IDH2 (p.R140Q; MAF 45%)|MLL (PTD; no MAF available)|WT1 (Intron 1 splice site (at invariant AG splice donor); MAF 90% )
aml_ohsu_2022	aml_ohsu_2022_2559	aml_ohsu_2022_2559_BA2427	53	60	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Azacitidine, Gemtuzumab|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Cytarabine	5	Induction|Re-induction	2	Standard Chemotherapy	1	Azacitidine, Gemtuzumab	Re-induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M4eo	Negative	FALSE	TRUE	FALSE	47,XX,t(16;16)(p13;q22),+22[20]	-1	Standard Chemotherapy	2	FALSE	Negative	AML	82.91506849315068	0:LIVING	CBFB inv(16)	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Post-Chemotherapy|Relapse	Peripheral Blood	Positive (ABNORMAL CD34+ BLAST POPULATION, 11%, EXPRESSING CD117, CD15,CD13, CD33 (DIM), AND HLA-DR, WITH ABERRANT EXPRESSION OF CD19(DIM-PARTIAL) AND CD22 (DIM-PARTIAL)ABNORMAL MONOCYTIC POPULATION EXPRESSING CD64, CD14, CD34(DIM), CD2 (DIM), CD7 (DIM), 	0	0.1	NA	Standard Chemotherapy	Yes	FLT3-D835
aml_ohsu_2022	aml_ohsu_2022_2560	aml_ohsu_2022_2560_BA2438	74	74	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	2	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY,idic(7)(q11.2)[1]/47,idem,+8[9]46,XY[10]	-1	Standard Chemotherapy	19	FALSE	Negative	AML	26.13698630136986	1:DECEASED	nuc ish(RUNX1T1x3,RUNX1x2)[133/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	Yes	No	Prostate Cancer	No	No	No	No	No	No	NA	NA	NA	RUNX1 (p.F330Sfs*271; 17.4%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33 (partial +), CD34(+), CD36(-), CD38(partial +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +), MPO (partial +), TdT(-)	0	1.133333333	NA	NA	Yes	BCOR (V1445fs*8; MAF 65%)|ETV6 (A215fs*2; MAF 35%)|RUNX1 (F330fs*154+; MAF 35%)|U2AF1 (S34F; MAF 34%)
aml_ohsu_2022	aml_ohsu_2022_2561	aml_ohsu_2022_2561_BA2906	5	5	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves1+2	Yes	ADE (Cytarabine, Daunorubicin & Etoposide)|Cyclophosphamide, TBI|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	46,XY[25]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	73.67671232876712	1:DECEASED	MLL rearrangement (76%)	Yes	No	B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged	No	No	No	No	No	No	White	9	Complete Response	NA	1	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Transplant|Post-Chemotherapy	Peripheral Blood	CD4, CD11b, CD15, CD33, bright CD34, CD38, CD58, CD64,CD71, CD117, CD123, HLA-DR and dim/partial MPO positive	0	0.066666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2562	aml_ohsu_2022_2562_BA2125	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	Azacitidine, Lenalidomide	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	FALSE	42~45,XX,add(5)(q13),der(17)add(17)(p11.2)add(17)(q11.2),-18,-22[cp6]/43~44,sl,add(13)(q32),add(14)(q11.2),+mar[cp12]/43~44,sl,add(14)(q11.2),-21,	28	Standard Chemotherapy	11	FALSE	Negative	AML	9.698630136986301	1:DECEASED	5q deletion (85%) | Loss of RARA on 17q21 (46%)	Yes	No	Basal Cell Carcinoma	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7, CD13, partial CD33, CD34, partial CD38, CD58, CD117, dim/partial CD123, partial TdT, HLA-DR positive.	0	0.666666667	TP53 (p.V173M; 77.4%)	Standard Chemotherapy	Yes	SUZ12 (V186D)|TP53 (V173M; MAF 80%)
aml_ohsu_2022	aml_ohsu_2022_2563	aml_ohsu_2022_2563_BA2812	46	46	0	NA	Leukemia	Acute Leukemias of Ambiguous Lineage	NA	NA	3	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Leukaemias Of Ambiguous Lineage	MissingKaryo	NA	NA	Negative	TRUE	FALSE	FALSE	NA	NA	None	6	FALSE	Negative	ALAL	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	MATCHED	FALSE	Mixed phenotype acute leukaemia, T/myeloid, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	14	0.366666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2565	aml_ohsu_2022_2565_BA2664	63	63	NA	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Alive	NA	2	Waves1+2	Yes	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	NA	Myelodysplastic Syndromes	NonAML	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX,add(5)(q11.2),inv(9)(p11q12)c[1]/46,idem,add(4)(p14),-add(5),+del(5)(q31q35),del(7)(q11.2q34),add(18)(q23) [cp4]/45,idem,-7,der(12)inv(12)(p13q24.1)add(12)(p13),-18,der(21)t(1;21)(p13;p11.2),+mar[cp11]/46,XX[4].	-1	Standard Chemotherapy	12	FALSE	Negative	MDS	1.4794520547945205	0:LIVING	nuc ish (D5S2064x2,D5S630x2,EGR1x1)[62/200],(D7Z1x2,D7S522x1)[79/200],(D8Z2,D20S108)x2[198],(RUNX1T1x2, RUNX1x3)[10/200],(5'MLL,3'MLL)x3~5(5'MLL con 3'MLLx3~5)[22/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2 (5'CBFB con 3'CBFBx2)[200]	Yes	No	Breast Cancer	Yes	No	No	No	No	No	White	NA	NA	NA	1	Female	MATCHED	TRUE	Myelodysplastic syndrome, unclassifiable	Residual Disease	Bone Marrow Aspirate	The cytospin and smear preparations reveal maturing hematopoietic precursors and scattered small lymphocytes. (no +/- data)	0	0.633333333	TP53 (p.H193Y; 42.5%)	NA	No	BRCA2 (T3085FS*26; MAF 45.0%)|TP53 (H193Y; MAF 65.0%)
aml_ohsu_2022	aml_ohsu_2022_2566	aml_ohsu_2022_2566_BA2577	10	12	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	1	Waves1+2	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	4	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M2	Negative	FALSE	TRUE	FALSE	47,XX,+10[19]/46,XX[1]	-1	Bone Marrow Transplant	2	FALSE	Negative	AML	70.45479452054795	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	33	Complete Response	NA	2	Female	UNMATCHED	FALSE	AML with mutated CEBPA	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	variable CD7, dim CD13, CD33, CD34 bright CD38,CD56, CD58, CD117, HLA-DR positive	568	0.066666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2566	aml_ohsu_2022_2566_BA2748	10	10	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	1	Waves1+2	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	4	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	3	FALSE	Negative	AML	70.45479452054795	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	33	Complete Response	NA	2	Female	UNMATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	variable CD7, variable CD13, CD33, partial CD34, bright CD38, partial CD56, CD58, variable CD71, CD117, CD123, HLA-DR, and MPO positive	0	0.133333333	NA	Standard Chemotherapy	Yes	CEBPA (p.G96fs*12; MAF ~50% )|CEBPA (p.G96fs*12; MAF ~50%)|CEBPA (p.R306_N307insPPT; MAF ~50%)|MLL (PTD (low level mutation))|NRAS (p.G12A, MAF 6%)|NRAS (p.G12A; MAF 6% )|NRAS (p.G12D; MAF 5% )|NRAS (p.G12D; MAF 5%)|NRAS (p.G13D; MAF 8%)|NRAS (p.G13R; MAF
aml_ohsu_2022	aml_ohsu_2022_2567	aml_ohsu_2022_2567_BA2511	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	4	Waves1+2	Yes	AG-221	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	AG-221	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M4	Negative	TRUE	FALSE	FALSE	46,XX,inv(3)?(q21q25)[21]	-1	Standard Chemotherapy	6	FALSE	Negative	AML	33.13972602739726	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	MATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34, CD117, CD38, CD56 (minor subset), partial CD13, partial CD33, CD11c, and HLA-DR	0	0.3	NA	NA	Yes	IDH2
aml_ohsu_2022	aml_ohsu_2022_2568	aml_ohsu_2022_2568_BA2880	85	85	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	NA	None	5	FALSE	Negative	AML	1.1178082191780823	0:LIVING	Normal	Yes	No	Not specified	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	Myeloid sarcoma	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.3	NA	NA	Yes	EZH2 (c.436G>C; p.D146H)|TET2 (c.5182G>T; p.E1728X)
aml_ohsu_2022	aml_ohsu_2022_2569	aml_ohsu_2022_2569_BA2768	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY,der(7)t(7;11)(q22;q13)[14]/46,XY[6]	-1	Bone Marrow Transplant	6	FALSE	Negative	AML	85.08493150684932	0:LIVING	Missing D7S486 signal (9.5%) | Three MLL signals (10%)	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	dim/partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR positive	19	0.233333333	NA	Standard Chemotherapy	Yes	DNMT3A (p.G413V; MAF 32%)|DNMT3A (p.R309G; MAF 31%)|IDH1 (p.R132C; MAF 33%)|MLL (PTD)
aml_ohsu_2022	aml_ohsu_2022_2570	aml_ohsu_2022_2570_BA2303	39	39	5.666666667	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Both	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Fludarabine, TBI	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, TBI	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	FALSE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	4	FALSE	Positive	AML	9.731506849315068	0:LIVING	NA	Yes	No	Cervical Cancer	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large pop. of promonocytes/monoblasts representing approx 57% of total leukocytes and increased atypicalCD117 pos, partial CD34 pos myeloblasts (partial CD7 pos) representing approx 6% of leukocytes consistent w/AMLw/monocytic differentiation.	0	0.166666667	NA	Standard Chemotherapy	No	DNMT3A (p.Arg882His; MAF 41.8%)|FLT3 (p.Tyr572Cys; MAF 1.2%)|FLT3 (p.Val581_Arg595dup; MAF 22%)|FLT3-ITD|NPM1 (p.Trp288fs; MAF 21.2%)
aml_ohsu_2022	aml_ohsu_2022_2571	aml_ohsu_2022_2571_BA2366	81	81	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	Venetoclax (ABT-199), Azacitidine	1	Experimental	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,-7,+8[7]/47,sl,+8[6]/46,XX[6]	-1	Standard Chemotherapy	27	FALSE	Negative	AML	27.221917808219178	0:LIVING	44% loss chromosome 7, 28% trisomy 8, 28% tetrasomy 8,	Yes	No	Bladder Cancer|Ovarian cancer	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	positive for CD34, CD38, dim CD45, CD117, HLA-DR and MPO	0	1.6	NA	NA	Yes	IDH1 (p.R132C; MAF 16.3%)
aml_ohsu_2022	aml_ohsu_2022_2572	aml_ohsu_2022_2572_BA2228	60	60	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	HiDAC|AG-221|3+7 (Cytarabine, Daunorubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	5	Consolidation|Salvage|Induction|Experimental	4	Standard Chemotherapy|Targeted Therapy - Other	2	AG-221	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Other	1	FALSE	Positive	AML	8.515068493150684	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Yes	No	Breast Cancer	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	The study reveals a minute subset of myeloblasts with mild immunophenotypic variation; the significance of this finding is unclear and it is not diagnostic for recurrent or persistent myeloid neoplasia. (No evidence of disease by flow)	0	0	NA	Standard Chemotherapy	Yes	FLT3 (R311Q; MAF 48%)
aml_ohsu_2022	aml_ohsu_2022_2573	aml_ohsu_2022_2573_BA2791	26	26	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves1+2	Yes	ATRA, Arsenic Trioxide	1	Consolidation|Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M3	Negative	TRUE	FALSE	FALSE	46,XY,t(15;17)(q24;q21.1)[10]/46,XY[10]	5	Standard Chemotherapy	17	FALSE	Negative	AML	6.9369863013698625	0:LIVING	nuc ish(PML,RARA)x3(PML con RARAx2)[173/200]	No	No	NA	No	No	No	No	No	No	NA	5	Complete Response	NA	1	Male	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-/small subset +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(equivocal/appears partial dim +), CD117(+), CD123(-), HLA-DR(-), MPO(appea	0	0.8	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2574	aml_ohsu_2022_2574_BA2282	41	44	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	Busulfan, Fludarabine|Etoposide, TBI|PETHEMA Trial LPA05 (ATRA (Tretinoin), Idarubicin, Mitoxantrone, Cytarabine)|Idarubicin, Mitoxantrone|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate	7	Allogeneic - Sibling|Consolidation|Induction|Maintenance|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant	2	Etoposide, TBI	Allogeneic - Sibling	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	NA	FALSE	Negative	AML	77.26027397260273	0:LIVING	48% PML/RARA translocation	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Post-Chemotherapy|Post-Transplant	Peripheral Blood	CD117+, HLA-DR negative, partial CD34+ (Right inguinal biopsy)	0	0	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2575	aml_ohsu_2022_2575_BA2464	40	40	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	ATRA, Arsenic Trioxide	1	Consolidation|Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	HISPANIC	M3	Negative	TRUE	FALSE	FALSE	46,XX,t(15;17)(q22;q21)[17]/46,XX[3]	193	Standard Chemotherapy	12	FALSE	Negative	AML	82.35616438356165	0:LIVING	58% PML-RARA  (c/w karyotype)	No	No	NA	No	No	No	No	No	No	White	33	Complete Response	NA	1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD58, CD64, CD117, CD123 and MPO positive	0	0.666666667	NA	Standard Chemotherapy	Yes	IKZF1 (p.E80X; MAF 37%)|WT1 (p.E340X; MAF 32%)
aml_ohsu_2022	aml_ohsu_2022_2576	aml_ohsu_2022_2576_BA2636	74	74	0	ASXL1 (p.G645Vfs*58; 43.8%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	4	Waves1+2	Yes	Hydroxyurea|Decitabine|Temozolomide, Vorinostat|Azacitidine, MLN4924	4	Salvage|Induction|Re-induction|Symptom Control	4	Standard Chemotherapy	1	Decitabine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY	-1	Standard Chemotherapy	6	FALSE	Negative	AML	11.736986301369862	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.3	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2577	aml_ohsu_2022_2577_BA2944	23	23	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)	2	Induction|Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M1	Negative	TRUE	FALSE	FALSE	46,XY,add(6)(q23),del(7)(q33),t(8;21)(q22;q22)[2]/46,sl,add(17)(p11.1)[5]/46,sdl1,add(16)(p11.2)[2]/46,sdl2,add(3)(q21)[8]/46,sdl3,add(20)(q11.2)[3]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	24.55890410958904	0:LIVING	62% t(8;21) (RUNX1T1;RUNX1) translocation present	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD34, CD38, CD117, HLA-DR, cMPO, CD19 and partial CD56	0	0.033333333	NA	Standard Chemotherapy	Yes	BRCA2 (c.6275_6276delTT; MAF unlisted)|BRCA2 (c.6859A>T; MAF unlisted)|FLT3-ITD (MAF unlisted)
aml_ohsu_2022	aml_ohsu_2022_2578	aml_ohsu_2022_2578_BA3043	51	51	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	46,XX[20]	3	Standard Chemotherapy	3	FALSE	Positive	AML	7.265753424657534	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim/partial CD7, variable CD13, CD33, dim/partial     CD64,     CD117, CD123, HLA-DR and cMPO positive	0	0.1	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 50%)|FLT3-ITD (exon 14 )|NPM1 (p.W288fs*12; MAF 40%)|WT1 (rs16754; no MAF available)
aml_ohsu_2022	aml_ohsu_2022_2579	aml_ohsu_2022_2579_BA3045	46	47	0.538461538	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Crenolanib|PLX3397|Fludarabine, Cyclophosphamide, Thiotepa, TBI|AC220 (Ambit)	7	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	6	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	46,X,t(X;11)(p22.1;q13),add(7)(p22),add(17)(q21)[cp3]/45,X,-X,add(1)(q21),add(2)(q37),add(5)(q35),add(7)[cp3]/46,XX[4]	-1	Targeted Therapy - Kinase Inhibitor(s)	5	FALSE	Negative	AML	15.747945205479454	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	9	Complete Response i	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Post-Transplant|Residual Disease	Peripheral Blood	CD2(dim +), CD7(-), CD13(partial dim +), CD14(-), CD15(partial +), CD33(+), CD34(+), CD38(partial +), CD45(moderately +), CD117(partial +), HLA-DR(variably +)	0	0.2	NA	Standard Chemotherapy	Yes	FLT3-D835 (NOT FOUNDATION NO MAF AVAILABLE)|FLT3-ITD (NOT FOUNDATION NO MAF AVAILABLE)
aml_ohsu_2022	aml_ohsu_2022_2580	aml_ohsu_2022_2580_BA3042	32	38	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	HiDAC|Decitabine, Sirolimus|Donor Lymphocyte Infusion|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, 	9	Consolidation|Salvage|Induction|Re-induction|Post-Transplant Relapse|Allogeneic - Matched Unrelated Donor	6	DLI|Standard Chemotherapy|Bone Marrow Transplant	3	Decitabine, Sirolimus	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M2	Negative	FALSE	FALSE	FALSE	46,XX[19]/46,XY[1]	127	Standard Chemotherapy	4	FALSE	Negative	AML	82.61917808219178	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with maturation	Residual Disease|Post-Transplant	Bone Marrow Aspirate	NA	488	0.166666667	NA	Standard Chemotherapy	Yes	CEBPA (Q305?Q312del RNVETQ; MAF 50%)|CEBPA (Y108*(premature stop codon); MAF 50%)|IKZF1 (p.G151R; MAF 40%)|NOTCH1 (p.G2152S; MAF: 50%)
aml_ohsu_2022	aml_ohsu_2022_2581	aml_ohsu_2022_2581_BA3047	63	63	0.538461538	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Allogeneic - Sibling|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Decitabine	Supportive/Palliative Care	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	TRUE	TRUE	49,XX,+X,+8,+10[13]/46,XY[7]	-1	Supportive/Palliative Care	4	FALSE	Positive	AML	5.523287671232877	1:DECEASED	Trisomy 8 (24%)	No	No	NA	No	No	Yes	Yes	No	No	White	-1	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	dim CD13, CD33, CD34, CD117, CD123, and dim HLADR	0	0.133333333	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 30%)|FLT3-ITD (Weakly positive; MAF 1.3%)|JAK3 (p.V722I; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2582	aml_ohsu_2022_2582_BA3049	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves1+2	Yes	Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	6	DLI|Standard Chemotherapy|Bone Marrow Transplant	3	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY[23]	269	Standard Chemotherapy	NA	FALSE	Negative	AML	50.728767123287675	1:DECEASED	Normal	No	No	NA	Yes	Yes	Yes	Yes	No	No	White	5	Complete Response	NA	1	Male	UNMATCHED	FALSE	Myeloid sarcoma	Post-Chemotherapy|Post-Transplant|Residual Disease	Bone Marrow Aspirate	NA	0	0	NA	Standard Chemotherapy	Yes	ZRSR2 (p.R452C; MAF 4%)
aml_ohsu_2022	aml_ohsu_2022_2583	aml_ohsu_2022_2583_BA3051	53	56	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	45~49,X,-Y,add(5)(q11.2),+der(9;8)(q10;q10),+10,der(11)t(11;17)(p15;q11.2)del(11)(q21q22),add(12)(q12),del(13)(q12q22),-17,add(18)(p11.2),add(19)(q13.3),-20,+1~4mar[cp4]/46,XX[16]	4	Standard Chemotherapy	1	FALSE	Negative	AML	30.18082191780822	1:DECEASED	nuc ish(RUNX1T1x3,RUNX1x2)[9/200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198](5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	NA	6	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(+), CD64(-), CD117(+), CD123(dim +), HLA-DR (+), MPO(few +), TdT(-).	0	0.033333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2584	aml_ohsu_2022_2584_BA3053	63	64	0.785714286	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Sorafenib	5	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M1	Positive	FALSE	FALSE	FALSE	46,XY[6]	-1	Targeted Therapy - Kinase Inhibitor(s)	3	FALSE	Positive	AML	12.986301369863014	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy|Post-Transplant	Peripheral Blood	NA	0	0.1	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2585	aml_ohsu_2022_2585_BA3054	50	53	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	AG-221|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	6	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	4	AG-221	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Targeted Therapy - Other	2	FALSE	Negative	AML	38.4986301369863	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	2	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	positive for CD13, CD33, CD34, CD38, dim CD45, CD117, HLA-DR and MPO	0	0.133333333	NA	Standard Chemotherapy	No	IDH2 (p.R172K; MAF 30.2%)|TET2 (p.G335D; MAF 20.7%)
aml_ohsu_2022	aml_ohsu_2022_2585	aml_ohsu_2022_2585_BA3056	50	53	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves1+2	Yes	AG-221|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	6	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	4	AG-221	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Targeted Therapy - Other	2	FALSE	Negative	AML	38.4986301369863	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	2	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease|Post-Transplant	Peripheral Blood	positive for CD13, CD33, CD34, CD38, dim CD45, CD117, HLA-DR and MPO	0	0.1	NA	Standard Chemotherapy	Yes	IDH2 (p.R172K; MAF 30.2%)|TET2 (p.G335D; MAF 20.7%)
aml_ohsu_2022	aml_ohsu_2022_2586	aml_ohsu_2022_2586_BA3058	56	58	0	ASXL1 (p.G646Wfs*12; 14.7%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|Azacitidine	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	AG-221	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	48,XY,+8,+8[14]/46,XY[6]	-1	Targeted Therapy - Other	6	FALSE	Negative	AML	44.64657534246575	1:DECEASED	Gain of chromosome 8 centromere, trisomy 3.5%, and terasomy 19.0%	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	positive for CD13, HLA-DR, CD34, and CD117, with aberrant expression of CD7 and aberrant loss of CD33, and with a subset of these blasts showing aberrant co-expression of CD34 and myeloperoxidase.	0	0.266666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.G642fs; MAF 26.4%)|IDH2 (p.R140Q; MAF 36.4%)|PHF6 (p.G306E; MAF 65%)|U2AF1 (p.Q157R; MAF 43.1%)
aml_ohsu_2022	aml_ohsu_2022_2587	aml_ohsu_2022_2587_BA3059	59	59	NA	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Alive	NA	5	Waves1+2	No	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	1	Unknown	1	Unknown	1	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	Unknown	NA	Myelodysplastic Syndromes	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,del(9)(q21q31-33)[10]/46,XX[10]	-1	Unknown	NA	FALSE	Negative	MDS	0.9534246575342467	0:LIVING	positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.	No	No	NA	Yes	No	No	No	No	No	NA	NA	NA	NA	2	Female	UNMATCHED	TRUE	Refractory cytopenia with multilineage dysplasia	Post-Chemotherapy	Peripheral Blood	NA	0	NA	NA	NA	No	ASXL1 (p.686_687del; MAF 40.4%)|ASXL1 (p.E1102D; MAF 30.7%)|CEBPA (p.E10K; MAF 26.7%)|RUNX1 (p.R142fs; MAF 30%)
aml_ohsu_2022	aml_ohsu_2022_2587	aml_ohsu_2022_2587_BA3061	59	59	NA	ASXL1 (p.C687Yfs*30; 28.6%)	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Alive	NA	5	Waves1+2	No	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	1	Unknown	1	Unknown	1	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	Unknown	NA	Myelodysplastic Syndromes	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,del(9)(q21q31-33)[10]/46,XX[10]	-1	Unknown	4	FALSE	Negative	MDS	0.9534246575342467	0:LIVING	positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.	No	No	NA	Yes	No	No	No	No	No	NA	NA	NA	NA	2	Female	UNMATCHED	TRUE	Refractory cytopenia with multilineage dysplasia	Post-Chemotherapy	Bone Marrow Aspirate	NA	0	0.166666667	NA	NA	No	ASXL1 (p.686_687del; MAF 40.4%)|ASXL1 (p.E1102D; MAF 30.7%)|CEBPA (p.E10K; MAF 26.7%)|RUNX1 (p.R142fs; MAF 30%)
aml_ohsu_2022	aml_ohsu_2022_2588	aml_ohsu_2022_2588_BA3062	40	47	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	8	Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	6	DLI|Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan	Allogeneic - Sibling	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	2	FALSE	Negative	AML	106.55342465753424	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	10	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML without maturation	Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	NA	0	0.066666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2589	aml_ohsu_2022_2589_BA3064	38	40	4	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves1+2	Yes	Azacitidine, Sorafenib|Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Sorafenib|Cladribine, Cytarabine, Idarubicin	6	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Experimental|Intensification|Re-induction	7	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	TRUE	FALSE	NA	38	Targeted Therapy - Kinase Inhibitor(s)	2	FALSE	Negative	AML	23.57260273972603	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Relapse|Post-Chemotherapy|Post-Transplant	Peripheral Blood	CD4,  CD11b, dim CD13, variable CD15, CD33, partial CD34  (approximately 25%), variable CD64 (dim to bright), CD117,  HLA-DR, and myeloperoxidase	0	0.066666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2590	aml_ohsu_2022_2590_BA3065	69	72	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Sorafenib|MiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	7	Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction|Maintenance|Supportive/Palliative Care	7	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	4	Sorafenib	Maintenance	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	TRUE	FALSE	46,XY[18]	-1	Targeted Therapy - Kinase Inhibitor(s)	4	FALSE	Positive	AML	101.1945205479452	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	32	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Transplant|Relapse|Post-Chemotherapy	Peripheral Blood	Immunophenotype: dim CD13, CD33, CD117, CD123 and MPO positive.	0	0.166666667	NA	Standard Chemotherapy	Yes	CEBPA (p.A240fs*83 (7 bp insertion with frameshift); MAF 19%)|CREBBP (p.P1150S; MAF 18%)|FLT3-ITD (MAF 56%)|IDH2 (p.R140Q; MAF 29%)|NPM1 (p.W288fs*12; MAF 29%)|SRSF2 (p.P95L; MAF 22%)
aml_ohsu_2022	aml_ohsu_2022_2591	aml_ohsu_2022_2591_BA3067	59	59	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|Azacitidine|Sorafenib	3	Allogeneic - Mismatched Unrelated Donor|Experimental|Maintenance	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7]	12	Targeted Therapy - Kinase Inhibitor(s)	2	FALSE	Negative	AML	2.5643835616438357	1:DECEASED	EGR-1/ D5S23, D5S721/CEP 8: 64/100 cells (56%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q, | 56/100 cells (56%) had a 2 red/ 4 green signal pattern, reflecting 4 copies of RUNX1 on 21q and consistent with the tetrasomy 21 observe	Yes	No	Bladder Cancer	Yes	Yes	No	No	No	No	White	NA	NA	NA	2	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Post-Transplant|Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, dim CD33, CD43, CD117	6	0.1	TP53 (p.X225_splice; 46.1%)	NA	Yes	GATA1 (p.G283R; MAF 50%)|MLL (Partial tandem duplication (Pathogenic) )|TP53 (Splice site mutation (mutation at 3' end of intron 6 at  invariant AG splice site); MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2591	aml_ohsu_2022_2591_BA3068	59	59	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	Fludarabine, Melphalan|Azacitidine|Sorafenib	3	Allogeneic - Mismatched Unrelated Donor|Experimental|Maintenance	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7]	12	Targeted Therapy - Kinase Inhibitor(s)	1	FALSE	Negative	AML	2.5643835616438357	1:DECEASED	94/100 cells (94%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q, as previously observed. There was no evidence for the previous trisomy 8.	Yes	No	Bladder Cancer	Yes	Yes	No	No	No	No	White	NA	NA	NA	2	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Post-Transplant|Residual Disease	Peripheral Blood	CD13, dim CD33, partial CD34, dim CD117	27	0.066666667	TP53 (p.X225_splice; 75.0%)	NA	No	GATA1 (p.G283R; MAF 50%)|MLL (Partial tandem duplication (Pathogenic) )|TP53 (Splice site mutation (mutation at 3' end of intron 6 at  invariant AG splice site); MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2592	aml_ohsu_2022_2592_BA3070	49	51	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	7	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care	6	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	4	Decitabine	Supportive/Palliative Care	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	115	Supportive/Palliative Care	2	FALSE	Negative	AML	31.956164383561646	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	Black	13	Complete Response	NA	3	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Post-Transplant	Peripheral Blood	NA	0	0.066666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2592	aml_ohsu_2022_2592_BA3071	49	51	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	7	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care	6	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	4	Decitabine	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY[19]	115	Supportive/Palliative Care	6	FALSE	Positive	AML	31.956164383561646	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	Black	13	Complete Response	NA	3	Male	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy|Post-Transplant	Peripheral Blood	NA	46	0.3	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2592	aml_ohsu_2022_2592_BA3072	49	51	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves1+2	Yes	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	7	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care	6	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	4	Decitabine	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY,t(6;19)(p23;q13.1)[11]/46,XY[9]	115	Supportive/Palliative Care	6	FALSE	Positive	AML	31.956164383561646	1:DECEASED	Positive (Cells Scored: 200 Probe(s): Leica DEK (SG) / NUP 214 (SO) t(6;9) DC, DF)	No	No	NA	No	No	No	No	No	No	Black	13	Complete Response	NA	3	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Post-Transplant|Residual Disease	Peripheral Blood	NA	129	0.266666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2593	aml_ohsu_2022_2593_BA3318	83	83	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,-15,+dic(1;15)(p11;p11)[10]/47,idem,+11[10]	NA	None	5	FALSE	Negative	AML	0.4273972602739726	0:LIVING	67.5% of cells had an extra copy of MLL(11q23)	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.3	NA	NA	Yes	IDH2 (p.172Arg>Lys)
aml_ohsu_2022	aml_ohsu_2022_2594	aml_ohsu_2022_2594_BA3385	50	50	0.492537313	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	HiDAC|7+3 (Cytarabine, Daunorubicin) plus Crenolanib|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	4	FALSE	Positive	AML	8.67945205479452	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Myeloid blasts immunophenotype:  CD7, partial CD13, CD33, partial CD34, CD117, HLA-DR and MPO | Monoblasts immunophenotype: dim CD4, CD11b, partial CD13, CD14, CD15, bright CD33, CD64, HLA-DR	0	0.133333333	NA	Standard Chemotherapy	Yes	DNMT3A (p.S714C; VAF 43%)|FLT3-ITD (p.E596delinsQVTGSSDNEYFYVDFRE (48-nucleotide internal tandem duplication); VAR 0.79; VAF 44%)|NPM1 (p.W288fs*12; VAF 44%)|WT1 (p.S381fs*4; VAF 43%)
aml_ohsu_2022	aml_ohsu_2022_2595	aml_ohsu_2022_2595_BA3300	0	0	0	NA	Leukemia	Acute Leukemias of Ambiguous Lineage	Dead-Disease	NA	1	Waves3+4	Yes	Cytarabine|Cytarabine, Mitoxantrone, Gemtuzumab ozogamicin|Cytarabine, Daunorubicin, and Etoposide|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	5	Induction|Intensification|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Leukaemias Of Ambiguous Lineage	Intermediate	UNKNOWN	NA	Negative	TRUE	FALSE	FALSE	46,XY,t(3;12)(q29;p13),ins(12;?)(p13;?)[20]	-1	Bone Marrow Transplant	NA	FALSE	Negative	ALAL	10.323287671232876	1:DECEASED	ETV6 is disrupted by the insertion of unidentified material within the locus.  Any fusion partners with the ETV6 rearrangements were not identified in this study.	No	No	NA	No	No	No	No	No	No	Declined	28	Complete Response	NA	1	Male	UNMATCHED	FALSE	Mixed phenotype acute leukaemia, T/myeloid, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	cCD3, CD7, CD11b, dim CD13, CD33, CD34, CD56, C117, MPO	0	0	NA	Standard Chemotherapy	Yes	FAT4 (p.S2691L; VAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2596	aml_ohsu_2022_2596_BA3128	33	33	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	8	Waves3+4	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|CECA (Cyclophosphamide, Etoposide, Carboplatin, Cytosine)|Cytarabine, OXi4503	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	Cytarabine, OXi4503	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	FALSE	FALSE	Normal	-1	Standard Chemotherapy	4	FALSE	Negative	AML	8.383561643835616	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.166666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2597	aml_ohsu_2022_2597_BA3149	63	63	0	ASXL1 (p.E635Rfs*15; 16.4%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves3+4	Yes	Azacitidine, BI 836858 (anti-CD33)	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Azacitidine, BI 836858 (anti-CD33)	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	NA	6	Standard Chemotherapy	13	FALSE	Negative	AML	0.8876712328767123	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	NA	NA	RUNX1 (p.M267Ifs*44; 77.6%)	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for CD13, CD33, CD34, dim CD45, CD38, CD117, HLA-DR and MPO	0	0.633333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2598	aml_ohsu_2022_2598_BA3372	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine, MGB453|MiDAC|Methotrexate	5	Consolidation|Salvage|Induction|Re-induction	4	Standard Chemotherapy|Intrathecal	2	Decitabine, MGB453	Salvage	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	49	Standard Chemotherapy	NA	FALSE	Negative	AML	12.328767123287673	1:DECEASED	Normal	Yes	No	Melanoma	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	NA	0	0	NA	Standard Chemotherapy	No	DNMT3A (p.N501S; MAF 52%)
aml_ohsu_2022	aml_ohsu_2022_2599	aml_ohsu_2022_2599_BA3132	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	47, XY, del (6) (q13q23), +8, der(20) t (20;?) (q11.2-13.1;?) [6]	NA	None	3	FALSE	Negative	AML	0.263013698630137	0:LIVING	There are only 6 metaphase cells available for analysis. All have clonal abnormalities including 6q deletion, trisomy 8 and rearrangement involving 20q. This karyotype is consistent with the clinical diagnosis of AML. (Cytogenetics)	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease	Bone Marrow Aspirate	Positive for CD34, HLADR, MPO, CD14 and CD33. Negative for CD117, CD11b, cd13 and CD64. (Bone Marrow Immunophenotyping)	0	0.2	NA	NA	Yes	IDH2 (p.R140Q, MAF 46%)|NRAS (p.Q61K, MAF 45%)|SRSF2 (p.P95H, MAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2600	aml_ohsu_2022_2600_BA3417	NA	50	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	NA	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	UNMATCHED	FALSE	Unknown	Unknown	Peripheral Blood	NA	0	0	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2601	aml_ohsu_2022_2601_BA3134	71	71	0	ASXL1 (p.G646Wfs*12; 16.3%)	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	8	Waves3+4	Yes	Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC|Unknown	4	Consolidation|Induction|Allogeneic - Child	3	Standard Chemotherapy|Bone Marrow Transplant	2	Unknown	Allogeneic - Child	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	47,XY,+8[1]/47,idem,del(3)(q21q27)[19]	-1	Bone Marrow Transplant	8	FALSE	Negative	AML	16.602739726027398	1:DECEASED	POSITIVE for RUNX1T1 copy number gain	Yes	No	Skin cancer	Yes	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.366666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2602	aml_ohsu_2022_2602_BA3335	56	56	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	Venetoclax (ABT-199), Azacitidine	1	Induction	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NA	NA	Positive	TRUE	FALSE	FALSE	46,XX[22]	30	Standard Chemotherapy	7	FALSE	Positive	AML	16.898630136986302	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	30	Refractory	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.266666667	NA	Standard Chemotherapy	Yes	DNMT3A (P38SRfs*22; VAF 22%)|FLT3-ITD|GATA2 (T354_T355 insF; VAF 15%)
aml_ohsu_2022	aml_ohsu_2022_2603	aml_ohsu_2022_2603_BA3264	41	41	1.127659574	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	ATRA, Arsenic Trioxide, Idarubicin|ATRA, Arsenic Trioxide	2	Consolidation|Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,XY,t(15;17)(q24;q21)[20]	200	Standard Chemotherapy	3	FALSE	Negative	AML	41.19452054794521	0:LIVING	PML/RARA (92% of  cells had the dual fusion signal pattern consistent with PML/RARA fusion and t(15;17).)	No	No	NA	No	No	No	No	No	No	White	26	Complete Response	NA	1	Male	UNMATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD11b, CD13, CD33, CD34, CD38, CD58, variable  CD64, CD117, CD123, partial HLA-DR and bright MPO	0	0.066666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (Mutant Allele Ratio:  0.85)
aml_ohsu_2022	aml_ohsu_2022_2604	aml_ohsu_2022_2604_BA3281	31	34	0	ASXL1 (p.G1397S; VAF 44%)	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|HiDAC|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Busulfan, Cyclophosphamide	8	Consolidation|Salvage|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	6	DLI|Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	TRUE	FALSE	37~40,XX,add(2)(p11.2),add(4)(q21),add(5)(q13),-7,-11,-11,add(12)(p11.2),-13,add(13)(q34),-17,-17,-18,-19,-19,del(20)(q22),add(21)(q22),+1~3mar[cp9]//46,XY[11]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	57.4027397260274	1:DECEASED	35% had one X signal and one Y signal, reflecting the donor sex chromosome complement; 65% had two X signals, reflecting the patient's sex chromosome complement.  | 46.5% reflected extra TP53 signals and was previously observed	No	No	NA	No	No	No	No	No	No	Unknown	-1	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Relapse|Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	partial, dim CD4, CD13, CD33, dim CD34, dim CD56, partial CD64, CD117 and variable HLA-DR	0	0.066666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.G1397S; VAF 44%)|BIRC6 (p.A500_M501insS; VAF 19%)|CREBBP (p.A1666T; VAF 2%)|CTLA4 (p.P21R; VAF 32%)|MAML1 (p.Q546R; VAF 20%)|TET2 (p.H1881R; VAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2605	aml_ohsu_2022_2605_BA3423	49	50	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	FALSE	FALSE	NA	114	Standard Chemotherapy	5	FALSE	Positive	AML	11.342465753424658	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	28	Unknown	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	Positive for CD34, CD117, HLADR, CD33 and CD13.  (Bone Marrow Immunophentyping)	0	0.233333333	NA	Standard Chemotherapy	Yes	FLT3-TKD
aml_ohsu_2022	aml_ohsu_2022_2606	aml_ohsu_2022_2606_BA3379	34	34	0.041666667	NA	Leukemia	Acute Leukemias of Ambiguous Lineage	Alive	NA	1	Waves3+4	Yes	Cyclophosphamide, TBI|7+3 (Cytarabine, Idarubicin)|HAM-VD (Cytarabine, Mitoxantrone, Vincristine, Dexamethasone)	3	Allogeneic - Sibling|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophosphamide, TBI	Allogeneic - Sibling	Initial Diagnosis	Acute Leukaemias Of Ambiguous Lineage	Intermediate	NON-HISPANIC	NA	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	5	FALSE	Negative	ALAL	99.35342465753425	0:LIVING	cryptic t(14;21) (54.5% of cells had three signals for AML1)	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	NA	1	Male	UNMATCHED	FALSE	Acute undifferentiated leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2 , CD7 , CD13 , CD34 , dim CD45 , CD117 , HLA-DR , TdT positive	0	0.166666667	NA	Standard Chemotherapy	Yes	FLT3-D835|FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2607	aml_ohsu_2022_2607_BA3416	54	54	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	mono	1	Waves3+4	Yes	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	1	Induction	1	Standard Chemotherapy	1	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY[20]	3	Standard Chemotherapy	1	FALSE	Negative	AML	0.7890410958904108	1:DECEASED	RUNX1:  17/200 (8.5%) interphase cells had three RUNX1 (21q22) signals. There was no evidence for RUNX1T1/RUNX1 fusion.	No	No	NA	No	No	No	No	No	No	White	3	Refractory	NA	1	Male	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Partial immunophenotype: CD33, cCD79a, CD117, HLA-DR, and cMPO	0	0.066666667	NA	Standard Chemotherapy	Yes	CBL (p.Q490E; VAF 52%)|CEBPA (p.K304_T318dup; VAF at least 70%)|CHD2 (p.R1354K; VAF 49%)|DOCK8 (p.E766K; VAF 46%)|FAT1 (p.E38K; VAF 49%)|GATA2 (p.R307L; VAF 41%)|RUNX1 (p.I366_G367dup; VAF 46%)
aml_ohsu_2022	aml_ohsu_2022_2608	aml_ohsu_2022_2608_BA3299	47	47	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves3+4	Yes	Busulfan, Fludarabine|HiDAC|3+7 (Cytarabine, Daunorubicin)	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	46,XX[20]	11	Bone Marrow Transplant	3	FALSE	Positive	AML	8.646575342465754	0:LIVING	An apparently NORMAL KARYOTYPE was observed in all 20 mitotic cells analyzed. Specifically, there was no significant numerical chromosomal abnormality and no clonal structural aberration of any chromosome detectable within the limits of resolution.  (Cyto	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for CD117, HLADR, CD33, CD11b, CD64 and MPO (partial).  (Bone Marrow Immunophenotyping)	0	0.133333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2609	aml_ohsu_2022_2609_BA3449	55	55	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	8	Waves3+4	Yes	Vidaza|Decitabine	2	Salvage|Supportive/Palliative Care	2	Standard Chemotherapy	1	Decitabine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	49,XY,dup(1)(p22.1p32.1), inv(3)(q21.3q26.2),+8,+12 ,+21[20]	-1	Standard Chemotherapy	4	FALSE	Negative	AML	0.03287671232876713	1:DECEASED	POSITIVE for RUNX1T1 and RUNX1 copy number gains	No	No	NA	Yes	Yes	No	No	No	No	White	NA	NA	RUNX1 (p.R76Pfs*62; 66.7%)	1	Male	UNMATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	NA	0	0.233333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2610	aml_ohsu_2022_2610_BA3130	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	48,XY,+7,+mar[4]/46,XY[16]	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	3.6164383561643834	1:DECEASED	Chromosome 7: 44% of cells had three signals for both chromosome 7 probes, consistent with trisomy 7	No	No	NA	No	No	Yes	Yes	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4, dim CD7, CD11b, CD13, variable CD14, CD16, dim CD33, dim CD 38, dim CD56, CD64.	0	0.2	NA	Standard Chemotherapy	Yes	BRAF (p.V600E; VAF 36%)|TET2 (p.A1355V; VAF 48%)|TET2 (p.Q803*; VAF 44%)|ZRSR2 (Splice site; VAF 92%)
aml_ohsu_2022	aml_ohsu_2022_2611	aml_ohsu_2022_2611_BA3123	69	69	0	ASXL1 (p.T514Nfs*15; 34.3%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Busulfan, Fludarabine|Venetoclax (ABT-199), Azacitidine|7+3 (Cytarabine, Daunorubicin) plus Glasdegib/placebo|MiDAC plus Glasdegib/placebo	4	Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Venetoclax (ABT-199), Azacitidine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	FALSE	46,XY[20]	149	Standard Chemotherapy	9	FALSE	Negative	AML	15.386301369863014	1:DECEASED	NA	Yes	Yes	Prostate Cancer	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	variable CD5, CD7, CD11b (partial), CD13, CD33 (dim), CD34, CD38 (dim), CD117, and HLA-DR	0	0.466666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.T514fs*15; VAF 37%)|BLM (p.N936D; VAF 50%)|CSF3R (p.R311C; VAF 50%)|KMT2A (p.D2911N; VAF 50%)|MSH2 (p.V437M; VAF 41%)|PCLO (p.D2885N; VAF 47%)|PRPF40B (p.P751S; VAF 51%)|SRSF2 (p.P95H; VAF 37%)|TCF3 (p.H344R; VAF 49%)|TET2 (p.Q1030*; VAF 43%)|TET
aml_ohsu_2022	aml_ohsu_2022_2612	aml_ohsu_2022_2612_BA3142	54	54	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Decitabine, MGB453|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Salvage|Induction|Re-induction	3	Standard Chemotherapy|Other	2	Decitabine, MGB453	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	43,XY,add(5)(q11.2),add(9)(q12),add(10)(p11.2),-12,idic(12)(p11.2),t(14;14)  (q31;q32),-16,-17,add(17)(q21),add(19)(p13),-20,add(21)(p11.2),+mar[19]/46,  XY[1]	56	Other	3	FALSE	Negative	AML	7.035616438356165	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, dim CD33, CD34, CD38, CD117, dim CD123,  HLA-DR positive	0	0.2	TP53 (p.V216M; 78.5%)	Standard Chemotherapy	Yes	TP53 (p.V216M; MAF 57%)
aml_ohsu_2022	aml_ohsu_2022_2613	aml_ohsu_2022_2613_BA3435	79	79	0.111111111	ASXL1 (p.G646Wfs*12; 30.2%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Decitabine|Azacitidine, BI 836858 (anti-CD33)	2	Salvage|Induction	2	Standard Chemotherapy	1	Decitabine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	47,XY,+8[18]/46,XY[2]	37	Standard Chemotherapy	7	FALSE	Negative	AML	4.438356164383562	1:DECEASED	CEP8 and RUNX1T1 (8q21.3): ~90% of cells had an extra signal for chromosome 8 probes, consistent with trisomy 8, as seen on metaphase analysis.	No	No	NA	No	No	No	No	No	No	White	50	Refractory	RUNX1 (p.T246Hfs*15; 25.0%)	1	Male	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD13, partial CD33, CD34, CD117, CD123, partial HLA-DR, and partial MPO	0	0.266666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 16%)|IDH1 (p.R132C; MAF 46%)|JAK2 (p.V617F; MAF 12%)|RUNX1 (p.T246fs*15; MAF 50%)|U2AF1 (p.Q157P; MAF 48%)
aml_ohsu_2022	aml_ohsu_2022_2614	aml_ohsu_2022_2614_BA3157	60	60	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	HiDAC|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	FALSE	FALSE	FALSE	46,XY,del(9)(q13q22)[20]	-1	Bone Marrow Transplant	8	FALSE	Positive	AML	46.849315068493155	0:LIVING	Normal	Yes	No	Basal Cell Carcinoma	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, variable CD34, CD38, CD58, CD117,  CD123, HLA-DR, variable MPO	0	0.433333333	NA	Standard Chemotherapy	Yes	NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.G13D; MAF 41%)|SF3B1 (p.T663I; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2615	aml_ohsu_2022_2615_BA3411	48	48	0	ASXL1 (p.L823*; 45.9%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	FALSE	FALSE	TRUE	47,XX,+8,del(8)(q11.2q22)[20]	-1	Standard Chemotherapy	8	FALSE	Negative	AML	11.539726027397261	0:LIVING	CEP 8: 73/100 cells (73%) had three signals, consistent with the extra chromosome 8 in the metaphase karyotype	No	No	NA	Yes	Yes	No	No	No	No	White	5	Complete Response	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD56, CD58,variable CD64, CD71, CD117, dim CD123, HLA-DR, MPO  (Myeloid Blasts) | CD11b, CD13, CD15, CD33, CD56, CD64, HLA-DR (Abnormal Monocytes)	0	0.366666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.L823; MAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2616	aml_ohsu_2022_2616_BA3355	70	70	0	ASXL1 (p.G646Wfs*12; 24.8%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	No	Azacitidine, Itacitinib|Azacitidine, BI 836858 (anti-CD33)	2	Induction	1	Targeted Therapy - Kinase Inhibitor(s)	1	Azacitidine, Itacitinib	Induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	45,XX,inv(3)(q21q26),-7[20]	8	Targeted Therapy - Kinase Inhibitor(s)	7	FALSE	Positive	AML	6.2465753424657535	1:DECEASED	Abnormal (MECOM/RPN1 Fusion: 99% of  cells had a 1r/1g/2f dual-fusion signal pattern, reflecting MECOM/RPN1  fusion)	No	No	NA	No	No	No	No	No	No	White	39	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.3	NA	Targeted Therapy - Kinase Inhibitor(s)	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2617	aml_ohsu_2022_2617_BA3222	21	22	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate	6	Consolidation|Salvage|Induction	3	Standard Chemotherapy|Intrathecal	2	Venetoclax (ABT-199), Azacitidine	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	49,XY,del(4)(q21),add(6)(q27),-17,add(19)(p13.3),+mar1X2,+mar2,+mar3 [cp13]/49,XY,add(4)(q21),-6,+8,+mar1X2,+mar4[cp6]/46,XY[1]	26	Standard Chemotherapy	3	FALSE	Negative	AML	10.389041095890411	1:DECEASED	51% had an abnormal signal pattern, reflecting the trisomy 8 in the metaphase karyotype and previously observed.  There was no evidence for RUNX1T1/RUNX1 fusion.  | 61% had a variant abnormal signal pattern, reflecting MLL rearrangement and previously obs	No	No	NA	No	No	No	No	No	No	White	4	Complete Response	NA	3	Male	UNMATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	dim CD4, CD13, CD33, CD34, dim CD56, CD64, HLA-DR+	267	0.166666667	NA	Standard Chemotherapy	No	KRAS (p.G13R; MAF 24%)|U2AF1 (p.S34F; MAF 24%)
aml_ohsu_2022	aml_ohsu_2022_2617	aml_ohsu_2022_2617_BA3374	21	21	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate	6	Consolidation|Salvage|Induction	3	Standard Chemotherapy|Intrathecal	2	Venetoclax (ABT-199), Azacitidine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	47~49,XY,+8[cp13]/46,XY[7]	26	Standard Chemotherapy	3	FALSE	Negative	AML	10.389041095890411	1:DECEASED	RUNX1T1/CEP8: 140/200 cells (70%) reflect the trisomy 8 in the metaphase karyotype; 20 cells (10%) reflect extra centromere signals only. It is possible the G-banded cell with two small markers reflects a small clone containing extra copiesof a derivativ	No	No	NA	No	No	No	No	No	No	White	4	Complete Response	NA	3	Male	UNMATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4, partial CD11b, CD13, CD33, dim CD22, CD34, variable CD56, variable CD64, CD117, HLA-DR, dim PAX5+	0	0.166666667	NA	Standard Chemotherapy	Yes	KRAS (p.G13R; MAF 37%)|U2AF1 (p.S34F; MAF 39%)
aml_ohsu_2022	aml_ohsu_2022_2617	aml_ohsu_2022_2617_BA3403	21	22	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate	6	Consolidation|Salvage|Induction	3	Standard Chemotherapy|Intrathecal	2	Venetoclax (ABT-199), Azacitidine	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Negative	FALSE	TRUE	FALSE	49,XY,+8,+mar1,+mar1[cp13]/49,idem,del(6)(q13q21)[8]	26	Standard Chemotherapy	2	FALSE	Negative	AML	10.389041095890411	1:DECEASED	RUNX1T1/CEP8: 95/100 cells (95%) had an abnormal 3 red/ 3 aqua signal  pattern, reflecting the trisomy 8 in the metaphase karyotype and previously  observed. There was no evidence for RUNX1T1/RUNX1 fusion. | MLL: 93/100 cells (93%) had a variant abnorma	No	No	NA	No	No	No	No	No	No	White	4	Complete Response	NA	3	Male	UNMATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD4, CD11b, CD13, variable CD14, CD15, CD33, CD34, variable CD38, CD56, CD58, CD64, variable CD117, and HLA-DR	99	0.133333333	NA	Standard Chemotherapy	No	KRAS (p.G13R; MAF 52%)|U2AF1 (p.S34F; MAF 49%)
aml_ohsu_2022	aml_ohsu_2022_2618	aml_ohsu_2022_2618_BA3139	30	31	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cytarabine	5	Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cytarabine	Re-induction	Relapse	Myelodysplastic Syndromes	NonInitial	NON-HISPANIC	NA	Negative	FALSE	TRUE	TRUE	40~42,X,-Y,dic(5;12)(q13;p11.2),del(7)(q22q36),add(9)(q31),add(13)(q22),ins(?;14)(?;q11.2),-15,add(15)(p11.2),del(16)(q11.1),-17,-18,add(19)(q13.4),-20,der(21)t(3;21)(q22.3;q13),+mar[cp12]/40~41,sl,add(2)(q31)[cp7]/46,XY[1]	5	Standard Chemotherapy	3	FALSE	Negative	AML	15.616438356164384	1:DECEASED	84.5% of cells were missing a signal for EGR1, consistent with 5q deletion, and as seen previously.	Yes	No	Dyskeratosis congenita	Yes	Yes	No	No	No	No	White	6	Refractory	NA	2	Male	UNMATCHED	FALSE	Unknown	Post-Chemotherapy|Post-Transplant|Relapse	Peripheral Blood	NA	504	0.133333333	TP53 (p.M340Cfs*5; 41.0%)|TP53 (p.R273H; 47.8%)	Standard Chemotherapy	Yes	BCL6 (p.C475R; VAF 6%)|TP53 (p.M340fs*5; MAF 42%)|TP53 (p.R273H; MAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2618	aml_ohsu_2022_2618_BA3285	30	31	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cytarabine	5	Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cytarabine	Re-induction	Residual	Myelodysplastic Syndromes	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	39~41,X,-Y,dic(5;12)(q13;p11.2),del(7)(q22q36),add(9)(q31),add(13)(q22),ins(?;14)(?;q11.2),-15,add(15)(p11.2),del(16)(q11.1),-17,-18.add(19)(q13.4),-20,der(21)t(3;21)(q22.3;q13)[cp16]/46,XY[5]	5	Standard Chemotherapy	4	FALSE	Negative	AML	15.616438356164384	1:DECEASED	84.5% of cells were missing a signal for EGR1, consistent with 5q deletion, and as seen previously.	Yes	No	Dyskeratosis congenita	Yes	Yes	No	No	No	No	White	6	Refractory	NA	2	Male	UNMATCHED	FALSE	Unknown	Post-Chemotherapy|Post-Transplant|Residual Disease	Peripheral Blood	NA	573	0.166666667	TP53 (p.M340Cfs*5; 50.0%)|TP53 (p.R273H; 42.2%)	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2619	aml_ohsu_2022_2619_BA3138	56	56	0	ASXL1 (p.G646Wfs*12; 31.3%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib	5	Salvage|Induction|Maintenance|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Other	2	Decitabine, Ruxolitinib	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	49,XY,+10,+13,+21[1]/51,sl,+9,+15[1]/49,sl,+8,-10[12]/46,XY[6]	-1	Standard Chemotherapy	6	FALSE	Negative	AML	5.391780821917808	1:DECEASED	Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, co	No	No	NA	No	No	Yes	Yes	No	No	White	5	Refractory	RUNX1 (p.S322*; 17.2%)	3	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	48	0.3	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2619	aml_ohsu_2022_2619_BA3229	56	56	0	ASXL1 (p.G646Wfs*12; 37.6%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib	5	Salvage|Induction|Maintenance|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Other	2	Decitabine, Ruxolitinib	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	49,XY,+10,+13,+21[6]/51,idem,+9,+15[14]	-1	Standard Chemotherapy	4	FALSE	Negative	AML	5.391780821917808	1:DECEASED	Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, co	No	No	NA	No	No	Yes	Yes	No	No	White	5	Refractory	RUNX1 (p.S322*; 49.8%)	3	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	partial CD11b, CD13, partial CD25, CD33, CD34, CD38, partial CD56, CD117 and HLA-DR positive	0	0.233333333	NA	Standard Chemotherapy	Yes	ASXL1 (p.G646fs*12; VAF 36%)|BRAF (p.G469R; VAF 36%)|CREBBP (p.F1703fs*33; VAF 12%)|CSF3R (p.T618I; VAF 5%)|EZH2 (p.F672L; VAF 73%)|FLT3 (p.V491L; VAF 53%)|NRAS (p.G12D; VAF 10%)|RUNX1 (p.G199E; VAF 7%)|RUNX1 (p.S322*; VAF 52%)
aml_ohsu_2022	aml_ohsu_2022_2619	aml_ohsu_2022_2619_BA3388	56	56	0	ASXL1 (p.G646Wfs*12; 37.2%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib	5	Salvage|Induction|Maintenance|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Other	2	Decitabine, Ruxolitinib	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	49,XY,+10,+13,+21[1]/51,sl,+9,+15[1]/49,sl,+8,-10[12]/46,XY[6]	-1	Standard Chemotherapy	5	FALSE	Negative	AML	5.391780821917808	1:DECEASED	Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, co	No	No	NA	No	No	Yes	Yes	No	No	White	5	Refractory	RUNX1 (p.S322*; 17.2%)	3	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	55	0.266666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2620	aml_ohsu_2022_2620_BA3208	70	70	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Ruxolitinib, Vyxeos (Daunorubicin, Cytarabine - liposomal)	1	Induction	1	Standard Chemotherapy	1	Ruxolitinib, Vyxeos (Daunorubicin, Cytarabine - liposomal)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Negative	FALSE	FALSE	TRUE	46,XX[18]	43	Standard Chemotherapy	9	FALSE	Negative	AML	2.7616438356164386	1:DECEASED	Normal	No	No	NA	No	No	No	No	Yes	Yes	White	43	Refractory	NA	1	Female	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	variable CD11b, CD13, CD33, CD34, variable CD38, dim variable cCD79a, CD117, HLA-DR, cMPO, and cTdT positive	0	0.466666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; VAF 47%)|FLT3-ITD (allelic ratio 0.03; VAF 3%)|KMT2A (PTD, exon 9/3 break)|TET2 (p.H578fs*2; VAF 36%)|TET2 (p.Y1345fs*14; VAF 27%)|WT1 (p.D367_V374delinsWS; VAF 3%)|WT1 (p.R370fs*6; VAF 5%)|WT1 (p.R380fs*5; VAF 2%)|WT1 (p.R380fs*5; VAF 47
aml_ohsu_2022	aml_ohsu_2022_2621	aml_ohsu_2022_2621_BA3369	73	73	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	FALSE	FALSE	FALSE	46,XY,inv(16)(p13.1q22)[cp20]	NA	None	4	FALSE	Negative	AML	0.3287671232876712	1:DECEASED	CBFB/MYH11: 93/100 cells (93%) had the abnormal 1 red/ 1 green/ 2 yellow signal pattern, reflecting CBFB/MYH11 fusion, consistent with the metaphase karyotype and the diagnosis of AML.	Yes	No	Melanoma	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	Myeloid blasts: CD13, CD33, CD34, dimCD38, CD117, dim HLA-DR, and MPO. | Promonocytes/monocytes: dimCD4, CD11b, bright CD13, variable CD14, bright CD33, CD64, variable HLA-DR positive	0	0.2	NA	NA	Yes	EP300 (p.S1033L; VAF 50%)|FLT3-TKD (p.D835V; VAF 26%)|KRAS (p.G12V; VAF 19%)|WT1 (p.T225M; VAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2622	aml_ohsu_2022_2622_BA3269	66	66	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves3+4	Yes	AG-221|Azacitidine	2	Supportive/Palliative Care	1	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Azacitidine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M0	Negative	TRUE	FALSE	FALSE	46,XX[19]	6	Standard Chemotherapy	5	FALSE	Positive	AML	2.0054794520547947	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD14, CD15, CD34, CD64 TdT) | positive (CD38, CD13, CD33, CD117, MPO, HLA-DR) | dim (CD11b, CD45)	0	0.2	NA	NA	Yes	DNMT3A (c.1903C>G; p.R635G (COSM144550) MAF 44%)|IDH2 (c.419G>A; p.R140Q (COSM41590) MAF 44%)|NPM1 (c.863_864insTCTG; p.W288fs (COSM158604) MAF 37%)
aml_ohsu_2022	aml_ohsu_2022_2623	aml_ohsu_2022_2623_BA3351	72	72	0.03092784	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	ATRA, Arsenic Trioxide	1	Induction	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,XX,t(15;17)(q22;q21)[20]	-1	Standard Chemotherapy	4	FALSE	Negative	AML	30.476712328767125	0:LIVING	positive for PML/RARA fusion	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD7, CD11b, CD13, CD15, CD16, CD33, CD38, CD56, CD64, CD117, CD123, and MPO positive	0	0.2	NA	Standard Chemotherapy	Yes	FLT3-ITD (allelic ratio 0.03; VAF 3.09%)|NRAS (p.A146T; VAF 19%)
aml_ohsu_2022	aml_ohsu_2022_2624	aml_ohsu_2022_2624_BA3217	60	60	0.960784314	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)	2	Allogeneic - Sibling|Induction	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	7	FALSE	Negative	AML	9.632876712328768	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (CD38, CD33, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD13, CD14, CD15, CD117, TdT) | Dim (CD11b, CD45, CD64)	0	0.266666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (ITD, c.1769_1770ins42; p.Y589_F590insl4 (MAF 38%))|IDH2 (c.419G>A; p.R140Q (MAF 48%))|STAG2 (c.3034delC; p.R1012fs (MAF 92%))
aml_ohsu_2022	aml_ohsu_2022_2625	aml_ohsu_2022_2625_BA3324	60	60	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Decitabine, MGB453|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Induction|Re-induction	2	Standard Chemotherapy	1	Decitabine, MGB453	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY,del(5)(q13q34),add(7)(q11.2),+11,add(12)(p13),-16, add(17)(p11.2)[cp17]/46,idem,add(4)(q35)[4]	84	Standard Chemotherapy	2	FALSE	Negative	AML	6.575342465753424	1:DECEASED	EGR-1/ D5S23, D5S721:  193/200 cells (96.5%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the metaphase karyotype.  | D7S522/ CEP 7:  191/200 cells (95.5%) had a 1 red/ 2 green signal pattern, indicating deleted 7q, consis	No	No	NA	No	No	No	No	No	No	White	15	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	variable CD4, dim CD7, dim CD11b, CD13, variable CD14, variable CD15, CD33, variable CD34, CD38, dim CD56, partial CD64, CD117, HLA-DR, MPO positive.	0	0.133333333	TP53 (p.L194R; 88.3%)	Standard Chemotherapy	Yes	PTPN11 (p.S502P; MAF 34%)|TP53 (p.L194R; MAF 87%)
aml_ohsu_2022	aml_ohsu_2022_2626	aml_ohsu_2022_2626_BA3095	27	27	0.818181818	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Ruxolitinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Busulfan, Cyclophosphamide|Ibrutinib	7	Consolidation|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Ruxolitinib	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	47,XX,+8[19]/46,XX[1]	-1	Targeted Therapy - Kinase Inhibitor(s)	6	FALSE	Negative	AML	49.70958904109589	0:LIVING	RUNX1T1 (8q21.3):  93% of cells had three signals for RUNX1T1 (8q21.3)  consistent with trisomy 8 as seen on metaphase analysis.	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Female	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD7, CD13, CD33, dimCD34, dimCD64, dim CD117, CD123, and dim HLA-DR+	0	0.233333333	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 50% )
aml_ohsu_2022	aml_ohsu_2022_2627	aml_ohsu_2022_2627_BA3450	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	7	Waves3+4	Yes	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	46~47,XX,add(3)(p13),del(5)(q13q33),der(14)t(14;17)(q32;q11.2),del(16)(q22),-17,-22,+2~4mar[cp19]/46,XX[1]	NA	None	NA	FALSE	Negative	AML	0.7232876712328767	1:DECEASED	NA	Yes	Yes	Breast Cancer	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for CD13, CD33, CD34, CD38, partial HLA-DR, CD117, and a minor population is also positive for MPO	0	0	TP53	NA	Yes	JAK2|TP53
aml_ohsu_2022	aml_ohsu_2022_2628	aml_ohsu_2022_2628_BA3341	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	No	Enasidenib	1	Induction	1	Targeted Therapy - Other	1	Enasidenib	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,del(7)(q22q32)[cp4]/46,XX[16]	-1	Targeted Therapy - Other	7	FALSE	Negative	AML	1.7095890410958905	0:LIVING	Evidence of deletion of the BCR (22q11.2) gene in 7% of the cells examined.	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	NA	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.333333333	NA	Targeted Therapy - Other	Yes	DNMT3A|IDH2 (p.172Arg>Lys)|KMT2A
aml_ohsu_2022	aml_ohsu_2022_2629	aml_ohsu_2022_2629_BA3117	35	35	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Fludarabine, Cyclophosphamide, TBI	5	Haploidentical - Parent|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Haploidentical - Parent	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	47,XY,del(9)(q13q22),+10[3]/46,XY[17]	-1	Bone Marrow Transplant	4	FALSE	Negative	AML	34.98082191780822	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	5	Complete Response	RUNX1 (p.R166Q; VAF 6%)	1	Male	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD33, CD34, CD38, CD117, HLA-DR, and MPO positive	0	0.2	NA	Standard Chemotherapy	Yes	CEBPA (p.A111fs*56; 35% (likely underestimate VAF))|CEBPA (p.D322delinsETQQKVLELTSDND; VAF 37% (likely underestimate VAF))|GATA2 (p.P304H; VAF 32%)|RUNX1 (p.R166Q; VAF 6%)
aml_ohsu_2022	aml_ohsu_2022_2630	aml_ohsu_2022_2630_BA3098	44	44	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves3+4	Yes	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,der(7)t(7;11)(q22;q13), inv(16)(p13.1q22)[15]/46,XY[5]	-1	Bone Marrow Transplant	NA	FALSE	Negative	AML	3.9123287671232876	0:LIVING	7cen (D7Z1), 7q31 (D7S486): deletion present | 11q23 (KMT2A; also known as MLL): gain present | 16q22 (CBFB): rearrangement present	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0	NA	Standard Chemotherapy	Yes	KIT (p.Tyr418_Arg420delinsArgTrpGly; MAF 10%)
aml_ohsu_2022	aml_ohsu_2022_2631	aml_ohsu_2022_2631_BA3114	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	mono	8	Waves3+4	Yes	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	1	Induction	1	Standard Chemotherapy	1	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Induction	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XX[20]	4	Standard Chemotherapy	5	FALSE	Positive	AML	3.057534246575343	1:DECEASED	Normal (Clonal aberrations were not identified in metaphase cells examined by conventional cytogenetic techniques* or for any loci examined by FISH methods.)	Yes	No	Endometrial cancer|Lobular carcinoma in situ	No	No	Yes	Yes	Yes	Yes	White	4	Unknown	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy	Peripheral Blood	NA	0	0.233333333	NA	Standard Chemotherapy	No	CEBPA (biallelic)|NPM1|PTPN11|TET2
aml_ohsu_2022	aml_ohsu_2022_2632	aml_ohsu_2022_2632_BA3216	73	73	0.428571429	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	mono	5	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	TRUE	FALSE	FALSE	NA	NA	None	6	FALSE	Negative	AML	0.526027397260274	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.233333333	NA	NA	Yes	FLT3-ITD (suspicious for D835 as well)
aml_ohsu_2022	aml_ohsu_2022_2633	aml_ohsu_2022_2633_BA3261	61	61	0	ASXL1 (p.A752Lfs*20; 43.9%)	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	bi	1	Waves3+4	Yes	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	45,X,-Y,del(11)(q12)[20]	-1	Bone Marrow Transplant	11	FALSE	Negative	AML	9.501369863013698	1:DECEASED	95/100 cells (95%) had a single signal, consistent with the deleted 11q in the metaphase karyotype. There was no evidence for MLL rearrangement.	No	No	NA	No	No	No	No	No	No	White	5	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, partial CD13, dim CD33, CD34, CD28, CD58, CD71, CD117, HLA-DR and MPO	0	0.566666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.A752fs*20; MAF 46%)|CEBPA (D105Vfs*64; MAF 45%)|CEBPA (H236Rfs*78; MAF 35%)|EP300 (p.R1627W ; MAF 46%)|IDH2 (p.R140Q, MAF 50%)|KMT2D (p.P647Q; MAF 43%)
aml_ohsu_2022	aml_ohsu_2022_2634	aml_ohsu_2022_2634_BA3305	84	84	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves3+4	Yes	Venetoclax (ABT-199), Azacitidine	1	Induction	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	47,XY,+8[12]/47,XY,+15[8]/46,XY[5]	344	Standard Chemotherapy	7	FALSE	Negative	AML	12.953424657534246	1:DECEASED	Gain of 8q22 and 15q22 sequences	No	No	NA	No	No	No	No	No	No	White	344	Complete Response	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.4	NA	Standard Chemotherapy	Yes	IDH2 (R140Q; VAF 51%)|NRAS (Q61K; VAF 27%)|SMC1A (E687*; VAF 64%)|SMC1A (R807H; VAF 13%)|SRSF2 (P95R; VAF 38%)
aml_ohsu_2022	aml_ohsu_2022_2635	aml_ohsu_2022_2635_BA3387	41	41	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	ATRA (Tretinoin)|7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY,t(8;21)(q22;q22)[20]	-1	Bone Marrow Transplant	3	FALSE	Negative	AML	96.06575342465754	0:LIVING	RUNX1-RUNX1T1 (All twenty metaphase cells examined had an 8;21 translocation withbreakpoints associated with AML1/ETO fusion.)	No	No	NA	No	No	No	No	No	No	White	1	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Peripheral Blood	partial CD11b, dim CD13, dim CD19, dim CD33, CD34,variable CD38, CD58, dim CD64, CD117, CD123, HLA-DR, dim MPO, and dim TDT	0	0.166666667	TP53 (p.R175H; 43.2%)	Standard Chemotherapy	Yes	NRAS (G12D; MAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2636	aml_ohsu_2022_2636_BA3422	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	Venetoclax (ABT-199), Azacitidine	1	Induction	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	7	FALSE	Positive	AML	17.128767123287673	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	Black	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.333333333	NA	Standard Chemotherapy	Yes	GATA2 (A372T; VAF 48%)|NPM1 (W288Cfs*12; VAF 39%)|TET2 ( E843*; VAF 47%)|TET2 (T1726Lfs*19; VAF 51%)
aml_ohsu_2022	aml_ohsu_2022_2637	aml_ohsu_2022_2637_BA3368	62	62	0	ASXL1 (p.G646Wfs*12; 29.2%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	47,XX,+8[4]/46,XX[16]	8	Standard Chemotherapy	9	FALSE	Negative	AML	17.786301369863015	0:LIVING	Positive for gain of centromere 8 sequences	Yes	No	Melanoma	No	No	No	No	No	No	White	8	Complete Response	RUNX1 (p.F416Lfs*185; 24.0%)	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.433333333	NA	Standard Chemotherapy	Yes	ASXL1 (G645Wfs*12; VAF 34%)|BCOR (Q1371*; 34%)|EZH2 (N673y; 40%)|EZH2 (N699D; VAF 37%)|GATA2 (S201*; VAF 37%)|PHF6 (R129*; VAF 42%)|RUNX1 (F416Lfs*185; VAF 38%)
aml_ohsu_2022	aml_ohsu_2022_2638	aml_ohsu_2022_2638_BA3163	43	43	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Azacitidine|Mitoxantrone	2	Induction|Supportive/Palliative Care	2	Standard Chemotherapy	1	Mitoxantrone	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	46,XX,t(9;11)(p22;q23)[15]/47,idem,+8[2]/46,XX[3]	0	Standard Chemotherapy	4	FALSE	Negative	AML	2.0383561643835617	1:DECEASED	MLL: 57/100 cells (57%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL (11q23) rearrangement, consistent with the 9;11  translocation observed in the metaphase karyotype. | RUNX1T1/RUNX1: 6/200 cells (3%) had a 3 red/ 2 green s	Yes	Yes	Breast Cancer	No	No	No	No	No	No	White	6	Refractory	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	dim CD4, CD11b, CD13, partial CD14, CD33,  CD38, variable CD56, CD58, CD64, dim CD71, dim CD123, and HLA-DR+	0	0.233333333	NA	Standard Chemotherapy	Yes	DNMT3A (Splice site mutation (invariant splice donor at end of exon 14; likely pathogenic); MAF 20%)
aml_ohsu_2022	aml_ohsu_2022_2639	aml_ohsu_2022_2639_BA3275	NA	NA	0.388888889	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	unknown	unknown	unknown	NA	NA	None	4	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	Unknown	Unknown	Peripheral Blood	NA	0	0.2	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2640	aml_ohsu_2022_2640_BA3334	76	76	0	ASXL1 (p.C687Yfs*30; 45.2%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	No	Entospletinib	1	Experimental	1	Targeted Therapy - Other	1	Entospletinib	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	NA	-1	Targeted Therapy - Other	5	FALSE	Negative	AML	1.5452054794520547	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.266666667	NA	NA	Yes	ASXL1|FLT3 (N841K)|SRSF2|STAG2
aml_ohsu_2022	aml_ohsu_2022_2641	aml_ohsu_2022_2641_BA3207	65	65	0	ASXL1 (p.G646Wfs*12; 35.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Methotrexate	2	Induction	1	Standard Chemotherapy|Intrathecal	2	Methotrexate	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	FALSE	FALSE	FALSE	46,XY[20]	6	Intrathecal	11	FALSE	Negative	AML	0.6904109589041096	1:DECEASED	Normal	Yes	No	Melanoma	No	No	No	No	No	No	White	-1	Complete Response	RUNX1 (p.F396Vfs*204; 55.4%)	1	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	CD11b, variable CD14, CD15, CD33, CD38, variable CD56,  CD58, CD64, CD123, HLA-DR, variable MPO	0	0.566666667	NA	Standard Chemotherapy	Yes	IDH1 (p.R132H; MAF 46%)|MLL (Partial tandem duplication )|NRAS (p.Q61R; MAF 45%)|RUNX1 (p.F396fs*204; MAF 46%)|SRSF2 (p.P95L; MAF 28%)
aml_ohsu_2022	aml_ohsu_2022_2642	aml_ohsu_2022_2642_BA3097	74	75	0	ASXL1 (p.G645Wfs*12; 40.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves3+4	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	5+2 (Cytarabine, Idarubicin)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY,t(12;18)(p13;q12)[20]	-1	Standard Chemotherapy	9	FALSE	Negative	AML	4.602739726027397	1:DECEASED	NA	No	No	NA	Yes	Yes	Yes	Yes	No	No	White	-1	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(+), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD33 (variably +), CD34(+), CD36(-), CD38(variably +), CD45(moderate to slightly dim +), CD56(-), CD64(partial +), CD117 (variably +), HLA-DR(partial +), MPO(-), and TdT(-).	0	0.5	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2643	aml_ohsu_2022_2643_BA3399	57	57	NA	ASXL1 (p.E865*; 39.7%)	Myelodysplastic/Myeloproliferative Neoplasms	Myelodysplastic/Myeloproliferative Neoplasms	Alive	NA	5	Waves3+4	Yes	NA	0	NA	0	NA	0	NONE	NONE	NA	Myelodysplastic/Myeloproliferative Neoplasms	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	47,XY,+21[19]	NA	None	5	FALSE	Negative	MDS/MPN	2.5643835616438357	0:LIVING	NA	Yes	Yes	Rectal Cancer	No	No	Yes	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	TRUE	unknown	NA	Bone Marrow Aspirate	positive for CD11b, CD13, CD33, CD34, CD38, dim CD45, CD117 and HLA-DR with aberrant expression of CD56	1	0.233333333	NA	NA	No	NA
aml_ohsu_2022	aml_ohsu_2022_2644	aml_ohsu_2022_2644_BA3210	74	75	0	ASXL1 (p.G646Wfs*12; 36.4%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	Yes	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	47,XX,+8,del(9)(q13q22),t(12;22)(p13;q13)[12]/46,XX[8]	-1	Standard Chemotherapy	8	FALSE	Negative	AML	10.027397260273972	0:LIVING	NA	No	No	NA	Yes	Yes	No	No	No	No	White	-1	Refractory	RUNX1 (p.L429Pfs*171; 82.9%)	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	NA	0	0.4	NA	Standard Chemotherapy	Yes	BCORL1 (K632fs*33)|CSF3R (T6181)|ETV6 (MN1-ETV6 fusion)|IDH2 (R140Q)|IDH2 (p.Arg140Gln)|PHF6|PTPN11 (E69K)|RUNX1 (L429fs*171)
aml_ohsu_2022	aml_ohsu_2022_2645	aml_ohsu_2022_2645_BA3221	45	45	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Daunorubicin) plus Sorafenib|HIDAC + Sorafenib|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	HIDAC + Sorafenib	Consolidation	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Negative	FALSE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	3	FALSE	Negative	AML	3.419178082191781	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	Declined	6	Complete Response	NA	2	Female	MATCHED	FALSE	AML without maturation	Post-Chemotherapy	Peripheral Blood	NA	29	0.133333333	NA	Standard Chemotherapy	No	CRLF2 (p.P224L; MAF 49%)|FLT3-ITD (MAF 2%)|KMT2D (p.R863P; MAF 48%)|PTPN11 (p.A72V; MAF 6%)|SETBP1 (p.P1134T, MAF 51%)
aml_ohsu_2022	aml_ohsu_2022_2645	aml_ohsu_2022_2645_BA3286	45	45	0.298701299	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Daunorubicin) plus Sorafenib|HIDAC + Sorafenib|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	HIDAC + Sorafenib	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	4	FALSE	Negative	AML	3.419178082191781	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	Declined	6	Complete Response	NA	2	Female	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dimCD7, dimCD13, CD33, CD34, CD38, variable CD64, dimCD117, CD123, HLA-DR, and MPO positive	0	0.1	NA	Standard Chemotherapy	Yes	FLT3-ITD (123 bp insertion; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2646	aml_ohsu_2022_2646_BA3158	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	Yes	NA	NA	NA	NA	NA	NA	NA	NA	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY,t(8;21)(q22;q22)[8]46,sl,del(9)(q13q22)[4]/47,sdl,+21[2]/47,sl,+21[4]/46,XY[2]	NA	NA	1	FALSE	Negative	AML	0.0	NA	This analysis showed evidence of t(8;21)(q22;q22) (RUNX1T1-RUNX1 translocation) in 196/200 (98.0 percent) cells scored. Of these cells, 20/200 (10.0 percent) showed the translocation accompanied by an additional copy of the RUNX1 locus.	Yes	No	Non-Hodgkins Lymphoma	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	NA	0	0.066666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2647	aml_ohsu_2022_2647_BA3431	45	45	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	7	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46[XX]	NA	None	5	FALSE	Positive	AML	2.2356164383561645	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	positive for CD11b, CD11c, CD14, CD64, CD33, CD38, HLA-DR and partial for CD13, CD15, cMPO	0	0.233333333	NA	NA	Yes	FLT3-TKD (MAF 1%)|NPM1 (MAF 39%)|PTPN11 (likely pathogenic)
aml_ohsu_2022	aml_ohsu_2022_2648	aml_ohsu_2022_2648_BA3280	51	51	0.136363636	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	9	FALSE	Positive	AML	2.695890410958904	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for CD117, CD13, CD33, and HLA-DR. Roughly half of the blasts were positive for CD34, roughly half of the blasts showed aberrant dim expression of CD7, and roughly half of the cells showed aberrant dim expression of CD19.	0	0.433333333	NA	Standard Chemotherapy	Yes	ASXL1|CEBPA|FLT3-ITD|NPM1|NRAS|PTPN11|STAG2
aml_ohsu_2022	aml_ohsu_2022_2649	aml_ohsu_2022_2649_BA3136	47	47	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XY,t(10;11)(p12;q23)[8]/45,sl,-Y[12]	133	Standard Chemotherapy	1	FALSE	Negative	AML	17.391780821917806	0:LIVING	86/100 cells (86%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting MLL (11q23) rearrangement and consistent with the 10;11 translocation observed in the metaphase karyotype.	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	UNMATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD4, CD9, CD11b, CD15, CD33, CD38, partial CD56, CD64, partial CD117, and partial HLA-DR+	0	0.033333333	NA	Standard Chemotherapy	Yes	FLT3 (p.I836del; VAF 3% (in frame deletion in the tyrosine kinase domain))|MLL (Partial tandem duplication (exon 11/3 breakpoint) )
aml_ohsu_2022	aml_ohsu_2022_2650	aml_ohsu_2022_2650_BA3227	70	70	0.149425287	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	MIDAC, Midostaurin|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Methotrexate|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	4	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	3	FALSE	Positive	AML	39.057534246575344	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD13, CD33, CD38, CD117, and MPO +	0	0.1	NA	Standard Chemotherapy	Yes	ATM (p.K1454N; VAF 49%)|BCL6 (p.A321V; VAF 49%)|FLT3-ITD (Allelic ratio: 0.32)|IDH2 (p.R140Q; VAF 49%)|NOTCH2 (p.P2377L; VAF 48%)|NPM1 (p.W288fs*12; VAF 69%)|NRAS (p.A59T; VAS 3%)
aml_ohsu_2022	aml_ohsu_2022_2651	aml_ohsu_2022_2651_BA3434	78	78	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|Azacitidine	3	Experimental|Supportive/Palliative Care	2	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	46,XX,del(9)(q22q22)[20]	0	Standard Chemotherapy	21	FALSE	Negative	AML	2.5972602739726027	1:DECEASED	With the TP53 probe set, 7/200 cells (3.5%) were missing a TP53  signal, within normal limits, but also this patient's previous abnormal  pattern.	No	No	NA	Yes	Yes	No	No	No	No	White	NA	NA	RUNX1 (p.T196Dfs*17; 40.6%)|RUNX1 (p.X20_splice; 49.2%)	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD58, CD117, HLA-DR, partial  MPO	0	1.166666667	NA	NA	Yes	DNMT3A (p.A644fs*7; MAF 37%)|ETV6 (p.L205fs*12; MAF 30%)|IKZF1 (p.N159S; MAF 35%)|NRAS (p.Q61H; MAF 31%)|RUNX1 (c.58+2T>C, Donor-splice-site mutation in intron 1; MAF 46%)|RUNX1 (p.T196fs*17; MAF 46%)|SF3B1 (p.K700E; MAF 51%)
aml_ohsu_2022	aml_ohsu_2022_2652	aml_ohsu_2022_2652_BA3174	61	61	0	ASXL1 (p.E635Rfs*15; 24.3%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	8	Waves3+4	Yes	Vidaza|7+3 (Cytarabine, Idarubicin)|Cytarabine, OXi4503|Velcade	4	Salvage|Induction|Supportive/Palliative Care	3	Standard Chemotherapy	1	Velcade	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY,del(5)(q13q33)[1]/4 7,idem,+21[14]/46,idem,id ic(21)(p12)[cp4]/47,idem, +21,idic(21)[1]	41	Standard Chemotherapy	4	FALSE	Negative	AML	9.304109589041097	1:DECEASED	POSITIVE for chromosome 5q copy number loss	No	No	NA	Yes	Yes	No	No	No	No	White	-1	Refractory	RUNX1 (p.R107H; 59.2%)	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	0	0.2	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2653	aml_ohsu_2022_2653_BA3394	NA	NA	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	5	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	Unknown	Unknown	Peripheral Blood	NA	0	0.233333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2654	aml_ohsu_2022_2654_BA3386	63	63	32.33333333	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|Gilteritinib or Placebo|MIDAC, Midostaurin|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Methotrexate	5	Consolidation|Induction|CNS|Maintenance|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Gilteritinib or Placebo	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	734	Targeted Therapy - Kinase Inhibitor(s)	4	FALSE	Positive	AML	34.38904109589041	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	dim CD7, partial CD11b, dim CD13, variable CD25, CD33, partial CD34, CD117, HLA-DR, and MPO positive	0	0.133333333	NA	Standard Chemotherapy	Yes	DNMT3A (p.G543C; VAF 49%)|FLT3-ITD (VAF 76%; VAR 13.3)|NPM1 (p.W288fs*12; VAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2655	aml_ohsu_2022_2655_BA3362	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX,der(1)t(1;1)(p36.3;q21),t(8;16)(p11.2;p13.3),add(15)(q24)[20]	-1	Standard Chemotherapy	5	FALSE	Negative	AML	0.7890410958904108	1:DECEASED	In 95/100 cells (95%), three  signals for chromosome 1q25 were observed, and only two signals for 1p36  were observed, consistent with gain of 1q by der(1)t(1;1)	No	No	NA	No	No	No	No	No	No	White	-1	Unknown	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4, CD11b, partial CD13, CD33, CD56, bright CD64, partial CD117, CD123, HLA-DR and partial MPO-positive	0	0.166666667	TP53 (p.R175H; 55.0%)	Standard Chemotherapy	Yes	FLT3 (p.D835E; MAF 42%)|TP53 (p.R175H; MAF 43%)
aml_ohsu_2022	aml_ohsu_2022_2656	aml_ohsu_2022_2656_BA3151	53	53	0.666666667	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Decitabine	2	Induction|Maintenance	2	Standard Chemotherapy	1	Decitabine	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	FALSE	FALSE	TRUE	45,XX,del(3)(p13p26),-5[cp3]/48,idem,+8,der(9;12)(q10;q10),+19,+21,idic(21)(p11.2)x2,+mar[cp5]/50,idem,+8,der(9)t(5;9)(p13;p13),+19,+21,+21,idic(21)x2,+mar[cp8]/50,idem,del(9)(p13p22),der(9)t(5;9),+19,+21,+21,idic(21)x2,+mar[cp4]	-1	Standard Chemotherapy	10	FALSE	Positive	AML	4.997260273972603	0:LIVING	NA	No	No	NA	No	No	No	No	Yes	Yes	White	-1	Refractory	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.4	TP53 (p.Y220H; 63.6%)	Standard Chemotherapy	Yes	TP53
aml_ohsu_2022	aml_ohsu_2022_2657	aml_ohsu_2022_2657_BA3297	46	46	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XX[20]	102	Standard Chemotherapy	2	FALSE	Positive	AML	38.1041095890411	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	Asian	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD13, CD33, CD38, CD117 and MPO+	0	0.066666667	NA	Standard Chemotherapy	Yes	IDH2 (p.R140Q; VAF 46%)|NPM1 (p.W288fs*12; VAF 40%)
aml_ohsu_2022	aml_ohsu_2022_2658	aml_ohsu_2022_2658_BA3225	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	NA	4	Standard Chemotherapy	4	FALSE	Positive	AML	0.526027397260274	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	4	UNKNOWN	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	Monocytic blast immunophenotype (75%):  CD11b, CD13, CD14, CD33, CD38, CD58, CD64, dim CD117, CD123, and dim HLA-DR+. | Myeloid blast immunophenotype (13%): dim CD13, CD33, CD38, CD58 dim CD117, dim CD123 and MPO+.           | Monoclonal plasma cell popul	0	0.2	NA	Standard Chemotherapy	Yes	GNA13 (p.T365S; MAF 46%)|NPM1 (p.W288fs*12; MAF 43%)|PHF6 (c.730-2A>G, Acceptor-splice-site mutation in intron 6; MAF 89%)|TET2 (c.3594+1G>T, Donor-splice-site mutation in intron 3; MAF 46%)|TET2 (p.D1242fs*11; MAF 42%)
aml_ohsu_2022	aml_ohsu_2022_2659	aml_ohsu_2022_2659_BA3421	52	52	0.724137931	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin) plus Midostaurin|Midostaurin|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Maintenance	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Midostaurin	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	TRUE	FALSE	FALSE	NA	13	Targeted Therapy - Kinase Inhibitor(s)	5	FALSE	Positive	AML	5.950684931506849	0:LIVING	Normal/Negative Rearrangement	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.133333333	NA	Standard Chemotherapy	Yes	DNMT3A (MAF 47%)|FLT3-ITD (2 on separate alleles: p.E604_F605insYDLKWE, MAF 19%; p.L601_K602ins18, MAF 9%)|NPM1 (MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2660	aml_ohsu_2022_2660_BA3094	23	23	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	UNKNOWN	M5	Negative	TRUE	FALSE	FALSE	46,XY,der(10)t(10;11)(p13;q23),der(11)t(10;11)(p13;q23)inv(11)(q13q23)[20]	-1	Bone Marrow Transplant	4	FALSE	Negative	AML	45.56712328767124	0:LIVING	MLL:  60% of cells had a split signal pattern consistent with MLL rearrangement. On available metaphase cells, there was a distal signal on chromosome 10p and the proximal signal was close to the chromosome 11 centromere, consistent with t(10;11) and inv(	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	UNMATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD4, variable CD13, CD33, CD38, variable CD56, CD58,  CD64, dim CD71, dim CD117, dim CD123 and HLA-DR+	0	0.233333333	NA	Standard Chemotherapy	Yes	NRAS (p.G12A; MAF 4%)|NRAS (p.Q61H; MAF 30%)
aml_ohsu_2022	aml_ohsu_2022_2661	aml_ohsu_2022_2661_BA3168	63	63	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine	3	Consolidation|Salvage|Induction|Re-induction	4	Standard Chemotherapy	1	Azacitidine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Negative	TRUE	FALSE	FALSE	42,XX,add(1)(q32),-5,-7,add(12)(p13),add(13)(q21.2),-17,-18,add(19)(q13.4)[3]/43,sl,+r[10]/44,sdl1,+8[6]/46,XX[1]	63	Standard Chemotherapy	3	FALSE	Negative	AML	15.715068493150685	1:DECEASED	19/20 metaphase cells analyzed comprised three related, complex abnormal clones, all with abnormalities of chromosomes 1q, 12p, 13q and 19q, and monosomies 5, 7, 17, and 18. 16 of these cells had a ring chromosome of unknown origin, 6 of which were also t	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD71, CD117 and HLA-DR+	0	0.166666667	TP53 (p.T155N; 81.0%)	Standard Chemotherapy	Yes	NOTCH1 (p.A2257V; MAF 52%)
aml_ohsu_2022	aml_ohsu_2022_2662	aml_ohsu_2022_2662_BA3169	88	88	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	47,XX,+8[4]/47,sl,add(10)(q22)[10]/89~94,sdlx2[cp3]/55,sl,+X,+6,+8,+ 8,+9,+13,+21,+22[2]/46,XX[1]	NA	None	6	FALSE	Positive	AML	0.1643835616438356	1:DECEASED	MLL (KMT2A) rearrangement in 94% of 200 cells | gain of 8q22 sequence in 94% of 200 cells	Yes	No	Uterine Sarcoma	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	positive for CD11b, dim CD7, CD13, CD14, CD33, CD38, CD15, CD45, CD56, CD64 and HLA-DR	0	0.3	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2663	aml_ohsu_2022_2663_BA3248	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MiDAC|7+3 (Cytarabine, Idarubicin) plus CX-01|IDAC	6	Consolidation|Salvage|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	6	Standard Chemotherapy|Bone Marrow Transplant	2	IDAC	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XX,t(3;21)(q26;q11.2)[1]/45,sl,-7[9]/45,sdl1,del(13)(q12q14)[10]	35	Standard Chemotherapy	4	FALSE	Negative	AML	50.56438356164384	0:LIVING	MECOM/RPN1: 65/100 cells (65%) had a 3 red/2 green, consistent with  disruption of MECOM (3q26.2). | D7S486/ CEP 7: 69/100 cells (69%) had a 1 red/ 1 green signal pattern,  indicating monosomy 7, consistent with the metaphase karyotype.	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD34, CD38, CD117, and HLA-DR positive with  partial dim expression of CD2, CD7, and CD11b	0	0.233333333	NA	Standard Chemotherapy	Yes	KRAS (p.G13D;  MAF 20%)|NRAS (p.G13D; MAF 13%)
aml_ohsu_2022	aml_ohsu_2022_2664	aml_ohsu_2022_2664_BA3153	49	49	0	NA	Leukemia	Acute Leukemias of Ambiguous Lineage	Alive	mono	5	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Leukaemias Of Ambiguous Lineage	Intermediate	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	3	FALSE	Negative	ALAL	14.958904109589042	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	Black	-1	Complete Response	NA	1	Male	MATCHED	FALSE	Mixed phenotype acute leukaemia, T/myeloid, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	Positive (CD38, CD7, CD2) | Negative (CD10, CD19, CD22, CD16, CD56, CD13, CD14, CD15, CD33, CD34, CD117, MPO, HLA-DR) | Dim Positive (cCD3, CD11b, CD64)	0	0.133333333	NA	Standard Chemotherapy	Yes	CEBPA ([c.937A>C; c.940G>A; c.941T>A;c.943C>G] p.K313_V314_L315delinsQKV)
aml_ohsu_2022	aml_ohsu_2022_2665	aml_ohsu_2022_2665_BA3200	76	76	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	SY-1425 (Tamibarotene) plus Azacitidine|Ruxolitinib, Venetoclax	2	Salvage|Induction	2	Standard Chemotherapy|Targeted Therapy - Other	2	Ruxolitinib, Venetoclax	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XX[8]	37	Standard Chemotherapy	4	FALSE	Positive	AML	13.972602739726028	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	Asian	357	Complete Response i	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD33, CD38, CD56, CD117, and cMPO positive	0	0.2	NA	Targeted Therapy - Other	Yes	NPM1 (p.W288fs*12; VAF 50%)|PHF6 (p.R274*; VAF 45%)|PRDM1 (p.P467L; VAF 48%)|TET2 (p.H1382R; VAF 50%)|TET2 (p.K1720*; VAF 48%)
aml_ohsu_2022	aml_ohsu_2022_2666	aml_ohsu_2022_2666_BA3413	31	31	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	3	Waves3+4	Yes	Busulfan, Fludarabine|CLAG (Cladribine, Cytarabine, Filgrastim)|7+3 (Cytarabine, Idarubicin, Dexamethasone)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,del(9)(q13q22)[5]/46,sl,del(11)(q13q23)[14]  /46,sdl,t(2;4;7)(q33;q21;p15),add(8)(p11.2)[2]	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	5.03013698630137	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.233333333	NA	Standard Chemotherapy	Yes	CEBPA (p.Ala111fs; MAF 44.5%)|CEBPA (p.Ser319_Asp320del; MAF 32.9%)|CSF3R (p.Thr618Ile; MAF 1.6%)|GATA2 (p.Arg330Gln; MAF 46%)
aml_ohsu_2022	aml_ohsu_2022_2667	aml_ohsu_2022_2667_BA3181	60	60	0	ASXL1 (p.R634Kfs*24; 38.6%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	8	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin, Dexamethasone)	2	Allogeneic - Sibling|Induction	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	6	FALSE	Negative	AML	6.96986301369863	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	1	Female	UNMATCHED	FALSE	Myeloid sarcoma	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.366666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2668	aml_ohsu_2022_2668_BA3206	35	35	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine, Venetoclax	3	Consolidation|Salvage|Induction|Re-induction	4	Standard Chemotherapy	1	Decitabine, Venetoclax	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	HISPANIC	M2	Negative	TRUE	FALSE	FALSE	45,X,-X,t(8;21)(q22;q22)[20]	165	Standard Chemotherapy	6	FALSE	Negative	AML	40.10958904109589	1:DECEASED	RUNX1T1(8q21.3)/RUNX1(21q22):  64% of cells had an atypical 1r/2g/1f  signal pattern, a fusion pattern consistent with t(8;21) as seen on metaphase analysis.  | All twenty metaphase cells examined were abnormal, with monosomy X and  t(8;21).	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	NA	1	Female	MATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, dim CD19, dim CD33, CD34, CD38, CD56, CD58, CD117, dim CD123, HLA-DR and MPO+	0	0.333333333	NA	Standard Chemotherapy	Yes	FLT3-ITD (MAF 5%)
aml_ohsu_2022	aml_ohsu_2022_2669	aml_ohsu_2022_2669_BA3447	67	67	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	7	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M1	Negative	TRUE	FALSE	FALSE	46XY	NA	None	6	FALSE	Negative	AML	8.186301369863013	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for CD13, CD33, CD34, CD38, CD117, HLA-DR, cytoplasmic myeloperoxidase (subset), and TdT (subset)	0	0.3	NA	NA	Yes	FLT3-ITD|NRAS|U2AF1
aml_ohsu_2022	aml_ohsu_2022_2670	aml_ohsu_2022_2670_BA3272	51	53	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	5	Allogeneic - Sibling|Consolidation|Salvage|Induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Negative	FALSE	TRUE	FALSE	46,XX,inv(16)(p13.1q22)[1]/46,XX[19]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	72.06575342465754	0:LIVING	CBFB: 12/200 cells (6%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and previously observed.	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	CD13, CD33, CD34, CD117, and HLA-DR positive	0	0.033333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2671	aml_ohsu_2022_2671_BA3365	29	30	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	7	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY,t(9;11)(p21;q23)[1]/46,idem,t(5;12)(q33;p13)[19]	NA	None	1	FALSE	Negative	AML	13.183561643835617	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	Black	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Post-Chemotherapy|Residual Disease	Peripheral Blood	Population 1: Immature blasts (80%) expressed dim CD45+, partial CD34+ (68% of total cells), CD117+, HLA DR+, CD13+, CD33++, CD123+, and CD64neg /dim+ | Population 2:  Monoblasts (11%) expressed bright CD33 ++, intermediate SSC, brighter CD45, brCD64++, C	0	0.066666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2672	aml_ohsu_2022_2672_BA3266	83	83	0.587301587	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XX[20]	NA	None	4	FALSE	Positive	AML	0.9205479452054794	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD4, CD7, partial CD9, CD13, CD25, CD33, partial CD34, CD38, CD117, CD123, HLA-DR and MPO-positive	0	0.166666667	NA	NA	Yes	BRAF (p.S87N; VAF 52%)|DNMT3A (p.R882C; VAF 47%)|FLT3-ITD (Allelic ratio: 0.464; VAF 31.7%)|IDH1 (p.R132H; VAF 32%)|IDH2 (p.R140Q; VAF 3%)|NPM1 (p.W288fs*12; VAF 42%)
aml_ohsu_2022	aml_ohsu_2022_2673	aml_ohsu_2022_2673_BA3108	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Vidaza, BI836858 (anti-CD33)|Azacitidine|Enasidenib|Incyte trial (azacitidine and JAK 1 inhibitor)	4	Salvage|Induction|Maintenance	3	Standard Chemotherapy|Targeted Therapy - Other	2	Enasidenib	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	48,XX,+8,+8,add(9)(q22)[1]/50,idem,+15,+18[5]/46,XX[14] (Six of twenty metaphase cells analyzed comprised two related hyperdiploid clones.)	28	Targeted Therapy - Other	6	FALSE	Negative	AML	53.917808219178085	0:LIVING	Results were consistent with tetrasomy 8 (RUNX1T1/CEP8) and trisomy 15 (PML) in approximately 50% of cells scored. All other probe results were within normal limits with no evidence for rearrangements or deletions.	No	No	NA	No	No	No	No	No	No	White	185	Refractory	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, moderate-dim  CD45, and CD117+	0	0.366666667	NA	Standard Chemotherapy	Yes	IDH2 (p.R140Q; MAF 43%)|U2AF1 (p.Q157P; MAF 17%)
aml_ohsu_2022	aml_ohsu_2022_2674	aml_ohsu_2022_2674_BA3397	79	79	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	FALSE	44,XY,-3,-5,dic(10;12)(q26;p13),add(11)(p15),-17,+mar[20]	NA	None	4	FALSE	Negative	AML	1.7753424657534247	1:DECEASED	ETV6 (12p13): 93.5% of cells were missing a signal for ETV6, consistent with 12p deletion resulting from dic(10;12).  | CEP17: 98.5% of cells were missing a signal for CEP17, consistent with monosomy 17.  | PML/RARA: 189/200 cells (94.5%) were missing a s	Yes	Yes	Prostate Cancer	No	No	No	No	No	No	White	NA	NA	NA	1	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, variable CD38, CD117, CD123, HLA-DR, partial MPO	0	0.166666667	TP53 (p.L194R; 86.6%)	NA	Yes	TP53 (p.L194R; MAF 80%)
aml_ohsu_2022	aml_ohsu_2022_2675	aml_ohsu_2022_2675_BA3370	69	69	0	ASXL1 (p.H631N; 29.3%)|ASXL1 (p.R634Gfs*22; 25.0%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	Yes	Azacitidine, BI 836858 (anti-CD33)	1	Induction	1	Standard Chemotherapy	1	Azacitidine, BI 836858 (anti-CD33)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	47,XY,+8[4]/46,XY[16]	-1	Standard Chemotherapy	11	FALSE	Negative	AML	1.347945205479452	0:LIVING	NA	Yes	No	Basal Cell Carcinoma	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.533333333	NA	Standard Chemotherapy	Yes	ASXL1|SRSF2|STAG2|TET2 (M1456fs*2 )
aml_ohsu_2022	aml_ohsu_2022_2676	aml_ohsu_2022_2676_BA3189	20	20	1	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|7+3 (Cytarabine, Daunorubicin) plus Midostaurin|Busulfan, Cyclophosphamide	5	Allogeneic - Sibling|Induction|Re-induction|Maintenance	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Sorafenib	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XY,del(2)(q11.2q21)[3]	317	Targeted Therapy - Kinase Inhibitor(s)	1	FALSE	Negative	AML	44.580821917808215	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD34, CD38, CD58, dim CD64, CD117,  variable MPO	0	0	NA	Standard Chemotherapy	Yes	FLT3-ITD (p.E608delinsDPVDFREYEYDLKWEFPRE; p.E598delinsDLSYVDFREYE;  ratio: ~1.0; Two visible FLT3 ITD insertions, one  of ~ 10 amino acids (predominating, with a high mutant allele ratio) and  one of ~18 amino acids (smaller sub-clone).)
aml_ohsu_2022	aml_ohsu_2022_2677	aml_ohsu_2022_2677_BA3289	61	61	0.587301587	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Supportive/Palliative Care	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M0	Positive	TRUE	FALSE	FALSE	NA	-1	Bone Marrow Transplant	9	FALSE	Negative	AML	5.819178082191781	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.266666667	NA	Standard Chemotherapy	Yes	DNMT3A|FLT3-ITD|TET2
aml_ohsu_2022	aml_ohsu_2022_2678	aml_ohsu_2022_2678_BA3223	69	69	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves3+4	Yes	Vidaza|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Decitabine|Fludarabine, Cyclophosphamide, TBI	5	Induction|Frontline|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Allogeneic - Matched Unrelated Donor	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	18	Bone Marrow Transplant	1	FALSE	Negative	AML	12.526027397260275	0:LIVING	NA	No	No	NA	Yes	Yes	No	No	No	No	White	7	Complete Response i	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy	Bone Marrow Aspirate	NOT DETECTED for the MLL partial tandem duplication (PTD).  (Bone Marrow Immunophenotype)	0	0.033333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2679	aml_ohsu_2022_2679_BA3454	82	82	0.960784314	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XX[20]	NA	None	3	FALSE	Positive	AML	0.4602739726027397	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD117, and MPO	0	0.1	NA	NA	Yes	DNMT3A (p.R882C; VAF 48%)|FLT3-ITD (VAF 44%; Allelic ratio 0.77)|NPM1 (p.W288fs*12; VAF 48%)
aml_ohsu_2022	aml_ohsu_2022_2680	aml_ohsu_2022_2680_BA3373	67	67	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Negative	FALSE	FALSE	TRUE	45,XX,t(3;3)(q21;q26),del(5)(q22q35),-7[20]	NA	None	3	FALSE	Negative	AML	1.610958904109589	1:DECEASED	EGR-1/ D5S23, D5S721: 96/100 cells (96%) had a 1 red/ 2 green signal  pattern, reflecting a deleted 5q, consistent with the metaphase karyotype. | D7S522/ CEP 7: 98/100 cells (98%) had a 1 red/ 1 green signal pattern,  reflecting monosomy 7, consistent 	No	No	NA	Yes	Yes	No	No	No	No	White	NA	NA	NA	1	Female	MATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD5, CD7, partial CD11b, CD13, CD33, CD34, variable  CD38, variable CD56, CD58, dim CD71, CD117, dim CD123, dim HLA-DR and MPO+	0	0.1	NA	NA	Yes	DNMT3A (p.R882H; MAF 48%)|NRAS (p.Q61R; MAF 29%)|PTPN11 (p.E69K; MAF 9%)
aml_ohsu_2022	aml_ohsu_2022_2681	aml_ohsu_2022_2681_BA3433	63	63	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin) plus Midostaurin	2	Allogeneic - Sibling|Induction	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M0	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	4	FALSE	Positive	AML	7.068493150684931	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	negative (CD19, CD22, CD7, CD11b, CD13, CD14, CD15, CD34, CD64, HLA-DR) | Dim (CD38, CD45) | Positive (CD56, CD33, CD117, MPO)	0	0.133333333	NA	Standard Chemotherapy	Yes	FLT3 (c.1818_1819ins26; p.P606_R607insCREYEYDLKWEFP; MAF 7%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 45%)|TET2 (C.3379C>t; p.Q1127X; MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2682	aml_ohsu_2022_2682_BA3262	78	78	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Azacitidine|Azacitidine, Lenalidomide|Decitabine	3	Maintenance|Supportive/Palliative Care	2	Standard Chemotherapy	1	Decitabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	MissingKaryo	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	NA	141	Standard Chemotherapy	NA	FALSE	Negative	AML	7.002739726027398	1:DECEASED	CEP7-7q31: Positive for heterozygous deletion 7q31 (44%).	No	No	NA	Yes	Yes	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	NA	0	0	NA	NA	Yes	FLT3 (N676K; MAF:30%)|GATA2 (A372T; MAF:50%)|NRAS (G13R; MAF: 5%)|U2AF1 (S34F; MAF:50%)
aml_ohsu_2022	aml_ohsu_2022_2683	aml_ohsu_2022_2683_BA3243	51	51	0.020408163	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	No	ATRA, Arsenic Trioxide	1	Experimental	1	Targeted Therapy - Other	1	ATRA, Arsenic Trioxide	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M3	Positive	TRUE	FALSE	FALSE	46,XY,t(15;17)(q24;q21.1)/46,XY	193	Targeted Therapy - Other	NA	FALSE	Negative	AML	34.55342465753425	0:LIVING	nuc ish(PML,RARA)x3(PML con RARAx2)[164/200] (Labs conducted twice on day of specimen collection. This is result 1 of 2 on 8/6/2013.) | nuc ish(PML,RARA)x3(PML con RARAx2)[190/200] (Labs conducted twice on day of specimen collection. This is result 2 of 2	No	No	NA	No	No	No	No	No	No	Unknown	NA	NA	NA	1	Male	UNMATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(partial +), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(+), CD117(+), HLA-DR(-), MPO(+), TdT(-) (Labs conducted twice on day of specimen collection	0	NA	NA	NA	Yes	FLT3-D835|FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2684	aml_ohsu_2022_2684_BA3296	18	18	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves3+4	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|Radiation	3	Re-induction|Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy|Bone Marrow Transplant|Other	3	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	NA	FALSE	Negative	AML	11.046575342465754	1:DECEASED	MLL (11q23):  88% of cells had a 0r1g1f split signal pattern consistent with rearrangement|9p21: 76% of cells were missing both signals for 9p21, consistent with homozygous deletion of 9p21|ETV6 (12p13): 68% of cells had an extra signal for ETV6 (Solid T	Yes	No	B lymphoblastic leukaemia/lymphoma	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	Myeloid sarcoma	Initial Acute Leukemia Diagnosis|Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	CD43, CD68, CD163 (weak) and lysozyme positive (Solid Tissue/Skin)	0	0	NA	NA	Yes	EP300 (p.P318A (possible germline polymorphism); MAF 41%)|FAM5C (p.R353C (possible germline polymorphism); MAF 44%)|NOTCH2 (p.E366V; MAF 65%)|PHF6 (p.T12fs*23 (5 bp insertion with frame-shift); MAF 40%)|PTPN11 (p.D61V (confirmed somatic); MAF 39%) (Solid 
aml_ohsu_2022	aml_ohsu_2022_2685	aml_ohsu_2022_2685_BA3293	53	55	11.5	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	TRUE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	3	FALSE	Positive	AML	27.452054794520546	1:DECEASED	NA	Yes	No	Cervical Cancer	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy|Post-Transplant	Leukapheresis	variable CD11b, CD13, CD33, dim CD123, partial HLA-DR, dim/partial MPO	0	0.1	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2686	aml_ohsu_2022_2686_BA3126	66	66	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	4	FALSE	Negative	AML	51.945205479452056	0:LIVING	MLL: 86% of cells had a split signal pattern consistent with MLL rearrangement.	No	No	NA	No	No	No	No	No	No	White	5	Complete Response	NA	1	Male	UNMATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, CD13, CD14, CD33, bright CD64, HLA-DR and partial MPO-positive	2	0.2	NA	Standard Chemotherapy	Yes	FLT3 (p.D835Y; MAF 35%)
aml_ohsu_2022	aml_ohsu_2022_2687	aml_ohsu_2022_2687_BA3209	68	69	0	ASXL1 (p.T806fs*16; VAF 4%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Enasidenib, Azacitidine|Enasidenib	4	Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	47,XX,+8[11]/46,XX[9]	-1	Bone Marrow Transplant	7	FALSE	Negative	AML	27.024657534246572	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD13, CD33, CD34, CD117, and HLA-DR|CD5, CD19, kappa positive(Small (1%) monoclonal B-cell population)	0	0.433333333	NA	Standard Chemotherapy	Yes	ASXL1 (p.T806fs*16; VAF 4%)|ASXL2 (p.M629fs*170; VAF 7%)|CXCR4 (p.E343*; VAF 1%)|DNMT3A (Splice site; VAF 42%)|DNMT3A (p.R899C; VAF 1%)|DNMT3A (p.V897I; VAF 44%)|ID3 (p.Y48N; VAF 1%)|IDH2 (p.R172K; VAF 47%)|IGLL5 (p.D49A; VAF 1%)|KMT2A (partial tandem dup
aml_ohsu_2022	aml_ohsu_2022_2688	aml_ohsu_2022_2688_BA3234	75	75	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XY[20]	8	Standard Chemotherapy	4	FALSE	Positive	AML	2.9917808219178084	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	8	UNKNOWN	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Monocytic population (about 80%) : dim CD4, dim CD9, CD11b, partial CD13,  partial CD14, CD15, subset CD16, CD33, CD38, CD56, CD64, and HLA-DR. | Myeloid blasts phenotype (8%): CD33, CD56, CD117, HLA-DR, and MPO	0	0.2	NA	Standard Chemotherapy	Yes	NPM1 (p.W288fs*12; VAF 24%)|SRSF2 (p.P95R; VAF 48%)|TET2 (p.R506*; VAF 95%)
aml_ohsu_2022	aml_ohsu_2022_2689	aml_ohsu_2022_2689_BA3408	64	64	0	ASXL1 (p.G646Wfs*12; 12.8%)	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	8	Waves3+4	Yes	Ruxolitinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Ruxolitinib	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	46,XX,der(2)del(2)(p23)inv(2)(p22q31),add(3)(p?14),der(12)add(12)(p11.2)t(3;12)(p?13;q?15)[12]/46,idem,der(7)t(7;11)(q11.2;q13)[7]/46,XX[1]	6	Supportive/Palliative Care	3	FALSE	Negative	AML	8.843835616438355	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	White	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	NA	1	0.1	NA	Standard Chemotherapy	Yes	KMT2A
aml_ohsu_2022	aml_ohsu_2022_2690	aml_ohsu_2022_2690_BA3419	87	87	0.639344262	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves3+4	Yes	Entospletinib	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Entospletinib	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	HISPANIC	NA	Positive	TRUE	FALSE	FALSE	NA	-1	Standard Chemotherapy	5	FALSE	Negative	AML	1.3150684931506849	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for dim CD7, CD11b, CD13, CD33, CD34, CD38, CD45, dim CD64, CD117, HLA-DR, and MPO	0	0.233333333	NA	NA	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2691	aml_ohsu_2022_2691_BA3407	29	29	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	6	Waves3+4	Yes	Bu/Cy/ATG|HiDAC|3+7 (Cytarabine, Daunorubicin)|Etoposide, Mitoxantrone|Clofarabine, Cytarabine	5	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Clofarabine, Cytarabine	Re-induction	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX,t(6;11)(q27;q23)[18]/46,XX[2]	6	Standard Chemotherapy	3	FALSE	Negative	AML	8.087671232876712	1:DECEASED	This test has detected  a 6;11 translocation in 18 of 20 metaphase cells analyzed. The translocation has led to rearrangement of the MLL gene as shown by FISH. This result is consistent with the diagnosis of AML. (Cytogenetics) | Except for 9;11 transloca	No	No	NA	No	No	No	No	No	No	NA	7	Refractory	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	Myeloblasts 1% positive for CD34, CD117, HLADR, CD13, CD33, for TDT and all B and T-cell markers. (Bone marrow Immunophenotyping)	38	0.1	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2692	aml_ohsu_2022_2692_BA3083	NA	57	5.666666667	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	unknown	unknown	unknown	NA	NA	None	8	FALSE	Positive	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Unknown	Peripheral Blood	NA	0	0.366666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2693	aml_ohsu_2022_2693_BA3087	31	31	0	ASXL1 (p.D821Efs*15; 26.7%)|ASXL1 (p.D821Wfs*6; 20.1%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine	4	Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY,del(5)(q13q33),t(10;11)(p13;q21)[15]/46,XY[5]	-1	Bone Marrow Transplant	10	FALSE	Negative	AML	35.276712328767125	0:LIVING	93% of cells were missing a signal for both 5q probes (EGR1, 5q31; and 5q33) but had two signals for 5p, consistent with 5q deletion.	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7, CD13, CD33, CD34, dim CD38, CD56, CD117, HLA-DR, partial MPO, and dim TDT.	0	0.466666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.D821fs*12; VAF 28%)|CREBBP (p.N970fs*21; VAF 8%)|JAK1 (p.T114A; VAF 49%)|KMT2D (p.R598H; VAF 49%)|WT1 (p.S165fs*35; VAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2694	aml_ohsu_2022_2694_BA3084	22	22	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone) + Midostaurin|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY,t(10;11)(p13;q23)[20]	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	10.783561643835617	1:DECEASED	MLL: 88% of cells had a 1g/0r/2f signal pattern, where the lone green signal was small and the green component suggesting a disruption of MLL (11q23) within the green portion of  the probe. This result is consistent with MLL rearrangement and with the t(	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	NA	1	Male	MATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Immunophenotype 1(15% WBCs): dim CD4, variable CD13, CD33, bright  CD34, CD58, CD64, CD117, CD123, variable MPO  | Immunophenotype 2 (79% WBCs): dim CD4, CD11b, variable CD13, CD33, CD38, CD58, CD64, CD117, CD123	0	0.266666667	NA	Standard Chemotherapy	Yes	FLT3-D835 (MAF: 31%)|KRAS (p.G12D; MAF 4%)
aml_ohsu_2022	aml_ohsu_2022_2695	aml_ohsu_2022_2695_BA3410	63	63	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	8	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Decitabine	2	Induction|Supportive/Palliative Care	2	Standard Chemotherapy|Supportive/Palliative Care	2	Decitabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	43-48,XY,add(2)(q11.2),add(3)(p13),add(3)(q29),del(5)(q15q33),der(7)add(7)(p11.2)add(7)(q22),?hsr(8)(q24),+10,+11, add(12)(p11.2),-13,add(14)(p13),add(15)(p12),add(15)(p13),-16,?hsr(16)(q22),-17,-20,+21,add(21)(q22),idic(21)(q22),-22, add(22)(p12),+mar1-5	67	Supportive/Palliative Care	4	FALSE	Negative	AML	8.21917808219178	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	8	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.166666667	TP53 (p.R248Q; 58.8%)	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2696	aml_ohsu_2022_2696_BA3353	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves3+4	Yes	Venetoclax (ABT-199), Azacitidine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	2	Induction|Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XX,del(5)(q13q33)[14]/46,XX[6]	-1	Bone Marrow Transplant	4	FALSE	Negative	AML	31.956164383561646	1:DECEASED	5q:  96% of cells were missing a signal for EGR1 (5q31) and 5q33, consistent with deletion, as seen on metaphase analysis.	No	No	NA	No	No	No	No	No	No	White	103	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, CD33, dim CD38, CD117, HLA-DR and variable MPO +	0	0.166666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.R749H; VAF 42%)|ETV6 (p.R378Q; VAF 52%)|JAK2 (p.V617F; VAF 3%)|KMT2D (Partial tandem duplications (exon 9/exon3))|STAT3 (p.D661Y; VAF 38%)
aml_ohsu_2022	aml_ohsu_2022_2697	aml_ohsu_2022_2697_BA3211	69	69	0.176470588	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Gilteritinib (ASP2215)|Azacitidine|RVD (Bortezomib, Dexamethasone, Lenalidomide)|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	4	Salvage|Induction|Maintenance	3	Standard Chemotherapy|Targeted Therapy - Other	2	Gilteritinib (ASP2215)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Positive	FALSE	FALSE	TRUE	46,XY,del(20)(q11.2)[cp20]	-1	Targeted Therapy - Other	8	FALSE	Negative	AML	2.4986301369863013	1:DECEASED	CEP 3:  16/100 cells (16%) had three signals, reflecting trisomy 3.	No	No	NA	Yes	Yes	No	No	No	No	White	6	Refractory	RUNX1 (p.R346Pfs*254; 37.7%)|RUNX1 (p.X269_splice; 43.5%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD43+ and dim CD45+ with dim CD13, dim CD33, dim CD38, partial CD11b, variable HLA-DR, and partial, dim CD117	0	0.333333333	NA	Standard Chemotherapy	Yes	FLT3-ITD (allelic ratio 0.84; VAF 45.7%)|KMT2A (PTD (exon 11/exon 3))|RUNX1 (splice site; VAF 43%)|U2AF1 (p.S34F; VAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2698	aml_ohsu_2022_2698_BA3428	64	64	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	8	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	47,XX,+8,inv(16)(p13.1q22.1)[20]	1	Standard Chemotherapy	5	FALSE	Negative	AML	29.654794520547945	1:DECEASED	POSITIVE for CBFB gene locus rearrangement | POSITIVE for chromosome RUNX1T1 loci copy number gain	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.3	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2699	aml_ohsu_2022_2699_BA3352	73	73	1.222222222	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	12	FALSE	Positive	AML	0.7232876712328767	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34(-), CD13(predominantly -), CD33(+), CD38(partial +), CD45(dim +), CD56(variably +), CD64(partial dim +), CD117(+),HLA-DR(-), MPO(+), TdT(-), other myeloid and lymphoid antigens(predominantly -).	0	0.466666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2700	aml_ohsu_2022_2700_BA3191	46	46	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	5+2 (Cytarabine, Idarubicin)|Azacitidine|Gemtuzumab|MiDAC|Decitabine	5	Consolidation|Salvage|Induction|Re-induction|Maintenance	5	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Gemtuzumab	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	NA	-1	Targeted Therapy - Kinase Inhibitor(s)	1	FALSE	Negative	AML	17.95068493150685	1:DECEASED	Positive for CBFB rearrangement. (96/100 cells (96%) reflected a loss of the distal green portion of one break-apart signal. Presence of an  inverted chromosome 16 was confirmed. In addition, metaphase FISH showed a  normal chromosome 16 with a yellow (r	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, dim CD33, CD34, CD38, CD117, CD123, HLA-DR  and dim MPO+. (Blast Immunophenotype) | CD11b, CD13, dim CD14, CD33, CD38, CD64,  HLA-DR, dim CD117, CD123 and dim MPO+ (Monocytic Immunophenotype)	0	0.066666667	NA	Standard Chemotherapy	Yes	GATA2 (p.T356A; MAF 41%)|NRAS (p.Q61K; MAF 41%)
aml_ohsu_2022	aml_ohsu_2022_2701	aml_ohsu_2022_2701_BA3405	67	67	0	ASXL1 (p.G646Wfs*12; 30.1%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves3+4	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Cytarabine	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M4	Negative	TRUE	FALSE	FALSE	NA	-1	Bone Marrow Transplant	9	FALSE	Negative	AML	5.819178082191781	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	7	Complete Response	RUNX1 (p.D198G; 94.2%)	1	Male	MATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.5	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2702	aml_ohsu_2022_2702_BA3156	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	8	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	M6	Negative	TRUE	FALSE	FALSE	45,XY,del(7)(p13),-9[7]/4 5-47,idem,+13,-15,add(19) (p13.3),+20[cp11]/ 46,XY[2]	-1	Standard Chemotherapy	2	FALSE	Negative	AML	1.643835616438356	1:DECEASED	POSITIVE for ABL1 gene locus copy number loss | POSITIVE for PML gene locus copy number loss	No	No	NA	No	No	No	No	No	No	NA	-1	Refractory	NA	1	Male	UNMATCHED	FALSE	Acute erythroid leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.133333333	TP53 (p.R273C; 67.5%)	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2703	aml_ohsu_2022_2703_BA3312	43	43	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	bi	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY,t(2;12)(p13;q13)[20]	132	Standard Chemotherapy	4	FALSE	Negative	AML	15.517808219178082	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, variable CD34, CD117, and HLA-DR positive (CD7, dim CD15, and MPO expression was noted on the prior flow cytometric analysis and was not tested in the current assay)	0	0.2	NA	Standard Chemotherapy	Yes	CEBPA (p.G36fs*122; VAF 45%)|CEBPA (p.Q311_Q312linsRKAKQRNVETQ; VAF 45%)|DNMT3A (p.R19P; VAF 48%)|EZH2 (p.K30fs*17 (loss of function); VAF 65%)|GATA2 (p.R362Q; VAF 47%)|NRAS (p.G13D; VAF 43%)
aml_ohsu_2022	aml_ohsu_2022_2704	aml_ohsu_2022_2704_BA3167	38	38	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	46,XY,t(9;11)(p22;q23),inv(9)(p11q12)	-1	Standard Chemotherapy	3	FALSE	Negative	AML	5.326027397260274	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.133333333	NA	Standard Chemotherapy	Yes	BCOR (D1006fs*16)|FLT3-D835|MLL (MLL-MLLT3 (AF9) Fusion)
aml_ohsu_2022	aml_ohsu_2022_2705	aml_ohsu_2022_2705_BA3081	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	8	Waves3+4	Yes	HiDAC|7+3 (Cytarabine, Idarubicin, Dexamethasone)|Fludarabine, Melphalan, ATG	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	50-55,XX,+X,+6,+8,+10,+12,+13,+14,+21,+22[cp 18]/46,XX[2].	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	6.180821917808219	1:DECEASED	POSITIVE for RUNX1T1 and RUNX1 copy number gains	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	RUNX1 (p.R162K; 58.7%)	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.233333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2706	aml_ohsu_2022_2706_BA3125	59	59	0.162790698	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin) plus Midostaurin	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Midostaurin	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	46,XY[20]	20	Standard Chemotherapy	5	FALSE	Positive	AML	1.0191780821917809	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	Black	20	Unknown	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	Myloid blast population, about 25%: variable CD13, CD33, partial CD34, CD38, CD117, CD123, HLA-DR and dim MPO | Monoblast population, about 50%: Dim CD9, bright CD11b, variable CD13, CD16, CD33, CD38, CD56, CD64, HLA-DR	0	0.2	NA	Standard Chemotherapy	Yes	BIRC6 (p.S3135C; VAF 52%)|BRCA2 (p.P59A; VAF 48%)|CDKN2C (p.D64N; VAF 51%)|DNAH5 (p.G2668R; VAF 48%)|DNMT3A (p.R882H; VAF 48%)|EFTUD1 (p.S504Y; VAF 49%)|FLT3-ITD (p.E598delinsDYVDFREYE (24-nucleotide ITD); VAR 0.082; VAF 5.2%)|FLT3-ITD (p.P606delinsPFREYE
aml_ohsu_2022	aml_ohsu_2022_2707	aml_ohsu_2022_2707_BA3319	22	22	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY,inv(16)(p13;q22)[20]	106	Standard Chemotherapy	3	FALSE	Negative	AML	46.323287671232876	0:LIVING	CBFB:  39% of cells had a 1r/1g/1f split signal pattern consistent with CBFB disruption and inv916), as seen on metaphase analysis.	No	No	NA	No	No	No	No	No	No	Pacific Islander	5	Complete Response	NA	1	Male	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Myeloid blast immunophenotype: CD13, CD33, CD34, CD38, CD58, CD117,  CD123, dim HLA-DR and MPO+  | Monocytic blast immunophenotype: CD11b, CD13, CD14, partial CD16, CD33,  dim CD34, CD38, CD58, CD64, CD117, dim CD123, HLA-DR and MPO+	0	0.2	NA	Standard Chemotherapy	Yes	KIT (p.D816Y; MAF 6%)|NRAS (p.Q61H; MAF 32%)
aml_ohsu_2022	aml_ohsu_2022_2708	aml_ohsu_2022_2708_BA3347	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	Venetoclax (ABT-199), Azacitidine	1	Induction	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M5	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	3	FALSE	Positive	AML	7.66027397260274	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Neagtive (CD10, CD19, CD16, CD14, CD34, CD117) | Bright Positive (CD64)	0	0.166666667	NA	Standard Chemotherapy	Yes	DNMT3A (c.2311T>C; p.R771X; MAF 40%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 38%)|TET2 (c.2827C>T; p.Q943X; MAF 80%)
aml_ohsu_2022	aml_ohsu_2022_2709	aml_ohsu_2022_2709_BA3118	45	45	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX[20]	92	Standard Chemotherapy	1	FALSE	Negative	AML	9.172602739726027	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	Asian	5	Complete Response	NA	1	Female	UNMATCHED	FALSE	Myeloid sarcoma	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.066666667	NA	Standard Chemotherapy	Yes	MYH11 (CBFB-MYH11 fusion)|NRAS (G12D)
aml_ohsu_2022	aml_ohsu_2022_2710	aml_ohsu_2022_2710_BA3288	70	70	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Induction	2	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	FALSE	FALSE	TRUE	44,XY,der(2)t(2;11)(p11.2;q13),add(3)(p12),-9,add(10)(q11.2),-12,add(16)(p13.1)[cp4]/43,idem,-add(10)(q11.2)[cp5]/46,XY[11]	-1	Standard Chemotherapy	6	FALSE	Negative	AML	3.8794520547945206	1:DECEASED	NA	No	No	NA	No	No	Yes	Yes	No	No	White	6	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, variable CD13, variable CD14, CD15, variable CD16, CD33, CD38, CD56, CD58, CD64, dim HLA-DR positive	0	0.333333333	TP53 (p.Y205H; 67.9%)	Standard Chemotherapy	Yes	PAX5 (P284A; MAF ~33%)|TET2 (Q876*; MAF ~50%)|TP53 (Y205H; MAF ~66%)
aml_ohsu_2022	aml_ohsu_2022_2711	aml_ohsu_2022_2711_BA3240	79	79	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Vyxeos (Daunorubicin, Cytarabine - liposomal)	1	Induction	1	Standard Chemotherapy	1	Vyxeos (Daunorubicin, Cytarabine - liposomal)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Negative	FALSE	FALSE	TRUE	51~52,XX,+2,+6,add(7)(q31),+8,+9,+10,+15[cp14]/50~52,idem,del(19)(q11.2)[cp  5]/46,XX[1]	-1	Standard Chemotherapy	12	FALSE	Negative	AML	0.6575342465753424	1:DECEASED	BCR/ABL/ASS: 72/100 cells had a variant abnormal fusion reflecting a single BCR/ABL fusion. The Philadelphia rearrangement was not visible in the metaphase karyotype  and is, thus, likely a cryptic rearrangement involving at least three chromosomes.    (T	No	No	NA	No	No	No	No	Yes	Yes	White	-1	Unknown	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, variable CD34, CD38, dim CD58, CD117, CD123,HLA-DR and dim MPO+	0	0.566666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882C; MAF 64%)|FLT3 (p.D835H; MAF 5%)|IDH1 (p.R132L; MAF 54%)
aml_ohsu_2022	aml_ohsu_2022_2712	aml_ohsu_2022_2712_BA3088	60	60	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	bi	1	Waves3+4	Yes	Ruxolitinib|Azacitidine|7+3 (Cytarabine, Daunorubicin) plus Glasdegib/placebo|MiDAC plus Glasdegib/placebo|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Maintenance|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Ruxolitinib	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	DECLINED	M2	Negative	TRUE	FALSE	FALSE	46,XY,del(20)(q11.2q13.3)[19]/46,XY[1]	25	Standard Chemotherapy	8	FALSE	Negative	AML	23.835616438356162	0:LIVING	81% of cells were missing a signal for 20q12 but had two signals for 20q telomere, consistent with interstitial deletion.	No	No	NA	No	No	No	No	No	No	Declined	5	Complete Response	RUNX1 (p.L98Sfs*24; 36.0%)	1	Male	MATCHED	FALSE	AML with mutated CEBPA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD11b, CD13, CD33, CD34, CD38, CD117, HLA-DR, partial TdT and MPO+	0	0.333333333	NA	Standard Chemotherapy	Yes	ASXL1 (p.C872*; VAF 1%)|CEBPA (p.F31fs*131; VAF 8%)|CEBPA (p.N321D; VAF 10%)|CEBPA (p.P23fs*137; VAF 39%)|CEBPA (p.T310_Q311insLDPAQ; VAF 33%)|IRF4 (p.H441L; VAF 50%)|RUNX1 (p.L98fs*24; VAF 49%)|SRSF2 (p.P95H; VAF 49%)|STAG2 (Splice site; VAF 90%)
aml_ohsu_2022	aml_ohsu_2022_2713	aml_ohsu_2022_2713_BA3110	51	51	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	2	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	HISPANIC	NA	Negative	unknown	FALSE	unknown	46,XY[20]	NA	None	4	FALSE	Negative	AML	3.978082191780822	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	MATCHED	FALSE	Unknown	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.233333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2714	aml_ohsu_2022_2714_BA3232	36	36	0.265822785	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Azacitidine, Sorafenib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Busulfan, Cyclophosphamide|Cytarabine, Methotrexate	6	Allogeneic - Sibling|Induction|Experimental|Re-induction|Maintenance	5	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Other	4	SY-1425 (Tamibarotene) plus Daratumumab	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	46,XX[20]	28	Targeted Therapy - Other	7	FALSE	Positive	AML	12.164383561643836	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD7, partial CD11b, variable CD13, CD33, CD64,  CD117, dim CD123, dim HLA-DR and partial MPO positive	0	0.3	NA	Standard Chemotherapy	Yes	BCOR (p.V89D; MAF 54%)|DNMT3A (p.R882H; MAF 51%)|FLT3-ITD (MAF 15%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12S; MAF 20%)
aml_ohsu_2022	aml_ohsu_2022_2715	aml_ohsu_2022_2715_BA3329	77	77	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	mono	5	Waves3+4	Yes	Venetoclax (ABT-199), Azacitidine|Azacitidine	2	Induction|Maintenance	2	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY,inv(4)(p14q21)[9]/47,sl,+8[2]/46,XY[10]	36	Standard Chemotherapy	4	FALSE	Negative	AML	3.715068493150685	1:DECEASED	Gain of chromosome 8 (trisomy)	No	No	NA	Yes	Yes	No	No	No	No	NA	36	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	NA	0	0.266666667	NA	Standard Chemotherapy	Yes	CEBPA (P189dup; VAF 30%)|ETV6 (N228S; VAF 52%)|SRSF2 (P95R; VAF 18%)|STAG2 (VAF 34%)|TET2 (Q745*; VAF 23%)
aml_ohsu_2022	aml_ohsu_2022_2716	aml_ohsu_2022_2716_BA3310	82	82	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY[20]	NA	None	8	FALSE	Positive	AML	0.5589041095890411	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD13, CD33, CD117 and MPO	0	0.433333333	NA	NA	Yes	CBL (p.G838V; VAF 48%)|CREBBP (p.N1615S; VAF 48%)|FLT3 (p.D839G; VAF 6%)|FLT3 (p.N676K; VAF 2%)|FLT3-ITD (Allelic ratio 0.01)|IDH2 (p.R140Q; VAF 46%)|KIT (p.D816V; VAF 4%)|KMT2D (p.F4579S; VAF 49%)|NPM1 (p.W288fs*12; VAF 46%)|SRSF2 (p.P95_R102del; VAF 45%
aml_ohsu_2022	aml_ohsu_2022_2717	aml_ohsu_2022_2717_BA3228	68	69	NA	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Azacitidine|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Cytarabine, Midostaurin	3	Induction|Re-induction|Supportive/Palliative Care	3	Standard Chemotherapy	1	Cytarabine, Midostaurin	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	FALSE	TRUE	46,XX,i(14)(q10)[8]/46,XX[12]	-1	Standard Chemotherapy	6	FALSE	Negative	AML	16.24109589041096	0:LIVING	IGH (14q32) breakapart probe set, as listed  below. 4/200 interphase cells had three intact signals, but one abnormal  metaphase was found, which had an IGH signal on either end of the  i(14)(q10).	No	No	NA	No	No	Yes	Yes	No	No	White	11	Refractory	RUNX1 (p.R320*; 49.8%)	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.266666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2718	aml_ohsu_2022_2718_BA3250	58	58	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY,inv(16)(p13q22)[20]	6	Standard Chemotherapy	1	FALSE	Negative	AML	0.7232876712328767	1:DECEASED	CBFB/MYH11:  165/200 cells (82.5%) had the abnormal 1 red/ 1 green/ 2 yellow signal pattern, reflecting CBFB/MYH11 fusion and consistent with the inverted chromosome 16 observed in the metaphase karyotype.	No	No	NA	No	No	No	No	No	No	White	6	UNKNOWN	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Myeloid blasts: CD13, CD33, CD34,  CD117, HLA-DR+ | Promonocytic/ monocytic population (56%): variable CD13, variable CD14, partial CD16, CD33, CD64, HLA-DR+	2	0.066666667	NA	Standard Chemotherapy	Yes	CARD11 (p.N191S; VAF 45%)|KRAS (p.G12V; VAF 4%)
aml_ohsu_2022	aml_ohsu_2022_2719	aml_ohsu_2022_2719_BA3171	55	55	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	43,XY,dic(5;12)(q11.2;p13),der(7)t(7;13)(q11.2;q12),i(8)(q10),+9,dup(11)(q2  3q23),-13,-15,-16,der(17)t(15;17)(q22;q23),-21,+mar[20]/46,XY[5]	-1	Bone Marrow Transplant	7	FALSE	Negative	AML	13.216438356164382	1:DECEASED	RUNX1T1/RUNX1: 86/100 cells (86%) reflecting the isochromosome 8q and the monosomy 21. No evidence for RUNX1T1/RUNX1fusion | EGR-1/ D5S23, D5S721: 89/100 cells (89%) consistent with missing 5q in the dicentric 5;12 | PML/RARA: Signal patterns were wit	No	No	NA	No	No	No	No	No	No	White	9	Complete Response	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD11c, CD13, CD33, CD34, CD38, CD56, CD64, CD117,HLA-DR; negative TdT, CD19 and CD10 (from bmbx 5/3/17)	0	0.4	TP53 (p.X125_splice; 75.0%)	Standard Chemotherapy	Yes	KRAS (p.G12D; MAF 35%)|TP53 (Splice site (5' splice site mutation in intron 4); MAF 69%)
aml_ohsu_2022	aml_ohsu_2022_2720	aml_ohsu_2022_2720_BA3311	74	74	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	48,XY,+11,+13[17]/46,XY[3]	6	Standard Chemotherapy	7	FALSE	Negative	AML	0.7890410958904108	1:DECEASED	MLL (11q23):  161/200 cells (80.5%) had three intact signals for MLL, consistent with the trisomy 11 seen on metaphase analysis.	Yes	Yes	Prostate Cancer	Yes	Yes	No	No	No	No	White	6	Unknown	NA	1	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD34, variable CD38, partial CD64, CD117, dim CD123, HLA-DR, partial TdT.	0	0.333333333	NA	Standard Chemotherapy	Yes	CBLB (p.V581M; MAF 52%)|DNMT3A (p.V877fs*4; MAF 40%)|MLL (Partial tandem duplication (exon 9/exon 3) )|NRAS (p.G12D; MAF 14%)|U2AF1 (p.S34F; MAF 43%)|WT1 (p.R353fs*15; MAF 26%)|WT1 (p.S364*; MAF 25%)
aml_ohsu_2022	aml_ohsu_2022_2721	aml_ohsu_2022_2721_BA3196	76	76	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Venetoclax (ABT-199), Azacitidine|Enasidenib|Ruxolitinib, Venetoclax	3	Salvage|Experimental	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	3	Enasidenib	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	47,XX,+2[8]/47,XX,+8[1]/46,XX[11]	-1	Targeted Therapy - Other	10	FALSE	Negative	AML	29.81917808219178	0:LIVING	MYCN (2p24.1)/CEP 2:  70/200 cells (35%) had three signals for both probes, reflecting trisomy 2.  | RUNX1 (8q21.3)/CEP 8:  12/200 cells (6%) had three signals for both probes, reflecting trisomy 8, previously suspected by FISH.  There was no evidence for	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease	Bone Marrow Aspirate	CD13, dim/partial CD33, CD34, CD38, CD117, HLA-DR+	0	0.5	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2722	aml_ohsu_2022_2722_BA3111	4	4	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|COG-AAML0431 (IT/IV Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Thioguanine)	4	Salvage|Induction	2	Standard Chemotherapy	1	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	MissingKaryo	NON-HISPANIC	M0	Negative	TRUE	FALSE	FALSE	NA	4	Standard Chemotherapy	4	FALSE	Negative	AML	7.857534246575343	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	Multiracial	10	Complete Response	NA	1	Female	UNMATCHED	FALSE	Myeloid leukaemia associated with Down syndrome	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD7, CD11b, CD33, CD38, partial CD117 positive	0	0.166666667	NA	Standard Chemotherapy	Yes	EFTUD1 (p.P545A; VAF 47%)|FAM47A (p.P545L; VAF 48%)|GATA1 (p.V32fs*7; VAF 39%)|JAK2 (p.V617F; VAF 40%)|MSH6 (p.D217G; VAF 48%)|SUZ12 (Splice site; VAF 38%)
aml_ohsu_2022	aml_ohsu_2022_2723	aml_ohsu_2022_2723_BA3283	NA	NA	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	2	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Unknown	Peripheral Blood	NA	0	0.1	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2724	aml_ohsu_2022_2724_BA3199	69	69	0	ASXL1 (p.K618_A619ins*; 43.5%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	mono	5	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[19]	7	Standard Chemotherapy	7	FALSE	Negative	AML	5.1287671232876715	1:DECEASED	Normal	Yes	No	Prostate Cancer	No	No	No	No	No	No	White	7	Refractory	RUNX1 (p.X269_splice; 48.1%)	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.333333333	NA	Standard Chemotherapy	Yes	ASXL1 (A619*; VAF 47%)|CEBPA (H24Afs*84; VAF 44%)|CEBPA (R165Afs*153; VAF 48%)|RUNX1 (VAF 45%)|SRSF2 (P95H; VAF 53%)|TET2 (S1486*; VAF 48%)
aml_ohsu_2022	aml_ohsu_2022_2725	aml_ohsu_2022_2725_BA3255	55	55	3	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Decitabine, Sorafenib |Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Decitabine, Sorafenib	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M0	Positive	TRUE	FALSE	FALSE	46,XY[20]	61	Standard Chemotherapy	14	FALSE	Positive	AML	8.942465753424658	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim partial CD4, dim partial CD7, dim CD11b, CD13, CD33,  partial CD34, CD38, CD58, dim CD71, CD117, CD123 and HLA-DR+	0	0.6	NA	Standard Chemotherapy	Yes	DNMT3A (Splice site (start of intron 18; likely pathogenic); MAF 47%)|FLT3-ITD (p.E598delinsDYVDFREYE; MAF 60%)|NPM1 (p.W290fs*10; MAF 45%)|WT1 (p.D464N; MAF 46%)
aml_ohsu_2022	aml_ohsu_2022_2726	aml_ohsu_2022_2726_BA3190	NA	NA	0	ASXL1 (p.G646Wfs*12; 26.8%)	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	5	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	Unknown	Unknown	Peripheral Blood	NA	0	0.3	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2727	aml_ohsu_2022_2727_BA3212	0	0	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide|Etoposide, Cytarabine	4	Consolidation|Induction|Intensification|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant	2	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Negative	TRUE	FALSE	FALSE	46,XX,der(1)t(1;9)(p36.1;q22),t(5;17)(p13;q21),der(5;9)(p10;p10),+8[12]/47,  sl,+20[7]64~69<3n>,XXX,+1,der(1)t(1;9)(p36.1;q22)x2,+5,t(5;17)(p13;q21)x2,+  6,-9,-11,+21[cp3]	4	Standard Chemotherapy	1	FALSE	Negative	AML	28.10958904109589	1:DECEASED	EGR-1/ D5S23, D5S721: 175/200 cells had a 1 red/2 green signal  pattern, indicating a deleted 5q. Five cells had a 2 red/ 4 green signal pattern consistent with the  two normal chromosomes 5 and the two derivative chromosomes (5;9),  resulting in loss of	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD4, CD7, partial CD13, CD33, CD71, partial CD117, CD123 and dim HLA-DR-positive	0	0.066666667	NA	Standard Chemotherapy	Yes	NRAS (p.G12D; MAF 29%)|NRAS (p.Q61K; MAF 6%)
aml_ohsu_2022	aml_ohsu_2022_2728	aml_ohsu_2022_2728_BA3430	60	60	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves3+4	Yes	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Negative	FALSE	FALSE	FALSE	NA	NA	None	5	FALSE	Negative	AML	0.03287671232876713	1:DECEASED	NA	Yes	No	Breast Cancer	No	No	No	No	No	No	White	NA	NA	NA	1	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	positive for CD11b, CD13, CD14, CD15, CD33, CD38, CD45, CD64, HLA-DR and MPO	1	0.2	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2729	aml_ohsu_2022_2729_BA3273	NA	NA	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	Yes	Cyclophoshamide, TBI, ATG|CALGB 10403	2	Induction|Allogeneic - Matched Unrelated Donor	2	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophoshamide, TBI, ATG	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M5	Negative	TRUE	FALSE	FALSE	47,XY,der(7)t(1;7)(q21;q36),+14[4]/46,XY[16]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	18.410958904109588	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2, D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2 [198],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(+), CD7(-), CD11b(few dim +), CD13(-), CD14(-), CD15(partial +), CD16(-), CD19(partial +), CD20(-), CD22(partial +), CD25(partial +), CD33(partial +), CD34(+), CD36(-), CD38(+), CD45(partial +) | CD64(-), CD79a(partial +), CD117 (-), HLA-DR(pa	0	0.033333333	NA	Standard Chemotherapy	Yes	IKZF1 (Foundation; S63fs*2)
aml_ohsu_2022	aml_ohsu_2022_2730	aml_ohsu_2022_2730_BA3367	NA	34	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	NA	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	Unknown	Unknown	Bone Marrow Aspirate	NA	0	0	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2731	aml_ohsu_2022_2731_BA3219	73	73	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Cytarabine	1	Induction	1	Standard Chemotherapy	1	Cytarabine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XY[15]	1	Standard Chemotherapy	4	FALSE	Positive	AML	0.1315068493150685	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	1	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	dim CD9, CD11b, variable CD13, partial CD14, dim CD15, dim CD16, CD33, CD38, dim CD56, CD64, CD123, and HLA-DR	0	0.166666667	NA	Standard Chemotherapy	Yes	CCND1 (p.R245W; VAF 48%)|DNMT3A (p.P633R; VAF 46%)|NPM1 (p.W288fs*12; VAF 46%)|NRAS (p.G13D; VAF 6%)|PTPN11 (p.T73I; VAF 33%)|TET2 (p.N926fs*28; VAF 16%)
aml_ohsu_2022	aml_ohsu_2022_2732	aml_ohsu_2022_2732_BA3246	56	56	0	ASXL1 (p.C632*; 20.8%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	3+4 (Cytarabine, Idarubicin)|HiDAC|MiDAC|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	3+4 (Cytarabine, Idarubicin)	Induction	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	4	Standard Chemotherapy	4	FALSE	Negative	AML	51.51780821917808	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	4	Complete Response	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy	Bone Marrow Aspirate	NA	0	0.266666667	NA	Standard Chemotherapy	No	ASXL1 (p.C632*; MAF 38%)
aml_ohsu_2022	aml_ohsu_2022_2733	aml_ohsu_2022_2733_BA3135	63	63	0.315789474	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	8	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	M1	Positive	TRUE	FALSE	FALSE	NA	7	Standard Chemotherapy	4	FALSE	Positive	AML	1.5780821917808217	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	Black	7	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD56 | dim CD15 | dim CD123	0	0.133333333	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2734	aml_ohsu_2022_2734_BA3226	75	75	0.960784314	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Positive	FALSE	FALSE	FALSE	46,XX[20]	NA	None	3	FALSE	Positive	AML	1.2164383561643834	1:DECEASED	Normal	Yes	Yes	Breast Cancer	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	dim CD11b, CD13, CD33, partial CD34, partial CD38, dim CD45, partial CD64, CD58, partial CD117, CD123 and partial MPO positive	0	0.066666667	NA	NA	Yes	FLT3-ITD (MAF 44%)
aml_ohsu_2022	aml_ohsu_2022_2735	aml_ohsu_2022_2735_BA3432	70	70	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	6	Waves3+4	Yes	3+7 (Cytarabine, Daunorubicin)|Gemtuzumab|Azacitidine|Decitabine	4	Salvage|Induction	2	Standard Chemotherapy	1	Azacitidine	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	44-46,XX,del(1)(p32),del(5)(q31q35),del(7)(q11.2q32),-9,-15,-16,-18,add (21)(q22),-22,-22,+3mar[cp3]/46,XX[7]	-1	Standard Chemotherapy	NA	FALSE	Negative	AML	4.898630136986301	0:LIVING	Clonal abnormalities including deletions in 1p, 5q and 7q are detected in 3 of 10 metaphase cells analyzed. Deletions in 5q and 7q are common abnormalities in MDS and also in AML as treatment related chromosome changes or in AML with myelodysplasia.  (Cyt	No	No	NA	No	No	No	No	No	No	White	11	Refractory	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	NOT DETECTED for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR). NOT DETECTED for the FLT3 TKD Mutation. POSITIVE for the MLL partial tandem duplication (PTD) at 2.61%. Pathogenic alterations are NOT DETECTED. These are positive for CD34, CD	0	0	NA	Standard Chemotherapy	Yes	MLL
aml_ohsu_2022	aml_ohsu_2022_2736	aml_ohsu_2022_2736_BA3384	39	39	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Radiation|Busulfan, Cyclophosphamide	7	Consolidation|Unknown|Induction|Maintenance|Allogeneic - Matched Unrelated Donor	5	DLI|Standard Chemotherapy|Bone Marrow Transplant|Other	4	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	47,XX,del(11)(q23),+21[20]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	49.70958904109589	0:LIVING	MLL: 97/100 cells (97%) had a 0 red/ 1 green/ 1 yellow signal pattern,  partially deleting the MLL region of 11q23 and consistent with the deleted 11q in the metaphase karyotype. | RUNX1T1/RUNX1: 95/100 cells (95%) had a 2 red/ 3 green signal pattern, c	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	RUNX1 (p.P49T; MAF 69%)	1	Female	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	partial CD11b, dim CD13, CD33, partial CD34, variable CD64, CD117, CD123, HLA-DR+	0	0.033333333	NA	Standard Chemotherapy	Yes	MLL (Possible subclone with partial tandem duplication)|RUNX1 (p.P49T; MAF 69%)
aml_ohsu_2022	aml_ohsu_2022_2737	aml_ohsu_2022_2737_BA3078	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M0	Negative	TRUE	FALSE	FALSE	46,XY[20]	6	Standard Chemotherapy	4	FALSE	Negative	AML	0.7890410958904108	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Leukapheresis	dimCD2, partial CD7, dimCD13, CD34, CD38, CD117, HLA-DR	0	0.2	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2738	aml_ohsu_2022_2738_BA3197	47	47	0.785714286	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	NA	NA	None	3	FALSE	Positive	AML	0.3287671232876712	1:DECEASED	PML/RARA: Negative	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	partial CD13, CD33, CD38, partial CD56, CD58, CD117,  CD123, and MPO positive	0	0.1	NA	NA	Yes	FLT3-ITD (p.F605delinsTGSSDNEYFYVDFREYEYDLKWEF; MAF 46%)|IDH1 (p.R132G; MAF 47%)|NOTCH1 (p.E1555V; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2739	aml_ohsu_2022_2739_BA3258	66	66	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|HiDAC, Mitoxantrone, CPI-613|Methotrexate	5	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	9	FALSE	Positive	AML	37.150684931506845	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	2	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7 and CD9, CD11b, dim CD13, CD14, CD15, CD33, CD38, partial CD56, CD64, HLA-DR+	0	0.466666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.N797D; VAF 46%)|IDH2 (p.R140Q; VAF 46%)|NPM1 (p.W288fs*12; VAF 46%)|NRAS (p.Q61P; VAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2739	aml_ohsu_2022_2739_BA3446	66	67	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|HiDAC, Mitoxantrone, CPI-613|Methotrexate	5	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Negative	FALSE	TRUE	FALSE	46,XX,del(14)(q21q31)[20]	-1	Bone Marrow Transplant	6	FALSE	Positive	AML	37.150684931506845	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	2	Female	MATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Peripheral Blood	Myeloid blasts: CD13, CD33, CD38, CD117, HLA-DR. | Blasts with monocytic features: CD11b, dim CD13, CD15, CD33, CD38, CD64, HLA-DR	366	0.366666667	NA	Standard Chemotherapy	No	BCOR (p.E1093K; VAF 48%)|DNMT3A (p.N797D; VAF 46%)|FAT4 (p.D1836N; VAF 41%)|IDH2 (p.R140Q; VAF 47%)|KMT2D (p.P647T; VAF 67%)|NPM1 (p.W288fs*12; VAF 43%)|NRAS (p.Q61P; VAF 46%)|RBBP6 (p.P1416A; VAF 51%)
aml_ohsu_2022	aml_ohsu_2022_2740	aml_ohsu_2022_2740_BA3162	20	20	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,inv(16)(p13.1q22)[20]	-1	Standard Chemotherapy	4	FALSE	Positive	AML	3.254794520547945	0:LIVING	Evidence of a CBFB [inv(16)] gene rearrangement in 98% of the cells.	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(-), CD5(-), CD7(-), CD8(-),CD10(-), CD11b(dim +), CD13(dim +),CD14(dim +), CD15(dim+CD16(-), CD20(-), CD22(-), CD25(dim +), CD33(dim +), CD34(+), CD38(+), CD36(subset +), CD56(-), CD64(subset +), CD79a +)(-), CD123(dim +), MPO(dim +), TdT(-), 	0	0.133333333	NA	Standard Chemotherapy	Yes	KIT (Y418_R420>RW; MAF 10.2%)|NRAS (G12s; MAF45.4%)
aml_ohsu_2022	aml_ohsu_2022_2741	aml_ohsu_2022_2741_BA3328	63	63	0.754385965	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|HiDAC|7+3 (Cytarabine, Idarubicin) plus Midostaurin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[15]	-1	Bone Marrow Transplant	9	FALSE	Positive	AML	5.49041095890411	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD13, CD33, CD38, partial CD56, CD58, CD64, dim CD117, CD123 and MPO+	0	0.333333333	NA	Standard Chemotherapy	Yes	DNMT3A (p.R326L; MAF 47%)|FLT3-ITD (MAF 43%; mutant allelic ratio 0.74)|IDH2 (p.R140Q; MAF 47%)|NPM1 (p.W288fs*12; MAF 48%)
aml_ohsu_2022	aml_ohsu_2022_2742	aml_ohsu_2022_2742_BA3339	NA	31	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	NA	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Unknown	Peripheral Blood	NA	0	0	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2743	aml_ohsu_2022_2743_BA3186	68	70	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|Azacitidine|MiDAC	3	Symptom Control|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	TRUE	TRUE	45,XY,add(3)(p22),-7,t(8;22)(q11.2;q11.2),add(11)(q23),-13,-15,-16,  der(17)t(7;17)(q11.2;p11.2),+3mar[cp3]/44~46,sl+der(8)t(8;21)(q11.2;q11.2),  -18[cp15]/44,sl,-add(3)(p22),+10,+13,+15,-18,-3mar[2]	-1	Bone Marrow Transplant	4	FALSE	Negative	AML	32.21917808219178	1:DECEASED	MLL: 97/100 cells (97%) had the variant abnormal 0 red/ 1 green/1 yellow  signal pattern, reflecting MLL (11q23) rearrangement and previously  observed.  | TP53/CEP 17: 99/100 cells (99%) had a 1 red/ 2 green signal pattern,  reflecting TP53 deletion, p	No	No	NA	No	No	No	No	Yes	Yes	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Relapse|Post-Chemotherapy|Post-Transplant	Peripheral Blood	dim CD4, dim CD7, dim CD33, CD34, dim CD56, CD58, dim  CD123, CD117 and HLA-DR positive	0	0.233333333	TP53 (p.R248W; 71.9%)	NA	Yes	JAK2 (p.V617F; MAF 88%)|SF3B1 (p.G740V; MAF 41%)|TET2 (p.E692fs*8; MAF 40%)|TP53 (p.R248W; MAF 78%)
aml_ohsu_2022	aml_ohsu_2022_2744	aml_ohsu_2022_2744_BA3390	NA	NA	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	3	FALSE	Positive	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Unknown	Peripheral Blood	NA	0	0.133333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2745	aml_ohsu_2022_2745_BA3259	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	46,XY[20]	-1	Standard Chemotherapy	10	FALSE	Negative	AML	9.435616438356163	1:DECEASED	normal	No	No	NA	Yes	Yes	No	No	No	No	White	-1	Refractory	RUNX1 (p.Q390Afs*210; 42.4%)	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, dim CD33, CD34, CD38, CD58, CD117, HLA-DR, and partial MPO	0	0.4	NA	Standard Chemotherapy	Yes	IDH2 (p.R140Q; MAF 50%)|RUNX1 (p.Q390Afs; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2746	aml_ohsu_2022_2746_BA3333	NA	NA	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	NA	None	9	FALSE	Positive	AML	0.06575342465753425	1:DECEASED	Normal	Yes	No	Prostate Cancer	Yes	Yes	No	No	No	No	White	NA	NA	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.433333333	NA	NA	Yes	FLT3-TKD (I836del; VAF 8%)|GATA2 (T358A;16%)|NPM1 (W288Cfs*12; VAF 46%)|SRSF2 (P95L; VAF 41%)|TET2 (A1344E; VAF 52%)|TET2 (R1440Tfs*38; VAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2747	aml_ohsu_2022_2747_BA3133	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Vidaza	1	Induction	1	Standard Chemotherapy	1	Vidaza	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	45,XY,del(5)(q13q33),-7,add(8)(q24.3),add(9)(q34),add(10)(q23),del(17)(p13)  ,add(18)(q23)[3]/47-49,sl,+2-4mar[cp12]/44,sl,-2,add(3)(p21),t(6;11)(p22;q1  4),-add(8)(q24.3),add(8)(p22),-9,add(9)(q33),-10,-13,add(21)(q21),+2mar[8]	-1	Standard Chemotherapy	6	FALSE	Negative	AML	1.6767123287671235	1:DECEASED	TP53 (17p13.1):  83% of cells were missing a signal for TP53, consistent with the 17p deletion seen on metaphase analysis.  | RUNX1 (21q22):  15.5% of cells were missing a signal for RUNX1. No  evidence for RUNX1/RUNX1T1 fusion.  | MECOM (3q26.2): 33% o	Yes	No	Skin cancer	Yes	Yes	No	No	No	No	White	-1	Unknown	RUNX1 (p.X170_splice; 26.1%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD58, CD71, CD117,  CD123, HLA-DR +	0	0.333333333	TP53 (p.Q167*; 91.3%)	Standard Chemotherapy	Yes	BCOR (p.Q1658H; MAF 100%)|RUNX1 (Splice Site; MAF 17%)|SF3B1 (p.K666M; MAF 47%)|SRSF2 (p.R180G; MAF 54%)|TP53 (p.Q167; MAF 65%)
aml_ohsu_2022	aml_ohsu_2022_2748	aml_ohsu_2022_2748_BA3332	26	26	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	7	Waves3+4	Yes	7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	46,XX	8	Standard Chemotherapy	3	FALSE	Positive	AML	23.671232876712327	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	8	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD117(+) myeloid precursors comprise 26%of total events and are positive for dim CD7, CD13, CD33, CD38, CD117, HLA-DR, and cyMPO. They are negative for CD34.	0	0.166666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2749	aml_ohsu_2022_2749_BA3375	63	63	0.754385965	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	NA	-1	Bone Marrow Transplant	5	FALSE	Positive	AML	5.6219178082191785	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD13, CD33, CD117 and MPO-positive	1	0.2	NA	Standard Chemotherapy	Yes	CHD2 (p.P1353L; VAF 50%)|CHEK2 (p.T410fs*15; VAF 51%)|FLT3 (p.N676K; VAF 4%)|FLT3-ITD (p.F594delinsLPSDNEYFYVDF (33-nucleotide internal tandem duplication); allelic ratio 0.85; VAF 46%)|IDH1 (p.R132S; VAF 47%)|KMT2A (p.F798L; VAF 49%)|NPM1 (p.W288fs*12; V
aml_ohsu_2022	aml_ohsu_2022_2750	aml_ohsu_2022_2750_BA3100	57	57	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|HiDAC|Venetoclax (ABT-199), Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	UNKNOWN	M2	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	3	FALSE	Positive	AML	19.627397260273973	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	4	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD117, and HLA-DR	0	0.166666667	NA	Standard Chemotherapy	Yes	ARID1B (p.G1483S; VAF 51%)|ATM (p.M3011V; VAF 49%)|DNMT1 (p.V1072I; VAF 48%)|DNMT3A (p.R882H; VAF 44%)|KMT2C (p.R3403C; VAF 50%)|MYD88 (p.A6fs*39; VAF 49%)|NBN (p.V210F; VAF 49%)|NPM1 (p.W288fs*12; VAF 62%)|NRAS (p.G12D; VAF 20%)|TET2 (p.R1359C; VAF 43%)
aml_ohsu_2022	aml_ohsu_2022_2751	aml_ohsu_2022_2751_BA3172	38	41	0	NA	Leukemia	Acute Leukemias of Ambiguous Lineage	Dead-Disease	NA	1	Waves3+4	Yes	ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Azacitidine|Azacitidine, Lenalidomide|Decitabine|Hydroxyurea|Etoposide, Mitoxantrone	7	Salvage|Induction|Re-induction|Supportive/Palliative Care	4	Standard Chemotherapy	1	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Leukaemias Of Ambiguous Lineage	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX,del(6)(q13)[cp3]/46,XX,t(4;7)(q11;p11)[2]	91	Standard Chemotherapy	7	FALSE	Negative	ALAL	37.347945205479455	1:DECEASED	Deletion of MB and 6q21 (Consistent with karyotype)	No	No	NA	No	No	No	No	No	No	Asian	-1	Unknown	NA	1	Female	UNMATCHED	FALSE	Mixed phenotype acute leukaemia, T/myeloid, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	385	0.3	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2752	aml_ohsu_2022_2752_BA3448	27	27	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Negative	TRUE	FALSE	FALSE	46,XX,t(6;11)(q27;q23)[25]	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	47.83561643835616	0:LIVING	MLL: 92/100 cells (92%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL rearrangement and consistent with the 6;11  translocation observed in a companion bone marrow G-banded chromosome  study. One metaphase cell showed the 6;11 	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13 , CD33 , partial CD34 , CD38 , CD58 , CD64 , CD71 , CD117 , CD123 and HLA-DR positive	0	0.266666667	NA	Standard Chemotherapy	Yes	KRAS (p.G12D; MAF 16%)|MLL (PTD)
aml_ohsu_2022	aml_ohsu_2022_2753	aml_ohsu_2022_2753_BA3290	66	67	0	ASXL1 (p.G646Wfs*12; 36.6%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	3	Induction|Supportive/Palliative Care	2	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	46,XY,del(12)(p11.2)[9]/46,XY[11]	6	Standard Chemotherapy	12	FALSE	Negative	AML	7.627397260273973	1:DECEASED	Normal	No	No	NA	No	No	No	No	Yes	Yes	White	6	Refractory	RUNX1 (p.D198N; MAF 6%)	1	Male	MATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	dim partial CD7, CD13, CD33, CD34, dim CD38, CD58,  CD117, dim CD123, HLA-DR and partial TdT+	0	0.666666667	NA	Standard Chemotherapy	Yes	RUNX1 (p.D198N; MAF 6%)|SF3B1 (p.K666N; MAF 45%)|SRSF2 (p.P95H; MAF 46%)
aml_ohsu_2022	aml_ohsu_2022_2754	aml_ohsu_2022_2754_BA3381	51	51	0	ASXL1 (p.G646Wfs*12; 32.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves3+4	Yes	HiDAC + Midostaurin|Fludarabine, TBI|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Decitabine, Venetoclax	5	Consolidation|Induction|Allogeneic - Child|Maintenance|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant	2	Decitabine, Venetoclax	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	5	FALSE	Negative	AML	15.978082191780823	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	Black	6	Complete Response	RUNX1 (p.F259Sfs*338; 18.3%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD58, dim CD71, CD117, dim CD123  and HLA-DR+	0	0.266666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.S1236A; MAF 51% )|CBL (p.R420Q, MAF 3%)|CBL (p.Y368_C372delinsP; MAF 9%)|DNMT3A (p.E616*; MAF 50%)|FLT3 (p.D835V; MAF 37%)|FLT3-ITD (Allelic Ratio = .03)|SF3B1 (p.K666N; MAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2755	aml_ohsu_2022_2755_BA3436	23	23	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	mono	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|FLAG-IDA, Gemtuzumab|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XX[8]	-1	Bone Marrow Transplant	5	FALSE	Positive	AML	49.64383561643835	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, partial CD34, CD38, CD58, dim CD71, CD117,  CD123, and cMPO+	0	0.2	NA	Standard Chemotherapy	Yes	CEBPA (p.A199fs*114; MAF 50%)|EZH2 (p.R288*; MAF46%)|GATA2 (p.A372T; MAF 31%)|NPM1 (p.W288fs*12; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2756	aml_ohsu_2022_2756_BA3292	64	65	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin) plus Samalizumab|MiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Bone Marrow Transplant|Targeted Therapy - Other	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	UNKNOWN	M2	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	1	FALSE	Negative	AML	56.81095890410959	0:LIVING	Normal	Yes	No	Amyloid angiopathy|Basal Cell Carcinoma|Bladder Cancer|Monoclonal Gammopathy of Undetermined Significance (MGUS)	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, dimCD38, CD71, CD117, dimCD123,  HLA-DR and dim MPO positive	0	0.066666667	NA	Targeted Therapy - Other	Yes	SRSF2 (p.P95R; MAF 3%)
aml_ohsu_2022	aml_ohsu_2022_2757	aml_ohsu_2022_2757_BA3194	NA	NA	0	NA	Leukemia	Acute Myeloid Leukemia	NA	mono	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	12	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Unknown	Peripheral Blood	NA	9	0.533333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2758	aml_ohsu_2022_2758_BA3152	74	74	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Azacitidine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Azacitidine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	43~44,XY,der(5)t(5;15)(q22;q11.2),add(6)(p23),-15,-16,-17,add(18)(q21),add(  19)(q13.1),-21,+mar1,+mar2[cp20]	3	Standard Chemotherapy	3	FALSE	Negative	AML	0.1643835616438356	1:DECEASED	Approximately 95% of cells had abnormal signal patterns consistent with the metaphase karyotype and reflecting deleted 5q, monosomy 16, monosomy 17, and monosomy 21.	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD11b, CD13, partial CD14, CD33, CD34, partial CD64, CD117, HLA-DR and dim MPO (+)	0	0.166666667	TP53 (p.Y220C; 90.9%)	NA	Yes	TP53 (p.Y220C;  MAF 91%)
aml_ohsu_2022	aml_ohsu_2022_2759	aml_ohsu_2022_2759_BA3137	39	39	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves3+4	Yes	Ruxolitinib|7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|HIDAC + Gemtuzumab Ozogamicin|Busulfan, Cyclophospha	7	Consolidation|Salvage|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	6	Standard Chemotherapy|Bone Marrow Transplant	2	Ruxolitinib	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY,inv(16)(p13.1q22)[20]	-1	Standard Chemotherapy	1	FALSE	Negative	AML	24.69041095890411	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD117, HLA-DR, MPO  (the monocytic cells show an aberrant immunophenotype: CD11b, CD13, variable CD14, variable CD15, CD33, CD64, HLA-DR positive)	0	0.066666667	NA	Standard Chemotherapy	Yes	CUX1 (p.V88I; VAF 50%)|NRAS (p.G13D; VAF 6%)|NRAS (p.Q61H ((different allele from p.Q61K); VAF 3%)|NRAS (p.Q61K (different allele from p.Q61H); VAF 18%)|PTPN11 (p.G60R; VAF 3%)|USH2A (p.R2557T; VAF 48%)
aml_ohsu_2022	aml_ohsu_2022_2760	aml_ohsu_2022_2760_BA3237	NA	76	0	ASXL1 (p.C594Mfs*25; 38.2%)	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	6	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Unknown	Peripheral Blood	NA	0	0.333333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2761	aml_ohsu_2022_2761_BA3179	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves3+4	Yes	Cytarabine|Azacitidine	2	Salvage|Induction	2	Standard Chemotherapy|Supportive/Palliative Care	2	Cytarabine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	47,XX,+8[1]/46,XX[19]	42	Standard Chemotherapy	6	FALSE	Negative	AML	2.893150684931507	1:DECEASED	5/200 (2.5%) interphase cells scored had three signals for both  probes, consistent with trisomy 8. One metaphase spread showed three  chromosomes 8, each with a centromere signal and a MYC signal in the long  arm.	No	No	NA	Yes	Yes	No	No	No	No	White	42	UNKNOWN	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD117 and HLA-DR+	0	0.366666667	NA	Standard Chemotherapy	Yes	BCOR (p.E130*, MAF 17%)|IDH2 (p.R140Q; MAF 4%)|KMT2D (p.P2938L; MAF 54%)|KMT2D (p.P657L; MAF 49%)|NRAS (p.T58I; MAF 6%)|PTPN11 (p.E76D; MAF 7%)|SRSF2 (p.P95H; MAF 31%)|STAG2 (p.R614*; MAF 16%)
aml_ohsu_2022	aml_ohsu_2022_2762	aml_ohsu_2022_2762_BA3409	64	65	1	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves3+4	Yes	J1219, quizartinib|7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|Sorafenib|Valproic Acid|E1906, topotecan, carboplatin	7	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	46,XX[20]	21	Targeted Therapy - Kinase Inhibitor(s)	7	FALSE	Negative	AML	8.810958904109588	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.333333333	NA	Standard Chemotherapy	Yes	FLT3-ITD
aml_ohsu_2022	aml_ohsu_2022_2763	aml_ohsu_2022_2763_BA3295	63	63	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin|HiDAC|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|FLAG-Ida-Mylotarg	5	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	UNKNOWN	M2	Negative	FALSE	FALSE	FALSE	46,XY,inv(16)(p13.1q22)[20]	-1	Bone Marrow Transplant	5	FALSE	Negative	AML	31.33150684931507	0:LIVING	CBFB/MYH11: 91% of cells had the 1r1g2f dual-fusion signal pattern consistent with CBFB/MYH11 fusion and inv(16).	Yes	Yes	Prostate Cancer	No	No	No	No	No	No	White	7	Complete Response	NA	1	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Myeloid blast population, about 25%: CD13, CD33, CD34, CD117, HLA-DR and MPO.   | Atypical monocyte population, about 20%: dim CD4, partial CD9, bright CD11b, CD13, CD14, CD33, CD64, HLA-DR and MPO	0	0.3	NA	Standard Chemotherapy	Yes	NOTCH1 (p.V1739M; VAF 48%)|NRAS (p.Q61K; VAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2764	aml_ohsu_2022_2764_BA3453	76	76	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	No	Decitabine	1	Supportive/Palliative Care	1	Targeted Therapy - Kinase Inhibitor(s)	1	Decitabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX[20]	9	Targeted Therapy - Kinase Inhibitor(s)	10	FALSE	Positive	AML	0.6246575342465753	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	A large blastic population, positive for CD13, CD15, CD33, CD38, dim CD45, dim CD64, CD117, HLA-DR, and MPO	0	0.4	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2765	aml_ohsu_2022_2765_BA3176	53	53	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	HiDAC|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MEC (Cytarabine, Etoposide, Mitoxantrone) plus Midostaurin	3	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone) plus Midostaurin	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	47,XX,+4[3]/46,XX[17]	-1	Standard Chemotherapy	11	FALSE	Positive	AML	10.717808219178082	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	4	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD7, CD13, CD33, CD38, CD117 and HLA-DR+	0	0.633333333	NA	Standard Chemotherapy	Yes	DNMT3A (p.N879D; VAF 37%)|NPM1 (p.W288fs*12; VAF 28%)|PTPN11 (p.A461T; VAF 3%)|RAD21 (p.E534*; VAF 4%)|SMC1A (p.R496H; VAF 31%)
aml_ohsu_2022	aml_ohsu_2022_2766	aml_ohsu_2022_2766_BA3380	21	23	5.666666667	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	7	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	NA	Positive	FALSE	FALSE	FALSE	Normal	NA	None	2	FALSE	Negative	AML	17.0958904109589	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.033333333	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2767	aml_ohsu_2022_2767_BA3203	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	6	Waves3+4	Yes	Busulfan, Fludarabine|HiDAC|3+7 (Cytarabine, Daunorubicin)	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	HISPANIC	NA	Negative	TRUE	FALSE	FALSE	NA	6	Bone Marrow Transplant	2	FALSE	Negative	AML	10.191780821917808	1:DECEASED	The translocations commonly seen in AML are not detected. 3 copies of RUNX1T1 gene at 8q22 are detected in 56% of cells. Loss of RUNX1 and RARA genes at 21q22 and 17q21 are detected in about 58% of cells Gain of MLL gene at 11q23 are detected in 82% of ce	No	No	NA	No	No	No	No	No	No	Unknown	7	Refractory	NA	1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	THESE ARE POSITIVE FOR HLA-DR, CD117, CD34, CD33 AND CD13. POSITIVE FOR HLA-DR, CD117, CD34, CD33 AND CD13. (Bone Marrow Immunnophenotype)	0	0.066666667	TP53 (p.P153Afs*28; 75.8%)	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2768	aml_ohsu_2022_2768_BA3154	29	29	0	NA	Leukemia	Acute Leukemias of Ambiguous Lineage	Dead-Other	NA	7	Waves3+4	Yes	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Leukaemias Of Ambiguous Lineage	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	30~35<1n>,XX,+1,+2,+6,+10,+11,+12,+18,+19,+21,+22[cp6]/46XX[20]	NA	None	3	FALSE	Negative	ALAL	8.416438356164385	1:DECEASED	Negative for 9;22 and MLL	Yes	No	Breast Cancer	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	Mixed phenotype acute leukaemia, B/myeloid, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for dim CD2 (aberrant), CD11b (aberrant), CD13, CD33, CD34, CD38, CD117, HLA-DR, and dim nTdT (aberrant)	0	0.133333333	TP53 (p.V122Dfs*26; 87.5%)	NA	Yes	CREBBP|NF1|TP53
aml_ohsu_2022	aml_ohsu_2022_2769	aml_ohsu_2022_2769_BA3185	75	75	0	ASXL1 (p.G646Wfs*12; 33.3%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	Entospletinib, Azacitidine|Entospletinib	2	Induction|Re-induction	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Entospletinib, Azacitidine	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	47,XY,+13[20]/47,XY,+8[1]	-1	Standard Chemotherapy	11	FALSE	Negative	AML	2.4657534246575343	0:LIVING	Low level gain of chromosome 8 sequences (trisomy). Loss of 21q22 sequences (monosomy)	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	RUNX1 (p.H105Afs*33; 41.2%)|RUNX1 (p.T104R; 53.3%)	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, HLA-DR, and CD34	0	0.433333333	NA	Targeted Therapy - Kinase Inhibitor(s)	Yes	ASXL1|RUNX1|SRSF2|TET2
aml_ohsu_2022	aml_ohsu_2022_2770	aml_ohsu_2022_2770_BA3180	27	27	0.886792453	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Azacitidine	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	TRUE	FALSE	FALSE	NA	-1	Bone Marrow Transplant	8	FALSE	Positive	AML	3.8136986301369866	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.333333333	NA	Standard Chemotherapy	Yes	FLT3-ITD|IDH2
aml_ohsu_2022	aml_ohsu_2022_2771	aml_ohsu_2022_2771_BA3395	68	68	NA	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine|Azacitidine, Lenalidomide|Decitabine	4	Unknown|Induction|Re-induction	3	Standard Chemotherapy	1	Decitabine	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	NA	FALSE	FALSE	FALSE	41~46,XY,add(4)(p16),del(5)(q15q33),inv(7)(q11q34),-13,add(14)(p11.1),-16,-17,-18,add(19)(q13.1),-20,i(21)(q10),+1~4mar[cp10]/43~45,idem,-add(4)(p16),der(4)add(4)(p16)add(4)(q31)[cp10]	9	Standard Chemotherapy	NA	FALSE	NA	AML	11.30958904109589	1:DECEASED	5q deletion (64%) | Monosomy 16 and derivative chromosome 16 (91%)	No	No	NA	No	No	No	No	No	No	White	7	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD13, CD33, CD34, CD56, CD117, dim CD123, HLA-DR, partial TdT positive	132	NA	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2772	aml_ohsu_2022_2772_BA3308	78	78	0	ASXL1 (p.G646Wfs*12; 34.3%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	No	AG-221|Imatinib|Midostaurin|Interferon	4	Salvage|Maintenance|Supportive/Palliative Care	3	Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	2	AG-221	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	47,XY,del(6)(q13),+8[8]/47,idem,-8,+13[2]/46,XY,del(13)(q14q22),del(20)(q11.2)[6]/46,XY[4]	191	Targeted Therapy - Kinase Inhibitor(s)	14	FALSE	Negative	AML	10.487671232876712	1:DECEASED	RUNX1T1: 22/200 cells (11%) had a 3 red/ 2 green signal  pattern, reflecting an extra RUNX1T1 (8q21.3) signal, consistent with the  trisomy 8 clone observed in the metaphase karyotype | RUNX1: 18/200 cells (9%) had a 2  red/ 3 green signal pattern, refle	No	No	NA	No	No	No	No	Yes	Yes	White	NA	NA	RUNX1 (p.R162S; 84.5%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	NA	0	0.766666667	TP53 (p.X187_splice; 9.3%)	NA	Yes	IDH2 (p.R140Q; MAF 45%)|KRAS (p.Q61R; MAF 5%)|NOTCH1 (p.P2412L; MAF 57%)|RUNX1 (p.R162S; MAF 74%)|SRSF2 (p.P95H; MAF 54%)|TP53 (Splice site; MAF 9%)
aml_ohsu_2022	aml_ohsu_2022_2773	aml_ohsu_2022_2773_BA3268	73	73	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Azacitidine, Ivosidenib|Ivosidenib	2	Induction|Maintenance	2	Standard Chemotherapy|Targeted Therapy - Other	2	Ivosidenib	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,X,-X,add(5)(q23),del(7)(q22),add(11)(p13),add(21)(q22),+mar1[9]/47,sl,add(3)(q28),+5,-add(5)(q23),+mar2[3]/46,XX[1]	-1	Targeted Therapy - Other	4	FALSE	Negative	AML	33.797260273972604	0:LIVING	D7S486/ CEP 7:  93/100 cells (90%) had a 1 red/ 2 green signal pattern, consistent with the deleted 7q observed in the metaphase karyotype.  | RUNX1T1/RUNX1:  10/200 cells (5%) had a 2 red/ 3 green signal pattern, suggesting low level presence of an extra	No	No	NA	No	No	No	No	No	No	White	324	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, dim CD13, CD33, CD34, CD38, CD117, partial HLA-DR, and partial MPO	0	0.2	NA	Standard Chemotherapy	Yes	DNMT3A (Splice site; VAF 46%)|IDH1 (p.R132S; VAF 44%)|STAG2 (p.F437fs*11; VAf 48%)
aml_ohsu_2022	aml_ohsu_2022_2774	aml_ohsu_2022_2774_BA3249	NA	28	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	2	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Unknown	Peripheral Blood	NA	0	0.066666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2775	aml_ohsu_2022_2775_BA3345	59	59	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	8	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	FALSE	FALSE	TRUE	47,XX,+8[20]	4	Standard Chemotherapy	4	FALSE	Negative	AML	1.8739726027397259	0:LIVING	POSITIVE for RUNX1T1 copy number gain	No	No	NA	Yes	Yes	No	No	No	No	Black	4	Complete Response	RUNX1 (p.S100F; 39.6%)	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.2	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2776	aml_ohsu_2022_2776_BA3146	42	42	0.176470588	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves3+4	Yes	HIDAC + Gemtuzumab Ozogamicin|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	5	FALSE	Positive	AML	4.602739726027397	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD7, CD13, CD25, CD33, partial CD34, CD117, dim CD123, HLA-DR, and MPO.	0	0.166666667	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882H; VAF 45%)|FLT3-ITD (allelic ratio 0.85; VAF 45.9%)|NPM1 (p.W288fs*12; VAF 69%)
aml_ohsu_2022	aml_ohsu_2022_2777	aml_ohsu_2022_2777_BA3230	71	71	0.694915254	ASXL1 (p.E635Rfs*15; 22.0%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XX,del(12)(p12p13)[23]	-1	Standard Chemotherapy	5	FALSE	Negative	AML	10.816438356164383	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	-1	UNKNOWN	NA	1	Female	UNMATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD5, CD13, dim CD33, CD34, variable CD38, CD58, CD117, dim CD123 and HLA-DR positive	0	0.2	NA	Standard Chemotherapy	Yes	CREBBP (W1745*; MAF ~50%)|FLT3-ITD (MAF ~50%)|SF3B1 (p.K666M; MAF ~50%)
aml_ohsu_2022	aml_ohsu_2022_2778	aml_ohsu_2022_2778_BA3119	61	61	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XX[20]	101	Standard Chemotherapy	6	FALSE	Positive	AML	25.775342465753425	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD33, CD38, CD117, MPO positive	0	0.266666667	NA	Standard Chemotherapy	Yes	ASXL1 (p.L1395V; VAF 50%)|IDH1 (p.R132H; VAF 45%)|KMT2D (p.R3167W; VAF 48%)|NPM1 (p.W288fs*12; VAF 48%)
aml_ohsu_2022	aml_ohsu_2022_2779	aml_ohsu_2022_2779_BA3205	49	49	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Decitabine	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	Inv(3)(q21q26.2)	4	Standard Chemotherapy	2	FALSE	Negative	AML	34.750684931506854	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.1	NA	Standard Chemotherapy	Yes	GATA2 (p.Y322C; VAF 32%)|SF3B1 (p.H662Q; VAF 39%)
aml_ohsu_2022	aml_ohsu_2022_2780	aml_ohsu_2022_2780_BA3451	47	47	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	UNKNOWN	M5	Negative	TRUE	FALSE	FALSE	46,XX[20]	95	Standard Chemotherapy	4	FALSE	Positive	AML	38.827397260273976	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4, CD11b, CD13, CD33, variable CD14, CD38,  dim CD56, CD58, bright CD64, dim CD123, HLA-DR, and partial MPO +	0	0.166666667	NA	Standard Chemotherapy	Yes	KRAS (p.G13D; MAF 36%)|NPM1 (p.W288fs*12; MAF 44%)|TET2 (p.Q897*; MAF 39%)
aml_ohsu_2022	aml_ohsu_2022_2781	aml_ohsu_2022_2781_BA3376	58	58	1.040816327	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	Gilteritinib or Placebo|HiDAC + Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Induction|Maintenance	4	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Gilteritinib or Placebo	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Other	2	FALSE	Positive	AML	26.400000000000002	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, CD13, CD33, variable CD34, CD38, CD117, CD123, and MPO positive	0	0.033333333	NA	Standard Chemotherapy	Yes	CEBPA (p.G242S; VAF 47%)|FLT3-ITD (allelic ratio 1.03; VAF 51%)|NPM1 (p.W290fs*10; VAF 49%)|SYNE1 (p.A2715G; VAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2782	aml_ohsu_2022_2782_BA3325	56	57	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|CSF1R inhibitor|IMGN779 (Immunogen Trial)|Decitabine	6	Salvage|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	3	Gilteritinib (ASP2215)	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Targeted Therapy - Kinase Inhibitor(s)	3	FALSE	Negative	AML	18.673972602739727	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.133333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2783	aml_ohsu_2022_2783_BA3175	62	63	0.234567901	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Decitabine, anti-PD1, anti-TIM3|7+3 (Cytarabine, Idarubicin)|JNJ-40346527 (CSF1R inhibitor)|Mitoxantrone|FLAG, Midostaurin	5	Salvage|Induction|Re-induction	3	Standard Chemotherapy|Targeted Therapy - Other	2	Mitoxantrone	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Positive	FALSE	FALSE	FALSE	46,XY,t(1;3)(p36;q21)[2]/46,sl,-1,+der(1)t(1;3)(p36;q21)[15]/46,sl,add(3)(q12)[2]/46,sl,-1,+t(1;3)(p36;q21),-3[1]	0	Standard Chemotherapy	8	FALSE	Negative	AML	12.263013698630136	1:DECEASED	MECOM/RPN1: 171/200 cells (85.5%) had a 2 red/ 3 green signal pattern,  reflecting an extra RPN1 (3q21.3) signal, consistent with RPN1 disruption  due to the 1;3 translocation observed in the metaphase karyotype. There  was no evidence for MECOM/RPN1 fu	No	No	NA	No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.D198N; 44.9%)	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD7, CD13, CD33, CD34, CD117, and HLA-DR positive	248	0.333333333	NA	Standard Chemotherapy	Yes	BCL2 (p.A32G; VAF 48%)|FLT3-ITD (p.N609delinsIIPCPEYDLKWEFPREN; VAF 19%, allelic ratio 0.24)|GATA2 (p.S201fs*1; VAF 13%)|NPM1 (p.H30Q; VAF 3%)|NRAS (p.G12D; VAF 72%)|RUNX1 (p.D198N; VAF 44%)|WT1 (p.R380fs*5; VAF 45%)|WT1 (p.V371fs*14; VAF 22%)|ZRSR2 (p.P3
aml_ohsu_2022	aml_ohsu_2022_2784	aml_ohsu_2022_2784_BA3173	45	46	0.075268817	NA	Leukemia	Acute Myeloid Leukemia	Dead-Unknown	NA	6	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	3	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	FALSE	FALSE	FALSE	46,XX,t(8;21)(q22;q22)[15]/46-47,sl,+6,add(13)(p11.2),add(15)(q26),-16,+19,+22[cp5]	4	Standard Chemotherapy	5	FALSE	Positive	AML	15.024657534246575	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	Black	7	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Residual Disease	Peripheral Blood	NA	0	0.133333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2785	aml_ohsu_2022_2785_BA3085	14	14	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Cytarabine	3	Induction|Intensification	2	Standard Chemotherapy|Intrathecal	2	HiDAC	Intensification	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	NA	Negative	TRUE	FALSE	FALSE	45,X,-X,t(8;21)(q22;q22)[20]	9	Standard Chemotherapy	1	FALSE	Negative	AML	50.07123287671233	0:LIVING	RUNX1T1/RUNX1: 92/100 cells (92%) had a 1red/ 1 green/ 2 yellow fusion signal pattern, reflecting RUNX1T1/RUNX1fusion	No	No	NA	No	No	No	No	No	No	White	17	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD13, dim CD19, CD33, CD34, CD38, CD58, CD117,  CD123, HLA-DR and MPO	0	0.033333333	NA	Standard Chemotherapy	Yes	NRAS (p.G12D; MAF 6%)
aml_ohsu_2022	aml_ohsu_2022_2786	aml_ohsu_2022_2786_BA3445	NA	NA	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	2	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	Unknown	Unknown	Peripheral Blood	NA	0	0.1	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2787	aml_ohsu_2022_2787_BA3354	83	83	0	ASXL1 (p.G646Wfs*12; 26.2%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Azacitidine	1	Maintenance	1	Standard Chemotherapy	1	Azacitidine	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	46,XY[19]	-1	Standard Chemotherapy	9	FALSE	Negative	AML	3.3863013698630136	1:DECEASED	Normal	No	No	NA	Yes	Yes	No	No	No	No	Unknown	NA	NA	RUNX1 (p.R204*; 43.0%)	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD58, CD117, and MPO	0	0.366666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2788	aml_ohsu_2022_2788_BA3357	75	75	0.162790698	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	mono	1	Waves3+4	Yes	Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|Gilteritinib, Decitabine|PIM kinase inhibitor	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy|Targeted Therapy - Other	2	PIM kinase inhibitor	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	47,XY,+21[2]/46,XY[18]	21	Targeted Therapy - Other	3	FALSE	Negative	AML	19.16712328767123	1:DECEASED	RUNX1 (21q22): 19/200 cells (9.5%) had three signals for RUNX1, consistent with trisomy 21.	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	dimCD7, dimCD11b, dimCD13, CD33, varibleCD34, CD38, CD117, partial HLA-DR, and MPO positive	0	0.1	NA	Standard Chemotherapy	Yes	CEBPA (p.R300_D301delinsQY; VAF 85%)|FLT3-ITD (VAF 15%; allelic ratio 0.18)|GATA2 (p.G320S; VAF 30%)|NOTCH1 (p.A929D; VAF 52%)|RAD21 (p.E447fs*19; VAF 3%)|RAD21 (p.N462fs*1; VAF 3%)
aml_ohsu_2022	aml_ohsu_2022_2789	aml_ohsu_2022_2789_BA3178	71	71	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	M5a	Negative	TRUE	FALSE	FALSE	49,XY,+8,+8,t(9;11)(p22;q23),+der(9)t(9;11)	-1	Standard Chemotherapy	NA	FALSE	Negative	AML	5.884931506849314	1:DECEASED	8q22 (RUNX1T1): gain of two copies present  11q23 (MLL): rearrangement present (95% RUNX, 91% MLL)	No	No	NA	No	No	No	No	No	No	NA	-1	UNKNOWN	NA	2	Male	UNMATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD4+, CD33+, CD117+, HLA-DR+ myeloblasts	7	NA	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2789	aml_ohsu_2022_2789_BA3282	71	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	3	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Re-induction	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M5a	Negative	FALSE	FALSE	FALSE	49,XY,+8,+8,t(9;11)(p22;q23),+der(9)t(9;11)	-1	Standard Chemotherapy	1	FALSE	Negative	AML	5.884931506849314	1:DECEASED	8q22 (RUNX1T1): gain of two copies present  11q23 (MLL): rearrangement present (95% RUNX, 91% MLL)	No	No	NA	No	No	No	No	No	No	NA	-1	UNKNOWN	NA	2	Male	UNMATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Post-Chemotherapy	Peripheral Blood	NA	178	0.033333333	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2790	aml_ohsu_2022_2790_BA3103	49	49	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,inv(16)(p13.1q22)[18]/46,XX[2]	-1	Standard Chemotherapy	5	FALSE	Negative	AML	7.397260273972603	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.166666667	NA	Standard Chemotherapy	Yes	KIT|KRAS|MYH11 (CBFB-MYH11 fusion)
aml_ohsu_2022	aml_ohsu_2022_2791	aml_ohsu_2022_2791_BA3129	NA	NA	0.204819277	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	unknown	unknown	unknown	NA	NA	None	4	FALSE	Positive	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Unknown	Peripheral Blood	NA	0	0.166666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2792	aml_ohsu_2022_2792_BA3271	62	62	0.666666667	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XX[20]	6	Standard Chemotherapy	9	FALSE	Positive	AML	0.7561643835616438	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Unknown	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD4, dim CD7, CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and dim partial MPO (Myeloid Blast Population) | CD4, CD11b, CD13, dim CD14, dim CD15, CD16, CD33, CD38, CD58, CD63, CD123, HLA-DR  (Promonocyte/Monocyte Blast Population)	0	0.333333333	NA	Standard Chemotherapy	Yes	FLT3-ITD (ITD; MAF 45%)|IDH2 (p.R140Q; MAF 38%)|NPM1 (p.W288fs*12; MAF 41%)
aml_ohsu_2022	aml_ohsu_2022_2793	aml_ohsu_2022_2793_BA3177	66	66	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	UNKNOWN	NA	Negative	TRUE	FALSE	FALSE	NA	NA	None	2	FALSE	Negative	AML	0.03287671232876713	1:DECEASED	NA	No	No	NA	No	No	No	No	No	No	Unknown	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Leukapheresis	partial CD1a, CD13, variable CD14, CD33, CD34, CD38, dim CD117, HLA-DR and cMPO	0	0.066666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2794	aml_ohsu_2022_2794_BA3327	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	7	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,del(1),del(5q),der(7)add(7)(p11.1)add(7)(q32),add(11)(q23),del(13)(q22)[12]/46,sl,-del(1),+der(1)del(1)(p13p32)del(1)(q12q25)[8]	NA	None	1	FALSE	Negative	AML	3.9452054794520546	1:DECEASED	negative for MLL and deletion 7	No	No	NA	No	No	No	No	No	No	White	NA	NA	RUNX1	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for dim CD2 (aberrant), CD11b (aberrant), CD13, CD33, CD34, CD38, CD117, HLA-DR, and dim nTdT (aberrant)	0	0.066666667	NA	NA	Yes	NRAS|PTPN11|RUNX1|STAG2
aml_ohsu_2022	aml_ohsu_2022_2795	aml_ohsu_2022_2795_BA3309	NA	NA	0.960784314	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Positive	unknown	unknown	unknown	NA	NA	None	6	FALSE	Positive	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	NA	UNMATCHED	FALSE	AML with mutated NPM1	Unknown	Leukapheresis	NA	0	0.266666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2796	aml_ohsu_2022_2796_BA3406	33	33	0.492537313	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	TRUE	FALSE	FALSE	46, XY[20]	6	Standard Chemotherapy	6	FALSE	Negative	AML	0.9863013698630136	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	NA	6	UNKNOWN	NA	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.233333333	NA	Standard Chemotherapy	Yes	BCOR (p.G1n1626; MAF 62.2%)|FLT3-ITD (p.Glu598_Tyr599ins9)|WT1 (p.Arg370fs; MAF 27.7%)
aml_ohsu_2022	aml_ohsu_2022_2797	aml_ohsu_2022_2797_BA3326	63	63	0	ASXL1 (p.G646Wfs*12; 36.6%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves3+4	Yes	Venetoclax (ABT-199), Azacitidine	1	Induction	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	47,XY,+6[4]/49,sl,+6,+22[2]/49,sl,+4,+8,i(8)(q10)x2[5]/47,XY,+r[2]/46,XY[7]	29	Standard Chemotherapy	3	FALSE	Negative	AML	1.7095890410958905	1:DECEASED	Gain of 8q22, 8 centromere and 16q22 sequences	Yes	No	Prostate Cancer	No	No	No	No	No	No	White	29	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.166666667	NA	Standard Chemotherapy	Yes	ASXL1 (G64Wfs*12; VAF 39%)|NRAS (Q61K; VAF 33%)|TET2 (Q892*; VAF 49%)
aml_ohsu_2022	aml_ohsu_2022_2798	aml_ohsu_2022_2798_BA3183	64	64	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Treatment	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	5	Consolidation|Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	46,XY[20]	-1	Bone Marrow Transplant	4	FALSE	Positive	AML	11.07945205479452	1:DECEASED	Normal	No	No	NA	No	No	Yes	Yes	No	No	White	5	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD13, CD33, CD38, CD58, CD117, CD123, partial MPO+	0	0.2	NA	Standard Chemotherapy	Yes	ATM (p.H1136R; MAF 45%)|DNMT3A (p.R882H; MAF 46%)|IDH1 (p.R132H; MAF 27%)|IDH2 (p.D314V (Low allele frequency, subclonal), MAF 2%)|IDH2 (p.R140Q; MAF 18%)|KRAS (p.G12A; MAF 3%)|NPM1 (p.W288fs*12; MAF 49%)|U2AF1 (p.D208E; MAF 46%)
aml_ohsu_2022	aml_ohsu_2022_2799	aml_ohsu_2022_2799_BA3439	68	68	0	ASXL1 (p.G644Wfs*12; 37.3%)	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	No	Ruxolitinib	1	Experimental	1	Targeted Therapy - Kinase Inhibitor(s)	1	Ruxolitinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	47,XY,+21[14]/46,XY[6]	-1	Targeted Therapy - Kinase Inhibitor(s)	5	FALSE	Negative	AML	19.33150684931507	1:DECEASED	Trisomy 21 (48.5% had an extra AML1 signal, consistent with the karyotype.)	No	No	NA	No	No	Yes	Yes	No	No	White	NA	NA	RUNX1 (p.R320*; 61.6%)	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	NA	0	0.266666667	NA	NA	Yes	JAK2 (87% allele burden)
aml_ohsu_2022	aml_ohsu_2022_2800	aml_ohsu_2022_2800_BA3284	56	56	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	1	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[20]	NA	None	7	FALSE	Positive	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, bright CD33, partial CD34, CD38, CD117, dim HLA-DR+, dim MPO	0	0.3	NA	NA	Yes	BLM (p.D1010fs*24; VAF 51%)|FLT3 (p.N676T; VAF 7%)|FLT3 (p.N841I; VAF 5%)|FLT3-D835 (p.D835H; VAF 7%)|FLT3-D835 (p.D835Y; VAF 6%)|NBN (p.L421S; VAF 48%)|NPM1 (p.W288fs*12; VAF 47%)|PTPN11 (p.E76Q; VAF 5%)|STAG2 (p.I1063fs*10; VAF 64%)
aml_ohsu_2022	aml_ohsu_2022_2801	aml_ohsu_2022_2801_BA3201	68	67	0	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Dead-Disease	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|Dasatinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine	5	Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Experimental|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	4	Decitabine	Experimental	NA	Myelodysplastic Syndromes	NonAML	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	45,X,-Y[4]/46,XY[16]	-1	Supportive/Palliative Care	4	FALSE	Negative	MDS	42.87123287671233	1:DECEASED	Normal	Yes	Yes	Dupuytren's|Skin cancer	Yes	Yes	No	No	No	No	White	912	Complete Response	NA	2	Male	UNMATCHED	TRUE	Unknown	NA	Bone Marrow Aspirate	NA	0	0.233333333	NA	Standard Chemotherapy	No	IKZF1 (p.C492G; MAF 9%)|KRAS (p.G12V; MAF 11%)|SF3B1 (p.K700E; MAF 13%)
aml_ohsu_2022	aml_ohsu_2022_2801	aml_ohsu_2022_2801_BA3358	68	67	0	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Dead-Disease	NA	1	Waves3+4	Yes	Fludarabine, Melphalan|Dasatinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine	5	Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Experimental|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	4	Decitabine	Experimental	NA	Myelodysplastic Syndromes	NonAML	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XY[14]	-1	Supportive/Palliative Care	1	FALSE	Negative	MDS	42.87123287671233	1:DECEASED	Normal	Yes	Yes	Dupuytren's|Skin cancer	Yes	Yes	No	No	No	No	White	912	Complete Response	NA	2	Male	UNMATCHED	TRUE	Unknown	NA	Bone Marrow Aspirate	NA	120	0.066666667	NA	Standard Chemotherapy	No	IKZF1 (p.C492G; MAF 4%)|KRAS (p.G12V; MAF 4%)|SF3B1 (p.K700E; MAF 7%)
aml_ohsu_2022	aml_ohsu_2022_2802	aml_ohsu_2022_2802_BA3204	58	58	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	7	Waves3+4	Yes	BP1001 plus LDAC	1	Experimental	1	Targeted Therapy - Other	1	BP1001 plus LDAC	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	FALSE	44-45,XY,-3,-5,der(7)del(7)(q22)inv(7)(p13q22),del(12)9p11.2),add(19)(q13.1),+mar[cp20]	28	Targeted Therapy - Other	2	FALSE	Negative	AML	2.6301369863013697	1:DECEASED	NA	Yes	No	Lung Cancer	No	No	No	No	No	No	White	NA	NA	NA	1	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	Myeloid blasts comprise 16% of total events and are positive for CD13, CD33, CD34, CD38 (reduced), CD117, HLA-DR and cyMPO. They are negative for CD11b, CD11c, CD14, CD15, CD56, CD64, TdT, B- and other T-cell markers	0	0.133333333	TP53 (p.G266R; 41.8%)|TP53 (p.Y220C; 46.5%)	NA	Yes	TP53
aml_ohsu_2022	aml_ohsu_2022_2803	aml_ohsu_2022_2803_BA3298	66	66	0	ASXL1 (p.G646Wfs*12; 11.9%)|ASXL1 (p.R417*; 23.6%)	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|IDAC	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,del(9)(q13q22)[4]/46,XY[16]	-1	Standard Chemotherapy	11	FALSE	Negative	AML	13.183561643835617	0:LIVING	This analysis showed evidence of t(8;21)(q22;q22) (RUNX1T1-RUNX1 translocation) in a total of 152/200 (76.0 percent) cells scored. The signal pattern observed with this probe set is suggestive of a  three-way rearrangement.  | A subset of these cells (109	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Male	MATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.533333333	NA	Standard Chemotherapy	Yes	ASXL1 (p.Gly646fs; MAF 2.4%)|ASXL1 (p.Ser1143Arg; MAF 49.2%)|KIT (p.Asn822Lys; MAF 5.6%)|NRAS (p.Gly12Cys; MAF 1.2%)|SF3A1 (p.Arg95Cys; MAF 49.9%)|TET2 (p.Gln913fs; MAF 3%)|TET2 (p.Glu537*; MAF 19.3%)
aml_ohsu_2022	aml_ohsu_2022_2804	aml_ohsu_2022_2804_BA3182	30	30	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA, Gemtuzumab|Methotrexate	4	Consolidation|Induction	2	Standard Chemotherapy|Intrathecal	2	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY,del(7)(q32q36),inv(16)(p13.1q22)[20]	38	Standard Chemotherapy	NA	FALSE	Negative	AML	35.37534246575342	0:LIVING	CBFB/MYH11: 90% of cells had a 1r1g2f dual-fusion signal pattern consistent with CBFB/MYH11 fusion and inv(16).	No	No	NA	No	No	No	No	No	No	White	5	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	Myeloid blast immunophenotype: CD13, CD33, CD34, CD117, HLA-DR, MPO positive | Aberrant monocytoid population with variable CD14, CD15, and CD64 expression	0	0	NA	Standard Chemotherapy	Yes	No clinically significant variants identified
aml_ohsu_2022	aml_ohsu_2022_2805	aml_ohsu_2022_2805_BA3242	65	66	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax	5	Induction|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	3	Ruxolitinib, Venetoclax	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Negative	FALSE	FALSE	FALSE	46,XY[20]	69	Targeted Therapy - Kinase Inhibitor(s)	4	FALSE	Negative	AML	17.786301369863015	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.D198N; 47.3%)	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	partial CD10, CD34, CD13, CD117, and HLA-DR	316	0.166666667	NA	Standard Chemotherapy	No	ATG2B (p.L1989V; VAF 51%)|CBL (p.V363_Q365del; VAF 34%)|FLT3-ITD (Allelic Ratio: ~0.013)|MED12 (p.N1049T; VAF 97%)|RTEL1 (p.S925Y; VAF 50%)|RUNX1 (p.D198N; VAF 47%)|SF3B1 (p.K666N; VAF 47%)|SH2B3 (p.S488Y; VAF 49%)
aml_ohsu_2022	aml_ohsu_2022_2805	aml_ohsu_2022_2805_BA3302	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax	5	Induction|Experimental|Re-Induction	2	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	3	Ruxolitinib, Venetoclax	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY[20]	69	Targeted Therapy - Kinase Inhibitor(s)	7	FALSE	Negative	AML	17.786301369863015	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.D198N; 47.7%)	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD10, CD13, CD33, CD34, subset CD79a, CD117, HLA-DR, partial MPO, and TDT+	0	0.266666667	NA	Standard Chemotherapy	Yes	CBL (p.V363_Q365del; VAF 31%)|RUNX1 (p.D198N; VAF 50%)|SF3B1 (p.K666N; VAF 51%)
aml_ohsu_2022	aml_ohsu_2022_2806	aml_ohsu_2022_2806_BA3260	72	72	0	ASXL1 (p.G646Wfs*12; 36.2%)	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Dead-Disease	NA	5	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	NA	Myelodysplastic Syndromes	NonAML	NA	NA	Negative	FALSE	FALSE	FALSE	46,XY[20]	NA	None	9	FALSE	Negative	MDS	10.126027397260273	1:DECEASED	Normal	No	No	NA	Yes	Yes	No	No	No	No	White	NA	NA	NA	1	Male	MATCHED	TRUE	Refractory cytopenia with multilineage dysplasia	NA	Bone Marrow Aspirate	NA	0	0.366666667	NA	NA	No	ASXL1 (G646Wfs*12; VAF 41%)|BRAF (G469A; VAF 50%)|ETV6 (VAF 48%)|KRAS (Y64N; VAF 10%)|SRSF2 (P95H; VAF 45%)
aml_ohsu_2022	aml_ohsu_2022_2807	aml_ohsu_2022_2807_BA3427	67	67	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	UNKNOWN	NA	Negative	TRUE	FALSE	FALSE	45,XY,-4,-5,del(6)(p24),add(7)(q21),der(9)t(9;14)(q12;q11.2),-14,-21,+22,ad  d(22)(p11.2)x2,+2mar[20]	NA	None	6	FALSE	Negative	AML	3.8465753424657536	1:DECEASED	EGR1/5p:  77% of cells were missing a signal for both probes, consistent  with monosomy, as seen on metaphase analysis.  | D7S486 (7q31): 73% of cells were missing a signal for D7S486 (7q31),  consistent deletion and with the add(7) seen on metaphase an	No	No	NA	No	No	No	No	No	No	Unknown	NA	NA	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, variable CD34, CD117, partial HLA-DR	0	0.266666667	TP53 (p.H179N; 16.9%)|TP53 (p.I195Mfs*13; 9.9%)|TP53 (p.I195Yfs*14; 11.4%)	NA	Yes	TP53 (p.H179N; MAF 63%)|TP53 (p.I195fs*52; MAF 39%)
aml_ohsu_2022	aml_ohsu_2022_2808	aml_ohsu_2022_2808_BA3401	58	58	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[4]	88	Standard Chemotherapy	6	FALSE	Positive	AML	38.53150684931507	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	variable CD11b, CD33, CD38, CD117, MPO positive	0	0.3	NA	Standard Chemotherapy	Yes	CEBPA (p.G242S; MAF 57%)|FLT3 (p.A680V; MAF 2%)|IDH1 (p.R132S; MAF 34%)|MPL (p.R102P; MAF 55%)|NPM1 (p.W288fs*12; MAF 35%)|PTPN11 (p.S502L; MAF 28%)|TCF3 (p.Q169K; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2809	aml_ohsu_2022_2809_BA3371	21	21	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	8	Waves3+4	Yes	HiDAC|7+3 (Cytarabine, Idarubicin)|Unknown|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Unknown	Allogeneic - Matched Unrelated Donor	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	4	FALSE	Negative	AML	22.290410958904108	1:DECEASED	Negative for RUNX1/RUNX1T1, KMT2A (MLL), CBFB	No	No	NA	No	No	No	No	No	No	White	2	Refractory	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	NA	0	0.233333333	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2810	aml_ohsu_2022_2810_BA3116	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	Azacitidine, BI 836858 (anti-CD33)	1	Induction	1	Standard Chemotherapy	1	Azacitidine, BI 836858 (anti-CD33)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	NA	-1	Standard Chemotherapy	4	FALSE	Negative	AML	2.728767123287671	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.2	NA	Standard Chemotherapy	Yes	ASXL1|TET2
aml_ohsu_2022	aml_ohsu_2022_2811	aml_ohsu_2022_2811_BA3306	26	26	19	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NA	NA	Positive	TRUE	FALSE	FALSE	NA	-1	Bone Marrow Transplant	5	FALSE	Positive	AML	9.501369863013698	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Dim Positive (CD13, MPO) | Dim Partial positive (CD34) | Variable partial positive (CD117)	0	0.166666667	NA	Standard Chemotherapy	Yes	FLT3-ITD (ITD, c.l815_1816ins30; p.F605_P606insl0 (MAF 49%))|IDH1 (c.395G>A; p.R132H (MAF 45%))|NPM1 (c.863_864insTCTG; p.W288fs (MAF 43%))
aml_ohsu_2022	aml_ohsu_2022_2812	aml_ohsu_2022_2812_BA3315	57	57	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	3	Salvage|Consolidation|Induction	3	Standard Chemotherapy	1	Decitabine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	69~82<3n>,X,-X,+4,+8,+8,+8,+8,+8,+8,-9,+10,-12,-15,-17,+18,+20,+21,+22,+1~2mar[cp13]/47~48,X,-X,+4,+6,+8,+8,-9,-16,-17,+mar[cp3]/92,XXXX[2]/46,XX[2]	0	Standard Chemotherapy	3	FALSE	Negative	AML	4.175342465753425	1:DECEASED	BCR/ABL: 38% of cells had three signals for BCR and another 18% of cells had three signals for BCR and for ABL/ASS.  | PML/RARA: 6% of cells had three signals for both probes.	No	No	NA	No	No	No	No	No	No	White	6	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	MPO, CD33, CD43, CD45, and CD117 positive	0	0.2	TP53 (p.V143M; 44.0%)	Standard Chemotherapy	Yes	BCL6 (p.R459C; VAF 44%)|IDH2 (p.R172K; VAF 14%)|NRAS (p.Q61K; VAF 12%)|TP53 (p.V143M; VAF 32%)
aml_ohsu_2022	aml_ohsu_2022_2813	aml_ohsu_2022_2813_BA3301	59	59	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	2	Waves3+4	Yes	Dasatinib|7+3 (Cytarabine, Idarubicin)|Sirolimus|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	5	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Experimental	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Dasatinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	TRUE	48,XY,+8,+9[20]	106	Targeted Therapy - Kinase Inhibitor(s)	4	FALSE	Negative	AML	8.12054794520548	1:DECEASED	nuc ish(D8Z2x3,D20S108x2)[170/200]	No	No	NA	Yes	Yes	No	No	No	No	Asian	6	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD2(-), CD4(appears partial dim +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(bright +), CD34(+), CD36(-), CD38(partial +), CD45(moderately +), CD56(partial +), CD64(partial +), CD117 (+), HLA-DR(+).	0	0.233333333	NA	Standard Chemotherapy	Yes	BCOR (P512fs*7; MAF 66%)|EP300 (R1462*; MAF 8%)|ETV6 (ETV6-FOXJ2)|HIST1H2BK (T20I; MAF 47%)|PTPN11 (S502P;MAF 41.0%)|STK11 (F354L;MAF 46.0%)|U2AF1 (S34F; MAF 38%)
aml_ohsu_2022	aml_ohsu_2022_2814	aml_ohsu_2022_2814_BA3270	47	47	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	DECLINED	NA	Negative	TRUE	FALSE	FALSE	46,XX[20	100	Standard Chemotherapy	3	FALSE	Positive	AML	14.202739726027398	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.133333333	NA	Standard Chemotherapy	Yes	DNMT3A (p.R882C; MAF 46%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12D; MAF 46%)
aml_ohsu_2022	aml_ohsu_2022_2815	aml_ohsu_2022_2815_BA3251	75	75	0.5625	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	5	Waves3+4	Yes	Venetoclax (ABT-199), Azacitidine	1	Induction	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Positive	TRUE	FALSE	FALSE	46,XX[20]	4	Standard Chemotherapy	6	FALSE	Negative	AML	0.4602739726027397	1:DECEASED	Normal	No	No	NA	No	No	No	No	No	No	White	4	Unknown	NA	1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (CD38, CD13, CD33, CD117, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD14, CD15, CD34, CD64, TdT, Glyc A) | DIM (CD45, CD71)	0	0.233333333	NA	Standard Chemotherapy	Yes	FLT3-ITD (c.1829_1830ins51; p.N609_L610ins17; MAF 19%)|IDH2 (c.419G>A; p.R140Q; MAF 48%)|RUNX1 (c.1041G>A; p.M347I; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2816	aml_ohsu_2022_2816_BA3420	75	75	NA	NA	Myelodysplastic Syndromes	Myelodysplastic Syndromes	Dead-Other	NA	1	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	NA	Myelodysplastic Syndromes	NonAML	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	47,XY,+19[12]/46,XY[8]	NA	None	11	FALSE	Negative	MDS	19.364383561643834	1:DECEASED	Normal	Yes	No	Squamous cell carcinoma|Renal cell carcinoma	Yes	No	No	No	No	No	White	NA	NA	NA	1	Male	MATCHED	TRUE	Myelodysplastic syndrome, unclassifiable	NA	Bone Marrow Aspirate	NA	1	0.633333333	NA	NA	No	ATM (p.R3047*; MAF 9%)|CSF3R (p.A832V; MAF 49%)|IDH2 (p.R140W; MAF 16%)|SRSF2 (p.P95_R102del; MAF 25%)
aml_ohsu_2022	aml_ohsu_2022_2817	aml_ohsu_2022_2817_BA3213	50	50	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XY,inv(16)(p13.1q22)[18]/47,sl,+9[2]	7	Standard Chemotherapy	1	FALSE	Negative	AML	17.621917808219177	0:LIVING	Positive for a CBFB rearrangement	No	No	NA	No	No	No	No	No	No	White	7	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	NA	0	0.066666667	NA	Standard Chemotherapy	Yes	CBL (L399V; VAF 50%)|KIT (N587_R588ins16; VAF 34%)
aml_ohsu_2022	aml_ohsu_2022_2818	aml_ohsu_2022_2818_BA3277	65	65	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	Venetoclax (ABT-199), Azacitidine	1	Induction	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	4	FALSE	Positive	AML	6.9369863013698625	0:LIVING	Normal	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive (CD38 dim, CD33 dim, CD45 dim, CD117 var, MPO var) | negative (CD10, CD19, CD20, CD22, CD23, Surf Kappa, Surf Lambda, FMC7, CD3, CD5, CD7, CD56, CD13, CD14, CD15, CD34) | PP (CD11b VAR, CD64 VAR, HLA-DR VAR)	0	0.166666667	NA	Standard Chemotherapy	Yes	IDH2 (c. 419G>A; p.R140Q; MAF 47%)|NPM1 (C.863_864insTCTG; p.W288fs; MAF 34%)|SRSF2 (c. 284C>A; p.P95H; MAF 47%)
aml_ohsu_2022	aml_ohsu_2022_2819	aml_ohsu_2022_2819_BA3160	60	61	0	ASXL1 (p.G646Wfs*12; 10.8%)	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	54~57,XY,+14,+19,+20,add(21)(q22),+add(21)x3~6,+22[cp19]/46,XY[1]	-1	Bone Marrow Transplant	3	FALSE	Negative	AML	32.843835616438355	1:DECEASED	Nineteen of twenty metaphase cells examined were abnormal, with extra  copies of chromosomes 14, 19, 20 and 22, and several copies, 4-7, of a  structurally-abnormal chromosome 21. This abnormal karyotype has been reported previously by an outside institu	No	No	NA	No	No	No	No	No	No	White	-1	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD10, bright CD13, CD33, CD34, CD56, CD117, partial CD123, dim HLA-DR	0	0.133333333	NA	Standard Chemotherapy	Yes	EZH2 (p.G179C; MAF 48%)|TET2 (p.S460F; MAF 50%)
aml_ohsu_2022	aml_ohsu_2022_2820	aml_ohsu_2022_2820_BA3214	NA	51	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	7	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	10	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	MATCHED	FALSE	Unknown	Unknown	Bone Marrow Aspirate	NA	0	0.566666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2821	aml_ohsu_2022_2821_BA3159	31	31	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves3+4	Yes	Etoposide, TBI|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Etoposide, TBI	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NA	NA	Negative	TRUE	FALSE	FALSE	46,XX,inv(16)(p13.1q22)[8]/46,XX[12]	-1	Bone Marrow Transplant	3	FALSE	Negative	AML	54.83835616438357	0:LIVING	inv(16) positive	No	No	NA	No	No	No	No	No	No	NA	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34+ myeloblasts (60%) and a small population of monoblasts (5%)	0	0.1	NA	Standard Chemotherapy	Yes	KIT
aml_ohsu_2022	aml_ohsu_2022_2822	aml_ohsu_2022_2822_BA3082	58	58	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Other	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	FALSE	FALSE	FALSE	46,XX,t(9;11)(p22;q23)[10]/46,XX[10]	-1	Bone Marrow Transplant	2	FALSE	Negative	AML	36.78904109589041	1:DECEASED	Ten of twenty metaphase cells examined were abnormal, with a t(9;11)  involving MLL; ten cells appeared normal female. | MLL: 35% of cells had the 1r/1g/1f split signal pattern consistent with rearrangement and with the t(9;11) seen on metaphase analysis	Yes	No	Breast Cancer	No	No	No	No	No	No	American Indian	-1	Refractory	NA	1	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	partial CD11b, partial CD13, CD33, bright CD38, CD58, bright CD64, and partial HLA-DR+	0	0.066666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2823	aml_ohsu_2022_2823_BA3187	76	78	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	8	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	3	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	Decitabine	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	M4	Negative	FALSE	TRUE	FALSE	46,XY,inv(16)(p13.1q22.1) [16]/46,idem,del(7)(q32)[ 4]	81	Standard Chemotherapy	2	FALSE	Negative	AML	29.62191780821918	0:LIVING	POSITIVE for CBFB gene locus rearrangement (separated by chromosome 16 inversion)	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Relapse	Bone Marrow Aspirate	NA	0	0.066666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2824	aml_ohsu_2022_2824_BA3418	72	72	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	8	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	NA	Negative	FALSE	FALSE	TRUE	45-46,X,-Y,t(3;3)(q21;q26 .2),del(4)(q12),-5,del(6) (q21),del(9)(q22),del(11) (p11.2),ins(15;5)(q12;p15 .2p15.2),add(16)(q22),-17,-20,-21,-22,+mar1-5[c p18]/ 46,XY[2]	7	Standard Chemotherapy	2	FALSE	Negative	AML	0.7890410958904108	1:DECEASED	NA	No	No	NA	Yes	Yes	No	No	No	No	Asian	7	Refractory	NA	1	Male	UNMATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.1	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2825	aml_ohsu_2022_2825_BA3415	79	79	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	49~50,XX,+X,-3,del(5)(q13q33),der(7)t(3;7)(q11.2;q21),+8,-9,  del(17)(p11.2),+18,+21,der(21)t(9;21)(q22;q22)X2,+22,+1~2mar[cp20]	NA	None	1	FALSE	Negative	AML	0.4602739726027397	1:DECEASED	EGR-1/ D5S23, D5S721:  97/100 cells (97%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the metaphase karyotype.  | CEP 8:  179/200 cells (89.5%) had three signals, consistent with the trisomy 8 in the metaphase karyotype. 	No	No	NA	No	No	No	No	No	No	White	NA	NA	NA	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD7, CD13, CD33, CD34, CD38, CD56,  CD117, HLA-DR, MPO	0	0.066666667	TP53 (p.R196*; 89.6%)	NA	Yes	CBL (p.L209V; MAF 92%)|FLT3 (p.L198F; MAF 52%)|TP53 (p.R196*; MAF 80%)
aml_ohsu_2022	aml_ohsu_2022_2826	aml_ohsu_2022_2826_BA3093	73	73	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	1	Waves3+4	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	2	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	92,XXYY[9]/46,XY[11]	-1	Bone Marrow Transplant	3	FALSE	Negative	AML	81.46849315068494	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	RUNX1 (L89fs*49; MAF 20-30%)	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, dim CD33, CD34, CD38, dim CD45, CD58, CD71, CD117,CD123, HLA-DR, and TdT positive	0	0.133333333	NA	Standard Chemotherapy	Yes	IDH1 (R132H; MAF 30%)|RUNX1 (L89fs*49; MAF 20-30%)
aml_ohsu_2022	aml_ohsu_2022_2827	aml_ohsu_2022_2827_BA3195	77	77	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	No	Venetoclax, Idasanutlin|anti-CD123, Decitabine|Enasidenib|cd47mAb	4	Salvage|Induction|Experimental	3	Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	2	Enasidenib	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	46,XY[19]	-1	Targeted Therapy - Kinase Inhibitor(s)	6	FALSE	Negative	AML	10.586301369863014	0:LIVING	Normal	No	No	NA	No	No	Yes	Yes	No	No	NA	-1	Refractory	RUNX1 (p.L98Pfs*40; 52.3%)|RUNX1 (p.N434Kfs*166; 32.4%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (CD38, CD15, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD33, CD64, TdT) | Dim Positive (CD45, CD117)	0	0.2	NA	Targeted Therapy - Kinase Inhibitor(s)	Yes	DNMT3A (c.2644C>T; p.R882C; MAF 47%)|IDH2 (c.419G>A; p.R140Q; MAF 48%)|JAK2 (c.1849G>T; p.V617F; MAF 50%)|RUNX1 (c.1289_1290insTGCC; p.P430fs; MAF 17%)|RUNX1 (c.1301 1302insA; p.N434s; MAF 21%)|RUNX1 (c.292_293insC; p.L98fs; MAF 45%)|SRSF2 (c.284C>A; p.
aml_ohsu_2022	aml_ohsu_2022_2828	aml_ohsu_2022_2828_BA3106	NA	NA	0	ASXL1 (p.R693*; 42.5%)	Leukemia	Acute Myeloid Leukemia	NA	NA	2	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NA	Negative	unknown	unknown	unknown	NA	NA	None	4	FALSE	Negative	AML	-0.03287671232876713	NA	NA	No	No	NA	No	No	No	No	No	No	White	NA	NA	RUNX1 (p.X170_splice; 34.7%)	1	Male	UNMATCHED	FALSE	Unknown	Unknown	Bone Marrow Aspirate	NA	12	0.266666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2829	aml_ohsu_2022_2829_BA3245	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	5	Waves3+4	Yes	Decitabine	1	Supportive/Palliative Care	1	Targeted Therapy - Kinase Inhibitor(s)	1	Decitabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	FALSE	FALSE	TRUE	47,XX,psu dic(5;7)(q13;p10),r(7)(p12q11.2),+8,der(12)del(12)(p11.2p13)add(12)(q24.1)[2]/ 44,sl,add(3)(q12),-r(7)(p12q11.2),-8,-der(12)del(12)(p11.2p13)add(12)(q24.1),idic(22)(p11.2), +der(?)(7qter- > 7q11.2::?- > cen- > ?::12q11- > 12qter)[16]/ 45,sdl1,+d	-1	Targeted Therapy - Kinase Inhibitor(s)	6	FALSE	Negative	AML	1.7424657534246575	0:LIVING	5p15.2/ 5q31 (EGR1) (ABNORMAL - Loss of 5q31 sequences) | 7 centromere/ 7q31 (ABNORMAL - Loss of 7q31 sequences, see interpretation) | 8 centromere/ 20q12 (ABNORMAL - Gain of chromosome 8 centromere, Normal 20q12) | RUNX1 (21q22.12)/ RUNX1T1(8q22) (Negati	Yes	No	Fallopian Tube Cancer	Yes	Yes	No	No	No	No	White	NA	NA	NA	1	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	Negative (CD19, CD22, CD56, CD14, CD15, CD64, MPO) | Positive (CD38, CD7, CD13, CD33, CD34, HLA-DR) | Dim (CD11b, CD45, CD117)	0	0.366666667	TP53 (p.L257Q; 84.5%)	NA	Yes	IDH2 (c.419G>A; p.R140Q; MAF 5%)|NRAS (c.!82A>T; p.Q61L; MAF 26%)|TP53 (c.770T>A; p.L257Q; MAF 92%)
aml_ohsu_2022	aml_ohsu_2022_2830	aml_ohsu_2022_2830_BA3079	68	68	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	3	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NA	NA	Negative	TRUE	FALSE	FALSE	45,XY,+1,der(1;14)(p10;q10),add(3)(p25),-5,del(12)(p11.2p13)[6]/44,XY,sl,del(7)(q11.2),der(8)del(8)(p21)t(8;17)(q24;q21),-17,+19,-22[cp10]/63<3n>,sdl1,-3,-4,-6,+8,del(8)(p21)x2,+9,+13,-15,-18,-21[cp4]	-1	Standard Chemotherapy	4	FALSE	Negative	AML	0.7561643835616438	0:LIVING	5p15.2 (D5S23): gain present  5q31 (EGR1): deletion present  7cen (D7Z1), 7q31 (D7S486): deletion and monosomy present  | t(8;21)(q22;q22) (RUNX1T1;RUNX1): gain present  11q23 (KMT2A; also known as MLL): gain present  16q22 (CBFB): gain present  17q21 (RA	No	No	NA	No	No	No	No	No	No	NA	-1	Unknown	NA	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	NA	0	0.133333333	TP53 (p.N239*; 57.9%)	Standard Chemotherapy	Yes	TP53 (p.Asn239*; MAF 58.4%)|TP53 (p.Ser166_Gln167del; MAF 12%)
aml_ohsu_2022	aml_ohsu_2022_2831	aml_ohsu_2022_2831_BA3141	NA	NA	0	NA	Leukemia	Acute Myeloid Leukemia	NA	NA	3	Waves3+4	No	NA	0	NA	0	NA	0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	NA	NA	None	4	FALSE	Negative	AML	0.0	NA	NA	No	No	NA	No	No	No	No	No	No	NA	NA	NA	NA	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Unknown	Bone Marrow Aspirate	NA	0	0.166666667	NA	NA	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2832	aml_ohsu_2022_2832_BA3124	62	62	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M6	Negative	TRUE	FALSE	FALSE	46,XX,del(16)(q22q23)[8]/46,XX[12]	-1	Bone Marrow Transplant	3	FALSE	Negative	AML	48.394520547945206	1:DECEASED	del(16q)	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	NA	1	Female	UNMATCHED	FALSE	Acute erythroid leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, dim CD14, CD33, CD34, CD38, CD58, CD123, CD117, HLA-DR, partial cTdT and cMPO positive	0	0.166666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2833	aml_ohsu_2022_2833_BA3412	74	74	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	Vidaza, BI836858 (anti-CD33)	1	Induction	1	Standard Chemotherapy	1	Vidaza, BI836858 (anti-CD33)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	46,XX,t(8;16)(p11.2;p13.3)[19] /46,XX[1]	90	Standard Chemotherapy	3	FALSE	Negative	AML	4.898630136986301	1:DECEASED	Normal	Yes	No	Breast Cancer	No	No	No	No	No	No	White	90	Refractory	NA	1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	dim CD4, dim CD11b, CD15, bright CD33, CD38, variable CD56, bright CD64, partial CD117, HLA-DR, MPO, and dim TdT+	0	0.133333333	NA	Standard Chemotherapy	Yes	KMT2D (p.R1918C; VAF 50%)|PTPN11 (p.S502P; VAF 41%)
aml_ohsu_2022	aml_ohsu_2022_2834	aml_ohsu_2022_2834_BA3438	53	53	0	NA	Leukemia	Acute Myeloid Leukemia	Dead-Disease	NA	1	Waves3+4	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	2	Induction|Re-induction	2	Standard Chemotherapy	1	5+2 (Cytarabine, Idarubicin)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	47,XY,der(5)t(5;17)(q12;q12),+8,+15,der(15)t(11;15)(q22;q24)dup(11)(q25q22)  ,del(16)(q22q24),-17,der(20;21)(p10;q10),+mar[16]/46,idem,der(10)t(10;11)(q  25;q23)t(5;11)(q12;q25),-mar[3]/46,XY[1]	4	Standard Chemotherapy	5	FALSE	Negative	AML	2.1369863013698627	1:DECEASED	EGR1: 90% of cells were missing a signal for EGR1 (5q31), consistent with  the der(5) seen on metaphase analysis.  | MLL (11q23):  97% of cells had two normal intact signals and a many other  intact signals per cells, suggesting amplification.  (On avai	No	No	NA	No	No	No	No	No	No	White	6	Refractory	NA	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4, dim CD20, dim CD11b, CD13, CD33, CD34, CD38, CD58,  variable CD64, partial dim CD117, MPO	0	0.233333333	TP53 (p.R248Q; 80.3%)	Standard Chemotherapy	Yes	MLL |TP53 (p.R248Q; MAF 82%)
aml_ohsu_2022	aml_ohsu_2022_2835	aml_ohsu_2022_2835_BA3109	56	63	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	Yes	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine, Trametinib	4	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	Azacitidine, Trametinib	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	FALSE	FALSE	46,XX,der(22)t(1;22)(q12;p11.2)[1]/46,XX[19]	-1	Standard Chemotherapy	4	FALSE	Positive	AML	96.2958904109589	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	RUNX1 (p.S100Lfs*38; 45.6%)	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	NA	0	0.166666667	NA	Standard Chemotherapy	Yes	NA
aml_ohsu_2022	aml_ohsu_2022_2835	aml_ohsu_2022_2835_BA3343	56	66	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	Yes	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine, Trametinib	4	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	Azacitidine, Trametinib	Salvage	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	unknown	unknown	unknown	46,XXder(22)t(1;22)(q12;p11.2)[1]/46,XX[19]	-1	Standard Chemotherapy	7	FALSE	Negative	AML	96.2958904109589	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	RUNX1 (p.S100Lfs*38; 36.8%)	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Unknown	Peripheral Blood	NA	893	0.366666667	NA	Standard Chemotherapy	No	NA
aml_ohsu_2022	aml_ohsu_2022_2835	aml_ohsu_2022_2835_BA3452	56	64	0	NA	Leukemia	Acute Myeloid Leukemia	Alive	NA	2	Waves3+4	Yes	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine, Trametinib	4	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	Azacitidine, Trametinib	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NA	NA	Negative	FALSE	TRUE	FALSE	46,XXder(22)t(1;22)(q12;p11.2)[1]/46,XX[19]	-1	Standard Chemotherapy	4	FALSE	Negative	AML	96.2958904109589	0:LIVING	NA	No	No	NA	No	No	No	No	No	No	White	-1	Complete Response	RUNX1 (p.S100Lfs*38; 47.8%)	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse	Peripheral Blood	NA	455	0.2	NA	Standard Chemotherapy	No	NA